▁National ▁trend s ▁in ▁patient ▁safety ▁for ▁four ▁common ▁conditions , ▁2005 -2011 .
▁The ▁effects ▁of ▁more ▁than ▁a ▁de cade ▁of ▁national ▁efforts ▁dedicated ▁to ▁improve ▁patient ▁safety ▁remain ▁large ly ▁un clear .
▁This ▁study ▁used ▁the ▁Medica re ▁Patient ▁Safety ▁Monitor ing ▁System ▁( MP SMS ) ▁database ▁to ▁assess ▁national ▁trend s ▁in ▁advers e ▁event ▁rates ▁between ▁2005 ▁through ▁2011 ▁for ▁patients ▁hospital ized ▁with ▁a cute ▁my o card ial ▁in far ction , ▁con ges tive ▁heart ▁failure , ▁pneu monia , ▁or ▁conditions ▁requiri ng ▁surgery .
▁The ▁analysis ▁included ▁a ▁large ▁study ▁sample ▁with ▁more ▁than ▁ 60,000 ▁patients ▁across ▁4 372 ▁hospital s .
▁The ▁results ▁show ▁a ▁significant ▁decline ▁in ▁advers e ▁event ▁rates ▁for ▁a cute ▁my o card ial ▁in far ction ▁and ▁con ges tive ▁heart ▁failure , ▁trans la ting ▁to ▁an ▁estima ted ▁8 1,000 ▁in - hospital ▁advers e ▁events ▁aver ted ▁in ▁2010 – 2011 .
▁However , ▁there ▁were ▁no ▁mea sur able ▁overall ▁improvement s ▁for ▁patients ▁admit ted ▁with ▁pneu monia ▁or ▁sur g ical ▁conditions .
▁Some ▁events , ▁such ▁as ▁pressure ▁ul cer s ▁in ▁sur g ical ▁patients , ▁actually ▁increased ▁de spite ▁considerable ▁national ▁attention ▁to ▁these ▁problems .
▁This ▁study ▁suggest s ▁that ▁national ▁patient ▁safety ▁initiative s ▁have ▁led ▁to ▁real ▁progress ▁in ▁some ▁areas ▁but ▁have ▁not ▁created ▁across - the - board ▁improvement s .
▁Cross - talk ▁between ▁the ▁heart ▁and ▁adi pose ▁tissu e ▁in ▁cache ctic ▁heart ▁failure ▁patients ▁with ▁respect ▁to ▁altera tions ▁in ▁body ▁composition : ▁a ▁prospect ive ▁study .
▁OB JE C TIVE S : ▁Card iac ▁cache xia ▁( CC ) ▁is ▁associated ▁with ▁changes ▁in ▁body ▁composition .
▁Li poly sis ▁and ▁increased ▁energy ▁ex pendi ture ▁caused ▁by ▁A - ▁and ▁B ▁na tri ure tic ▁pe pti des ▁( NP s ) ▁have ▁been ▁suggest ed ▁to ▁play ▁a ▁role ▁in ▁CC .
▁We ▁test ed ▁the ▁hypothe sis ▁that ▁neuro hormon es ▁and ▁adi pok ines ▁are ▁associated ▁with ▁body ▁composition ▁in ▁CC ▁and ▁that ▁a ▁progressive ▁loss ▁of ▁fat ▁free ▁mass ▁( FF M ) ▁and ▁fat ▁mass ▁( FM ) ▁takes ▁place .
▁ MET HOD S : ▁Body ▁composition ▁with ▁regard ▁to ▁F FM , ▁FM , ▁and ▁body ▁fat ▁distribution ▁was ▁assess ed ▁by ▁dual ▁energy ▁X - ray ▁ab sor pti ometr y ▁( D XA ) ▁in ▁19 ▁non - dia be tic ▁patients ▁with ▁chronic ▁heart ▁failure ▁( CH F ) ▁and ▁CC ▁and ▁38 ▁control s ▁( non - ca che ctic ▁CHF ▁and ▁individuals ▁with ▁prior ▁my o card ial ▁in far ction - bo th ▁n ▁= ▁19 ) ▁who ▁were ▁followed ▁for ▁12 ▁months .
▁Bio mark ers ▁of ▁neuro hormon al ▁stimul ation , ▁ inflammation , ▁and ▁en dot heli al ▁dys function ▁were ▁measure d .
▁RESULT S : ▁N - termin al ▁pro B NP ▁( NT - pro B NP ), ▁mid region al ▁pro AN P ▁( MR - pro AN P ), ▁and ▁total ▁adi pon ect in ▁were ▁eleva ted ▁in ▁CHF ▁( p < 0.00 1) ▁and ▁cor related ▁invers ely ▁to ▁B MI ▁and ▁FM .
▁An ▁in verse ▁corre lation ▁was ▁observe d ▁between ▁pro - ad re nom edu llin ▁( MR - pro AD M ) ▁and ▁F FM .
▁During ▁follow ▁up ▁body ▁weight ▁was ▁un alter ed ▁in ▁all ▁groups ▁even ▁though ▁FM ▁increased ▁by ▁1. 35 ▁kg ▁( p < 0.0 5) ▁and ▁F FM ▁decrease d ▁by ▁0.5 ▁kg ▁( p < 0.0 5) ▁in ▁CC ▁patients .
▁The ▁la tter ▁cor related ▁invers ely ▁to ▁base line ▁NT - pro B NP , ▁MR - pro AN P , ▁and ▁MR - pro AD M ▁( p < 0.0 5) .
▁No ▁corre lation ▁to ▁changes ▁in ▁FM ▁was ▁found .
▁CON CL USI ONS : ▁FM ▁was ▁associated ▁with ▁plasma ▁ NP s ▁and ▁total ▁adi pon ect in ▁at ▁base line ; ▁where as ▁changes ▁in ▁FM ▁and ▁F FM ▁did ▁not ▁corre late ▁to ▁changes ▁in ▁ NP s ▁or ▁adi pon ect in ▁during ▁follow ▁up .
▁Pro spec tive ly , ▁F FM ▁decrease d ▁but ▁FM ▁increased , ▁de spite ▁stable ▁body ▁weight ▁in ▁CC .
▁ Diagnos is ▁of ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction : ▁role ▁of ▁clinic al ▁Do pp ler ▁e cho card i ography .
▁In ▁developed ▁countries , ▁at ▁least ▁38 – 5 4% ▁of ▁patients ▁with ▁heart ▁failure ▁show ▁pres er ved ▁left ▁vent ri cular ▁( LV ) ▁e je ction ▁ fraction .
▁The ▁prevale nce ▁of ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( H FP EF ) ▁is ▁ste adi ly ▁increasing ▁and ▁its ▁prognos is ▁is ▁poor .
▁LV ▁dia sto lic ▁dys function , ▁either ▁alone ▁or ▁in ▁combination ▁with ▁other ▁factors ▁( figur e ▁1) , ▁is ▁the ▁major ▁under ly ing ▁mechanism ▁of ▁H FP EF .
▁In ▁the ▁general ▁population , ▁the ▁presence ▁of ▁even ▁mild ▁clinic al ▁dia sto lic ▁dys function ▁has ▁been ▁associated ▁with ▁prono un ced ▁increase s ▁in ▁all ▁cause ▁mortal ity .
▁H ence , ▁the ▁ diagnos is ▁of ▁clinic al ▁( prog nosti c ) ▁dia sto lic ▁dys function ▁leading ▁to ▁H FP EF ▁is ▁of ▁critical ▁importance .
▁The ▁European ▁Society ▁of ▁Card i ology ▁guidelines ▁based ▁definition ▁of ▁H FP EF ▁requires ▁a ▁presence ▁of ▁sign s ▁and ▁symptoms ▁of ▁heart ▁failure , ▁pres er ved ▁LV ▁e je ction ▁ fraction ▁of ▁a ▁non - dila ted ▁left ▁vent ric le , ▁and ▁evidence ▁of ▁dia sto lic ▁dys function ▁( impa i red ▁LV ▁relax ation ▁or ▁increased ▁LV ▁dia sto lic ▁sti ff ness ) ▁with ▁eleva ted ▁LV ▁fill ing ▁pressure s .
▁LV ▁dia sto lic ▁dys function ▁and ▁fill ing ▁pressure s ▁can ▁be ▁assess ed ▁non - in va sive ly ▁using ▁Do pp ler ▁e cho card i ography .
▁Treatment ▁of ▁an emia ▁in ▁patients ▁with ▁heart ▁disease : ▁a ▁clinic al ▁practice ▁guide line ▁from ▁the ▁American ▁College ▁of ▁Physic ians .
▁Description : ▁The ▁American ▁College ▁of ▁Physic ians ▁( A CP ) ▁developed ▁this ▁guide line ▁to ▁present ▁the ▁evidence ▁and ▁provide ▁clinic al ▁recommendations ▁on ▁the ▁treatment ▁of ▁an emia ▁and ▁ir on ▁de fici en cy ▁in ▁adult ▁patients ▁with ▁heart ▁disease .
▁Method s : ▁This ▁guide line ▁is ▁based ▁on ▁published ▁literature ▁in ▁the ▁English ▁language ▁on ▁an emia ▁and ▁ir on ▁de fici en cy ▁from ▁1947 ▁to ▁July ▁2012 ▁that ▁was ▁identified ▁using ▁MED LINE ▁and ▁the ▁Co ch rane ▁Library .
▁Literatur e ▁was ▁rea sses sed ▁in ▁April ▁2013, ▁and ▁additional ▁studies ▁were ▁included .
▁Out com es ▁evaluat ed ▁for ▁this ▁guide line ▁included ▁mortal ity ; ▁hospital ization ; ▁exercise ▁ tolerance ; ▁quality ▁of ▁life ; ▁and ▁cardiovascular ▁events ▁( de fin ed ▁as ▁my o card ial ▁in far ction , ▁con ges tive ▁heart ▁failure ▁ex ace rb ation , ▁ar rhythm ia , ▁or ▁cardiac ▁death ) ▁and ▁har ms , ▁including ▁hyper tension , ▁ve nous ▁ thro mbo e mbol ic ▁events , ▁and ▁ ische mic ▁cerebro vas cular ▁events .
▁The ▁target ▁audience ▁for ▁this ▁guide line ▁includes ▁all ▁clinic ians , ▁and ▁the ▁target ▁patient ▁population ▁is ▁a ne mic ▁or ▁ir on - d eficient ▁adult ▁patients ▁with ▁heart ▁disease .
▁This ▁guide line ▁grade s ▁the ▁evidence ▁and ▁recommendations ▁using ▁the ▁A CP ' s ▁clinic al ▁practice ▁guidelines ▁grad ing ▁system .
▁Re com mend ation ▁1: ▁A CP ▁recommend s ▁using ▁a ▁restrict ive ▁red ▁blood ▁cell ▁trans fusion ▁strategy ▁( tri gger ▁hem o glob in ▁thre s hold ▁of ▁7 ▁to ▁8 ▁g / d L ▁compared ▁with ▁higher ▁hem o glob in ▁levels ) ▁in ▁hospital ized ▁patients ▁with ▁corona ry ▁heart ▁disease .
▁( Gra de : ▁we ak ▁recommend ation ; ▁low - quality ▁evidence ) ▁Re com mend ation ▁2: ▁A CP ▁recommend s ▁against ▁the ▁use ▁of ▁er y thro po ies is - stimul ating ▁agents ▁in ▁patients ▁with ▁mild ▁to ▁moderat e ▁an emia ▁and ▁con ges tive ▁heart ▁failure ▁or ▁corona ry ▁heart ▁disease .
▁( Gra de : ▁strong ▁recommend ation ; ▁moderat e - quality ▁evidence ) ▁Treatment ▁of ▁an emia ▁in ▁patients ▁with ▁heart ▁disease : ▁a ▁systematic ▁review .
▁Back ground : ▁The ▁benefits ▁of ▁an emia ▁treatment ▁in ▁patients ▁with ▁heart ▁disease ▁are ▁un certa in .
▁Pur pose : ▁To ▁evaluat e ▁the ▁benefits ▁and ▁har ms ▁of ▁treatment s ▁for ▁an emia ▁in ▁adults ▁with ▁heart ▁disease .
▁Data ▁Source s : ▁MED LINE , ▁ EMBA SE , ▁and ▁Co ch rane ▁database s ; ▁clinic al ▁trial ▁registri es ; ▁reference ▁list s ; ▁and ▁technical ▁ad visor s .
▁Study ▁Select ion : ▁English - language ▁trial s ▁of ▁blood ▁trans fusion s , ▁ir on , ▁or ▁er y thro po ies is - stimul ating ▁agents ▁in ▁adults ▁with ▁an emia ▁and ▁con ges tive ▁heart ▁failure ▁or ▁corona ry ▁heart ▁disease ▁and ▁observation al ▁studies ▁of ▁trans fusion .
▁Data ▁Extra ction : ▁Data ▁on ▁study ▁design , ▁population ▁character istic s , ▁hem o glob in ▁levels , ▁and ▁health ▁outcome s ▁were ▁extract ed .
▁Tri als ▁were ▁assess ed ▁for ▁quality .
▁Data ▁Syn the sis : ▁Low - streng th ▁evidence ▁from ▁6 ▁trial s ▁and ▁26 ▁observation al ▁studies ▁suggest s ▁that ▁liberal ▁trans fusion ▁protocol s ▁do ▁not ▁improve ▁short - term ▁mortal ity ▁rates ▁compared ▁with ▁less ▁aggressiv e ▁protocol s ▁( com bin ed ▁relative ▁risk ▁among ▁trial s , ▁0 . 94 ▁[ 95% ▁CI , ▁0 . 61 ▁to ▁1.4 2] ; ▁I 2 ▁= ▁16. 8%) , ▁although ▁decrease d ▁mortal ity ▁rates ▁occur red ▁in ▁a ▁small ▁trial ▁of ▁patients ▁with ▁the ▁a cute ▁corona ry ▁syndrome ▁(1 . 8% ▁vs . ▁13. 0% ; ▁P ▁= ▁0.0 32) .
▁Moder ate - streng th ▁evidence ▁from ▁3 ▁trial s ▁of ▁intra ven ous ▁ir on ▁found ▁improve d ▁short - term ▁exercise ▁ tolerance ▁and ▁quality ▁of ▁life ▁in ▁patients ▁with ▁heart ▁failure .
▁Moder ate - ▁to ▁high - streng th ▁evidence ▁from ▁17 ▁trial s ▁of ▁er y thro po ies is - stimul ating ▁agent ▁ therapy ▁found ▁they ▁offered ▁no ▁consistent ▁benefits , ▁but ▁their ▁use ▁may ▁be ▁associated ▁with ▁har ms , ▁such ▁as ▁ve nous ▁ thro mbo e mbol ism .
▁Limit ations : ▁Fe w ▁trial s ▁have ▁examine d ▁trans fusion s ▁in ▁patients ▁with ▁heart ▁disease , ▁and ▁observation al ▁studies ▁are ▁potential ly ▁con found ed ▁by ▁indica tion .
▁Data ▁support ing ▁ir on ▁use ▁come ▁main ly ▁from ▁1 ▁large ▁trial , ▁and ▁long - term ▁effects ▁are ▁un know n .
▁Conclu sion : ▁High er ▁trans fusion ▁thre s hold s ▁do ▁not ▁consistent ly ▁improve ▁mortal ity ▁rates , ▁but ▁large ▁trial s ▁are ▁needed .
▁Intra ven ous ▁ir on ▁may ▁help ▁to ▁alle via te ▁symptoms ▁in ▁patients ▁with ▁heart ▁failure ▁and ▁ir on ▁de fici en cy ▁and ▁also ▁warrant s ▁further ▁study .
▁Er y thro po ies is - stimul ating ▁agents ▁do ▁not ▁seem ▁to ▁benefit ▁patients ▁with ▁mild ▁to ▁moderat e ▁an emia ▁and ▁heart ▁disease ▁and ▁may ▁be ▁associated ▁with ▁serious ▁har ms .
▁Remote ▁ ische mic ▁condition ing ▁for ▁patients ▁with ▁heart ▁failure ?
▁Management ▁of ▁patients ▁with ▁heart ▁failure ▁( HF ), ▁ stemming ▁from ▁ ische mic ▁and ▁non ische mic ▁cardio my o pathi es , ▁continues ▁to ▁be ▁problematic , ▁de spite ▁the ▁in road s ▁made ▁in ▁the ▁ pharma c ological ▁arma ment arium , ▁by ▁implant able ▁cardio ver ter ▁de fi br illa tors , ▁cardiac ▁re syn chron ization ▁ therapy , ▁and ▁the ▁eventual ▁resort ▁to ▁cardiac ▁transplant ation , ▁and ▁left ▁and / or ▁right ▁vent ri cular ▁assist ▁devices .
▁Both ▁patients ▁with ▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁and ▁patients ▁with ▁ HF ▁with ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁are ▁admit ted ▁to ▁the ▁hospital ▁frequently ▁and ▁serial ly ▁and ▁keep ▁physician s ▁busy , ▁in ▁the ▁a cute ▁and ▁out patient ▁setting s , ▁for ▁their ▁management , ▁also ▁prompt ing ▁them ▁to ▁search ▁for ▁better ▁ways ▁to ▁deal ▁with ▁this ▁worldwide ▁epidemi c ▁and ▁its ▁impact ▁on ▁medical ▁resources ▁and ▁financial ▁costs .
▁Comments ▁on ▁" the ▁role ▁of ▁the ▁emergency ▁department ▁in ▁a cute ▁heart ▁failure ▁clinic al ▁trial s - En rich ing ▁patient ▁ identification ▁and ▁en roll ment " ▁by ▁Collins ▁et ▁al .
▁As ▁the ▁author s ▁suggest , ▁patient ▁categori z ation ▁in ▁the ▁emergency ▁department ▁is ▁perhaps ▁the ▁single ▁most ▁important ▁component ▁that ▁is ▁not ▁focused ▁on ▁in ▁modern ▁a cute ▁heart ▁failure ▁( A HF ) ▁clinic al ▁studies .
▁However , ▁patients ▁with ▁A HF ▁are ▁highly ▁hetero gene ous , ▁and ▁appropriate ▁risk ▁strat ification ▁is ▁essential ▁in ▁conduct ing ▁studies ▁in ▁this ▁area .
▁Pred ic tors ▁of ▁mortal ity ▁in ▁patients ▁with ▁an ▁implant able ▁cardiac ▁de fi br illa tor : ▁a ▁systematic ▁review ▁and ▁meta - analys is .
▁BA CK GRO UND : ▁Many ▁current ▁predict ors ▁of ▁mortal ity ▁in ▁heart ▁failure ▁( HF ) ▁were ▁evaluat ed ▁before ▁the ▁use ▁of ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁( IC D s ).
▁We ▁conduct ed ▁a ▁meta - analys is ▁to ▁identify ▁factors ▁associated ▁with ▁mortal ity ▁in ▁I CD - HF ▁patients .
▁ MET HOD S : ▁We ▁search ed ▁in ▁Med Line , ▁ EMBA SE , ▁and ▁C INA HL ▁in ▁May ▁2012.
▁Two ▁review ers ▁selected ▁cita tions ▁that ▁included ▁ambula tory ▁I CD ▁patients ▁and ▁address ed ▁the ▁association ▁between ▁any ▁predict or ▁and ▁mortal ity ▁using ▁multi vari able ▁re gression .
▁We ▁meta - ana ly zed ▁mortal ity ▁using ▁random - effect s ▁models .
▁RESULT S : ▁Of ▁10 , 420 ▁studies ▁review ed , ▁72 ▁studies ▁evaluat ing ▁63 ▁predict ors ▁on ▁25 7,6 92 ▁I CD ▁patients ▁proved ▁eligible .
▁High ▁confidence ▁in ▁estima tes ▁was ▁found ▁for ▁age ▁( haz ard ▁ratio ▁[ HR ] , ▁1. 45 ▁for ▁10- year ▁increase ; ▁95% ▁confidence ▁interval ▁[ CI ] , ▁1.3 5-1 . 56) , ▁base line ▁glo mer ular ▁filtr ation ▁rate ▁( HR , ▁1. 25 ▁for ▁15- m L / min ▁decrease ; ▁95% ▁CI , ▁1.1 5-1 . 35) , ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁( HR , ▁1. 54 ; ▁95% ▁CI , ▁1. 38 -1 . 71) , ▁diabetes ▁( HR , ▁1. 56 ; ▁95% ▁CI , ▁1.3 7-1 . 79) , ▁per i pher al ▁vas cular ▁disease ▁( HR , ▁1. 43 ; ▁95% ▁CI , ▁1. 2-1 . 72 ), ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁( HR , ▁0 . 77 ▁for ▁10% ▁increase ; ▁95% ▁CI , ▁0 . 73 -0 . 83) , ▁and ▁appropriate ▁or ▁in appropria te ▁I CD ▁shock s ▁( HR , ▁2. 34 ; ▁95% ▁CI ▁1. 59 -3 . 44) ▁New ▁York ▁Heart ▁Association ▁class , ▁at rial ▁fi bril lation , ▁and ▁con ges tive ▁ HF ▁were ▁strong ly ▁associated ▁with ▁mortal ity ▁but ▁the ▁confidence ▁in ▁estima tes ▁was ▁low .
▁I sche mic ▁cardio my o pathy ▁and ▁male ▁sex ▁were ▁not ▁independent ▁predict ors ▁of ▁mortal ity .
▁CON CL USI ONS : ▁This ▁meta - analys is ▁identified ▁strong ▁reliable ▁mortal ity ▁predict ors ▁in ▁I CD - HF ▁patients .
▁Age , ▁renal ▁dys function , ▁chronic ▁ob struct ive ▁pulmonar y ▁disease , ▁diabetes , ▁per i pher al ▁vas cular ▁disease , ▁decrease d ▁left ▁vent ri cular ▁e je ction ▁ fraction , ▁and ▁I CD ▁shock s ▁during ▁follow - up ▁were ▁strong ▁predict ors ▁of ▁mortal ity ; ▁ ische mic ▁cardio my o pathy ▁and ▁male ▁sex ▁were ▁not .
▁Fur ther ▁research ▁is ▁needed ▁to ▁study ▁other ▁potential ▁predict ors , ▁particularly ▁bio mark ers .
▁Low - dos e ▁dop amine ▁or ▁low - dos e ▁nesi riti de ▁in ▁a cute ▁heart ▁failure ▁with ▁renal ▁dys function : ▁the ▁RO SE ▁a cute ▁heart ▁failure ▁random ized ▁trial .
▁IMPORT ANCE : ▁Small ▁studies ▁suggest ▁that ▁low - dos e ▁dop amine ▁or ▁low - dos e ▁nesi riti de ▁may ▁enhance ▁de con gestion ▁and ▁pre serve ▁renal ▁function ▁in ▁patients ▁with ▁a cute ▁heart ▁failure ▁and ▁renal ▁dys function ; ▁however , ▁nei ther ▁strategy ▁has ▁been ▁rigor ously ▁test ed .
▁OB JE C TIVE : ▁To ▁test ▁the ▁2 ▁independent ▁hypothe ses ▁that , ▁compared ▁with ▁place bo , ▁addition ▁of ▁low - dos e ▁dop amine ▁(2 ▁μ g / kg / min ) ▁or ▁low - dos e ▁nesi riti de ▁( 0.00 5 ▁μ g / kg / min ▁without ▁bol us ) ▁to ▁di ure tic ▁ therapy ▁will ▁enhance ▁de con gestion ▁and ▁pre serve ▁renal ▁function ▁in ▁patients ▁with ▁a cute ▁heart ▁failure ▁and ▁renal ▁dys function .
▁DESIGN , ▁SET TING , ▁AND ▁PARTI CI PAN TS : ▁Multi center , ▁double - blind , ▁place bo - control led ▁clinic al ▁trial ▁( Re nal ▁Optim ization ▁Strategie s ▁Evalua tion ▁[ ROS E ] ) ▁of ▁360 ▁hospital ized ▁patients ▁with ▁a cute ▁heart ▁failure ▁and ▁renal ▁dys function ▁( estima ted ▁glo mer ular ▁filtr ation ▁rate ▁of ▁15 -60 ▁m L / min /1 . 73 ▁m 2) , ▁random ized ▁within ▁24 ▁hours ▁of ▁ad mission .
▁En roll ment ▁occur red ▁from ▁September ▁2010 ▁to ▁March ▁2013 ▁across ▁26 ▁sites ▁in ▁North ▁America .
▁INTER VEN TIONS : ▁Participa nts ▁were ▁random ized ▁in ▁an ▁open , ▁1:1 ▁al location ▁ratio ▁to ▁the ▁dop amine ▁or ▁nesi riti de ▁strategy .
▁With in ▁each ▁strategy , ▁participants ▁were ▁random ized ▁in ▁a ▁double - blind , ▁2:1 ▁ratio ▁to ▁active ▁treatment ▁or ▁place bo .
▁The ▁dop amine ▁( n ▁= ▁122 ) ▁and ▁nesi riti de ▁( n ▁= ▁119 ) ▁groups ▁were ▁independent ly ▁compared ▁with ▁the ▁poole d ▁place bo ▁group ▁( n ▁= ▁119 ).
▁M AIN ▁ OUT COM ES ▁AND ▁ME A SU RES : ▁Co prima ry ▁end ▁points ▁included ▁72 - ho ur ▁cum ul ative ▁urin e ▁volume ▁( de con gestion ▁end ▁point ) ▁and ▁the ▁change ▁in ▁se rum ▁cyst atin ▁C ▁from ▁en roll ment ▁to ▁72 ▁hours ▁( ren al ▁function ▁end ▁point ).
▁RESULT S : ▁Compar ed ▁with ▁place bo , ▁low - dos e ▁dop amine ▁had ▁no ▁significant ▁effect ▁on ▁72 - ho ur ▁cum ul ative ▁urin e ▁volume ▁( dop amine , ▁85 24 ▁m L ; ▁95% ▁CI , ▁79 17 -9 131 ▁vs ▁place bo , ▁8 296 ▁m L ; ▁95% ▁CI , ▁7 762 - 88 30 ▁; ▁difference , ▁ 229 ▁m L ; ▁95% ▁CI , ▁- 7 14 ▁to ▁11 71 ▁m L ; ▁P ▁= ▁ . 59) ▁or ▁on ▁the ▁change ▁in ▁cyst atin ▁C ▁level ▁( dop amine , ▁0.1 2 ▁mg / L ; ▁95% ▁CI , ▁0.0 6-0 . 18 ▁vs ▁place bo , ▁0.1 1 ▁mg / L ; ▁95% ▁CI , ▁0.0 6-0 . 16 ; ▁difference , ▁ 0.01 ; ▁95% ▁CI , ▁- 0.0 8 ▁to ▁0 . 10 ; ▁P ▁= ▁ . 72 ).
▁Similar ly , ▁low - dos e ▁nesi riti de ▁had ▁no ▁significant ▁effect ▁on ▁72 - ho ur ▁cum ul ative ▁urin e ▁volume ▁( nesi riti de , ▁8 574 ▁m L ; ▁95% ▁CI , ▁80 14 -9 134 ▁vs ▁place bo , ▁8 296 ▁m L ; ▁95% ▁CI , ▁7 762 - 88 30 ; ▁difference , ▁ 279 ▁m L ; ▁95% ▁CI , ▁- 6 18 ▁to ▁11 76 ▁m L ; ▁P ▁= ▁ . 49) ▁or ▁on ▁the ▁change ▁in ▁cyst atin ▁C ▁level ▁( nesi riti de , ▁0.0 7 ▁mg / L ; ▁95% ▁CI , ▁0.0 1-0 . 13 ▁vs ▁place bo , ▁0.1 1 ▁mg / L ; ▁95% ▁CI , ▁0.0 6-0 . 16 ; ▁difference , ▁- 0.0 4 ; ▁95% ▁CI , ▁- 0.1 3 ▁to ▁0.0 5 ; ▁P ▁= ▁ . 36) .
▁Compar ed ▁with ▁place bo , ▁there ▁was ▁no ▁effect ▁of ▁low - dos e ▁dop amine ▁or ▁nesi riti de ▁on ▁seconda ry ▁end ▁points ▁reflect ive ▁of ▁de con gestion , ▁renal ▁function , ▁or ▁clinic al ▁outcome s .
▁CON C LU SION ▁AND ▁RE LEV ANCE : ▁In ▁participants ▁with ▁a cute ▁heart ▁failure ▁and ▁renal ▁dys function , ▁nei ther ▁low - dos e ▁dop amine ▁nor ▁low - dos e ▁nesi riti de ▁enhance d ▁de con gestion ▁or ▁improve d ▁renal ▁function ▁when ▁added ▁to ▁di ure tic ▁ therapy .
▁Participa ting ▁in ▁a ▁multi hospital ▁study ▁to ▁promote ▁ adoption ▁of ▁heart ▁failure ▁guidelines : ▁lessons ▁for ▁nurse ▁leaders .
▁Many ▁multi site ▁studies ▁in ▁practice ▁setting s ▁focus ▁on ▁improving ▁process es ▁of ▁care , ▁adopt ing ▁evidence - based ▁practice s , ▁and ▁improving ▁patient ▁outcome s .
▁While ▁specific ▁research ▁questions ▁may ▁be ▁the ▁focus , ▁it ▁is ▁the ▁implementation ▁issues ▁and ▁strategie s ▁that ▁reveal ▁how ▁individuals ▁and ▁organization s ▁are ▁pro found ly ▁transform ed .
▁Utili zing ▁volunt ary ▁testimoni es ▁and ▁conversation s ▁with ▁participat ing ▁nurse s , ▁the ▁benefits ▁of ▁involve ment ▁in ▁a ▁multi site ▁study ▁extend ▁beyond ▁meeting ▁Magnet ( ® ) ▁research ▁requirements .
▁Systems ▁prote o mics ▁of ▁cardiac ▁chr omat in ▁ identifi es ▁nucleo lin ▁as ▁a ▁regulator ▁of ▁growth ▁and ▁cel lular ▁plastic ity ▁in ▁cardio my o cy tes .
▁My o cy te ▁hyper trop hy ▁antecede nt ▁to ▁heart ▁failure ▁involve s ▁changes ▁in ▁global ▁gene ▁expression , ▁although ▁the ▁preced ing ▁mechanism s ▁to ▁coordinat e ▁DNA ▁access i bility ▁on ▁a ▁genom ic ▁scale ▁are ▁un know n .
▁Chro mat in - as soci ated ▁protein s ▁alter ▁chr omat in ▁structure ▁by ▁changing ▁their ▁association ▁with ▁DNA , ▁there by ▁al tering ▁the ▁gene ▁expression ▁profile .
▁Little ▁is ▁known ▁about ▁the ▁global ▁changes ▁in ▁chr omat in ▁sub prote om es ▁that ▁ac company ▁heart ▁failure , ▁and ▁the ▁mechanism s ▁by ▁which ▁these ▁protein s ▁alter ▁chr omat in ▁structure .
▁The ▁present ▁study ▁tests ▁the ▁fundamental ▁hypothe sis ▁that ▁cardiac ▁growth ▁and ▁plastic ity ▁in ▁the ▁setting ▁of ▁disease ▁recap it ulat es ▁conserve d ▁development al ▁chr omat in ▁remodel ing ▁events .
▁We ▁used ▁quantitat ive ▁prote o mics ▁to ▁identify ▁chr omat in - as soci ated ▁protein s ▁extract ed ▁via ▁detergent ▁and ▁to ▁quanti fy ▁changes ▁in ▁their ▁abunda nce ▁during ▁disease .
▁Our ▁study ▁identified ▁ 321 ▁protein s ▁in ▁this ▁sub prote ome , ▁demonstrat ing ▁it ▁to ▁have ▁modest ▁conserva tion ▁(3 7% ) ▁with ▁that ▁reveal ed ▁using ▁strong ▁acid .
▁Of ▁these ▁protein s , ▁176 ▁exhibi ted ▁alter ed ▁expression ▁during ▁cardiac ▁hyper trop hy ▁and ▁failure ; ▁we ▁conduct ed ▁ex tensi ve ▁functional ▁character ization ▁of ▁one ▁of ▁these ▁protein s , ▁Nu cle olin .
▁Mor pho lino - based ▁knock down ▁of ▁nucleo lin ▁nearly ▁a boli shed ▁protein ▁expression ▁but ▁surprising ly ▁had ▁little ▁impact ▁on ▁gross ▁ morph ological ▁development .
▁However , ▁heart s ▁of ▁fish ▁la cking ▁Nu cle olin ▁display ed ▁severe ▁development al ▁im pair ment , ▁ab normal ▁cha mber ▁pattern ing ▁and ▁functional ▁deficit s , ▁os tensi bly ▁due ▁to ▁defect s ▁in ▁cardiac ▁loop ing ▁and ▁my o cy te ▁differenti ation .
▁The ▁mechanism s ▁under ly ing ▁these ▁defect s ▁involve ▁per tur bed ▁bone ▁mor pho gene tic ▁protein ▁4 ▁expression , ▁decrease d ▁r RNA ▁tran scription , ▁and ▁a ▁shift ▁to ▁more ▁hetero ch ro matic ▁chr omat in .
▁This ▁study ▁reports ▁the ▁quantitat ive ▁analysis ▁of ▁a ▁new ▁chr omat in ▁sub prote ome ▁in ▁the ▁normal ▁and ▁disease d ▁mouse ▁heart .
▁Vali da tion ▁studies ▁in ▁the ▁complementar y ▁model ▁system ▁of ▁zebra fish ▁examine ▁the ▁role ▁of ▁Nu cle olin ▁to ▁orchestr ate ▁genom ic ▁re programm ing ▁events ▁shared ▁between ▁development ▁and ▁disease .
▁Risk ▁factors ▁and ▁outcome s ▁associated ▁with ▁the ▁development ▁of ▁my o card ial ▁ ische mic ▁events ▁in ▁patients ▁who ▁receive ▁cardiac ▁re syn chron ization ▁ therapy .
▁There ▁are ▁limited ▁data ▁regarding ▁risk ▁factors ▁for ▁the ▁development ▁of ▁ ische mic ▁events ▁( IE s ) ▁among ▁patients ▁with ▁ ische mic ▁cardio my o pathy ▁( IC ) ▁who ▁receive ▁cardiac ▁re syn chron ization ▁ therapy ▁with ▁a ▁de fi br illa tor ▁( C RT - D ) ▁and ▁their ▁effect ▁on ▁the ▁ef fica cy ▁of ▁the ▁device .
▁The ▁present ▁study ▁population ▁compris ed ▁1,0 45 ▁patients ▁with ▁IC ▁en roll ed ▁in ▁the ▁Multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁Tri al - Card iac ▁Re syn chron ization ▁Therapy .
▁We ▁used ▁multi varia te ▁Co x ▁proportion al ▁hazard s ▁re gression ▁model ing ▁to ▁identify ▁risk ▁factors ▁for ▁the ▁development ▁of ▁IE ▁( com pris ing ▁hospital ization ▁for ▁a cute ▁corona ry ▁syndrome s ▁and / or ▁corona ry ▁intervention s ▁during ▁the ▁trial ) ▁among ▁study ▁patients .
▁Time - dependent ▁analysis ▁was ▁perform ed ▁to ▁identify ▁the ▁effect ▁of ▁IE ▁on ▁the ▁risk ▁for ▁subsequent ▁heart ▁failure ▁( HF ) ▁or ▁death ▁in ▁C RT - D ▁recipient s .
▁Independent ▁predict ors ▁for ▁the ▁development ▁of ▁IE ▁among ▁study ▁patients ▁included ▁previous ▁re vas cular ization ▁( co ron ary ▁arter y ▁by pass ▁surgery : ▁hazard ▁ratio ▁[ HR ] ▁1. 88 , ▁p ▁= ▁0.0 03 ; ▁per cuta ne ous ▁corona ry ▁intervention : ▁HR ▁3. 21 , ▁p ▁< 0.00 1) ▁and ▁increased ▁sy sto lic ▁blood ▁pressure ▁( HR ▁1. 67 , ▁p ▁= ▁0.0 2) , ▁where as ▁a ▁left ▁bund le ▁bran ch ▁block ▁pattern ▁on ▁the ▁base line ▁electro card i ogram ▁was ▁associated ▁with ▁reduce d ▁risk ▁for ▁IE ▁( HR ▁0 . 62 , ▁p ▁= ▁0.0 2) .
▁Treatment ▁with ▁C RT - D ▁did ▁not ▁have ▁a ▁significant ▁effect ▁on ▁IE ▁risk ▁compared ▁with ▁de fi br illa tor - on ly ▁ therapy ▁( HR ▁0 . 87 , ▁p ▁= ▁0.5 1) .
▁Time - dependent ▁analysis ▁showed ▁that ▁the ▁development ▁of ▁IE s ▁among ▁C RT - D ▁recipient s ▁was ▁associated ▁with ▁more ▁than ▁two fold ▁( p ▁= ▁ 0.01 ) ▁increased ▁risk ▁for ▁subsequent ▁heart ▁failure ▁or ▁death .
▁In ▁conclusion , ▁our ▁data ▁suggest ▁that ▁treatment ▁with ▁C RT - D ▁does ▁not ▁reduce ▁the ▁risk ▁of ▁IE ▁in ▁patients ▁with ▁IC ▁and ▁that ▁the ▁benefit ▁of ▁C RT - D ▁is ▁att en u ated ▁after ▁the ▁development ▁of ▁IE s ▁in ▁this ▁population .
▁Age - dependent ▁effect ▁of ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁on ▁long - term ▁mortal ity ▁in ▁patients ▁with ▁heart ▁failure ▁( from ▁the ▁Heart ▁Fail ure ▁Survey ▁in ▁IS ra el ).
▁Con tempor ary ▁heart ▁failure ▁( HF ) ▁ therapie s ▁have ▁not ▁result ed ▁in ▁improve d ▁outcome s ▁among ▁patients ▁with ▁ HF ▁and ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁( LV EF ).
▁We ▁so ught ▁to ▁evaluat e ▁the ▁differenti al ▁effect ▁of ▁LV EF ▁on ▁long - term ▁mortal ity ▁after ▁hospital ization ▁for ▁a cute ▁de com pensa ted ▁ HF ▁in ▁a ▁real - world ▁setting .
▁All - ca use ▁mortal ity ▁at ▁4 ▁years ▁after ▁hospital ization ▁for ▁ HF ▁was ▁assess ed ▁by ▁LV EF ▁( cate gor ized ▁as ▁pres er ved ▁[ ≥ 50% ] , ▁mild ly ▁[ 40% ▁to ▁4 9% ] , ▁moderat ely ▁[ 30% ▁to ▁3 9% ] , ▁and ▁severe ly ▁[ < 30% ] ▁reduce d ) ▁among ▁1,6 20 ▁patients ▁en roll ed ▁in ▁the ▁Heart ▁Fail ure ▁Survey ▁in ▁IS ra el .
▁Am ong ▁the ▁study ▁patients , ▁30% ▁had ▁pres er ved ▁LV EF ▁and ▁20% , ▁25% , ▁and ▁25% , ▁had ▁mild , ▁moderat e , ▁and ▁severe ▁reduc tions ▁in ▁LV EF , ▁respective ly .
▁Multi varia te ▁analysis ▁showed ▁that ▁patients ▁with ▁pres er ved ▁LV EF ▁had ▁a ▁similar ▁risk ▁of ▁long - term ▁mortal ity ▁as ▁patients ▁with ▁mild ▁or ▁moderat e ▁re duction ▁in ▁LV EF ▁( haz ard ▁ratio ▁[ HR ] ▁0 . 92 ▁[ p ▁= ▁0 . 40 ] ▁and ▁1. 01 ▁[ p ▁= ▁0 . 90 ] , ▁respective ly ) ▁while ▁severe ly ▁reduce d ▁LV EF ▁con fer red ▁increased ▁increase ▁rate ▁compared ▁with ▁pres er ved ▁LV EF ▁( HR ▁1. 20 , ▁p ▁= ▁0.0 4) .
▁Inter action ▁term ▁analysis ▁showed ▁that ▁the ▁risk ▁associated ▁with ▁severe ly ▁reduce d ▁LV EF ▁was ▁evident ▁only ▁among ▁patients ▁ ≤ 75 ▁years ▁( HR ▁1. 49 , ▁p ▁= ▁0.0 03) , ▁where as ▁among ▁older ▁patients , ▁there ▁was ▁no ▁difference ▁in ▁the ▁risk ▁of ▁long - term ▁mortal ity ▁between ▁those ▁with ▁pres er ved ▁versus ▁severe ly ▁reduce d ▁LV EF ▁( HR ▁1. 02 ▁[ p ▁= ▁0 . 86 ] ; ▁p ▁value ▁for ▁age - by - LV EF ▁interaction ▁= ▁0.0 3) .
▁In ▁conclusion , ▁patients ▁hospital ized ▁for ▁ HF ▁who ▁have ▁pres er ved ▁LV EF ▁experience ▁similar ▁long - term ▁mortal ity ▁as ▁patients ▁with ▁mild ▁or ▁moderat e ▁reduc tions ▁in ▁LV EF , ▁where as ▁severe ly ▁reduce d ▁LV EF ▁remain s ▁an ▁independent ▁predict or ▁of ▁long - term ▁mortal ity ▁in ▁this ▁population .
▁The ▁differenti al ▁effect ▁of ▁LV EF ▁on ▁long - term ▁mortal ity ▁is ▁significantly ▁att en u ated ▁in ▁the ▁older ▁age ▁group .
▁Change s ▁in ▁circula ting ▁pro gen itor ▁cell s ▁are ▁associated ▁with ▁outcome ▁in ▁heart ▁failure ▁patients : ▁a ▁longitud in al ▁study .
▁BA CK GRO UND : ▁Circula ting ▁pro gen itor ▁cell s ▁( C PC s ) ▁are ▁involved ▁in ▁the ▁process ▁of ▁en dot heli al ▁repair ▁and ▁are ▁a ▁prognos tic ▁factor ▁in ▁cardiovascular ▁disease s .
▁We ▁evaluat ed ▁the ▁association ▁between ▁serial ▁measure ments ▁of ▁C PC s ▁and ▁functional ▁capacity ▁and ▁outcome s ▁in ▁heart ▁failure ▁( HF ).
▁ MET HOD S : ▁We ▁included ▁156 ▁consecutiv e ▁consenti ng ▁ambula tory ▁ HF ▁patients ▁( le ft ▁vent ri cular ▁e je ction ▁ fraction ▁< ▁40% ).
▁We ▁evaluat ed ▁C PC s ▁and ▁functional ▁capacity ▁( pe ak ▁VO 2) ▁every ▁6 ▁months ▁for ▁up ▁to ▁2 ▁years .
▁C PC s ▁were ▁measure d ▁as ▁early - out g row th ▁colon y - form ing ▁unit s ▁( EO - C FU s ) ▁and ▁circula ting ▁CD 34 + , ▁V EG FR 2 + ▁and / or ▁CD 133 + ▁cell s .
▁We ▁record ed ▁mortal ity , ▁ HF ▁hospital ▁ad missions , ▁transplant , ▁and ▁vent ri cular ▁assist ▁device .
▁RESULT S : ▁The ▁mean ▁age ▁was ▁55 ▁ ± ▁15 ▁years .
▁A ▁decrease ▁in ▁CD 34 + VE G FR 2 + ▁cell s ▁was ▁independent ly ▁associated ▁with ▁increased ▁functional ▁capacity ; ▁a ▁10- cell ▁decrease ▁in ▁CD 34 + VE G FR 2 + ▁cell s ▁was ▁associated ▁with ▁an ▁increase ▁of ▁0.2 ▁m L / kg / min ▁in ▁pe ak ▁VO 2 ▁( P ▁< ▁0.0 5) .
▁We ▁found ▁an ▁interaction ▁effect ▁( P ▁= ▁0.0 2) ▁between ▁ EO - C FU s ▁and ▁diabetes : ▁in ▁patients ▁without ▁diabetes , ▁a ▁10- EO - C FU ▁increase ▁was ▁independent ly ▁associated ▁with ▁increased ▁pe ak ▁VO 2 ▁of ▁0.2 8 ▁m L / kg / min ▁( P ▁= ▁ 0.01 ), ▁and ▁in ▁patients ▁with ▁diabetes , ▁a ▁decrease ▁in ▁ EO - C FU s ▁was ▁associated ▁with ▁an ▁increased ▁pe ak ▁VO 2 ▁( P ▁< ▁0.0 5) .
▁High er ▁ EO - C FU s ▁were ▁associated ▁with ▁reduce d ▁mortal ity ▁( haz ard ▁ratio , ▁0.2 5 ; ▁95% ▁confidence ▁interval , ▁0.0 9 -0 . 69) .
▁CON CL USI ONS : ▁We ▁not ed ▁differenti al ▁relations ▁between ▁C PC s ▁and ▁outcome s ▁in ▁patients ▁with ▁vs ▁without ▁diabetes .
▁High er ▁ EO - C FU s ▁and ▁lower ▁CD 34 + VE G FR 2 + ▁cell s ▁were ▁associated ▁with ▁improve d ▁functional ▁capacity ▁and ▁reduce d ▁mortal ity ▁in ▁non dia be tic ▁patients .
▁In ▁patients ▁with ▁diabetes , ▁lower ▁ EO - C FU s ▁were ▁associated ▁with ▁improve d ▁functional ▁capacity .
▁The ▁basis ▁for ▁these ▁difference s ▁requires ▁further ▁examina tion .
▁Im plication s ▁of ▁ metric ▁choice ▁for ▁common ▁applications ▁of ▁read mission ▁metri cs .
▁OB JE C TIVE : ▁To ▁quanti fy ▁the ▁differenti al ▁impact ▁on ▁hospital ▁performance ▁of ▁three ▁read mission ▁metri cs : ▁all - ca use ▁read mission ▁( A CR ), ▁3 M ▁Potential ▁Prev en table ▁Read mission ▁( P PR ), ▁and ▁Center s ▁for ▁Medica re ▁and ▁Medica id ▁30- day ▁read mission ▁( C MS ).
▁D ATA ▁S OUR CES : ▁2000 -2009 ▁California ▁Office ▁of ▁State wide ▁Health ▁Plan ning ▁and ▁Development ▁Patient ▁Dis charge ▁Data ▁Non public ▁file .
▁ STU DY ▁DESIGN : ▁We ▁calcula ted ▁30- day ▁read mission ▁rates ▁using ▁three ▁metri cs , ▁for ▁three ▁disease ▁groups : ▁heart ▁failure ▁( HF ), ▁a cute ▁my o card ial ▁in far ction ▁( AMI ), ▁and ▁pneu monia .
▁U sing ▁each ▁ metric , ▁we ▁calcula ted ▁the ▁absolute ▁change ▁and ▁corre lation ▁between ▁performance ; ▁the ▁percent ▁of ▁hospital s ▁remain ing ▁in ▁extreme ▁deci les ▁and ▁level ▁of ▁agreement ; ▁and ▁difference s ▁in ▁longitud in al ▁performance .
▁PRI N CI PAL ▁FIN DING S : ▁Ave rage ▁hospital ▁rates ▁for ▁ HF ▁patients ▁and ▁the ▁CMS ▁ metric ▁were ▁generally ▁higher ▁than ▁for ▁other ▁conditions ▁and ▁metri cs .
▁Corre lation s ▁between ▁the ▁A CR ▁and ▁CMS ▁metri cs ▁were ▁highest ▁( r ▁= ▁0 . 67 - 0.8 4) .
▁Rate s ▁calcula ted ▁using ▁the ▁P PR ▁and ▁either ▁A CR ▁or ▁CMS ▁metri cs ▁were ▁moderat ely ▁cor related ▁( r ▁= ▁0 . 50 -0 . 67) .
▁Bet we en ▁47 ▁and ▁75 ▁percent ▁of ▁hospital s ▁in ▁an ▁extreme ▁de cile ▁according ▁to ▁one ▁ metric ▁remain ed ▁when ▁using ▁a ▁different ▁ metric .
▁Corre lation s ▁among ▁metri cs ▁were ▁modest ▁when ▁me as uring ▁hospital ▁longitud in al ▁change .
▁CON CL USI ONS : ▁Different ▁approach es ▁to ▁computing ▁read missions ▁can ▁produce ▁different ▁hospital ▁ranking s ▁and ▁impact ▁pay - for - per form ance .
▁Care ful ▁consideration ▁should ▁be ▁placed ▁on ▁read mission ▁ metric ▁choice ▁for ▁these ▁applications .
▁Remote ▁monitoring ▁after ▁recent ▁hospital ▁dis charge ▁in ▁patients ▁with ▁heart ▁failure : ▁a ▁systematic ▁review ▁and ▁network ▁meta - analys is .
▁CON TEX T : ▁Read mission ▁to ▁hospital ▁for ▁heart ▁failure ▁is ▁common ▁after ▁recent ▁dis charge .
▁Remote ▁monitoring ▁( RM ) ▁strategie s ▁have ▁the ▁potential ▁to ▁deliver ▁speciali sed ▁care ▁and ▁management ▁and ▁may ▁be ▁one ▁way ▁to ▁meet ▁the ▁growing ▁needs ▁of ▁the ▁heart ▁failure ▁population .
▁OB JE C TIVE : ▁To ▁determine ▁whether ▁RM ▁strategie s ▁improve ▁outcome s ▁for ▁adults ▁who ▁have ▁been ▁recently ▁dis charge d ▁( < 28 ▁days ) ▁following ▁an ▁un plan ned ▁ad mission ▁due ▁to ▁heart ▁failure .
▁ STU DY ▁DESIGN : ▁System a tic ▁review ▁and ▁network ▁meta - analys is .
▁D ATA ▁S OUR CES : ▁Four teen ▁electronic ▁database s ▁( including ▁MED LINE , ▁ EMBA SE ▁and ▁Psy c INFO ) ▁were ▁search ed ▁to ▁January ▁2012, ▁and ▁supplement ed ▁by ▁hand - search ing ▁relevant ▁articles .
▁ STU DY ▁SE LEC TION : ▁All ▁random ised - control led ▁trial s ▁( RC T s ) ▁or ▁observation al ▁co hor t ▁studies ▁with ▁a ▁contemporane ous ▁control ▁group ▁were ▁included .
▁RM ▁intervention s ▁included ▁home ▁tele monitor ing ▁( TM ) ▁( including ▁implant ed ▁monitoring ▁devices ) ▁with ▁medical ▁support ▁provided ▁during ▁office ▁hours ▁or ▁24/7 ▁and ▁structure d ▁telephone ▁support ▁( ST S ) ▁programme s ▁deliver ed ▁via ▁human - to - human ▁contact ▁( HH ) ▁or ▁human - to - machine ▁interface ▁( HM ).
▁D ATA ▁EXTRA C TION : ▁Data ▁were ▁extract ed ▁and ▁valid ity ▁was ▁assess ed ▁independent ly ▁by ▁two ▁review ers .
▁RESULT S : ▁T went y - one ▁R CT s ▁that ▁en roll ed ▁63 17 ▁patients ▁were ▁identified ▁(11 ▁studies ▁evaluat ed ▁S TS ▁(10 ▁of ▁which ▁were ▁ HH , ▁while ▁1 ▁was ▁ HM ), ▁9 ▁studies ▁assess ed ▁TM , ▁and ▁1 ▁study ▁assess ed ▁both ▁S TS ▁and ▁TM ).
▁No ▁trial ▁of ▁implant ed ▁monitoring ▁devices ▁met ▁the ▁inclusi on ▁criteri a .
▁Compar ed ▁with ▁usual ▁care , ▁although ▁not ▁reach ing ▁stati tis tical ▁significa nce , ▁RM ▁trend ed ▁to ▁reduce ▁all - ca use ▁mortal ity ▁for ▁S TS ▁ HH ▁( HR : ▁0 . 77 , ▁95% ▁cred ible ▁interval ▁( C r I ): ▁0.5 5 , ▁1. 08) , ▁TM ▁during ▁office ▁hours ▁( HR : ▁0 . 76 , ▁95% ▁Cr I : ▁0 . 49 , ▁1. 18) ▁and ▁TM 24 /7 ▁( HR : ▁0 . 49 , ▁95% ▁Cr I : ▁0 . 20 , ▁1. 18) .
▁Ex clusi on ▁of ▁one ▁trial ▁that ▁provided ▁better - than - u sual ▁support ▁to ▁the ▁control ▁group ▁rendere d ▁each ▁of ▁the ▁above ▁comparison s ▁statistic ally ▁significant .
▁No ▁beneficia l ▁effect ▁on ▁mortal ity ▁was ▁observe d ▁with ▁S TS ▁ HM .
▁Re duction s ▁were ▁also ▁observe d ▁in ▁all - ca use ▁hospital isation s ▁for ▁TM ▁intervention s ▁but ▁not ▁for ▁S TS ▁intervention s .
▁Care ▁package s ▁generally ▁improve d ▁health - related ▁quality - of - life ▁and ▁were ▁acceptable ▁to ▁patients .
▁CON CL USI ONS : ▁S TS ▁ HH ▁and ▁TM ▁with ▁medical ▁support ▁provided ▁during ▁office ▁hours ▁showed ▁beneficia l ▁trend s , ▁particularly ▁in ▁ reducing ▁all - ca use ▁mortal ity ▁for ▁recently ▁dis charge d ▁patients ▁with ▁heart ▁failure .
▁Where ▁' u sual ' ▁care ▁is ▁less ▁good , ▁the ▁impact ▁of ▁RM ▁is ▁likely ▁to ▁be ▁greater .
▁Investiga tion ▁of ▁apo pto sis ▁in ▁a ▁can ine ▁model ▁of ▁chronic ▁heart ▁failure ▁induc ed ▁by ▁ta chy car dia .
▁Participa tion ▁of ▁apo pto sis ▁during ▁the ▁development ▁of ▁pa cing - indu ced ▁dil ated ▁cardio my o pathy ▁is ▁not ▁fully ▁understood .
▁After ▁7 ▁weeks ▁rapid ▁right ▁vent ri cular ▁pa cing , ▁gene ▁expression s ▁of ▁Bax , ▁B cl -2 ▁and ▁Cas pas e -3 ▁were ▁measure d ▁by ▁RT Q - PC R ▁from ▁interven tri cular ▁sept um ▁bio psi es ▁that ▁were ▁taken ▁week ly ▁in ▁21 ▁beag le ▁dog s ▁during ▁the ▁development ▁of ▁heart ▁failure .
▁We ▁evaluat ed ▁protein ▁levels ▁of ▁these ▁gene s ▁by ▁Western ▁blot ▁and ▁DNA ▁fragment ation ▁by ▁TU NEL ▁method ▁from ▁auto psy ▁sample s .
▁Gene ▁expression ▁of ▁Bax ▁remain ed ▁un change d ▁during ▁the ▁pa cing ▁period ; ▁B cl -2 ▁m RNA ▁expression ▁trans ient ly ▁decrease d ▁in ▁moderat e ▁heart ▁failure ▁and ▁their ▁ratio ▁( B cl - 2/ Ba x ) ▁was ▁not ▁significantly ▁alter ed .
▁Cas pas e -3 ▁gene ▁expression ▁increased ▁in ▁heart ▁failure .
▁Compar ed ▁to ▁the ▁control ▁group , ▁expression ▁of ▁Bax ▁and ▁B cl -2 ▁protein s ▁and ▁their ▁ratio ▁were ▁increased ▁in ▁dog s ▁only ▁after ▁4 ▁weeks ▁of ▁pa cing .
▁No ▁band ▁of ▁activa ted ▁Cas pas e ▁was ▁found ▁in ▁the ▁normal ▁nor ▁in ▁the ▁pace d ▁my o car dium .
▁In ▁the ▁TU NEL ▁as say ▁there ▁was ▁no ▁significant ▁difference ▁between ▁numbers ▁of ▁apo pto tic ▁cell s ▁in ▁any ▁of ▁the ▁groups , ▁although ▁a ▁few ▁TU NEL - posi tive ▁cell s ▁were ▁detect ed ▁in ▁the ▁pace d ▁groups .
▁Our ▁results ▁are ▁not ▁in ▁f avour ▁of ▁apo pto sis ▁in ▁the ▁path ogen es is ▁of ▁heart ▁failure ▁in ▁this ▁model ▁and ▁may ▁be ▁it ▁could ▁be ▁attribut ed ▁to ▁activa tion ▁of ▁other ▁systems .
▁Up tit ration ▁of ▁re nin - angi oten sin ▁system ▁block er ▁and ▁beta - block er ▁ therapy ▁in ▁patients ▁hospital ized ▁for ▁heart ▁failure ▁with ▁reduce d ▁versus ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction s .
▁In ▁ambula tory ▁patients ▁with ▁heart ▁failure ▁( HF ) ▁and ▁reduce d ▁e je ction ▁ fraction ▁( r EF ), ▁re nin - angi oten sin ▁system ▁( RAS ) ▁and ▁β - block ers ▁at ▁guide line - re com mend ed ▁target ▁dose ▁reduce ▁all - ca use ▁mortal ity ▁and ▁read missions .
▁Bene fit s ▁in ▁ HF ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( p EF ), ▁as ▁well ▁as ▁up tit ration ▁after ▁a ▁hospital ization , ▁remain ▁un certa in .
▁This ▁study ▁assess es ▁the ▁impact ▁of ▁ RAS - ▁and ▁β - block er ▁up ti tra tions ▁in ▁patients ▁with ▁H Fr EF ▁versus ▁ HF p EF ▁during ▁and ▁immediately ▁after ▁a ▁hospital ▁ad mission .
▁In ▁consecutiv e ▁patients ▁(20 9 ▁H Fr EF ▁with ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁< 40% ▁and ▁108 ▁ HF p EF ▁with ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁ ≥ 40% ), ▁ RAS - ▁and ▁β - block er ▁dose ▁changes ▁were ▁followed ▁during ▁6 ▁months ▁after ▁an ▁index ▁ HF ▁hospital ization .
▁Patient s ▁with ▁a ▁ RAS - ▁and ▁β - block er ▁dose ▁increase ▁of ▁ ≥ 10% ▁of ▁the ▁recommended ▁target ▁dose ▁were ▁compared ▁with ▁patients ▁without ▁up tit ration .
▁Patient s ▁who ▁received ▁up tit ration ▁were ▁significantly ▁young er , ▁with ▁a ▁higher ▁heart ▁rate ▁and ▁better ▁renal ▁function , ▁and ▁received ▁spi rono lac tone ▁more ▁often .
▁Both ▁ RAS - ▁and ▁β - block er ▁up ti tra tions ▁were ▁associated ▁with ▁significant ▁reduc tions ▁in ▁the ▁com posit e ▁end - point ▁of ▁all - ca use ▁mortal ity ▁or ▁ HF ▁read missions ▁in ▁H Fr EF ▁( haz ard ▁ratio ▁[ HR ] ▁0.3 6 , ▁95% ▁confidence ▁interval ▁[ CI ] ▁0.2 2 ▁to ▁0 . 60 ▁and ▁HR ▁0.5 1 , ▁95% ▁CI ▁0.3 2 ▁to ▁0 . 81 , ▁respective ly ).
▁After ▁correct ion ▁for ▁age , ▁heart ▁rate , ▁blood ▁pressure , ▁renal ▁function , ▁and ▁spi rono lac tone ▁use , ▁this ▁association ▁remain ed ▁significant ▁for ▁ RAS ▁block ers ▁( HR ▁0.5 4 , ▁95% ▁CI ▁0.3 1 ▁to ▁0 . 93 , ▁p ▁= ▁0.0 27) ▁but ▁not ▁for ▁β - block ers ▁( HR ▁0 . 65 , ▁95% ▁CI ▁0.3 9 ▁to ▁1. 09 , ▁p ▁= ▁0.1 01) .
▁No ▁benefit ▁of ▁ RAS - ▁or ▁β - block er ▁up tit ration ▁was ▁observe d ▁in ▁ HF p EF .
▁In ▁conclusion , ▁up tit ration ▁of ▁neuro hu moral ▁block ers ▁after ▁an ▁ HF ▁hospital ization ▁is ▁more ▁frequently ▁perform ed ▁in ▁young er ▁patients ▁with ▁low ▁co - mor bid ity ▁burde n .
▁ RAS - block er ▁up tit ration ▁independent ly ▁predict s ▁clinic al ▁outcome ▁in ▁patients ▁with ▁H Fr EF ▁but ▁not ▁in ▁those ▁with ▁ HF p EF .
▁Relation ship ▁between ▁sex , ▁e je ction ▁ fraction , ▁and ▁B - type ▁na tri ure tic ▁pe pti de ▁levels ▁in ▁patients ▁hospital ized ▁with ▁heart ▁failure ▁and ▁associations ▁with ▁in hospital ▁outcome s : ▁finding s ▁from ▁the ▁Get ▁With ▁The ▁Guide line - He art ▁Fail ure ▁Registr y .
▁BA CK GRO UND : ▁In ▁heart ▁failure ▁( HF ), ▁there ▁are ▁known ▁difference s ▁in ▁plasma ▁B - type ▁na tri ure tic ▁pe pti de ▁( B NP ) ▁levels ▁between ▁reduce d ▁and ▁pres er ved ▁e je ction ▁ fraction ▁( EF ), ▁but ▁few ▁ HF ▁studies ▁have ▁explore d ▁sex ▁difference s .
▁We ▁so ught ▁to ▁evaluat e ▁the ▁relationship ▁between ▁sex , ▁EF , ▁and ▁B NP ▁in ▁ HF ▁patients ▁and ▁determine ▁prognos tic ▁significa nce ▁of ▁B NP ▁as ▁it ▁relat es ▁to ▁sex ▁and ▁EF .
▁ MET HOD S : ▁We ▁included ▁hospital s ▁in ▁Get ▁With ▁The ▁Guide lines - He art ▁Fail ure ▁that ▁admit ted ▁9 9,9 30 ▁ HF ▁patients ▁with ▁reduce d ▁( EF ▁< 40% ), ▁border line ▁( EF ▁40% -4 9% ), ▁or ▁pres er ved ▁( EF ▁ ≥ 50% ) ▁EF .
▁The ▁primary ▁end ▁point ▁was ▁in hospital ▁mortal ity .
▁Multi varia te ▁models ▁were ▁used ▁to ▁comp ute ▁odds ▁ratio s ▁while ▁account ing ▁for ▁hospital ▁cluster ing .
▁RESULT S : ▁There ▁were ▁47 , 02 5 ▁patients ▁with ▁reduce d ▁(3 7% ▁female ), ▁13, 950 ▁with ▁border line ▁(4 8% ▁female ), ▁and ▁38 , 955 ▁with ▁pres er ved ▁(6 5% ▁female ) ▁EF .
▁Women ▁compared ▁with ▁men ▁had ▁higher ▁ad mission ▁media n ▁B NP ▁levels ▁with ▁the ▁greatest ▁difference ▁among ▁reduce d ▁EF ▁and ▁small est ▁difference ▁among ▁pres er ved ▁EF ▁( media n ▁B NP ▁in ▁women ▁vs ▁men : ▁EF ▁reduce d ▁1,2 59 ▁vs ▁1,1 13 ▁p g / m L , ▁border line ▁8 21 ▁vs ▁7 32 ▁p g / m L , ▁and ▁pres er ved ▁ 559 ▁vs ▁540 ▁p g / m L ; ▁P ▁< ▁ . 001 ▁all ▁comparison s ).
▁E je ction ▁ fraction ▁and ▁sex ▁were ▁independent ly ▁associated ▁with ▁B NP .
▁In hospital ▁mortal ity ▁was ▁2. 7% , ▁and ▁patients ▁above ▁the ▁media n ▁B NP ▁level ▁had ▁higher ▁mortal ity ▁than ▁those ▁below .
▁After ▁adjust ing ▁for ▁over ▁20 ▁clinic al ▁variable s , ▁the ▁ability ▁of ▁B NP ▁to ▁predict ▁in hospital ▁mortal ity ▁was ▁similar ▁among ▁all ▁sub group s ▁( P ▁for ▁hetero gene ity ▁= ▁ . 47) .
▁CON CL USI ONS : ▁In ▁a ▁large ▁registr y , ▁we ▁found ▁that ▁de spite ▁sex / EF ▁difference s ▁in ▁B NP ▁values , ▁there ▁was ▁no ▁significant ▁difference ▁in ▁the ▁ability ▁of ▁B NP ▁to ▁predict ▁in hospital ▁mortal ity ▁among ▁these ▁sub group s .
▁Presenta tion , ▁ diagnos is , ▁and ▁medical ▁management ▁of ▁heart ▁failure ▁in ▁children : ▁Canadian ▁Card io vas cular ▁Society ▁guidelines .
▁Pediatri c ▁heart ▁failure ▁( HF ) ▁is ▁an ▁important ▁cause ▁of ▁morbi d ity ▁and ▁mortal ity ▁in ▁child hood .
▁This ▁article ▁present s ▁guidelines ▁for ▁the ▁recognition , ▁ diagnos is , ▁and ▁early ▁medical ▁management ▁of ▁ HF ▁in ▁in fan cy , ▁child hood , ▁and ▁adolesce nce .
▁The ▁guidelines ▁are ▁intended ▁to ▁assist ▁prac ti tioner s ▁in ▁office - based ▁or ▁emergency ▁room ▁practice , ▁who ▁encounter ▁children ▁with ▁un diagnos ed ▁heart ▁disease ▁and ▁symptoms ▁of ▁possible ▁ HF , ▁rather ▁than ▁those ▁who ▁have ▁already ▁received ▁sur g ical ▁palli ation .
▁The ▁guidelines ▁have ▁been ▁developed ▁using ▁the ▁Grad ing ▁of ▁Re com mend ations ▁Assessment , ▁Development ▁and ▁Evalua tion ▁( GRAD E ) ▁method ology , ▁and ▁are ▁ac com pani ed ▁by ▁practical ▁Re com mend ations ▁for ▁their ▁application ▁in ▁the ▁clinic al ▁setting , ▁supplement ed ▁by ▁online ▁material .
▁This ▁work ▁does ▁not ▁include ▁Re com mend ations ▁for ▁advanced ▁management ▁in vol ving ▁vent ri cular ▁assist ▁devices , ▁or ▁other ▁device ▁ therapie s .
▁Heart ▁failure ▁and ▁cognitive ▁im pair ment : ▁relationships ▁with ▁mortal ity .
▁We ▁read ▁the ▁article ▁by ▁Do d son ▁et ▁al ▁with ▁interest .
▁The ▁author s ▁evaluat ed ▁how ▁often ▁the ▁nurse ▁assessment ▁of ▁cognitive ▁im pair ment ▁at ▁hospital ization ▁was ▁document ed ▁by ▁the ▁physician ▁at ▁the ▁time ▁of ▁dis charge ▁in ▁a ▁co hor t ▁of ▁el der ly ▁patients ▁hospital ized ▁for ▁heart ▁failure .
▁Sub se quen t ly , ▁the ▁author s ▁anal y zed ▁the ▁association ▁of ▁cognitive ▁im pair ment ▁with ▁6- mont h ▁mortal ity ▁or ▁read mission .
▁Rate s ▁of ▁ED ▁visit s ▁and ▁of ▁in tuba tions ▁for ▁con ges tive ▁heart ▁failure ▁decline d ▁from ▁1996 ▁to ▁2008.
▁OB JE C TIVE : ▁Many ▁advance s ▁have ▁been ▁made ▁recently ▁in ▁the ▁treatment ▁of ▁con ges tive ▁heart ▁failure ▁( CH F ).
▁We ▁hypothe size ▁that ▁this ▁should ▁have ▁result ed ▁in ▁few er ▁CHF ▁patients ▁present ing ▁to ▁the ▁emergency ▁department ▁( ED ) ▁and ▁few er ▁being ▁in tuba ted .
▁DESIGN : ▁Retro spec tive ▁co hor t .
▁SET TING : ▁consecutiv e ▁patients ▁seen ▁by ▁ED ▁physician s ▁in ▁4 ▁subur ban ▁hospital s ▁in ▁New ▁Jersey ▁and ▁New ▁York ▁from ▁1996 ▁to ▁2008.
▁OB JE C TIVE : ▁PRO TO CO L : ▁We ▁class ified ▁patients ▁as ▁having ▁CHF ▁based ▁on ▁International ▁Classifica tion ▁of ▁Disease s , ▁Nin th ▁Re vision , ▁code s .
▁For ▁each ▁year ▁of ▁the ▁study , ▁we ▁determine d ▁CHF ▁visit ▁rates ▁( as ▁a ▁percentage ▁of ▁total ▁ED ▁visit s ) ▁and ▁calcula ted ▁the ▁percentage ▁of ▁CHF ▁patients ▁in tuba ted .
▁We ▁used ▁the ▁Student ▁t ▁test , ▁calcula ted ▁95% ▁confidence ▁interval s ▁( CI s ), ▁and ▁perform ed ▁re gression ▁analyse s .
▁RESULT S : ▁Of ▁the ▁2 , 374 , 428 ▁ED ▁visit s , ▁3 2,0 36 ▁( 1.3 %) ▁were ▁for ▁CHF .
▁The ▁mean ▁age ▁of ▁the ▁CHF ▁patients ▁was ▁76 ▁ ± ▁14 ▁years , ▁and ▁5 7% ▁were ▁female .
▁Con ges tive ▁heart ▁failure ▁visit s ▁decline d ▁from ▁1. 6% ▁of ▁all ▁ED ▁visit s ▁in ▁1996 ▁to ▁1. 2% ▁in ▁2008, ▁a ▁2 6% ▁relative ▁decrease ▁( 95% ▁CI : ▁21% - 30% , ▁P ▁< ▁ . 001 , ▁corre lation ▁co e ffi cient ▁R (2) ▁= ▁0 . 94 , ▁P ▁< ▁ . 001 ).
▁Of ▁the ▁CHF ▁patients , ▁ 778 ▁( 2.4 %) ▁were ▁in tuba ted .
▁In tub ation ▁rates ▁decline d ▁from ▁3. 6% ▁in ▁1996 ▁to ▁1. 7% ▁in ▁2008, ▁a ▁5 3% ▁( 95% ▁CI : ▁3 1% -6 8% , ▁P ▁< ▁ . 001 , ▁R (2) ▁= ▁0 . 83 , ▁P ▁< ▁ . 001 ) ▁relative ▁decrease .
▁CON C LU SION : ▁The ▁rates ▁of ▁annual ▁ED ▁visit s ▁for ▁CHF ▁and ▁in tub ation ▁rates ▁decline d ▁from ▁1996 ▁to ▁2008.
▁These ▁decrease s ▁are ▁most ▁likely ▁due ▁to ▁better ▁CHF ▁treatment s .
▁Hem o dynamic ▁ph eno type ▁of ▁the ▁fail ing ▁Font an ▁in ▁an ▁adult ▁population .
▁Font an ▁failure ▁can ▁occur ▁even ▁with ▁normal ▁sy sto lic ▁vent ri cular ▁function ▁and ▁often ▁in ▁the ▁context ▁of ▁significant ▁ liver ▁disease .
▁We ▁hypothe s ized ▁that ▁Font an ▁failure ▁is ▁hem o dynamic ally ▁distinct ▁from ▁traditional ▁heart ▁failure ▁and ▁character ized ▁by ▁low ▁system ic ▁vas cular ▁resist ance ▁( S VR ) ▁index ▁and ▁pres er ved ▁cardiac ▁index .
▁T went y - s even ▁symptom a tic ▁adult ▁Font an ▁( SAF ) ▁patients ▁who ▁under went ▁cat heter ization ▁from ▁2001 ▁to ▁2011 ▁constitu ted ▁our ▁study ▁group .
▁Fi ft y - four ▁predomina nt ly ▁as ym pto matic ▁pediatr ic ▁Font an ▁( PF ) ▁patients ▁who ▁under went ▁cat heter ization ▁during ▁the ▁same ▁period ▁were ▁random ly ▁selected ▁to ▁perform ▁a ▁control : case ▁co hor t ▁analysis .
▁Clinic al ▁comparison s ▁were ▁made ▁between ▁the ▁2 ▁groups .
▁The ▁adults ▁were ▁more ▁symptom a tic ▁than ▁the ▁ PF ▁co hor t ▁( New ▁York ▁Heart ▁Association ▁classes ▁I ▁and ▁II ▁or ▁III ▁and ▁IV : ▁4 8% ▁or ▁5 2% ▁[ SAF ] ▁vs ▁9 4% ▁or ▁6% ▁[ PF ] , ▁respective ly , ▁p ▁< 0.01 ).
▁ SAF ▁versus ▁ PF ▁mean ▁cat heter ization ▁finding s ▁were ▁central ▁ve nous ▁pressure ▁18 ▁ ± ▁6 ▁versus ▁14 ▁ ± ▁3 ▁mm ▁H g ▁( p ▁< 0.01 ), ▁S VR ▁index ▁1,6 80 ▁ ± ▁ 368 ▁versus ▁1,9 60 ▁ ± ▁550 ▁dyn ▁s / cm (5) / m (2) ▁( p ▁= ▁0.0 2) , ▁and ▁cardiac ▁index ▁2. 7 ▁ ± ▁ 0.8 ▁versus ▁ 2.8 ▁ ± ▁ 0.7 ▁L / min / m (2) ▁( p ▁= ▁0 . 25) .
▁By ▁imagin g , ▁the ▁ SAF ▁co hor t ▁demonstrat ed ▁a ▁greater ▁incide nce ▁of ▁ab normal ▁ liver ▁texture ▁changes ▁(9 6% ▁vs ▁75% , ▁p ▁= ▁0.0 4) ▁and ▁no du lar ity ▁(7 7% ▁vs ▁4 2% , ▁p ▁= ▁0.0 2) .
▁In ▁conclusion , ▁adult ▁patients ▁with ▁fail ing ▁Font an ▁circulation ▁had ▁a ▁lower ▁S VR ▁index ▁and ▁similar ▁cardiac ▁index ▁compared ▁with ▁the ▁pediatr ic ▁co hor t .
▁Live r ▁disease ▁in ▁the ▁adults ▁was ▁more ▁advanced .
▁Our ▁data ▁suggest ▁that ▁Font an ▁failure ▁is ▁a ▁distinct ▁circula tory ▁de rang ement ▁with ▁hem o dynamic ▁features ▁similar ▁to ▁portal ▁hyper tension , ▁al be it ▁with ▁limited ▁ability ▁to ▁aug ment ▁cardiac ▁output .
▁Compar ison ▁of ▁predict ors ▁of ▁heart ▁failure - related ▁hospital ization ▁or ▁death ▁in ▁patients ▁with ▁versus ▁without ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction .
▁Heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ) ▁is ▁recognize d ▁as ▁a ▁major ▁cause ▁of ▁cardiovascular ▁morbi d ity ▁and ▁mortal ity .
▁An ▁ability ▁to ▁identify ▁patients ▁with ▁ HF p EF ▁who ▁are ▁at ▁increased ▁risk ▁for ▁advers e ▁outcome s ▁can ▁facilita te ▁their ▁more ▁care ful ▁management .
▁We ▁studie d ▁the ▁patients ▁having ▁heart ▁failure ▁( HF ) ▁using ▁data ▁from ▁the ▁Heart ▁Fail ure ▁Ad her ence ▁and ▁Re tention ▁Tri al ▁( HAR T ).
▁H ART ▁en roll ed ▁90 2 ▁patients ▁in ▁the ▁New ▁York ▁Heart ▁Association ▁( NY HA ) ▁class ▁II ▁or ▁III ▁who ▁had ▁been ▁recently ▁hospital ized ▁for ▁ HF ▁to ▁study ▁the ▁impact ▁of ▁self - management ▁counsel ing ▁on ▁the ▁primary ▁outcome ▁of ▁death ▁or ▁ HF ▁hospital ization .
▁In ▁H ART , ▁208 ▁patients ▁had ▁ HF p EF ▁and ▁69 2 ▁had ▁ HF ▁with ▁reduce d ▁e je ction ▁ fraction ▁( HF r EF ) ▁and ▁were ▁followed ▁for ▁a ▁media n ▁of ▁1,0 80 ▁days .
▁Two ▁final ▁multi varia te ▁models ▁were ▁developed .
▁In ▁patients ▁having ▁ HF p EF , ▁predict ors ▁of ▁primary ▁outcome ▁were ▁male ▁gender ▁( odd s ▁ratio ▁[ OR ] ▁3. 45 , ▁p ▁= ▁0.0 04) , ▁NY HA ▁class ▁III ▁( OR ▁3. 05 , ▁p ▁= ▁0.0 08) , ▁distance ▁covered ▁on ▁a ▁6- minut e ▁walk ▁test ▁(6 - MW T ) ▁of ▁< 6 20 ▁feet ▁( OR ▁2. 81 , ▁p ▁= ▁0.0 13) , ▁and ▁< 80% ▁ad her ence ▁to ▁pre scribe d ▁medication s ▁( OR ▁2. 61 , ▁p ▁= ▁0.0 18) .
▁In ▁patients ▁having ▁H Fr EF , ▁the ▁predict ors ▁were ▁being ▁on ▁di ure tics ▁( OR ▁3. 06 , ▁p ▁= ▁0.0 01) , ▁having ▁ ≥ 3 ▁co - mor bid ities ▁( OR ▁2. 11 , ▁p ▁= ▁ 0.00 01) , ▁distance ▁covered ▁on ▁a ▁6- MW T ▁of ▁< 6 20 ▁feet ▁( OR ▁1. 94 , ▁p ▁= ▁0.0 01) , ▁NY HA ▁class ▁III ▁( OR ▁1. 90 , ▁p ▁= ▁0.0 01) , ▁and ▁age ▁> 65 ▁years ▁( OR ▁1. 63 , ▁p ▁= ▁ 0.01 ).
▁In ▁conclusion , ▁indicator s ▁of ▁functional ▁status ▁(6 - MW T ▁and ▁NY HA ▁class ) ▁were ▁common ▁to ▁both ▁patients ▁with ▁ HF p EF ▁and ▁those ▁with ▁H Fr EF , ▁where as ▁gender ▁and ▁ad her ence ▁to ▁pre scribe d ▁ therapy ▁were ▁unique ▁to ▁patients ▁having ▁ HF p EF ▁in ▁predict ing ▁death ▁or ▁ HF ▁hospital ization .
▁Exerci se ▁training ▁in ▁patients ▁with ▁chronic ▁heart ▁failure ▁promote s ▁resto ration ▁of ▁high - dens ity ▁lipo prote in ▁functional ▁properties .
▁R ATION ALE : ▁High - dens ity ▁lipo prote in ▁( HD L ) ▁ex ert s ▁en dot heli al - protec tive ▁effects ▁via ▁stimul ation ▁of ▁en dot heli al ▁cell ▁( EC ) ▁ni tric ▁oxid e ▁( NO ) ▁production .
▁This ▁function ▁is ▁im pair ed ▁in ▁patients ▁with ▁cardiovascular ▁disease .
▁ Protect ive ▁effects ▁of ▁exercise ▁training ▁( ET ) ▁on ▁en dot heli al ▁function ▁have ▁been ▁demonstrat ed .
▁OB JE C TIVE : ▁This ▁study ▁was ▁perform ed ▁to ▁evaluat e ▁the ▁impact ▁of ▁ET ▁on ▁HD L - media ted ▁protect ive ▁effects ▁and ▁the ▁respective ▁molecular ▁path ways ▁in ▁patients ▁with ▁chronic ▁heart ▁failure ▁( CH F ).
▁ MET HOD S ▁AND ▁RESULT S : ▁HD L ▁was ▁isola ted ▁from ▁16 ▁healthy ▁control s ▁( HD L ( health y ) ) ▁and ▁16 ▁patients ▁with ▁CHF - NY HA - III ▁( HD L ( NY HA - III b ) ) ▁before ▁and ▁after ▁ET , ▁as ▁well ▁as ▁from ▁8 ▁patients ▁with ▁CHF - NY HA - II ▁( HD L ( NY HA - II ) ).
▁EC s ▁were ▁in cuba ted ▁with ▁HD L , ▁and ▁ phos phor y lation ▁of ▁e NOS - Ser (1 177 ), ▁e NOS - Th r ( 495 ), ▁PK C - β II - Ser ( 660 ), ▁and ▁p 70 S 6 K - Ser (4 11) ▁was ▁evaluat ed .
▁HD L - bound ▁malo ndi alde hy de ▁and ▁HD L - indu ced ▁NO ▁production ▁by ▁EC ▁were ▁quant ified .
▁En dot heli al ▁function ▁was ▁assess ed ▁by ▁flow - media ted ▁di la tation .
▁The ▁prote ome ▁of ▁HD L ▁parti cles ▁was ▁profil ed ▁by ▁shot gun ▁ LC - MS / MS .
▁In cuba tion ▁of ▁EC ▁with ▁HD L ( NY HA - III b ) ▁trigger ed ▁a ▁lower ▁stimul ation ▁of ▁ phos phor y lation ▁at ▁e NOS - Ser (1 177 ) ▁and ▁a ▁higher ▁ phos phor y lation ▁at ▁e NOS - Th r (4 95) ▁when ▁compared ▁with ▁HD L ( health y ).
▁This ▁was ▁associated ▁with ▁lower ▁NO ▁production ▁of ▁EC .
▁In ▁addition , ▁an ▁eleva ted ▁activa tion ▁of ▁p 70 S 6 K , ▁PK C - β II ▁by ▁HD L ( NY HA - III b ), ▁and ▁a ▁higher ▁amount ▁of ▁malo ndi alde hy de ▁ bound ▁to ▁HD L ( NY HA - III b ) ▁compared ▁with ▁HD L ( health y ) ▁was ▁measure d .
▁In ▁healthy ▁individuals , ▁ET ▁had ▁no ▁effect ▁on ▁HD L ▁function , ▁where as ▁ET ▁of ▁CHF - NY HA - III b ▁significantly ▁improve d ▁HD L ▁function .
▁A ▁corre lation ▁between ▁changes ▁in ▁HD L - indu ced ▁NO ▁production ▁and ▁flow - media ted ▁di la tation ▁improvement ▁by ▁ET ▁was ▁evident .
▁CON CL USI ONS : ▁These ▁results ▁demonstrat e ▁that ▁HD L ▁function ▁is ▁im pair ed ▁in ▁CHF ▁and ▁that ▁ET ▁improve d ▁the ▁HD L - media ted ▁vas cular ▁effects .
▁This ▁may ▁be ▁one ▁mechanism ▁how ▁ET ▁ex ert s ▁beneficia l ▁effects ▁in ▁CHF .
▁Determina tion ▁of ▁a ▁predict ive ▁cut off ▁value ▁of ▁NT - pro B NP ▁testing ▁for ▁long - term ▁survival ▁in ▁ED ▁patients ▁with ▁a cute ▁heart ▁failure .
▁OB JE C TIVE : ▁The ▁main ▁objective ▁of ▁this ▁study ▁was ▁to ▁determine ▁a ▁predict ive ▁cut off ▁value ▁for ▁plasma ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁( NT - pro B NP ) ▁that ▁could ▁successful ly ▁predict ▁the ▁long - term ▁(4 - year ) ▁survival ▁of ▁patients ▁with ▁a cute ▁heart ▁failure ▁( HF ) ▁at ▁the ▁time ▁of ▁ad mission ▁to ▁the ▁emergency ▁department ▁( ED ).
▁To ▁our ▁best ▁knowledge , ▁our ▁study ▁is ▁the ▁first ▁research ▁done ▁to ▁identify ▁a ▁predict ive ▁cut off ▁value ▁for ▁ad mission ▁NT - pro B NP ▁to ▁the ▁pre script ive ▁4- year ▁survival ▁of ▁patients ▁admit ted ▁to ▁ED ▁with ▁a cute ▁ HF ▁ diagnos is .
▁ MET HOD S : ▁NT - pro B NP ▁levels ▁were ▁measure d ▁in ▁plasma ▁obtain ed ▁from ▁99 ▁patients ▁with ▁dys pne a ▁and ▁left ▁vent ri cular ▁dys function ▁upon ▁ad mission ▁to ▁the ▁ED .
▁The ▁end ▁point ▁was ▁survival ▁from ▁the ▁time ▁of ▁inclusi on ▁through ▁4 ▁years .
▁RESULT S : ▁The ▁mean ▁age ▁of ▁the ▁patients ▁in ▁this ▁study ▁was ▁7 1.1 ▁ ± ▁10. 3 ▁years ; ▁50 ▁of ▁these ▁patients ▁were ▁female .
▁During ▁the ▁4- year ▁follow - up ▁period , ▁76 ▁patients ▁die d ; ▁sur viv ors ▁were ▁significantly ▁young er ▁than ▁non - sur viv ors ▁( 64 . 26 ▁ ± ▁11. 42 ▁years ▁vs ▁72 . 83 ▁ ± ▁11. 07 ▁years , ▁P ▁= ▁ . 002 ).
▁The ▁optimal ▁NT - pro B NP ▁cut off ▁point ▁for ▁predict ing ▁4- year ▁survival ▁at ▁the ▁time ▁of ▁ad mission ▁was ▁2 300 ▁p g / m L , ▁which ▁had ▁85 . 9% ▁ sensitiv ity ▁and ▁39 . 1% ▁specific ity ▁( 95% ▁confidence ▁interval , ▁area ▁under ▁the ▁cur ve : ▁0 . 639 , ▁P ▁= ▁ . 044 ).
▁CON C LU SION : ▁Elev ated ▁NT - pro B NP ▁levels ▁at ▁the ▁time ▁of ▁ad mission ▁are ▁a ▁strong ▁and ▁independent ▁predict or ▁of ▁all - ca use ▁mortal ity ▁in ▁patients ▁with ▁a cute ▁ HF ▁4 ▁years ▁after ▁ad mission .
▁Fur ther more , ▁the ▁optimal ▁cut off ▁level ▁of ▁NT - pro B NP ▁used ▁to ▁predict ▁4- year ▁survival ▁had ▁high ▁ sensitiv ity .
▁However , ▁especially ▁in ▁the ▁case ▁of ▁long - term ▁survival , ▁additional ▁prospect ive , ▁large , ▁and ▁multi center ▁studies ▁are ▁required ▁to ▁confirm ▁our ▁results .
▁A ▁novel ▁heart ▁failure ▁mi ce ▁model ▁of ▁hyper tensi ve ▁heart ▁disease ▁by ▁ang io ten sin ▁II ▁in fusion , ▁nep hr ecto my , ▁and ▁salt ▁load ing .
▁Although ▁the ▁mouse ▁heart ▁failure ▁( HF ) ▁model ▁of ▁hyper tensi ve ▁heart ▁disease ▁( H HD ) ▁is ▁useful ▁to ▁investiga te ▁the ▁pat ho phy si ology ▁and ▁new ▁ therapeut ic ▁target s ▁for ▁H HD , ▁the ▁model ▁using ▁simple ▁experimental ▁procedure s ▁and ▁stable ▁ph eno type s ▁has ▁not ▁been ▁established .
▁This ▁study ▁ai med ▁to ▁develop ▁a ▁novel ▁mouse ▁ HF ▁model ▁of ▁H HD ▁by ▁com bi ning ▁salt ▁load ing ▁and ▁un ine ph r ecto my ▁with ▁ANG ▁II ▁in fusion .
▁E ight - week - old ▁C 57 BL /6 ▁male ▁mi ce ▁were ▁treated ▁with ▁ANG ▁II ▁in fusion ▁( AT ), ▁ANG ▁II ▁in fusion ▁and ▁un ine ph r ecto my ▁( AN ), ▁ANG ▁II ▁in fusion ▁and ▁salt ▁load ing ▁( AS ), ▁or ▁ANG ▁II ▁in fusion , ▁un ine ph r ecto my , ▁and ▁salt ▁load ing ▁( ANS ).
▁Sy sto lic ▁blood ▁pressure ▁was ▁significantly ▁eleva ted ▁and ▁left ▁vent ri cular ▁( LV ) ▁hyper trop hy ▁was ▁found ▁in ▁AT , ▁AN , ▁AS , ▁and ▁ ANS ▁mi ce , ▁and ▁there ▁were ▁no ▁significant ▁difference s ▁in ▁those ▁parameter s ▁between ▁the ▁four ▁groups .
▁At ▁6 ▁w k ▁after ▁the ▁procedure s , ▁only ▁ ANS ▁mi ce ▁showed ▁significant ▁decrease s ▁in ▁LV ▁ fraction al ▁short en ing ▁and ▁increase s ▁in ▁lung ▁weight ▁with ▁a ▁high ▁incide nce .
▁This ▁ph eno type ▁was ▁reproduc ible , ▁and ▁there ▁were ▁few ▁per i operativ e ▁or ▁early ▁death s ▁in ▁the ▁experimental ▁procedure s .
▁Sever e ▁LV ▁fibro sis ▁was ▁found ▁in ▁ ANS ▁mi ce .
▁O xi da tive ▁stress ▁was ▁enhance d ▁and ▁small ▁GT Pas e ▁Rac 1 ▁activity ▁was ▁up regula ted ▁in ▁the ▁heart s ▁of ▁ ANS ▁mi ce .
▁After ▁the ▁addition ▁of ▁salt ▁load ing ▁and ▁un ine ph r ecto my ▁to ▁the ▁ANG ▁II ▁in fusion ▁mouse ▁model , ▁cardiac ▁function ▁was ▁significantly ▁im pair ed , ▁and ▁mi ce ▁developed ▁ HF .
▁This ▁might ▁be ▁a ▁novel ▁and ▁useful ▁mouse ▁ HF ▁model ▁to ▁study ▁the ▁transition ▁from ▁compensa ted ▁LV ▁hyper trop hy ▁to ▁ HF ▁in ▁H HD .
▁Tro ponin ▁T ▁and ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de : ▁a ▁bio mark er ▁approach ▁to ▁predict ▁heart ▁failure ▁risk - - the ▁at hero sc ler osis ▁risk ▁in ▁communities ▁study .
▁BA CK GRO UND : ▁Am ong ▁the ▁various ▁cardiovascular ▁disease s , ▁heart ▁failure ▁( HF ) ▁is ▁projecte d ▁to ▁have ▁the ▁largest ▁increase s ▁in ▁incide nce ▁over ▁the ▁coming ▁de cade s ; ▁therefore , ▁improving ▁ HF ▁predict ion ▁is ▁of ▁significant ▁value .
▁We ▁evaluat ed ▁whether ▁cardiac ▁trop onin ▁T ▁( c T n T ) ▁measure d ▁with ▁a ▁high - sensitiv ity ▁as say ▁and ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁( NT - pro B NP ), ▁bio mark ers ▁strong ly ▁associated ▁with ▁incident ▁ HF , ▁improve ▁ HF ▁risk ▁predict ion ▁in ▁the ▁Ath eros cle rosi s ▁Risk ▁in ▁Communi ties ▁( ARI C ) ▁study .
▁ MET HOD S : ▁U sing ▁sex - specific ▁models , ▁we ▁added ▁c T n T ▁and ▁NT - pro B NP ▁to ▁age ▁and ▁race ▁(" labora tory ▁report " ▁model ) ▁and ▁to ▁the ▁A RIC ▁ HF ▁model ▁( include s ▁age , ▁race , ▁sy sto lic ▁blood ▁pressure , ▁anti hy per tensi ve ▁medication ▁use , ▁current / former ▁smoking , ▁diabetes , ▁body ▁mass ▁index , ▁pre valent ▁corona ry ▁heart ▁disease , ▁and ▁heart ▁rate ) ▁in ▁9 868 ▁participants ▁without ▁pre valent ▁ HF ; ▁area ▁under ▁the ▁receive r ▁operating ▁character istic ▁cur ve ▁( AU C ), ▁integrat ed ▁discrimina tion ▁improvement , ▁net ▁re class ification ▁improvement ▁( N RI ), ▁and ▁model ▁fit ▁were ▁described .
▁RESULT S : ▁Over ▁a ▁mean ▁follow - up ▁of ▁10. 4 ▁years , ▁ 970 ▁participants ▁developed ▁incident ▁ HF .
▁A dding ▁c T n T ▁and ▁NT - pro B NP ▁to ▁the ▁A RIC ▁ HF ▁model ▁significantly ▁improve d ▁all ▁statistic al ▁parameter s ▁( AU C s ▁increased ▁by ▁0.0 40 ▁and ▁0.0 57 ; ▁the ▁continuo us ▁NR Is ▁were ▁50 . 7% ▁and ▁54 . 7% ▁in ▁women ▁and ▁men , ▁respective ly ).
▁Interes ting ly , ▁the ▁simple r ▁laborator y ▁report ▁model ▁was ▁statistic ally ▁no ▁different ▁than ▁the ▁A RIC ▁ HF ▁model .
▁CON CL USI ONS : ▁c T n T ▁and ▁NT - pro B NP ▁have ▁significant ▁value ▁in ▁ HF ▁risk ▁predict ion .
▁A ▁simple ▁sex - specific ▁model ▁that ▁includes ▁age , ▁race , ▁c T n T , ▁and ▁NT - pro B NP ▁( which ▁can ▁be ▁incorpora ted ▁in ▁a ▁laborator y ▁report ) ▁provides ▁a ▁good ▁model , ▁where as ▁adding ▁c T n T ▁and ▁NT - pro B NP ▁to ▁clinic al ▁character istic s ▁results ▁in ▁an ▁excellent ▁ HF ▁predict ion ▁model .
▁Sur vi val ▁after ▁left ▁vent ri cular ▁assist ▁device ▁with ▁and ▁without ▁temporar y ▁right ▁vent ri cular ▁support .
▁BA CK GRO UND : ▁Right ▁vent ri cular ▁( RV ) ▁failure ▁after ▁the ▁ insertion ▁of ▁a ▁left ▁vent ri cular ▁assist ▁device ▁( L VAD ) ▁historical ly ▁results ▁in ▁poor ▁outcome s .
▁Patient s ▁requiri ng ▁temporar y ▁ RV ▁support ▁after ▁L VAD ▁ insertion ▁are ▁a ▁hetero gene ous ▁group ▁of ▁patients ▁consist ing ▁of ▁those ▁in ▁cardio ge nic ▁shock ▁after ▁my o card ial ▁in far ction , ▁to ▁those ▁with ▁chronic ▁de com pensa ted ▁heart ▁failure .
▁For ▁patients ▁requiri ng ▁bi ven tri cular ▁support , ▁we ▁have ▁used ▁a ▁hybrid ▁system ▁consist ing ▁of ▁a ▁Heart Mate ▁II ▁L VAD ▁and ▁Centri Mag ▁right ▁vent ri cular ▁assist ▁device ▁( R VAD ).
▁The ▁purpose ▁of ▁this ▁study ▁was ▁to ▁determine ▁the ▁1- year ▁survival ▁in ▁patients ▁requiri ng ▁isola ted ▁L VAD ▁and ▁patients ▁requiri ng ▁bi ven tri cular ▁support .
▁ MET HOD S : ▁All ▁patients ▁who ▁under went ▁Heart Mate ▁II ▁L VAD ▁alone ▁or ▁in ▁con jun ction ▁with ▁a ▁temporar y ▁Centri Mag ▁R VAD ▁were ▁examine d ▁from ▁2006 ▁to ▁2011.
▁Pre operativ e ▁demo graphic s , ▁operativ e ▁outcome s , ▁and ▁survival ▁were ▁anal y zed .
▁RESULT S : ▁A ▁total ▁of ▁139 ▁patients ▁required ▁Heart Mate ▁II ▁ insertion ; ▁34 ▁(24 %) ▁required ▁bi ven tri cular ▁support ▁at ▁the ▁time ▁of ▁Heart Mate ▁II ▁implant ation .
▁The ▁mean ▁du ration ▁of ▁bi ven tri cular ▁support ▁was ▁17 ▁ ± ▁11. 9 ▁days ▁( range , ▁6 ▁to ▁56 ▁days ) ▁with ▁91 . 8% ▁( n ▁= ▁31 ) ▁of ▁R VAD s ▁successful ly ▁ex plant ed .
▁Sur vi val ▁to ▁hospital ▁dis charge ▁was ▁not ▁different ▁between ▁groups ▁(9 5.2 ▁versus ▁88 . 2% ; ▁p ▁= ▁0.2 ).
▁However , ▁1- year ▁survival ▁was ▁significantly ▁greater ▁in ▁patients ▁who ▁required ▁isola ted ▁Heart Mate ▁II ▁L VAD ▁(8 7% ▁versus ▁7 7% ; ▁p ▁= ▁0.0 3) .
▁CON CL USI ONS : ▁Bi ven tri cular ▁support ▁using ▁a ▁Heart Mate ▁II ▁L VAD ▁and ▁Centri Mag ▁R VAD ▁result ed ▁in ▁limited ▁mortal ity ▁at ▁hospital ▁dis charge .
▁However ▁bi ven tri cular ▁dys function ▁does ▁not ▁have ▁a ▁favorable ▁outcome ▁at ▁1 ▁year ▁when ▁compared ▁with ▁patients ▁requiri ng ▁isola ted ▁Heart Mate ▁II .
▁Should ▁e ligi bility ▁for ▁heart ▁transplant ation ▁be ▁a ▁require ment ▁for ▁left ▁vent ri cular ▁assist ▁device ▁use ?
▁Re com mend ations ▁based ▁on ▁a ▁systematic ▁review .
▁Le ft ▁vent ri cular ▁assist ▁devices ▁( L VAD s ) ▁are ▁used ▁in ▁chronic ▁end - s tage ▁heart ▁failure ▁as ▁" bridge ▁to ▁transplant ation " ▁( B TT ) ▁and , ▁more ▁recently , ▁for ▁transplant - ine ligi ble ▁patients ▁as ▁" de stin ation ▁ therapy " ▁( DT ).
▁We ▁review ed ▁the ▁evidence ▁on ▁clinic al ▁effects ▁and ▁cost - effect ive ness ▁of ▁2 ▁types ▁of ▁continuo us - flow ▁L VAD s ▁( He art Mate ▁II ▁[ HM ▁II ] ▁and ▁Heart War e ), ▁for ▁B TT ▁and ▁ DT ▁patients .
▁We ▁systematic ally ▁search ed ▁the ▁scientific ▁literature ▁( Jan uar y ▁2008 - Jun e ▁2012) ▁and ▁identified ▁14 ▁clinic al ▁studies ▁( ap prox ima tely ▁2 900 ▁ HM ▁II ▁and ▁approximately ▁200 ▁Heart War e ▁patients ), ▁and ▁3 ▁economic ▁evaluation s ▁( HM ▁II ) ▁using ▁simula tion ▁models .
▁Data ▁were , ▁however , ▁limited ▁to ▁2-3 ▁studies ▁per ▁outcome .
▁We ▁made ▁policy ▁recommendations ▁on ▁the ▁basis ▁of ▁our ▁systematic ▁review .
▁Although ▁complica tions ▁after ▁implant ation ▁are ▁frequent , ▁L VAD ▁ therapy ▁is ▁often ▁highly ▁effective ▁across ▁transplant ation ▁e ligi bility ▁status ▁and ▁device , ▁with ▁1- year ▁survival ▁reach ing ▁8 6% ▁for ▁B TT ▁and ▁7 8% ▁for ▁ DT ▁( com par ed ▁with ▁25% ▁for ▁medical ▁ therapy ).
▁Nei ther ▁B TT ▁nor ▁ DT ▁currently ▁meet ▁traditional ▁cost - effect ive ness ▁limit s ▁in ▁models ▁using ▁historical ▁data , ▁although ▁B TT ▁is ▁standard ▁practice ▁for ▁a ▁limited ▁number ▁of ▁patients ▁in ▁many ▁region s .
▁We ▁found ▁that ▁B TT ▁and ▁ DT ▁as ▁implant ation ▁strategie s ▁tend ▁to ▁be ▁no ▁longer ▁mutual ly ▁exclusive .
▁We ▁conclude ▁that ▁evidence ▁is ▁ sufficient ▁to ▁support ▁L VAD ▁use , ▁regardless ▁of ▁transplant ation ▁e ligi bility ▁status , ▁as ▁long ▁as ▁patients ▁are ▁carefully ▁selected ▁and ▁program ▁infrastructure ▁and ▁budget ▁are ▁adequat e .
▁However , ▁evidence ▁gap s , ▁limitation s ▁in ▁economic ▁models , ▁and ▁the ▁lack ▁of ▁Canadian ▁data ▁point ▁to ▁the ▁importance ▁of ▁mandato ry , ▁systematic ▁monitoring ▁of ▁L VAD ▁use ▁and ▁outcome s .
▁Effect s ▁of ▁bi ven tri cular ▁pa cing ▁on ▁left ▁heart ▁twist ▁and ▁strain ▁in ▁a ▁por cine ▁model ▁of ▁right ▁heart ▁failure .
▁BA CK GRO UND : ▁Bi ven tri cular ▁pa cing ▁( Bi VP ) ▁improve s ▁cardiac ▁output ▁( CO ) ▁in ▁selected ▁cardiac ▁surgery ▁patients , ▁but ▁response ▁remain s ▁variable , ▁necessitat ing ▁a ▁better ▁understanding ▁of ▁the ▁mechanism .
▁According ly , ▁we ▁used ▁spec kle ▁track ing ▁e cho card i ography ▁( STE ) ▁to ▁anal y ze ▁Bi VP ▁during ▁a cute ▁right ▁vent ri cular ▁pressure ▁over load ▁( RV PO ).
▁MAT ERIA LS ▁AND ▁ MET HOD S : ▁In ▁ni ne ▁pig s , ▁the ▁inferior ▁ve na ▁ca va ▁( IV C ) ▁was ▁snar ed ▁to ▁decrease ▁CO ▁and ▁establish ▁a ▁control ▁model .
▁Heart ▁block ▁was ▁induc ed , ▁the ▁pulmonar y ▁arter y ▁snar ed , ▁and ▁Bi VP ▁initiat ed .
▁E cho card i ogram s ▁of ▁the ▁left ▁vent ri cular ▁mid pap illa ry ▁level ▁were ▁taken ▁at ▁var ying ▁at rio ven tri cular ▁de lay ▁( AV D ) ▁and ▁interven tri cular ▁de lay ▁( VV D ) ▁for ▁ STE ▁analysis ▁of ▁regional ▁circum fer ential ▁strain ▁( CS ) ▁and ▁radi al ▁strain ▁( RS ).
▁E cho card i ogram s ▁were ▁taken ▁of ▁the ▁left ▁vent ri cular ▁base , ▁mid pap illa ry , ▁and ▁ap ex ▁during ▁base line , ▁IV C ▁oc clusi on , ▁and ▁each ▁Bi VP ▁setting ▁for ▁ STE ▁analysis ▁of ▁twist , ▁ap ical ▁and ▁bas al ▁rota tions , ▁CS , ▁RS , ▁and ▁synchron y .
▁Indi ces ▁were ▁cor related ▁against ▁CO ▁with ▁mix ed ▁linear ▁models .
▁RESULT S : ▁During ▁IV C ▁oc clusi on , ▁CO ▁cor related ▁with ▁twist , ▁ap ical ▁ro tation , ▁RS , ▁RS ▁synchron y , ▁and ▁CS ▁( P ▁< ▁0.0 5) .
▁During ▁ RV PO ▁with ▁Bi VP , ▁CO ▁only ▁cor related ▁with ▁RS ▁synchron y ▁and ▁CS ▁( P ▁< ▁0.0 5) .
▁During ▁AV D ▁and ▁VVD ▁variation s , ▁CO ▁was ▁associated ▁with ▁free ▁wall ▁RS ▁( P ▁< ▁0.0 08) .
▁CO ▁cor related ▁with ▁sept al ▁wall ▁CS ▁during ▁AV D ▁variation ▁and ▁free ▁wall ▁CS ▁during ▁VVD ▁variation ▁( P ▁< ▁0.0 08) .
▁CON CL USI ONS : ▁In ▁an ▁open ▁che st ▁model , ▁twist , ▁RS , ▁RS ▁synchron y , ▁and ▁CS ▁anal y zed ▁by ▁ STE ▁may ▁be ▁non in va sive ▁sur roga tes ▁for ▁changes ▁in ▁CO . ▁During ▁ RV PO , ▁changes ▁in ▁RS ▁synchron y ▁and ▁CS ▁with ▁var ying ▁regional ▁strain ▁contribution s ▁may ▁be ▁the ▁primary ▁mechanism ▁in ▁which ▁Bi VP ▁improve s ▁CO .
▁La ck ▁of ▁corre lation ▁of ▁remain ing ▁indice s ▁may ▁reflect ▁posts y sto lic ▁function .
▁Mit ral ▁sten osis ▁rever sed ▁by ▁medical ▁treatment ▁for ▁heart ▁failure .
▁It ▁is ▁reported ▁that ▁functional ▁mit ral ▁sten osis ▁frequently ▁develop s ▁after ▁ring ▁ann ulo plast y ▁for ▁ ische mic ▁mit ral ▁re gur gi tation .
▁The ▁mechanism ▁is ▁a ▁combination ▁of ▁ann ular ▁size ▁re duction ▁by ▁surgery ▁and ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing , ▁restrict ing ▁the ▁anterior ▁le a flet ▁opening ▁due ▁to ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁with ▁left ▁vent ri cular ▁di la tation .
▁We ▁report ▁the ▁case ▁of ▁a ▁57 - year - old ▁man ▁who ▁had ▁a ▁history ▁of ▁successful ▁mit ral ▁val ve ▁plast y ▁for ▁de genera tive ▁mit ral ▁re gur gi tation .
▁Four ▁years ▁later ▁he ▁developed ▁heart ▁failure , ▁severe ▁hyper tension , ▁mild ▁mit ral ▁re gur gi tation , ▁and ▁significant ▁mit ral ▁sten osis , ▁which ▁were ▁rever sed ▁by ▁aggressiv e ▁medical ▁treatment ▁for ▁heart ▁failure .
▁Fun ction al ▁mit ral ▁sten osis ▁( MS ) ▁frequently ▁develop s ▁after ▁ring ▁ann ulo plast y ▁for ▁ ische mic ▁mit ral ▁re gur gi tation ▁( MR ).
▁The ▁mechanism ▁is ▁a ▁combination ▁of ▁ann ular ▁size ▁re duction ▁by ▁surgery ▁and ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing , ▁restrict ing ▁the ▁anterior ▁le a flet ▁opening ▁due ▁to ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁with ▁left ▁vent ri cular ▁( LV ) ▁di la tation .
▁Fun ction al ▁MS ▁has ▁not ▁been ▁reported ▁in ▁patients ▁with ▁de genera tive ▁MR .
▁However , ▁functional ▁MS ▁could ▁develop ▁even ▁in ▁patients ▁with ▁a ▁history ▁of ▁successful ▁val ve ▁plast y ▁and ▁ann ular ▁size ▁re duction ▁for ▁de genera tive ▁MR ▁if ▁the ▁LV ▁were ▁dil ated ▁by ▁another ▁disease .
▁In ▁addition , ▁because ▁functional ▁MS ▁is ▁dynamic ▁and ▁proportion al ▁to ▁LV ▁di la tation , ▁treatment ▁for ▁heart ▁failure ▁( HF ), ▁ac ting ▁to ▁reduce ▁the ▁LV ▁size , ▁can ▁potential ly ▁improve ▁such ▁functional ▁MS . ▁A ▁52 - year - old ▁man ▁had ▁ HF ▁with ▁severe ▁MR ▁due ▁to ▁pro lapse ▁of ▁a ▁de genera tive ▁mit ral ▁val ve ▁in ▁2008.
▁He ▁had ▁grade ▁4 /6 ▁holo sy sto lic ▁mur mur ▁and ▁a ▁third ▁heart ▁sound ▁in ▁the ▁ap ex .
▁His ▁blood ▁pressure ▁was ▁120 / 70 ▁mm ▁H g , ▁he ▁under went ▁mit ral ▁val ve ▁plast y ▁for ▁de genera tive ▁MR , ▁he ▁had ▁P 3 ▁pro lapse ▁with ▁2 ▁chor dal ▁rup tures ▁and ▁he ▁under went ▁tri ang ular ▁res ection , ▁edge - to - ed ge ▁an asto mos is , ▁and ▁ring ▁ann ulo plast y ▁with ▁a ▁Ph y sio ▁Ring ▁30 ▁( Ed ward s ▁Life science s , ▁Ir vine , ▁CA ) ▁of ▁just ▁size .
▁After ▁the ▁surgery , ▁ HF ▁disappear ed ▁and ▁post operativ e ▁e cho card i ography ▁confirm ed ▁a ▁normal ▁size d ▁LV ▁with ▁an ▁end - dia sto lic ▁volume ▁index ▁of ▁71 ▁m L / m 2 , ▁normal ▁LV ▁e je ction ▁ fraction ▁of ▁0 . 70 , ▁no ▁MR ▁and ▁pres er ved ▁mit ral ▁val ve ▁opening ▁with ▁a ▁mit ral ▁val ve ▁area ▁( M VA ) ▁of ▁1.8 ▁cm 2 , ▁and ▁a ▁mean ▁pressure ▁gradi ent ▁of ▁4.4 ▁mm ▁H g ▁( F ig ▁1 A ).
▁The ▁M VA ▁was ▁obtain ed ▁by ▁a ▁continu ity ▁e qu ation ▁( LV ▁end - dia sto lic ▁volume ▁- ▁LV ▁end - sy sto lic ▁volume ▁= ▁mit ral ▁fill ing ▁flow ▁volume ▁= ▁M VA ▁× ▁veloci ty ▁time ▁integral ▁of ▁mit ral ▁fill ing ▁flow ▁by ▁continuo us ▁wa ve ▁Do pp ler ▁e cho card i ography ), ▁which ▁can ▁be ▁utilize d ▁even ▁in ▁the ▁presence ▁of ▁MR . ▁His ▁mit ral ▁val ve ▁plast y ▁was ▁successful ly ▁perform ed ▁without ▁major ▁concern s .
▁He ▁developed ▁ HF ▁again ▁4 ▁years ▁later .
▁This ▁time , ▁he ▁had ▁severe ▁hyper tension ▁of ▁19 1/10 4 ▁mm ▁H g , ▁diabetes ▁mell itus , ▁and ▁grade ▁2 ▁to ▁3 /6 ▁sy sto lic ▁as ▁well ▁as ▁dia sto lic ▁mur mur s ▁were ▁audi ble ▁at ▁the ▁ap ex .
▁E cho card i ography ▁demonstrat ed ▁moderat ely ▁dil ated ▁LV ▁with ▁an ▁end - dia sto lic ▁volume ▁index ▁of ▁84 ▁m L / m 2 , ▁reduce d ▁LV ▁e je ction ▁ fraction ▁of ▁0 . 40 , ▁mild ▁MR , ▁and ▁limited ▁mit ral ▁val ve ▁opening , ▁result ing ▁in ▁a ▁significant ▁MS ▁with ▁an ▁M VA ▁of ▁1.2 ▁cm 2 ▁and ▁a ▁mean ▁pressure ▁gradi ent ▁of ▁ 8.4 ▁mm ▁H g ▁( F ig ▁1 B ).
▁Corona ry ▁ang i ography ▁reveal ed ▁no ▁significant ▁les ions ▁in ▁the ▁major ▁branche s .
▁The ▁patient ▁was ▁diagnose d ▁as ▁hyper tensi ve ▁LV ▁dys function ▁with ▁mild ▁MR ▁and ▁significant ▁MS .
▁Both ▁sy sto lic ▁and ▁dia sto lic ▁mit ral ▁le a flet ▁motion s ▁were ▁restrict ed ▁without ▁any ▁clear ▁organic ▁les ion .
▁The ▁et i ology ▁of ▁the ▁MR ▁and ▁MS ▁was ▁diagnose d ▁as ▁functional .
▁As ▁significant ▁MS ▁was ▁associated ▁with ▁ HF , ▁sur g ical ▁indica tion ▁for ▁MS ▁was ▁discuss ed .
▁The ▁possibility ▁of ▁MS ▁to ▁improve ▁after ▁medical ▁treatment ▁for ▁ HF ▁was ▁considered ▁because ▁functional ▁MS ▁is ▁highly ▁dynamic ▁and ▁can ▁potential ly ▁respond ▁to ▁medical ▁treatment .
▁Con se quen t ly , ▁surgery ▁was ▁not ▁perform ed ▁and ▁aggressiv e ▁medical ▁treatment ▁for ▁ HF ▁and ▁hyper tension ▁with ▁vaso dila tors ▁and ▁di ure tics ▁was ▁started .
▁His ▁ HF ▁symptom ▁as ▁well ▁as ▁cardiac ▁mur mur s ▁disappear ed ▁with ▁a ▁re duction ▁in ▁blood ▁pressure ▁to ▁140 / 80 ▁mm ▁H g .
▁Rep e ated ▁e cho card i ography ▁4 ▁months ▁later ▁demonstrat ed ▁a ▁re duction ▁in ▁LV ▁end - dia sto lic ▁volume ▁of ▁66 ▁m L / m 2 , ▁disappear ance ▁of ▁MR , ▁improvement ▁of ▁the ▁mit ral ▁val ve ▁opening ▁to ▁an ▁M VA ▁of ▁1.7 ▁cm 2 , ▁and ▁a ▁mean ▁pressure ▁gradi ent ▁of ▁ 4.6 ▁mm ▁H g ▁( F ig ▁1 C ).
▁In ▁this ▁patient ▁there ▁was ▁no ▁MS ▁before ▁the ▁surgery ▁by ▁e cho card i ography .
▁Direct ▁observation ▁at ▁the ▁time ▁of ▁surgery ▁also ▁confirm ed ▁no ▁finding s ▁of ▁rhe u matic ▁or ▁other ▁causes ▁of ▁MS . ▁After ▁the ▁surgery , ▁M VA ▁was ▁reduce d ▁but ▁only ▁modest ly .
▁Possi ble ▁reasons ▁for ▁the ▁modest ▁re duction ▁in ▁M VA ▁could ▁be ▁ann ular ▁size ▁re duction ▁by ▁the ▁sur g ical ▁ring ▁implant ation ▁and ▁mild ▁restriction ▁of ▁le a flet ▁motion ▁by ▁the ▁le a flet ▁res ection ▁and ▁edge - to - ed ge ▁an asto mos is .
▁However , ▁the ▁degree ▁of ▁MS ▁early ▁after ▁surgery ▁was ▁not ▁significant , ▁with ▁an ▁M VA ▁of ▁1.8 ▁cm 2.
▁Mit ral ▁re gur gi tation ▁as ▁well ▁as ▁ HF ▁symptoms ▁disappear ed ▁after ▁the ▁surgery .
▁Therefore , ▁the ▁surgery ▁was ▁successful .
▁However , ▁this ▁patient ▁developed ▁ HF ▁4 ▁years ▁later .
▁At ▁this ▁time , ▁he ▁had ▁severe ▁hyper tension , ▁moderat e ▁LV ▁di la tation , ▁LV ▁dys function , ▁mild ▁MR , ▁and ▁significant ▁MS . ▁As ▁the ▁mit ral ▁val ve ▁demonstrat ed ▁restrict ed ▁ closure ▁and ▁opening ▁without ▁any ▁clear ▁organic ▁les ion , ▁being ▁consistent ▁with ▁sy sto lic ▁and ▁dia sto lic ▁te ther ing , ▁a ▁functional ▁et i ology ▁of ▁MR ▁and ▁MS ▁was ▁considered .
▁There ▁have ▁been ▁reports ▁demonstrat ing ▁development ▁of ▁functional ▁MS ▁following ▁ring ▁ann ulo plast y ▁for ▁ ische mic ▁MR ▁with ▁LV ▁di la tation .
▁This ▁patient ▁showed ▁that ▁functional ▁MS ▁could ▁develop ▁even ▁in ▁a ▁patient ▁with ▁successful ▁val ve ▁plast y ▁for ▁de genera tive ▁MR , ▁if ▁the ▁LV ▁is ▁dil ated ▁by ▁another ▁disease .
▁Because ▁functional ▁MS ▁is ▁dynamic ▁and ▁proportion al ▁to ▁LV ▁di la tation , ▁the ▁degree ▁of ▁functional ▁MS ▁can ▁potential ly ▁var y ▁considera bly .
▁At ▁the ▁time ▁of ▁second ▁ HF ▁4 ▁years ▁after ▁val ve ▁plast y , ▁MS ▁was ▁significant ▁with ▁an ▁M VA ▁of ▁1.2 ▁cm 2.
▁According ▁to ▁the ▁guide line , ▁the ▁MS ▁at ▁that ▁time ▁could ▁be ▁considered ▁indicati ve ▁for ▁surgery .
▁After ▁aggressiv e ▁medical ▁treatment ▁for ▁ HF , ▁the ▁ HF ▁symptom ▁disappear ed ▁and ▁the ▁MS ▁was ▁rever sed ▁to ▁an ▁M VA ▁of ▁1.7 ▁cm 2.
▁At ▁this ▁point , ▁insigni fica nt ▁MS ▁can ▁be ▁considered ▁as ▁not ▁indicati ve ▁for ▁surgery .
▁Therefore , ▁the ▁sur g ical ▁indica tions ▁need ▁to ▁be ▁carefully ▁evaluat ed ▁in ▁patients ▁with ▁functional ▁MS .
▁In ▁addition ▁to ▁the ▁le a flet ▁configuration s , ▁the ▁serial ▁evaluation ▁strong ly ▁suggest ed ▁that ▁the ▁MS ▁in ▁this ▁patient ▁was ▁sub val vu lar ▁and ▁therefore ▁dynamic , ▁as ▁op posed ▁to ▁ann ular ▁MS ▁with ▁a ▁fixed ▁ring ▁size .
▁This ▁case ▁report ▁demonstrat es ▁that ▁functional ▁MS ▁could ▁develop ▁even ▁in ▁a ▁patient ▁with ▁a ▁history ▁of ▁successful ▁val ve ▁plast y ▁for ▁de genera tive ▁MR , ▁if ▁the ▁LV ▁is ▁dil ated ▁by ▁another ▁disease .
▁Fun ction al ▁MS ▁can ▁potential ly ▁be ▁rever sed ▁by ▁medical ▁treatment ▁and ▁thu s ▁requires ▁care ful ▁evaluation ▁of ▁the ▁sur g ical ▁indica tions .
▁Risk ▁strat ification ▁for ▁death ▁and ▁all - ca use ▁hospital ization ▁in ▁heart ▁failure ▁clinic ▁out patient s .
▁BA CK GRO UND : ▁Most ▁heart ▁failure ▁( HF ) ▁risk ▁strat ification ▁models ▁were ▁developed ▁for ▁in patient ▁use , ▁and ▁available ▁out patient ▁models ▁use ▁a ▁complex ▁set ▁of ▁variable s .
▁We ▁hypothe s ized ▁that ▁routine ly ▁collect ed ▁clinic al ▁data ▁could ▁predict ▁the ▁6- mont h ▁risk ▁of ▁death ▁and ▁all - ca use ▁medical ▁hospital ization ▁in ▁ HF ▁clinic ▁out patient s .
▁ MET HOD S ▁AND ▁RESULT S : ▁U sing ▁a ▁quality ▁improvement ▁database ▁and ▁multi vari able ▁Co x ▁model ing , ▁we ▁deri ved ▁the ▁Heart ▁Fail ure ▁Patient ▁Sever ity ▁Index ▁( HF PSI ) ▁in ▁the ▁University ▁of ▁Michigan ▁ HF ▁clinic ▁( UM ▁co hor t , ▁n ▁= ▁1,5 36 ; ▁3 14 ▁reached ▁primary ▁outcome ).
▁We ▁external ly ▁valida ted ▁the ▁ HF PSI ▁in ▁the ▁Ann ▁Ar bor ▁Veteran s ' ▁Affairs ▁ HF ▁clinic ▁( VA ▁co hor t , ▁n ▁= ▁4 45 ; ▁106 ▁outcome s ) ▁and ▁explore d ▁" real - time " ▁ HF PSI ▁use ▁( VA - RT ▁co hor t , ▁n ▁= ▁ 486 ; ▁141 ▁outcome s ) ▁by ▁track ing ▁VA ▁patients ▁for ▁6 ▁months ▁from ▁their ▁most ▁recently ▁calcula ted ▁ HF PSI , ▁rather ▁than ▁using ▁an ▁arbitra ry ▁start ▁date ▁for ▁the ▁co hor t .
▁The ▁ HF PSI ▁model ▁included ▁blood ▁u rea ▁nit rogen , ▁B - type ▁na tri ure tic ▁pe pti de , ▁New ▁York ▁Heart ▁Association ▁class , ▁diabetes ▁status , ▁history ▁of ▁at rial ▁fi bril lation / flu tter , ▁and ▁all - ca use ▁hospital ization ▁within ▁the ▁prior ▁1 ▁and ▁2 ▁to ▁6 ▁months .
▁The ▁concorda nce ▁c ▁statistic s ▁in ▁the ▁UM / VA / VA - RT ▁co hor ts ▁were ▁ 0.7 1/ 0.6 8/ 0.7 4 .
▁Ka plan - Me ier ▁cur ves ▁and ▁log - rank ▁testing ▁demonstrat ed ▁excellent ▁risk ▁strat ification , ▁particularly ▁between ▁a ▁large , ▁low - risk ▁group ▁( 40% ▁of ▁patients , ▁6- mont h ▁event ▁rates ▁in ▁the ▁UM / VA / VA - RT ▁co hor ts ▁8% /12 % /12 %) ▁and ▁a ▁small , ▁high - risk ▁group ▁( 10% ▁of ▁patients , ▁6- mont h ▁event ▁rates ▁in ▁the ▁UM / VA / VA - RT ▁co hor ts ▁5 7% /5 8% /7 9% ).
▁CON CL USI ONS : ▁The ▁ HF PSI ▁use s ▁read ily ▁available ▁data ▁to ▁predict ▁the ▁6- mont h ▁risk ▁of ▁death ▁and / or ▁all - ca use ▁medical ▁hospital ization ▁in ▁ HF ▁clinic ▁out patient s ▁and ▁could ▁potential ly ▁help ▁allo cate ▁special ized ▁ HF ▁resources ▁within ▁health ▁systems .
▁Inc iden ce ▁and ▁predict ors ▁of ▁end - s tage ▁renal ▁disease ▁in ▁out patient s ▁with ▁sy sto lic ▁heart ▁failure .
▁BA CK GRO UND : ▁Ren al ▁dys function ▁is ▁an ▁important ▁prognos tic ▁factor ▁in ▁heart ▁failure ▁( HF ), ▁but ▁whether ▁this ▁dys function ▁progress es ▁to ▁end - s tage ▁renal ▁disease ▁( ES RD ) ▁is ▁un know n .
▁Therefore , ▁we ▁examine d ▁incide nce ▁and ▁predict ors ▁of ▁ES RD ▁in ▁out patient s ▁with ▁ HF .
▁ MET HOD S ▁AND ▁RESULT S : ▁Patient s ▁with ▁sy sto lic ▁ HF ▁were ▁identified ▁in ▁The ▁Danish ▁Heart ▁Fail ure ▁database ▁and ▁new - ons et ▁ES RD ▁from ▁the ▁Danish ▁Registr y ▁on ▁Dia lys is .
▁Ren al ▁function ▁was ▁estima ted ▁by ▁The ▁Chro nic ▁Kid ney ▁Disease ▁Epidemi ology ▁Col labora tion ▁e qu ation ▁and ▁patients ▁groupe d ▁by ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁( e G FR ) - group ▁I : ▁ ≥ 60 ▁m L / min ▁per ▁1. 73 ▁m (2) , ▁group ▁II : ▁30 ▁to ▁59 ▁m L / min ▁per ▁1. 73 ▁m (2) , ▁group ▁III : ▁15 ▁to ▁29 ▁m L / min ▁per ▁1. 73 ▁m (2) , ▁group ▁IV : ▁< 15 ▁m L / min ▁per ▁1. 73 ▁m (2) .
▁Co x ▁hazard ▁models ▁for ▁time ▁to ▁ES RD , ▁to ▁death , ▁and ▁the ▁com posit e ▁end ▁point ▁of ▁ES RD ▁or ▁death ▁were ▁construct ed ▁and ▁predict ors ▁of ▁ES RD ▁identified .
▁A ▁total ▁of ▁8 204 ▁patients ▁were ▁included ▁in ▁the ▁analyse s .
▁Media n ▁age ▁was ▁70 ▁years ▁( Q , ▁61 - 77 ), ▁2 8% ▁were ▁women , ▁media n ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁was ▁30% ▁( Q , ▁24- 40) , ▁and ▁media n ▁e G FR ▁was ▁68 ▁( Q , ▁51 - 85) ▁m L / min ▁per ▁1. 73 ▁m (2) .
▁Fort y - one ▁patients ▁developed ▁ES RD ▁( 1.3 / 1000 ▁patient - year s ).
▁Base line ▁e G FR ▁group ▁II ▁( P < 0.00 1) , ▁e G FR ▁group ▁III ▁( P < 0.00 1) , ▁e G FR ▁group ▁IV ▁( P < 0.00 1) , ▁un control led ▁hyper tension ▁( P = 0.0 49) , ▁need ▁of ▁di ure tics , ▁and ▁age ▁< 60 ▁years ▁( P = 0.0 16) ▁were ▁associated ▁with ▁time ▁to ▁ES RD .
▁CON CL USI ONS : ▁ES RD ▁is ▁rare ▁in ▁out patient s ▁with ▁sy sto lic ▁ HF ▁and ▁is ▁main ly ▁observe d ▁in ▁patients ▁with ▁an ▁e G FR ▁< 30 ▁m L / min ▁per ▁1. 73 ▁m (2) .
▁A ▁low ▁e G FR , ▁age ▁< 60 ▁years , ▁need ▁of ▁di ure tics , ▁and ▁un control led ▁hyper tension ▁identify ▁patients ▁with ▁an ▁increased ▁risk ▁for ▁ES RD .
▁Solu ble ▁concentration s ▁of ▁the ▁inter le u kin ▁receptor ▁family ▁member ▁ST 2 ▁and ▁beta - block er ▁ therapy ▁in ▁chronic ▁heart ▁failure .
▁BA CK GRO UND : ▁Con centra tions ▁of ▁solu ble ▁( s ) ST 2 ▁predict ▁prognos is ▁in ▁heart ▁failure .
▁We ▁recently ▁found ▁changing ▁dos es ▁of ▁β - block er ▁( BB ) ▁may ▁affect ▁s ST 2 ▁concentration s .
▁It ▁remain s ▁un clear ▁whether ▁s ST 2 ▁concentration s ▁identify ▁benefit ▁of ▁BB ▁ therapy , ▁however .
▁ MET HOD S ▁AND ▁RESULT S : ▁A ▁total ▁of ▁151 ▁subject s ▁with ▁heart ▁failure ▁attribut able ▁to ▁left ▁vent ri cular ▁sy sto lic ▁dys function ▁were ▁examine d ▁in ▁this ▁post ▁hoc ▁analysis ; ▁> 9 6% ▁were ▁taking ▁BB ▁at ▁en roll ment .
▁Medica tion ▁regime n ▁and ▁s ST 2 ▁values ▁were ▁obtain ed ▁during ▁10 ▁months .
▁Card io vas cular ▁events ▁were ▁examine d ▁as ▁a ▁function ▁of ▁base line ▁s ST 2 ▁status ▁( low ▁ ≤ 35 ▁versus ▁high ▁> 35 ▁ng / m L ) ▁and ▁final ▁achieve d ▁BB ▁dose ▁( high ▁ ≥ 50 ▁versus ▁low ▁< 50 ▁mg ▁daily ▁equivalent ▁dose ▁of ▁met o pro lol ▁suc cina te ).
▁Patient s ▁with ▁low ▁s ST 2 ▁ti tra ted ▁to ▁high - dos e ▁BB ▁had ▁the ▁lo west ▁cardiovascular ▁event ▁rate ▁at ▁0.5 3 ▁events ▁( P = 0.00 1) , ▁and ▁lo west ▁cum ul ative ▁hazard ▁( P = 0.00 3) .
▁Those ▁with ▁low ▁s ST 2/ low - dos e ▁BB , ▁or ▁high ▁s ST 2/ high - dos e ▁BB ▁had ▁intermedi ate ▁outcome s ▁(0 . 92 ▁and ▁1. 19 ▁events ).
▁Patient s ▁with ▁high ▁s ST 2 ▁treated ▁with ▁low - dos e ▁BB ▁had ▁the ▁highest ▁cardiovascular ▁event ▁rate ▁(2 . 08 ▁events ) ▁and ▁the ▁highest ▁cum ul ative ▁hazard .
▁Compar ed ▁with ▁low ▁s ST 2/ high - dos e ▁BB , ▁those ▁with ▁high ▁s ST 2 ▁treated ▁with ▁low - dos e ▁BB ▁had ▁an ▁odds ▁ratio ▁of ▁6. 77 ▁( P < 0.00 1) ▁for ▁a ▁cardiovascular ▁event .
▁Patient s ▁with ▁low ▁s ST 2/ low - dos e ▁BB ▁or ▁high ▁s ST 2/ high - dos e ▁BB ▁had ▁intermedi ate ▁odds ▁ratio s ▁for ▁cardiovascular ▁events ▁( P =0 . 18 ▁and ▁0.0 2) .
▁Similar ▁results ▁were ▁found ▁for ▁heart ▁failure ▁hospital ization ▁and ▁cardiovascular ▁death .
▁CON CL USI ONS : ▁Although ▁BB ▁ therapy ▁ex er ted ▁dose - related ▁benefits ▁across ▁all ▁study ▁participants , ▁s ST 2 ▁measure ment ▁ identifi es ▁patients ▁with ▁chronic ▁heart ▁failure ▁who ▁may ▁particularly ▁benefit ▁from ▁higher ▁BB ▁dos es .
▁Ni tro x yl ▁( H NO ): ▁A ▁novel ▁approach ▁for ▁the ▁a cute ▁treatment ▁of ▁heart ▁failure .
▁BA CK GRO UND : ▁The ▁ni tro x yl ▁( H NO ) ▁donor , ▁Angeli ' s ▁salt , ▁ex ert s ▁positive ▁in o tropi c , ▁ lusi tropi c , ▁and ▁vaso dila tor ▁effects ▁in ▁vivo ▁that ▁are ▁c AMP ▁independent .
▁It s ▁clinic al ▁useful ness ▁is ▁limited ▁by ▁chemical ▁in st ability ▁and ▁co genera tion ▁of ▁nit rite ▁which ▁itself ▁has ▁vas cular ▁effects .
▁Here , ▁we ▁report ▁on ▁effects ▁of ▁a ▁novel , ▁stable , ▁pure ▁H NO ▁donor ▁( C XL -10 20) ▁in ▁isola ted ▁my oc ty es ▁and ▁intact ▁heart s ▁in ▁experimental ▁models ▁and ▁in ▁patients ▁with ▁heart ▁failure ▁( HF ).
▁ MET HOD S ▁AND ▁RESULT S : ▁C XL -10 20 ▁convert s ▁sole ly ▁to ▁H NO ▁and ▁in active ▁C XL -10 51 ▁with ▁a ▁t 1/2 ▁of ▁2 ▁minutes .
▁In ▁adult ▁mouse ▁vent ri cular ▁my o cy tes , ▁it ▁dose ▁dependent ly ▁increased ▁sar com ere ▁short en ing ▁by ▁75% ▁to ▁2 10% ▁(50 -500 ▁μ mol / L ), ▁with ▁a ▁ ≈ 30% ▁ rise ▁in ▁the ▁pe ak ▁Ca (2 +) ▁trans ient ▁only ▁at ▁higher ▁dos es .
▁Nei ther ▁inhibi tion ▁of ▁protein ▁kina se ▁A ▁nor ▁solu ble ▁gua ny late ▁cy cla se ▁alter ed ▁this ▁contract ile ▁response .
▁Un like ▁iso prot eren ol , ▁C XL -10 20 ▁was ▁equal ly ▁effective ▁in ▁my o cy tes ▁from ▁normal ▁or ▁fail ing ▁heart s .
▁In ▁an est het ized ▁dog s ▁with ▁corona ry ▁micro e mbol ization - indu ced ▁ HF , ▁C XL -10 20 ▁reduce d ▁left ▁vent ri cular ▁end - dia sto lic ▁pressure ▁and ▁my o card ial ▁oxygen ▁consum p tion ▁while ▁increasing ▁e je ction ▁ fraction ▁from ▁2 7% ▁to ▁40% ▁and ▁maximal ▁vent ri cular ▁power ▁index ▁by ▁4 2% ▁( bo th ▁P < 0.0 5) .
▁In ▁ conscious ▁dog s ▁with ▁ta chy pac ing - indu ced ▁ HF , ▁C XL -10 20 ▁increased ▁contract ility ▁assess ed ▁by ▁end - sy sto lic ▁elastan ce ▁and ▁provided ▁ve no arte rial ▁di lation .
▁Heart ▁rate ▁was ▁minimal ly ▁alter ed .
▁In ▁patients ▁with ▁sy sto lic ▁ HF , ▁C XL -10 20 ▁reduce d ▁both ▁left ▁and ▁right ▁heart ▁fill ing ▁pressure s ▁and ▁system ic ▁vas cular ▁resist ance , ▁while ▁increasing ▁cardiac ▁and ▁stroke ▁volume ▁index .
▁Heart ▁rate ▁was ▁un change d , ▁and ▁arterial ▁pressure ▁decline d ▁modest ly .
▁CON CL USI ONS : ▁These ▁data ▁show ▁the ▁functional ▁ef fica cy ▁of ▁a ▁novel ▁pure ▁H NO ▁donor ▁to ▁enhance ▁my o card ial ▁function ▁and ▁present ▁first - in - man ▁evidence ▁for ▁its ▁potential ▁useful ness ▁in ▁ HF .
▁E cho car dio graphic ▁predict ors ▁of ▁rever se ▁remodel ing ▁after ▁cardiac ▁re syn chron ization ▁ therapy ▁and ▁subsequent ▁events .
▁BA CK GRO UND : ▁Studies ▁of ▁e cho car dio graphic ▁predict ors ▁of ▁response ▁after ▁cardiac ▁re syn chron ization ▁ therapy ▁( C RT ) ▁have ▁large ly ▁involved ▁single ▁parameter s .
▁We ▁hypothe s ized ▁that ▁com bi ning ▁parameter s ▁would ▁be ▁more ▁robust ▁and ▁so ught ▁to ▁develop ▁a ▁multi para metric ▁e cho car dio graphic ▁score ▁for ▁predict ing ▁C RT ▁response .
▁ MET HOD S ▁AND ▁RESULT S : ▁Global ▁longitud in al ▁strain ▁of ▁left ▁vent ric le ▁was ▁added ▁to ▁standard ▁e cho car dio graphic ▁measure ments ▁in ▁ 334 ▁consecutiv e ▁patients ▁(2 24 ▁men ; ▁mean , ▁65 ± 12 ▁years ) ▁who ▁under went ▁base line ▁e cho card i ography ▁before ▁C RT ▁and ▁under went ▁follow - up ▁e cho card i ogram s ▁at ▁1 ▁year .
▁Re gression ▁analysis ▁was ▁perform ed ▁to ▁create ▁an ▁e cho car dio graphic ▁score ▁for ▁predict ion ▁of ▁LV ▁rever se ▁remodel ing ▁( de fin ed ▁as ▁ ≥ 15% ▁re duction ▁in ▁the ▁LV ▁end - sy sto lic ▁volume ).
▁Co x ▁proportion al ▁hazard s ▁models ▁were ▁used ▁to ▁identify ▁the ▁association ▁of ▁the ▁score ▁with ▁death , ▁transplant ation ▁or ▁LV ▁assist ▁device ▁implant ation , ▁and ▁heart ▁failure ▁hospital ization ▁during ▁57 ± 22 ▁months ▁of ▁follow - up .
▁LV ▁rever se ▁remodel ing ▁( n = 161 ; ▁4 8%) ▁was ▁associated ▁with ▁pre - C RT ▁LV ▁end - dia sto lic ▁ dimension ▁index ▁< 3.1 ▁cm / m (2) , ▁global ▁longitud in al ▁strain ▁of ▁left ▁vent ric le ▁< - 7% , ▁left ▁at rial ▁area ▁< 26 ▁cm (2) , ▁right ▁vent ri cular ▁end - dia sto lic ▁area ▁index ▁< 1 0.0 ▁cm (2) / m (2) , ▁right ▁at rial ▁area ▁< 20 ▁cm (2) , ▁and ▁right ▁vent ri cular ▁ fraction al ▁area ▁change ▁ ≥ 3 5% .
▁Combi n ation ▁of ▁these ▁into ▁an ▁e cho car dio graphic ▁score ▁allowed ▁predict ion ▁of ▁LV ▁rever se ▁remodel ing ▁with ▁a ▁ sensitiv ity ▁of ▁8 4% ▁and ▁a ▁specific ity ▁of ▁7 9% .
▁During ▁follow - up , ▁there ▁were ▁134 ▁death s , ▁18 ▁heart ▁transplant ations / LV ▁assist ▁device ▁implant ations , ▁and ▁93 ▁heart ▁failure ▁ad missions .
▁The ▁score ▁was ▁associated ▁with ▁heart ▁failure ▁ad mission , ▁heart ▁transplant ation / LV ▁assist ▁device , ▁or ▁death ▁( haz ard ▁ratio , ▁0 . 97 ; ▁95% ▁confidence ▁interval , ▁0 . 95 -0 . 98 ; ▁P < 0.00 1) ▁and ▁all - ca use ▁death ▁( haz ard ▁ratio , ▁0 . 97 ; ▁95% ▁confidence ▁interval , ▁ 0.9 6-0 . 98 ; ▁P < 0.00 1) , ▁independent ▁of ▁age , ▁sex , ▁ ische mic ▁cause , ▁and ▁initial ▁functional ▁class .
▁CON CL USI ONS : ▁A ▁multi para metric ▁e cho car dio graphic ▁score ▁is ▁helpful ▁in ▁select ing ▁patients ▁likely ▁to ▁under go ▁rever se ▁remodel ing ▁after ▁C RT ▁and ▁predict s ▁clinic al ▁outcome s .
▁Effective ness ▁and ▁safety ▁of ▁spi rono lac tone ▁for ▁sy sto lic ▁heart ▁failure .
▁Al do ster one ▁receptor ▁anta gon ists ▁have ▁been ▁shown ▁in ▁random ized ▁trial s ▁to ▁reduce ▁morbi d ity ▁and ▁mortal ity ▁in ▁adults ▁with ▁symptom a tic ▁sy sto lic ▁heart ▁failure .
▁We ▁studie d ▁the ▁effective ness ▁and ▁safety ▁of ▁spi rono lac tone ▁in ▁adults ▁with ▁new ly ▁diagnose d ▁sy sto lic ▁heart ▁failure ▁in ▁clinic al ▁practice .
▁We ▁identified ▁all ▁adults ▁with ▁new ly ▁diagnose d ▁heart ▁failure , ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁of ▁< 40% , ▁and ▁no ▁previous ▁spi rono lac tone ▁use ▁from ▁2006 ▁to ▁2008 ▁in ▁Kaiser ▁Permanent e ▁Northern ▁California .
▁We ▁exclu ded ▁patients ▁with ▁base line ▁se rum ▁creati nine ▁level ▁of ▁> 2.5 ▁mg / dl ▁or ▁a ▁se rum ▁po tas s ium ▁level ▁of ▁> 5.0 ▁m E q / L .
▁We ▁used ▁Co x ▁re gression ▁with ▁time - var ying ▁co varia tes ▁to ▁evaluat e ▁the ▁independent ▁association ▁between ▁spi rono lac tone ▁use ▁and ▁death , ▁hospital ization , ▁severe ▁hyper kal emia , ▁and ▁a cute ▁ki dne y ▁injury .
▁Am ong ▁2,5 38 ▁eligible ▁patients ▁with ▁a ▁media n ▁follow - up ▁of ▁2.5 ▁years , ▁5 21 ▁patients ▁(2 2%) ▁initiat ed ▁spi rono lac tone , ▁which ▁was ▁not ▁associated ▁with ▁risk ▁of ▁hospital ization ▁( ad just ed ▁hazard ▁ratio ▁0 . 91 , ▁95% ▁confidence ▁interval ▁0 . 77 ▁to ▁1. 08) ▁or ▁death ▁( ad just ed ▁hazard ▁ratio ▁0 . 93 , ▁confidence ▁interval ▁0 . 60 ▁to ▁1. 44) .
▁Cru de ▁rates ▁of ▁severe ▁hyper kal emia ▁and ▁a cute ▁ki dne y ▁injury ▁during ▁spi rono lac tone ▁use ▁were ▁similar ▁to ▁that ▁seen ▁in ▁clinic al ▁trial s .
▁Spir ono lac tone ▁was ▁independent ly ▁associated ▁with ▁a ▁3.5 - fold ▁increased ▁risk ▁of ▁hyper kal emia ▁but ▁not ▁with ▁a cute ▁ki dne y ▁injury .
▁With in ▁a ▁diverse ▁community - based ▁co hor t ▁with ▁incident ▁sy sto lic ▁heart ▁failure , ▁use ▁of ▁spi rono lac tone ▁was ▁not ▁independent ly ▁associated ▁with ▁risk s ▁of ▁hospital ization ▁or ▁death .
▁Our ▁finding s ▁suggest ▁that ▁the ▁benefits ▁of ▁spi rono lac tone ▁in ▁clinic al ▁practice ▁may ▁be ▁reduce d ▁compared ▁with ▁other ▁guide line - re com mend ed ▁medication s .
▁Vas cular ▁en dot heli al ▁growth ▁factor ▁block ade ▁prevent s ▁the ▁beneficia l ▁effects ▁of ▁beta - block er ▁ therapy ▁on ▁cardiac ▁function , ▁ang io gene sis , ▁and ▁remodel ing ▁in ▁heart ▁failure .
▁BA CK GRO UND : ▁Imp aire d ▁ang io gene sis ▁in ▁the ▁post - my o card ial ▁in far ction ▁heart ▁contribute s ▁to ▁the ▁progression ▁to ▁heart ▁failure .
▁The ▁inhibi tion ▁of ▁vas cular ▁en dot heli al ▁growth ▁factor ▁( VE GF ) ▁signal ing ▁has ▁been ▁shown ▁to ▁be ▁crucial ▁for ▁the ▁transition ▁from ▁compensa tory ▁hyper trop hy ▁to ▁cardiac ▁failure .
▁Important ly , ▁β - ad r energi c ▁receptor ▁block er ▁ therapy ▁has ▁been ▁also ▁shown ▁to ▁improve ▁my o card ial ▁per fusion ▁by ▁en han cing ▁neo angi ogen es is ▁in ▁the ▁fail ing ▁heart .
▁ MET HOD S ▁AND ▁RESULT S : ▁E ight ▁weeks ▁from ▁sur g ically ▁induc ed ▁my o card ial ▁in far ction , ▁heart ▁failure ▁rat s ▁were ▁random ized ▁to ▁receive ▁bis o pro lol ▁( B ) ▁or ▁vehicle .
▁At ▁the ▁end ▁of ▁a ▁10- week ▁treatment ▁period , ▁e cho card i ography ▁reveal ed ▁reduce d ▁cardiac ▁diameter s ▁and ▁improve d ▁cardiac ▁function ▁in ▁B - tre ated ▁compared ▁with ▁vehicle - tre ated ▁rat s .
▁More over , ▁B ▁treatment ▁was ▁associated ▁with ▁increased ▁cardiac ▁ang io gene sis ▁and ▁in ▁vivo ▁corona ry ▁per fusion ▁and ▁reduce d ▁cardiac ▁fibro sis .
▁Important ly , ▁2 ▁weeks ▁after ▁B ▁treatment ▁was ▁started , ▁increased ▁cardiac ▁VE GF ▁expression ▁and ▁Akt ▁and ▁en dot heli al ▁NO ▁synth ase ▁activa tion ▁were ▁observe d ▁by ▁compar ing ▁B - tre ated ▁with ▁drug - un tre ated ▁fail ing ▁heart s .
▁To ▁test ▁whether ▁the ▁pro angi ogen ic ▁effects ▁of ▁B ▁act ▁via ▁activa tion ▁of ▁VE GF ▁path way , ▁rat s ▁were ▁intra ven ously ▁inject ed ▁with ▁a den ovi ral ▁ve ctor ▁en co ding ▁a ▁de co y ▁VE GF ▁receptor ▁( Ad - F lk ) ▁or ▁a ▁control ▁ade no virus ▁( Ad - C ), ▁at ▁the ▁start ▁of ▁the ▁treatment ▁with ▁B .
▁After ▁10 ▁weeks , ▁his t ological ▁analysis ▁reveal ed ▁reduce d ▁cap illa ry ▁and ▁corona ry ▁per fusion ▁in ▁B - tre ated ▁plus ▁Ad - F lk ▁rat s ▁compared ▁with ▁B - tre ated ▁plus ▁Ad - C ▁rat s .
▁More over , ▁VE GF ▁inhibi tion ▁counter a cted ▁the ▁positive ▁effects ▁of ▁B ▁on ▁cardiac ▁function ▁and ▁remodel ing .
▁CON CL USI ONS : ▁β - Block ade ▁promote s ▁cardiac ▁ang io gene sis ▁in ▁heart ▁failure ▁via ▁activa tion ▁of ▁VE GF ▁signal ing ▁path way .
▁β - Block er - indu ced ▁enhance ment ▁of ▁cardiac ▁ang io gene sis ▁is ▁essential ▁for ▁the ▁favorable ▁effects ▁of ▁this ▁ therapy ▁on ▁cardiac ▁function ▁and ▁remodel ing .
▁Do ▁outcome s ▁for ▁patients ▁with ▁heart ▁failure ▁var y ▁by ▁emergency ▁department ▁volume ?
▁Back ground — He art ▁failure ▁is ▁a ▁common ▁Emer gen cy ▁Department ▁( ED ) ▁presentation ▁but ▁whether ▁ED ▁volume ▁influence s ▁patient ▁outcome s ▁is ▁un know n .
▁Method s ▁and ▁Results — Re tro spec tive ▁co hor t ▁of ▁all ▁adults ▁present ing ▁to ▁93 ▁ED s ▁between ▁1999 ▁and ▁2009 ▁with ▁a ▁most ▁responsible ▁ diagnos is ▁of ▁heart ▁failure ▁( n = 44 ▁925 ▁ED ▁visit s ; ▁mean ▁age , ▁76 . 4 ▁years ).
▁Case s ▁seen ▁in ▁low - volu me ▁ED s ▁had ▁less ▁como rbi di ties ▁and ▁were ▁less ▁likely ▁to ▁be ▁hospital ized ▁(5 4.5 %) ▁than ▁those ▁seen ▁in ▁medium ▁( 61 . 8% ; ▁adjust ed ▁odds ▁ratio ▁[ a OR ] ▁1. 16 , ▁[ 95% ▁confidence ▁interval ▁{ CI } ▁1. 10 – 1.2 3] ) ▁or ▁high - volu me ▁ED s ▁( 73 . 6% ; ▁a OR , ▁1. 95 ▁[ 95% ▁CI , ▁1. 83 – 2. 07 ] ).
▁Of ▁patients ▁treated ▁and ▁released , ▁low - volu me ▁ED ▁cases ▁exhibi ted ▁higher ▁risk ▁of ▁death / hospital ization / ED ▁visit ▁in ▁the ▁subsequent ▁7 ▁(22 . 0% ) ▁and ▁30 ▁days ▁(4 4.9 %) ▁than ▁medium ▁(16 . 3% ; ▁a OR , ▁0 . 81 ▁[ 95% ▁CI , ▁0 . 73 – 0.9 0 ] , ▁and ▁35 . 3% ; ▁a OR , ▁0 . 79 ▁[ 95% ▁CI , ▁0 . 73 – 0.8 6 ] ) ▁or ▁high - volu me ▁ED ▁cases ▁(13 . 0% ; ▁a OR , ▁0 . 69 ▁[ 95% ▁CI , ▁0 . 61 – 0.7 8 ] , ▁and ▁30 . 2% ; ▁a OR , ▁0 . 67 ▁[ 95% ▁CI , ▁0 . 61 – 0.7 4 ] ).
▁Of ▁patients ▁hospital ized ▁at ▁the ▁time ▁of ▁their ▁index ▁ED ▁visit , ▁low - volu me ▁ED ▁cases ▁exhibi ted ▁a ▁higher ▁risk ▁of ▁30- day ▁death / all - ca use ▁read mission ▁(24 . 3% ) ▁than ▁those ▁seen ▁in ▁medium ▁(21 . 9% ; ▁a OR , ▁0 . 83 ▁[ 95% ▁CI , ▁0 . 76 – 0.9 1] ) ▁or ▁high - volu me ▁ED s ▁(18 . 1% ; ▁a OR , ▁0 . 77 ▁[ 95% ▁CI , ▁0 . 70 – 0.8 5 ] ).
▁Conclu sions — Lo w - volu me ▁ED s ▁were ▁more ▁likely ▁to ▁dis charge ▁patients ▁with ▁heart ▁failure ▁home , ▁but ▁low - volu me ▁ED ▁cases ▁exhibi ted ▁worse ▁outcome s ▁( driv en ▁large ly ▁by ▁read missions ▁or ▁repeat ▁ED ▁visit s ).
▁Interven tions ▁to ▁improve ▁management ▁of ▁a cute ▁heart ▁failure ▁are ▁required ▁at ▁low - volu me ▁sites .
▁Xan thi ne ▁oxid ase ▁inhibi tion ▁pre serve s ▁left ▁vent ri cular ▁sy sto lic ▁but ▁not ▁dia sto lic ▁function ▁in ▁cardiac ▁volume ▁over load .
▁Xan thi ne ▁oxid ase ▁( XO ) ▁is ▁increased ▁in ▁human ▁and ▁rat ▁left ▁vent ri cular ▁( LV ) ▁my o cy tes ▁with ▁volume ▁over load ▁( VO ) ▁of ▁mit ral ▁re gur gi tation ▁and ▁a orto ca val ▁fi stu la ▁( AC F ).
▁In ▁the ▁setting ▁of ▁increased ▁ATP ▁demand , ▁ XO - media ted ▁ ROS ▁can ▁decrease ▁mito cho ndri al ▁respira tion ▁and ▁contract ile ▁function .
▁Thu s , ▁we ▁test ed ▁the ▁hypothe sis ▁that ▁ XO ▁inhibi tion ▁improve s ▁cardio my o cy te ▁bio ener ge tics ▁and ▁LV ▁function ▁in ▁chronic ▁A CF ▁in ▁the ▁rat .
▁Spr a gue - Da w ley ▁rat s ▁were ▁random ized ▁to ▁either ▁sham ▁or ▁A CF ▁ ± ▁allo puri nol ▁(100 ▁mg · kg ( -1) · day ( -1) , ▁n ▁ ≥ 7 ▁rat s / group ).
▁E cho card i ography ▁at ▁8 ▁w k ▁demonstrat ed ▁a ▁similar ▁3 7% ▁increase ▁in ▁LV ▁end - dia sto lic ▁ dimension ▁( P ▁< ▁0.0 01) , ▁a ▁two fold ▁increase ▁in ▁LV ▁end - dia sto lic ▁pressure / wall ▁stress ▁( P ▁< ▁0.0 5) , ▁and ▁a ▁two fold ▁increase ▁in ▁lung ▁weight ▁( P ▁< ▁0.0 5) ▁in ▁treated ▁and ▁un tre ated ▁A CF ▁groups ▁versus ▁the ▁sham ▁group .
▁LV ▁e je ction ▁ fraction , ▁veloci ty ▁of ▁circum fer ential ▁short en ing , ▁maximal ▁sy sto lic ▁elastan ce , ▁and ▁contract ile ▁efficiency ▁were ▁significantly ▁de press ed ▁in ▁A CF ▁and ▁significantly ▁improve d ▁in ▁A CF ▁+ ▁allo puri nol ▁rat s , ▁all ▁of ▁which ▁occur red ▁in ▁the ▁ absence ▁of ▁changes ▁in ▁the ▁maximum ▁O 2 ▁consum p tion ▁rate ▁measure d ▁in ▁isola ted ▁cardio my o cy tes ▁using ▁the ▁extra cel lular ▁flux ▁anal y zer .
▁However , ▁the ▁improvement ▁in ▁contract ile ▁function ▁is ▁not ▁parallel ed ▁by ▁any ▁att en u ation ▁in ▁LV ▁di la tation , ▁LV ▁end - dia sto lic ▁pressure / wall ▁stress , ▁and ▁lung ▁weight .
▁In ▁conclusion , ▁allo puri nol ▁improve s ▁LV ▁contract ile ▁function ▁and ▁efficiency ▁possibly ▁by ▁di mini shing ▁the ▁known ▁ XO - media ted ▁ ROS ▁effects ▁on ▁my o fila ment ▁Ca (2 +) ▁ sensitiv ity .
▁However , ▁LV ▁remodel ing ▁and ▁dia sto lic ▁properties ▁are ▁not ▁improve d , ▁which ▁may ▁explain ▁the ▁failure ▁of ▁ XO ▁inhibi tion ▁to ▁improve ▁symptoms ▁and ▁hospital ization s ▁in ▁patients ▁with ▁severe ▁heart ▁failure .
▁Use ful ness ▁of ▁tissu e ▁Do pp ler ▁imagin g ▁for ▁assess ing ▁left ▁vent ri cular ▁fill ing ▁pressure ▁in ▁patients ▁with ▁stable ▁severe ▁sy sto lic ▁heart ▁failure .
▁The ▁ratio ▁of ▁early ▁transmit ral ▁blood ▁flow ▁veloci ty ▁over ▁tissu e ▁Do pp ler ▁early ▁dia sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁( E / e ' ) ▁was ▁found ▁un re li able ▁for ▁estima ting ▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁( PC WP ) ▁in ▁patients ▁with ▁de com pensa ted ▁sy sto lic ▁heart ▁failure ▁( HF ).
▁The ▁objective ▁of ▁this ▁study ▁was ▁to ▁test ▁its ▁reli ability ▁in ▁stable ▁ HF .
▁Therefore , ▁130 ▁consecutiv e ▁patients ▁with ▁a ▁left ▁vent ri cular ▁( LV ) ▁e je ction ▁ fraction ▁of ▁<3 5% ▁and ▁stable ▁ HF ▁under went ▁right - side d ▁cardiac ▁cat heter ization ▁and ▁trans t hora cic ▁e cho card i ography ▁with ▁measure ment ▁of ▁transmit ral ▁flow ▁veloci ties ▁( E , ▁A ) ▁and ▁mit ral ▁ann ulus ▁veloci ties ▁during ▁sy stol e ▁( s ' ) ▁and ▁dia stol e ▁( e ' ).
▁Me an ▁age ▁was ▁56 ▁ ± ▁11 ▁years ▁and ▁mean ▁LV ▁e je ction ▁ fraction ▁was ▁28 ▁ ± ▁8% ; ▁4 8% ▁had ▁PC WP ▁of ▁> 15 ▁mm ▁H g .
▁E / e ' sept al ▁cor related ▁more ▁strong ly ▁with ▁PC WP ▁( r ▁= ▁0.5 3) ▁compared ▁with ▁E / e ' lateral ▁( r ▁= ▁0 . 41) ▁and ▁E / e ' me an ▁( r ▁= ▁0 . 50 ; ▁all ▁p ▁values ▁< 0.00 1) .
▁The ▁area ▁under ▁the ▁receive r ▁operating ▁character istic ▁cur ve ▁( AU C ) ▁of ▁E / e ' ▁ratio s ▁for ▁PC WP ▁estima tion ▁was ▁0 . 79 ▁( 95% ▁confidence ▁interval ▁[ CI ] ▁0 . 70 ▁to ▁0 . 87) ▁for ▁E / e ' sept al , ▁0 . 72 ▁( 95% ▁CI ▁0 . 63 ▁to ▁0 . 82) ▁for ▁E / e lateral , ▁and ▁0 . 79 ▁( 95% ▁CI ▁0 . 70 ▁to ▁0 . 87) ▁for ▁E / eme an ▁( all ▁p ▁values ▁< 0.00 01) .
▁A UC s ▁of ▁E / e sept al ▁and ▁E / eme an ▁did ▁not ▁var y ▁with ▁s ' sept al , ▁QR S ▁ width , ▁or ▁re syn chron ization .
▁U sing ▁a ▁cut off ▁of ▁8 , ▁negative ▁predict ive ▁value ▁of ▁E / e ' sept al ▁was ▁8 9% ▁and ▁negative ▁like li hood ▁ratio ▁of ▁0.1 5 .
▁E / e ' lateral ▁showed ▁good ▁diagnostic ▁performance ▁only ▁in ▁patients ▁with ▁s ' lateral ▁of ▁> 4.5 ▁cm / s ▁( n ▁= ▁77 , ▁5 9% ; ▁A UC ▁= ▁0 . 82 ; ▁95% ▁CI ▁0 . 71 ▁to ▁0 . 92 ; ▁s ' lateral ▁of ▁ ≤ 4.5 ▁cm / s : ▁A UC ▁= ▁0.5 4 ; ▁95% ▁CI ▁0.3 8 ▁to ▁0 . 70 ; ▁p ▁= ▁0.0 05) .
▁In ▁conclusion , ▁e ' ▁is ▁useful ▁for ▁estima ting ▁LV ▁fill ing ▁pressure ▁in ▁stable ▁severe ▁sy sto lic ▁ HF .
▁E / e ' sept al ▁showed ▁good ▁diagnostic ▁performance ▁for ▁detect ing ▁normal ▁fill ing ▁pressure s .
▁Tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁and ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁relationship ▁in ▁heart ▁failure : ▁an ▁index ▁of ▁right ▁vent ri cular ▁contract ile ▁function ▁and ▁prognos is .
▁Abstract ▁E cho - der i ved ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁( PAS P ) ▁and ▁right ▁vent ri cular ▁( RV ) ▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁( TA PS E ; ▁from ▁the ▁end ▁of ▁dia stol e ▁to ▁end - sy stol e ) ▁are ▁of ▁basic ▁relevan ce ▁in ▁the ▁clinic al ▁follow - up ▁of ▁heart ▁failure ▁( HF ) ▁patients , ▁carry ing ▁two - ▁to ▁three fold ▁increase ▁in ▁cardiac ▁risk ▁when ▁increased ▁and ▁reduce d , ▁respective ly .
▁We ▁hypothe s ized ▁that ▁the ▁relationship ▁between ▁T AP SE ▁( long itud in al ▁ RV ▁fiber ▁short en ing ) ▁and ▁PAS P ▁( force ▁generate d ▁by ▁the ▁ RV ) ▁provides ▁an ▁index ▁of ▁in ▁vivo ▁ RV ▁length - force ▁relationship , ▁with ▁their ▁ratio ▁better ▁disc los ing ▁prognos is .
▁Two ▁hundred ▁nin ety - th re e ▁ HF ▁patients ▁with ▁reduce d ▁( HF r EF , ▁n ▁= ▁247 ) ▁or ▁with ▁pres er ved ▁left ▁vent ri cular ▁( LV ) ▁e je ction ▁ fraction ▁( HF p EF , ▁n ▁= ▁46 ) ▁under went ▁e cho - D opp ler ▁studies ▁and ▁N - termin al ▁pro - bra in - type ▁na tri ure tic ▁pe pti de ▁assessment ▁and ▁were ▁track ed ▁for ▁advers e ▁events .
▁The ▁media n ▁follow - up ▁du ration ▁was ▁20. 8 ▁mo .
▁T AP SE ▁vs . ▁PAS P ▁relationship ▁showed ▁a ▁down ward ▁re gression ▁line ▁shift ▁in ▁non sur viv ors ▁who ▁were ▁more ▁frequently ▁present ing ▁with ▁higher ▁PAS P ▁and ▁lower ▁T AP SE .
▁H Fr EF ▁and ▁ HF p EF ▁patients ▁exhibi ted ▁a ▁similar ▁distribution ▁along ▁the ▁re gression ▁line .
▁Give n ▁the ▁T AP SE , ▁PAS P , ▁and ▁T AP SE - to - PAS P ▁ratio ▁( TA PS E / PAS P ) ▁colli ne ar ity , ▁separate ▁Co x ▁re gression ▁and ▁Ka plan - Me ier ▁analyse s ▁were ▁perform ed : ▁one ▁with ▁T AP SE ▁and ▁PAS P ▁as ▁individual ▁measure s , ▁and ▁the ▁other ▁com bi ning ▁them ▁in ▁ratio ▁form .
▁Hazard ▁ratio s ▁for ▁variable s ▁ret ained ▁in ▁the ▁multi varia te ▁re gression ▁were ▁as ▁follow s : ▁T AP SE / PAS P ▁ </ ≥ ▁0.3 6 ▁mm / mm H g ▁[ haz ard ▁ratio ▁( HR ): ▁10. 4 , ▁P ▁< ▁ 0.00 1] ; ▁T AP SE ▁ </ ≥ ▁16 ▁mm ▁( HR : ▁5.1 , ▁P ▁< ▁ 0.01 ); ▁New ▁York ▁Heart ▁Association ▁functional ▁class ▁ </ ≥ ▁3 ▁( HR : ▁4.4 , ▁P ▁< ▁0.0 01) ; ▁E / e ' ▁( HR : ▁4.1 , ▁P ▁< ▁0.0 01) .
▁This ▁study ▁shows ▁that ▁the ▁T AP SE ▁vs . ▁PAS P ▁relationship ▁is ▁shift ed ▁down ward ▁in ▁non sur viv ors ▁with ▁a ▁similar ▁distribution ▁in ▁H Fr EF ▁and ▁ HF p EF , ▁and ▁their ▁ratio ▁improve s ▁prognos tic ▁resolution .
▁The ▁T AP SE ▁vs . ▁PAS P ▁relationship ▁as ▁a ▁possible ▁index ▁of ▁the ▁length - force ▁relationship ▁may ▁be ▁a ▁step ▁forward ▁for ▁a ▁more ▁efficient ▁ RV ▁function ▁evaluation ▁and ▁is ▁not ▁affected ▁by ▁the ▁quality ▁of ▁LV ▁dys function .
▁The ▁bottle ne ck ▁sten t ▁model ▁for ▁chronic ▁my o card ial ▁ ische mia ▁and ▁heart ▁failure ▁in ▁pig s .
▁A ▁large ▁animal ▁model ▁of ▁chronic ▁my o card ial ▁ ische mia ▁and ▁heart ▁failure ▁is ▁crucial ▁for ▁the ▁development ▁of ▁novel ▁ therapeut ic ▁approach es .
▁In ▁this ▁study ▁we ▁developed ▁a ▁novel ▁per cuta ne ous ▁one - ▁and ▁two - ves sel ▁model ▁for ▁chronic ▁my o card ial ▁ ische mia ▁using ▁a ▁sten t ▁co ated ▁with ▁a ▁poly te tra flu oro e thy lene ▁tube ▁for med ▁in ▁a ▁bottle ne ck ▁shape .
▁The ▁bottle ne ck ▁sten t ▁was ▁implant ed ▁in ▁the ▁proxima l ▁left ▁anterior ▁descend ing ▁( LAD ) ▁or ▁proxima l ▁circum flex ▁arter y ▁( LC X ), ▁or ▁in ▁both ▁proxima l ▁ LC X ▁and ▁mid ▁ LAD ▁1 ▁w k ▁later ▁(2 - ves sel ▁model ), ▁and ▁pig s ▁were ▁followed ▁for ▁4-5 ▁w k .
▁E je ction ▁ fraction ▁( EF ), ▁in far ct ▁size , ▁col lateral ▁growth , ▁and ▁my o card ial ▁per fusion ▁were ▁assess ed .
▁Pig s ▁were ▁given ▁anti ar rhythm ic ▁medication ▁to ▁prevent ▁sud den ▁death .
▁The ▁oc clusi on ▁time ▁of ▁the ▁bottle ne ck ▁sten t ▁and ▁the ▁tim ing ▁of ▁my o card ial ▁in far ction ▁could ▁be ▁modul ated ▁by ▁the ▁du ration ▁of ▁anti plate let ▁medication .
▁Fra ction al ▁flow ▁reserve ▁measure ments ▁and ▁posi tron ▁e mission ▁tom ography ▁imagin g ▁showed ▁severe ▁ ische mia ▁after ▁bottle ne ck ▁sten ting ▁cover ing ▁over ▁50% ▁of ▁the ▁left ▁vent ric le ▁in ▁the ▁proxima l ▁ LAD ▁model .
▁Complete ▁corona ry ▁oc clusi on ▁was ▁necessary ▁for ▁significant ▁col lateral ▁growth , ▁which ▁mostly ▁had ▁occur red ▁already ▁during ▁the ▁first ▁w k ▁after ▁the ▁sten t ▁oc clusi on .
▁Dyna mic ▁and ▁competitive ▁col lateral ▁growth ▁pattern s ▁were ▁observe d .
▁EF ▁decline d ▁from ▁64 ▁to ▁4 1% ▁in ▁the ▁ LC X ▁model ▁and ▁to ▁4 4% ▁in ▁the ▁ LAD ▁model ▁4 ▁w k ▁after ▁sten ting ▁with ▁12 ▁and ▁21% ▁in far cted ▁left ▁vent ric le ▁in ▁the ▁ LC X ▁and ▁ LAD ▁models , ▁respective ly .
▁The ▁mortal ity ▁was ▁32 ▁and ▁3 7% ▁in ▁the ▁ LC X ▁and ▁ LAD ▁models ▁but ▁very ▁(7 1%) ▁high ▁in ▁the ▁two - ves sel ▁disease ▁model .
▁The ▁implant ation ▁of ▁a ▁novel ▁bottle ne ck ▁sten t ▁in ▁the ▁proxima l ▁ LAD ▁or ▁ LC X ▁is ▁a ▁novel ▁por cine ▁model ▁of ▁rever sible ▁my o card ial ▁ ische mia ▁( open ▁sten t ) ▁and ▁ ische mic ▁heart ▁failure ▁( oc clu ded ▁sten t ) ▁and ▁is ▁fe a sible ▁for ▁the ▁development ▁of ▁new ▁ therapeut ic ▁approach es .
▁Select ive ▁heart ▁rate ▁re duction ▁with ▁i va bra dine ▁un load s ▁the ▁left ▁vent ric le ▁in ▁heart ▁failure ▁patients .
▁OB JE C TIVE S : ▁The ▁study ▁ai med ▁to ▁determine ▁whether ▁isola ted ▁heart ▁rate ▁( HR ) ▁re duction ▁with ▁i va bra dine ▁reduce s ▁after load ▁of ▁patients ▁with ▁sy sto lic ▁heart ▁failure .
▁BA CK GRO UND : ▁The ▁effective ▁arterial ▁elastan ce ▁( E a ) ▁represent s ▁resist ive ▁and ▁pulsa tile ▁after load ▁of ▁the ▁heart ▁deri ved ▁from ▁the ▁pressure ▁volume ▁relation .
▁HR ▁modul ates ▁Ea , ▁and , ▁therefore , ▁after load ▁burde n .
▁ MET HOD S : ▁Am ong ▁the ▁patients ▁with ▁sy sto lic ▁heart ▁failure ▁( ej ection ▁ fraction ▁ ≤ 35 %) ▁random ized ▁to ▁either ▁place bo ▁or ▁i va bra dine ▁in ▁the ▁SHI FT ▁( Sy sto lic ▁Heart ▁Fail ure ▁Treatment ▁With ▁the ▁If ▁In hib itor ▁I va bra dine ▁Tri al ), ▁275 ▁patients ▁( n ▁= ▁132 , ▁place bo ; ▁n ▁= ▁143 , ▁i va bra dine ▁7.5 ▁mg ▁twice ▁a ▁day ) ▁were ▁included ▁in ▁the ▁e cho car dio graphic ▁sub stu dy .
▁Ea , ▁total ▁arterial ▁compliance ▁( TAC ), ▁and ▁end - sy sto lic ▁elastan ce ▁( E es ) ▁were ▁calcula ted ▁at ▁base line ▁and ▁after ▁8 ▁months ▁of ▁treatment .
▁Blood ▁pressure ▁was ▁measure d ▁by ▁arm ▁cu ff ; ▁stroke ▁volume ▁( SV ), ▁e je ction ▁ fraction , ▁and ▁end - dia sto lic ▁volume ▁were ▁assess ed ▁by ▁e cho card i ography .
▁RESULT S : ▁At ▁base line ▁Ea , ▁ TAC , ▁HR , ▁and ▁E es ▁did ▁not ▁differ ▁significantly ▁between ▁i va bra dine - ▁and ▁place bo - tre ated ▁patients .
▁After ▁8 ▁months ▁of ▁treatment , ▁HR ▁was ▁significantly ▁reduce d ▁in ▁the ▁i va bra dine ▁group ▁( p ▁< ▁ 0.00 01) ▁and ▁was ▁ac com pani ed ▁by ▁marked ▁re duction ▁in ▁Ea ▁( p ▁< ▁ 0.00 01) ▁and ▁improve d ▁ TAC ▁( p ▁= ▁0.0 04) ▁compared ▁with ▁place bo .
▁Although ▁contract ility ▁remain ed ▁un change d , ▁vent ri cular - arte rial ▁coup ling ▁was ▁marked ly ▁improve d ▁( p ▁= ▁0.0 02) , ▁result ing ▁in ▁a ▁higher ▁SV ▁( p ▁< ▁ 0.00 01) ▁in ▁the ▁i va bra dine - tre ated ▁patients .
▁CON CL USI ONS : ▁I sol ated ▁HR ▁re duction ▁by ▁i va bra dine ▁improve s ▁ TAC , ▁thu s ▁ reducing ▁Ea .
▁Because ▁E es ▁is ▁un alter ed , ▁improve d ▁vent ri cular - arte rial ▁coup ling ▁is ▁responsible ▁for ▁increased ▁SV .
▁Therefore , ▁un load ing ▁of ▁the ▁heart ▁may ▁contribute ▁to ▁the ▁beneficia l ▁effect ▁of ▁isola ted ▁HR ▁re duction ▁in ▁patients ▁with ▁sy sto lic ▁heart ▁failure .
▁Relation ▁of ▁pre operativ e ▁se rum ▁album in ▁levels ▁to ▁survival ▁in ▁patients ▁under go ing ▁left ▁vent ri cular ▁assist ▁device ▁implant ation .
▁Hypo album in emia ▁has ▁been ▁recognize d ▁as ▁a ▁prognos tic ▁indicator ▁in ▁patients ▁with ▁heart ▁failure .
▁We ▁ai med ▁to ▁investiga te ▁the ▁association ▁of ▁hypo album in emia ▁with ▁post operativ e ▁mortal ity ▁in ▁patients ▁under go ing ▁left ▁vent ri cular ▁assist ▁device ▁( L VAD ) ▁implant ation .
▁We ▁studie d ▁27 2 ▁consecutiv e ▁patients ▁under go ing ▁L VAD ▁implant ation ▁from ▁2000 ▁to ▁2010 ▁at ▁our ▁institution .
▁Pre operativ e ▁clinic al ▁character istic s ▁and ▁laborator y ▁variable s ▁associated ▁with ▁mortal ity ▁were ▁anal y zed .
▁Post operativ e ▁survival ▁of ▁patients ▁with ▁pre operativ e ▁hypo album in emia ▁( < 3.5 ▁g / dl , ▁n ▁= ▁125 ) ▁and ▁those ▁with ▁normal ▁album in ▁concentration ▁( ≥ 3.5 ▁g / dl , ▁n ▁= ▁147 ) ▁was ▁compared .
▁Sur vi val ▁after ▁L VAD ▁surgery ▁was ▁better ▁in ▁patients ▁with ▁normal ▁album in ▁levels ▁compared ▁with ▁those ▁with ▁hypo album in emia ▁before ▁surgery ▁(3 ▁and ▁12 ▁months : ▁93 . 2% ▁vs ▁82 . 4% ▁and ▁88 . 4% ▁vs ▁75 . 2% , ▁respective ly , ▁p ▁< 0.00 1) .
▁Multi varia te ▁analysis ▁reveal ed ▁that ▁pre operativ e ▁album in ▁was ▁independent ly ▁associated ▁with ▁mortal ity ▁after ▁L VAD ▁implant ation ▁( haz ard ▁ratio ▁0.5 21 , ▁95% ▁confidence ▁interval ▁0.2 90 ▁to ▁ 0.9 34 ; ▁p ▁= ▁0.0 29 . )
▁Fur ther more , ▁the ▁impact ▁of ▁normal ization ▁of ▁album in ▁levels ▁during ▁L VAD ▁support ▁on ▁post operativ e ▁survival ▁was ▁anal y zed ▁in ▁both ▁groups .
▁Sub group ▁analysis ▁of ▁patients ▁with ▁pre operativ e ▁hypo album in emia ▁and ▁post operativ e ▁normal ization ▁of ▁album in ▁levels ▁( n ▁= ▁81 ) ▁showed ▁improve d ▁survival ▁compared ▁with ▁those ▁who ▁remain ed ▁hypo album in emia ▁( n ▁= ▁44 ) ▁or ▁those ▁who ▁had ▁de cre as ing ▁album in ▁levels ▁during ▁L VAD ▁support ▁( n ▁= ▁40 ; ▁3- mont h ▁survival : ▁92 . 6% ▁vs ▁63 . 6% ▁and ▁65 . 0% ; ▁p ▁< 0.01 ).
▁In ▁conclusion , ▁pre operativ e ▁hypo album in emia ▁is ▁associated ▁with ▁poor ▁prognos is ▁after ▁L VAD ▁surgery .
▁Post operativ e ▁normal ization ▁of ▁album in ▁level ▁is ▁associated ▁with ▁improve d ▁survival .
▁Attention ▁to ▁album in ▁levels ▁by ▁correct ing ▁nutrition , ▁ inflammation , ▁and ▁he pati c ▁function ▁could ▁be ▁an ▁effective ▁way ▁to ▁improve ▁prognos is ▁in ▁patients ▁evaluat ed ▁for ▁L VAD ▁implant ation .
▁Sur g ical ▁correct ion ▁of ▁a or tic ▁val ve ▁insu ffi cie ncy ▁after ▁left ▁vent ri cular ▁assist ▁device ▁implant ation .
▁OB JE C TIVE S : ▁New - ons et ▁a or tic ▁insu ffi cie ncy ▁( AI ) ▁can ▁be ▁encounter ed ▁after ▁institut ing ▁mechanic al ▁circula tory ▁support ▁and ▁seems ▁more ▁common ▁and ▁severe ▁with ▁continuo us ▁flow ▁( CF ) ▁left ▁vent ri cular ▁assist ▁devices ▁( L VAD s ) ▁compared ▁with ▁pulsa tile ▁devices .
▁Treatment ▁algorithm s ▁for ▁de ▁novo , ▁post - L VAD ▁AI ▁have ▁not ▁been ▁well ▁define d .
▁In ▁the ▁present ▁report , ▁we ▁have ▁described ▁6 ▁patients ▁who ▁under went ▁a or tic ▁val ve ▁surgery ▁for ▁new - ons et ▁post - L VAD ▁AI .
▁ MET HOD S : ▁From ▁2005 ▁to ▁2011, ▁271 ▁patients ▁under went ▁L VAD ▁implant ation .
▁Of ▁these ▁L VAD s , ▁225 ▁were ▁CF ▁devices ▁( 203 ▁Heart Mate ▁II ▁devices , ▁Thor a tec ▁Corp , ▁Ple asan ton , ▁Cali f ; ▁and ▁22 ▁H VAD ▁devices , ▁Heart War e ▁In t l , ▁Inc , ▁Fram ing ham , ▁Mass ).
▁The ▁patients ▁were ▁examine d ▁for ▁new - ons et ▁severe ▁AI ▁requiri ng ▁sur g ical ▁intervention .
▁RESULT S : ▁During ▁follow - up , ▁6 ▁CF ▁L VAD ▁patients ▁developed ▁new , ▁severe ▁AI ▁that ▁was ▁ac com pani ed ▁by ▁heart ▁failure .
▁After ▁medical ▁ therapy ▁had ▁failed , ▁4 ▁patients ▁under went ▁redo ▁ster no to my ▁for ▁a or tic ▁val ve ▁procedure s ▁(1 ▁bio pro sthetic ▁val ve ▁replace ment , ▁1 ▁Da cro n ▁patch ▁ closure , ▁and ▁2 ▁a or tic ▁val ve ▁repair s ), ▁and ▁2 ▁patients ▁under went ▁trans cat heter ▁a or tic ▁val ve ▁procedure , ▁with ▁1 ▁requiri ng ▁revision ▁by ▁open ▁surgery ▁for ▁a or tic ▁val ve ▁replace ment .
▁Of ▁the ▁6 ▁patients , ▁5 ▁experienced ▁significant ▁improvement ▁in ▁functional ▁capacity ▁and ▁symptoms .
▁One ▁patient ▁die d ▁post operativ ely ▁seconda ry ▁to ▁multi organ ▁failure ▁and ▁se psis .
▁CON CL USI ONS : ▁Sur g ical ▁treatment ▁of ▁post - L VAD ▁AI ▁with ▁a or tic ▁val ve ▁over se wing ▁or ▁le a flet ▁repair ▁or ▁by ▁bio pro sthetic ▁a or tic ▁val ve ▁replace ment ▁is ▁effective ▁at ▁resto ring ▁functional ▁capacity ▁for ▁CF ▁L VAD ▁patients ▁who ▁develop ▁symptom a tic , ▁severe ▁AI ▁and ▁can ▁be ▁perform ed ▁safe ly ▁with ▁good ▁results .
▁Vario us ▁trans cat heter ▁approach es ▁to ▁these ▁difficult ▁problems ▁are ▁also ▁available ▁and ▁offer ▁less ▁invasi ve ▁alternative s ▁to ▁convention al ▁surgery .
▁Clinic al ▁character istic s ▁and ▁outcome s ▁of ▁young ▁and ▁very ▁young ▁adults ▁with ▁heart ▁failure : ▁The ▁CHA RM ▁programme ▁( Can des ar tan ▁in ▁Heart ▁Fail ure ▁Assessment ▁of ▁Re duction ▁in ▁Mor t ality ▁and ▁Morbi d ity ).
▁OB JE C TIVE S : ▁This ▁study ▁so ught ▁to ▁determine ▁the ▁character istic s ▁and ▁outcome s ▁of ▁young ▁adults ▁with ▁heart ▁failure ▁( HF ).
▁BA CK GRO UND : ▁Fe w ▁studies ▁have ▁focused ▁on ▁young ▁and ▁very ▁young ▁adults ▁with ▁ HF .
▁ MET HOD S : ▁Patient s ▁were ▁categori zed ▁into ▁5 ▁age ▁groups : ▁20 ▁to ▁39 , ▁40 ▁to ▁49 , ▁50 ▁to ▁59 , ▁60 ▁to ▁69 , ▁and ▁ ≥ 70 ▁years .
▁RESULT S : ▁The ▁young est ▁patients ▁with ▁ HF ▁were ▁more ▁likely ▁to ▁be ▁obes e ▁( yo ung est ▁vs . ▁old est : ▁body ▁mass ▁index ▁ ≥ 35 ▁kg / m (2) : ▁23% ▁vs . ▁6% ), ▁of ▁black ▁et hni city ▁(18 % ▁vs . ▁2% ), ▁and ▁have ▁ idio pathi c - dila ted ▁cardio my o pathy ▁(6 2% ▁vs . ▁9 %) ▁( all ▁p ▁< ▁ 0.00 01) .
▁They ▁were ▁less ▁likely ▁to ▁ad here ▁to ▁medication ▁( no nadh er ence ▁in ▁young est ▁vs . ▁old est : ▁2 4% ▁vs . ▁7% , ▁p ▁= ▁0.0 01) , ▁salt ▁in take , ▁and ▁other ▁dieta ry ▁measure s ▁(2 1% ▁vs . ▁ 9% , ▁p ▁= ▁0.0 02) .
▁The ▁young est ▁patients ▁were ▁less ▁likely ▁to ▁have ▁clinic al ▁and ▁radi ological ▁sign s ▁of ▁ HF ▁during ▁hospital ization .
▁Quality ▁of ▁life ▁was ▁worse , ▁but ▁all - ca use ▁mortal ity ▁was ▁lo west ▁in ▁the ▁young est ▁age ▁group ▁(3 - year ▁mortal ity ▁rates ▁across ▁the ▁respective ▁age ▁categorie s : ▁12% , ▁13% , ▁13% , ▁19% , ▁and ▁31 %, ▁respective ly ).
▁Compar ed ▁with ▁the ▁referent ▁age ▁group ▁of ▁60 ▁to ▁69 ▁years , ▁both ▁all - ca use ▁and ▁cardiovascular ▁mortal ity ▁were ▁lower ▁in ▁the ▁young est ▁group ▁even ▁after ▁multi vari able ▁adjust ment ▁( haz ard ▁ratio : ▁0 . 60 , ▁95% ▁confidence ▁interval : ▁0.3 6 ▁to ▁ 1.00 ; ▁p ▁= ▁0.0 49 , ▁and ▁hazard ▁ratio : ▁0 . 71 , ▁95% ▁confidence ▁interval : ▁0 . 42 ▁to ▁1. 18 , ▁p ▁= ▁0.1 86 , ▁respective ly ).
▁Three - year ▁ HF ▁hospital ization ▁rates ▁were ▁24 %, ▁15% , ▁15% , ▁22% , ▁and ▁2 8% ▁in ▁a ges ▁20 ▁to ▁39 , ▁40 ▁to ▁49 , ▁50 ▁to ▁59 , ▁60 ▁to ▁69 , ▁and ▁ ≥ 70 ▁years , ▁respective ly ▁( p ▁< ▁ 0.00 01) .
▁CON CL USI ONS : ▁Beyond ▁di ver gent ▁et i ology ▁and ▁como rbi di ties , ▁young er ▁patients ▁exhibi ted ▁stri king ▁difference s ▁in ▁presentation ▁and ▁outcome s ▁compared ▁with ▁older ▁counter part s .
▁Clinic al ▁and ▁radi ological ▁sign s ▁of ▁ HF ▁were ▁less ▁common , ▁yet ▁quality ▁of ▁life ▁was ▁more ▁significantly ▁im pair ed .
▁Fa tal ▁and ▁non fa tal ▁outcome s ▁were ▁discord ant , ▁with ▁better ▁survival ▁de spite ▁higher ▁hospital ization ▁rates .
▁Rand om ized ▁trial ▁of ▁Nordic ▁walking ▁in ▁patients ▁with ▁moderat e ▁to ▁severe ▁heart ▁failure .
▁BA CK GRO UND : ▁Patient s ▁with ▁heart ▁failure ▁are ▁a ▁growing ▁population ▁within ▁cardiac ▁rehabilita tion .
▁The ▁purpose ▁of ▁this ▁study ▁was ▁to ▁compare , ▁through ▁a ▁single - centre , ▁parallel - group , ▁random ized ▁control led ▁trial , ▁the ▁effects ▁of ▁Nordic ▁walking ▁and ▁standard ▁cardiac ▁rehabilita tion ▁care ▁on ▁functional ▁capacity ▁and ▁other ▁outcome s ▁in ▁patients ▁with ▁moderat e ▁to ▁severe ▁heart ▁failure .
▁ MET HOD S : ▁Bet we en ▁2008 ▁and ▁2009, ▁54 ▁patients ▁( a ged ▁6 2.4 ▁ ± ▁11. 4 ▁years ) ▁with ▁heart ▁failure ▁( me an ▁e je ction ▁ fraction ▁= ▁26. 9% ▁ ± ▁5.0 %) ▁were ▁random ly ▁assign ed ▁to ▁standard ▁cardiac ▁rehabilita tion ▁care ▁( n ▁= ▁27 ) ▁or ▁Nordic ▁walking ▁( n ▁= ▁27 ); ▁both ▁groups ▁perform ed ▁200 ▁to ▁400 ▁minutes ▁of ▁exercise ▁per ▁week ▁for ▁12 ▁weeks .
▁The ▁primary ▁outcome , ▁measure d ▁after ▁12 ▁weeks , ▁was ▁functional ▁capacity ▁assess ed ▁by ▁a ▁6- minut e ▁walk ▁test ▁(6 MW T ).
▁RESULT S : ▁Compar ed ▁with ▁standard ▁care , ▁Nordic ▁walking ▁led ▁to ▁higher ▁functional ▁capacity ▁( Δ ▁12 5.6 ▁ ± ▁59 . 4 ▁m ▁vs ▁Δ ▁5 7.0 ▁ ± ▁7 1.3 ▁m ▁travel led ▁during ▁6 MW T ; ▁P ▁= ▁0.0 01) , ▁greater ▁self - report ed ▁physical ▁activity ▁( Δ ▁15 8.5 ▁ ± ▁11 8.5 ▁minutes ▁vs ▁Δ ▁15 5.5 ▁ ± ▁12 5.6 ▁minutes ; ▁P ▁= ▁0.0 49) , ▁increased ▁right ▁grip ▁strength ▁( Δ ▁2.3 ▁ ± ▁3.5 ▁kg ▁vs ▁Δ ▁0.3 ▁ ± ▁3.1 ▁kg ; ▁P ▁= ▁0.0 26) , ▁and ▁few er ▁ depressiv e ▁symptoms ▁( Hospital ▁An xie ty ▁and ▁De pression ▁Scal e ▁score ▁= ▁Δ ▁- 1.7 ▁ ± ▁2.4 ▁vs ▁Δ ▁- 0.8 ▁ ± ▁3.1 ; ▁P ▁= ▁0.0 14) .
▁No ▁significant ▁difference s ▁were ▁found ▁for ▁pe ak ▁aero bic ▁capacity , ▁left - hand ▁grip ▁strength , ▁body ▁weight , ▁wa ist ▁circum ferenc e , ▁or ▁symptoms ▁of ▁anxiety .
▁CON CL USI ONS : ▁Nordic ▁walking ▁was ▁superior ▁to ▁standard ▁cardiac ▁rehabilita tion ▁care ▁in ▁improving ▁functional ▁capacity ▁and ▁other ▁important ▁outcome s ▁in ▁patients ▁with ▁heart ▁failure .
▁This ▁exercise ▁modal ity ▁is ▁a ▁promis ing ▁alternative ▁for ▁this ▁population .
▁Le ft ▁vent ri cular ▁e je ction ▁time ▁in ▁a cute ▁heart ▁failure ▁complicat ing ▁pre cap illa ry ▁pulmonar y ▁hyper tension .
▁BA CK GRO UND : ▁Novel ▁non in va sive ▁tools ▁may ▁improve ▁the ▁management ▁of ▁patients ▁with ▁pulmonar y ▁hyper tension ▁( PH ) ▁experi en cing ▁heart ▁failure .
▁Major ▁right ▁vent ric le ▁over load ▁lead s ▁to ▁decrease d ▁stroke ▁volume , ▁which ▁short ens ▁left ▁vent ri cular ▁e je ction ▁time ▁( L VET ).
▁Our ▁arterial ▁ton ometr y ▁study ▁test ed ▁the ▁hypothe sis ▁that ▁L VET ▁car ries ▁prognos tic ▁value ▁in ▁patients ▁with ▁pre cap illa ry ▁PH ▁with ▁heart ▁failure .
▁ MET HOD S : ▁Clinic al , ▁biologi c , ▁and ▁radi al ▁arter y ▁ton ometr y ▁variable s ▁were ▁prospect ive ly ▁obtain ed ▁at ▁ad mission ▁and ▁at ▁day ▁3 ▁to ▁5 ▁in ▁53 ▁consecutiv e ▁patients ▁with ▁PH ▁admit ted ▁to ▁our ▁ ICU ▁for ▁clinic al ▁deteriora tion .
▁L VET ▁was ▁measure d ▁from ▁the ▁reconstru cted ▁a or tic ▁pressure ▁cur ve .
▁RESULT S : ▁Over all ▁ ICU ▁mortal ity ▁( media n ▁stay , ▁5 ▁days ) ▁was ▁17% .
▁At ▁ad mission , ▁the ▁L VET ▁was ▁short er ▁in ▁patients ▁with ▁un favor able ▁outcome ▁( media n , ▁228 ▁milli second s ▁[ 25 th - 75 th ▁percent ile s , ▁212 - 278 ▁milli second s ] ▁vs ▁25 7 ▁milli second s ▁[ 2 37 -27 7 ▁milli second s ] , ▁P ▁= ▁ . 03 2) , ▁where as ▁other ▁to no metric ▁indice s ▁were ▁similar .
▁The ▁L VET ▁at ▁entry ▁(23 7 ▁milli second s ) ▁had ▁7 3% ▁ sensitiv ity ▁and ▁8 9% ▁specific ity ▁for ▁identify ing ▁death ▁in ▁the ▁ ICU .
▁Other ▁prognos tic ▁factors ▁at ▁ad mission ▁were ▁higher ▁se rum ▁levels ▁of ▁brain ▁na tri ure tic ▁pe pti de ▁( B NP ) ▁and ▁creati nine ▁and ▁lower ▁na trem ia .
▁Do bu tamine ▁require ment , ▁higher ▁fur os em ide ▁dose , ▁and ▁higher ▁oxygen ▁flow ▁were ▁associated ▁with ▁un favor able ▁outcome .
▁At ▁the ▁second ▁evaluation , ▁higher ▁se rum ▁levels ▁of ▁creati nine ▁and ▁B NP , ▁higher ▁fur os em ide ▁dose ▁and ▁oxygen ▁flow , ▁and ▁dobu tamine ▁or ▁no re pine ph rine ▁require ment ▁were ▁associated ▁with ▁poor ▁outcome .
▁The ▁change ▁in ▁L VET ▁between ▁ad mission ▁and ▁follow - up ▁measure ment ▁was ▁not ▁associated ▁with ▁outcome .
▁The ▁90- day ▁mortal ity ▁was ▁2 8% .
▁CON CL USI ONS : ▁Short en ed ▁L VET ▁at ▁ ICU ▁ad mission ▁was ▁a ▁prognos tic ▁factor ▁in ▁patients ▁with ▁pre cap illa ry ▁PH ▁with ▁heart ▁failure .
▁Previous ly ▁document ed ▁prognos tic ▁factors ▁were ▁also ▁confirm ed ▁in ▁this ▁co hor t .
▁Right ▁at rial ▁my xo ma ▁complicat ed ▁by ▁pulmonar y ▁e mbol ism ▁and ▁reveal ed ▁by ▁right ▁heart ▁failure .
▁My xo mas ▁are ▁the ▁most ▁common ▁type ▁of ▁cardiac ▁benign ▁tumor s ▁and ▁most ▁of ▁them ▁are ▁located ▁in ▁the ▁left ▁at rium , ▁followed ▁by ▁the ▁right ▁at rium .
▁My xo mas ▁in ▁the ▁right ▁at rium ▁may ▁rare ly ▁embo lize ▁to ▁the ▁pulmonar y ▁arterial ▁vas cula ture .
▁Here , ▁we ▁present ▁a ▁case ▁report ▁of ▁a ▁patient ▁with ▁right ▁at rial ▁my xo ma ▁and ▁massive ▁e mbol ism ▁to ▁the ▁pulmonar y ▁arteri es ▁treated ▁sur g ically ▁with ▁right ▁at rial ▁mass ▁remo val ▁and ▁pulmonar y ▁e mbol ecto my .
▁The ▁right ▁at rium ▁mass ▁presente d ▁with ▁pro lapse ▁through ▁the ▁tri cus pid ▁val ve ▁causing ▁a ▁ste no tic ▁physio log y .
▁The ▁left ▁pulmonar y ▁arter y ▁was ▁completed ▁occ lud ed ▁and ▁the ▁right ▁pulmonar y ▁arter y ▁was ▁parti ally ▁ob struct ed .
▁Sur g ical ▁tac tics ▁included ▁a ▁brief ▁hypothe r mic ▁circula tory ▁arrest .
▁The ▁patient ▁had ▁an ▁un event ful ▁recovery ▁and ▁was ▁as ym pto matic ▁after ▁6 ▁months ▁of ▁follow - up .
▁Heart ▁failure ▁risk ▁among ▁patients ▁with ▁rhe um ato id ▁ar thri tis ▁starting ▁a ▁T NF ▁anta gon ist .
▁BA CK GRO UND : ▁While ▁heart ▁failure ▁( HF ) ▁is ▁associated ▁with ▁eleva tions ▁in ▁tumor ▁nec rosi s ▁factor ▁( TN F ) α , ▁several ▁trial s ▁of ▁T NF ▁anta gon ists ▁showed ▁no ▁benefit ▁and ▁possibly ▁worse ning ▁of ▁disease ▁in ▁those ▁with ▁known ▁severe ▁ HF .
▁We ▁studie d ▁the ▁risk ▁of ▁new ▁or ▁re current ▁ HF ▁among ▁a ▁group ▁of ▁patients ▁receiving ▁these ▁agents ▁to ▁treat ▁rhe um ato id ▁ar thri tis ▁( RA ).
▁ MET HOD S : ▁We ▁used ▁data ▁from ▁four ▁different ▁US ▁health care ▁programme s .
▁Subject s ▁with ▁RA ▁receiving ▁met ho tre xa te ▁were ▁eligible ▁to ▁enter ▁the ▁study ▁co hor t ▁if ▁they ▁added ▁or ▁switch ed ▁to ▁a ▁T NF ▁anta gon ist ▁or ▁another ▁non - bi ological ▁disease ▁mod ifying ▁anti r heu matic ▁drug ▁( n b DM ARD ).
▁These ▁groups ▁were ▁compared ▁in ▁Co x ▁re gression ▁models ▁strat ified ▁by ▁pro pens ity ▁score ▁de cile ▁and ▁adjust ed ▁for ▁oral ▁gluco cor tico id ▁dos age , ▁prior ▁ HF ▁hospital isation s , ▁and ▁the ▁use ▁of ▁loop ▁di ure tics .
▁RESULT S : ▁We ▁compared ▁8 656 ▁new ▁users ▁of ▁a ▁n b DM ARD ▁with ▁11 ▁ 587 ▁new ▁users ▁of ▁a ▁T NF ▁anta gon ist ▁with ▁similar ▁base line ▁co varia tes .
▁The ▁HR ▁for ▁the ▁T NF ▁anta gon ists ▁compared ▁with ▁n b DM ARD ▁was ▁0 . 85 ▁( 95% ▁CI ▁0 . 63 ▁to ▁1. 14) .
▁The ▁HR ▁was ▁also ▁not ▁eleva ted ▁in ▁subject s ▁with ▁a ▁history ▁of ▁ HF .
▁But , ▁it ▁was ▁eleva ted ▁prior ▁to ▁2002 ▁( HR ▁2. 17 , ▁95% ▁CI ▁0 . 45 ▁to ▁10. 50 , ▁test ▁for ▁interaction ▁p = 0.0 36) .
▁Oral ▁gluco cor tico ids ▁were ▁associated ▁with ▁a ▁dose - related ▁gradi ent ▁of ▁ HF ▁risk : ▁compared ▁with ▁no ▁use , ▁1 ≤ 5 ▁mg ▁HR ▁1. 30 ▁( 95% ▁CI ▁0 . 91 ▁to ▁1. 85) , ▁ ≥ 5 ▁mg ▁HR ▁1. 54 ▁( 95% ▁CI ▁1. 09 ▁to ▁2. 19) .
▁CON CL USI ONS : ▁T NF ▁anta gon ists ▁were ▁not ▁associated ▁with ▁a ▁risk ▁of ▁ HF ▁hospital ▁ad missions ▁compared ▁with ▁n b DM ARD s ▁in ▁this ▁RA ▁population .
▁U sing ▁exercise ▁to ▁improve ▁quality ▁of ▁life ▁for ▁people ▁with ▁heart ▁failure .
▁Abstract ▁In ▁the ▁current ▁economic ▁climate ▁within ▁the ▁NH S , ▁behaviour al - change ▁intervention s ▁in ▁chronic ▁disease ▁such ▁as ▁exercise ▁programme s ▁will ▁be ▁time - limit ed ▁within ▁a cute ▁hospital ▁facilities .
▁The ▁challenge ▁is ▁to ▁deliver ▁cost - effect ive , ▁participa tory , ▁population - specific ▁health ▁intervention s ▁that ▁result ▁in ▁mea sur able ▁benefits .
▁ MET HOD OLO GY : ▁A ▁mix ed - met hod s ▁study ▁was ▁under tak en ▁to ▁assess ▁the ▁benefits ▁of ▁participation ▁in ▁a ▁structure d ▁exercise ▁programme ▁for ▁patients ▁with ▁heart ▁failure .
▁Prima ry ▁outcome s ▁were ▁improvement s ▁in ▁functional ▁capacity ▁and ▁quality ▁of ▁life .
▁Second ary ▁outcome ▁measure s ▁related ▁to ▁patient ▁satisfaction ▁and ▁sustain ability ▁of ▁the ▁intervention ▁post ▁study .
▁RESULT S : ▁Over all ▁significant ▁improvement s ▁were ▁not ▁found ▁in ▁quality ▁of ▁life ▁or ▁functional ▁capacity ; ▁some ▁participants ▁demonstrat ed ▁significant ▁improvement s ▁with ▁others ▁showing ▁minor ▁improvement ▁or ▁no ▁improvement ▁in ▁one ▁or ▁both ▁domain s .
▁CON CL USI ONS : ▁A nec do tal ▁evidence ▁of ▁perc ei ved ▁benefit ▁was ▁express ed ▁in ▁participant ▁satisfaction ▁response s .
▁Second ary ▁outcome s ▁were ▁met ▁in ▁relation ▁to ▁sustain ability ▁with ▁commission ing ▁of ▁hospital - ▁and ▁community - based ▁programme s ▁on ▁complet ion ▁of ▁the ▁study .
▁Fra il ty ▁and ▁risk ▁for ▁heart ▁failure ▁in ▁older ▁adults : ▁the ▁health , ▁ aging , ▁and ▁body ▁composition ▁study .
▁OB JE C TIVE : ▁The ▁a im ▁of ▁this ▁study ▁was ▁to ▁assess ▁the ▁association ▁between ▁fra il ty ▁and ▁risk ▁for ▁heart ▁failure ▁( HF ) ▁in ▁older ▁adults .
▁BA CK GRO UND : ▁Fra il ty ▁is ▁common ▁in ▁the ▁el der ly ▁and ▁is ▁associated ▁with ▁advers e ▁health ▁outcome s .
▁Impact ▁of ▁fra il ty ▁on ▁ HF ▁risk ▁is ▁not ▁known .
▁ MET HOD S : ▁We ▁assess ed ▁the ▁association ▁between ▁fra il ty , ▁using ▁the ▁Health ▁ABC ▁Short ▁Physic al ▁Performance ▁Bat tery ▁( H ABC ▁Bat tery ) ▁and ▁the ▁Gill ▁index , ▁and ▁incident ▁ HF ▁in ▁28 25 ▁participants ▁a ged ▁70 ▁to ▁79 ▁years .
▁RESULT S : ▁Me an ▁age ▁of ▁participants ▁was ▁74 ▁ ± ▁3 ▁years ; ▁4 8% ▁were ▁men ▁and ▁5 9% ▁were ▁white .
▁During ▁a ▁media n ▁follow ▁up ▁of ▁11. 4 ▁( 7.1 -11 . 7) ▁years , ▁ 466 ▁participants ▁developed ▁ HF .
▁Compar ed ▁to ▁non - fra il ▁participants , ▁moderat e ▁( HR ▁1. 36 , ▁95% ▁CI ▁1. 08 -1 . 71) ▁and ▁severe ▁fra il ty ▁( HR ▁1. 88 , ▁95% ▁CI ▁1.0 2-3 . 47) ▁by ▁Gill ▁index ▁was ▁associated ▁with ▁a ▁higher ▁risk ▁for ▁ HF .
▁H ABC ▁Bat tery ▁score ▁was ▁linear ly ▁associated ▁with ▁ HF ▁risk ▁after ▁adjust ing ▁for ▁the ▁Health ▁ABC ▁ HF ▁Model ▁( HR ▁1. 24 , ▁95% ▁CI ▁1.1 3-1 . 36 ▁per ▁SD ▁decrease ▁in ▁score ) ▁and ▁remain ed ▁significant ▁when ▁control led ▁for ▁death ▁as ▁a ▁competi ng ▁risk ▁( HR ▁1. 30 ; ▁95% ▁CI ▁1.0 0-1 . 55) .
▁Results ▁were ▁comparable ▁across ▁age , ▁sex , ▁and ▁race , ▁and ▁in ▁sub - group s ▁based ▁on ▁diabetes ▁mell itus ▁or ▁cardiovascular ▁disease ▁at ▁base line .
▁Add i tion ▁of ▁H ABC ▁Bat tery ▁score s ▁to ▁the ▁Health ▁ABC ▁ HF ▁Risk ▁Model ▁improve d ▁discrimina tion ▁( change ▁in ▁C - index , ▁0.0 14 ; ▁95% ▁CI ▁0.0 18 - 0.0 10) ▁and ▁appropriate ly ▁re class ified ▁13. 4% ▁( net - re class ification - improv ement ▁0.0 73 , ▁95% ▁CI ▁0.0 2 1-0 . 125 ; ▁P ▁= ▁ . 006 ) ▁of ▁participants ▁(8 . 3% ▁who ▁developed ▁ HF ▁and ▁5. 1% ▁who ▁did ▁not ).
▁CON CL USI ONS : ▁Fra il ty ▁is ▁independent ly ▁associated ▁with ▁risk ▁of ▁ HF ▁in ▁older ▁adults .
▁The ▁role ▁of ▁vaso press in ▁in ▁con ges tive ▁heart ▁failure .
▁Neuro hormon al ▁ab normal ities ▁contribute ▁to ▁the ▁pat ho phy si ology ▁of ▁con ges tive ▁heart ▁failure ▁( CH F ).
▁Success ful ▁approach es ▁to ▁improving ▁the ▁prognos is ▁of ▁patients ▁with ▁CHF ▁are ▁based ▁large ly ▁on ▁ therapeut ic ▁interrupt ion ▁of ▁activa ted ▁neuro hormon al ▁systems .
▁The ▁use ▁of ▁anta gon ists ▁and ▁inhibi tors ▁of ▁the ▁re nin - angi oten sin - al do ster one ▁and ▁sympa the tic ▁ner vous ▁systems ▁has ▁significantly ▁improve d ▁clinic al ▁outcome s ▁in ▁CHF .
▁Exc es sive ▁secret ion ▁of ▁argi nine ▁vaso press in ▁( A VP ) ▁has ▁the ▁potential ▁for ▁delete rious ▁effects ▁on ▁various ▁physio logic ▁process es ▁in ▁CHF ▁In hib i tion ▁of ▁A VP ▁through ▁vaso press in ▁receptor ▁anta gon ist ▁ therapy ▁is ▁a ▁potential ly ▁beneficia l ▁new ▁ therapeut ic ▁approach ▁to ▁CHF .
▁N fat ▁and ▁mi R -25 ▁coopera te ▁to ▁re activa te ▁the ▁tran scription ▁factor ▁Hand 2 ▁in ▁heart ▁failure .
▁Although ▁aber rant ▁re activa tion ▁of ▁em bry o nic ▁gene ▁programs ▁is ▁in trica tely ▁link ed ▁to ▁path ological ▁heart ▁disease , ▁the ▁tran scription ▁factors ▁driving ▁these ▁gene ▁programs ▁remain ▁ill - de fin ed .
▁Here ▁we ▁report ▁that ▁increased ▁calci ne uri n / N fat ▁signal ling ▁and ▁decrease d ▁mi R -25 ▁expression ▁integrat e ▁to ▁re - express ▁the ▁basic ▁heli x - loop - heli x ▁( b HL H ) ▁tran scription ▁factor ▁d HAND ▁( al so ▁known ▁as ▁Hand 2) ▁in ▁the ▁disease d ▁human ▁and ▁mouse ▁my o car dium .
▁In ▁line , ▁mu tant ▁mi ce ▁over express ing ▁Hand 2 ▁in ▁otherwise ▁healthy ▁heart ▁muscle ▁cell s ▁developed ▁a ▁ph eno type ▁of ▁path ological ▁hyper trop hy .
▁Con verse ly , ▁condition al ▁gene - tar get ed ▁Hand 2 ▁mi ce ▁demonstrat ed ▁a ▁marked ▁resist ance ▁to ▁pressure - over load - indu ced ▁hyper trop hy , ▁fibro sis , ▁vent ri cular ▁dys function ▁and ▁in duction ▁of ▁a ▁fet al ▁gene ▁program .
▁Fur ther more , ▁in ▁vivo ▁inhibi tion ▁of ▁mi R -25 ▁by ▁a ▁specific ▁anta go mir ▁evo ked ▁spontane ous ▁cardiac ▁dys function ▁and ▁sensi t ized ▁the ▁mur ine ▁my o car dium ▁to ▁heart ▁failure ▁in ▁a ▁Hand 2- dependent ▁manner .
▁Our ▁results ▁reveal ▁that ▁signal ling ▁casca des ▁integrat e ▁with ▁micro RNA s ▁to ▁induc e ▁the ▁expression ▁of ▁the ▁b HL H ▁tran scription ▁factor ▁Hand 2 ▁in ▁the ▁post na tal ▁mamma lian ▁my o car dium ▁with ▁impact ▁on ▁em bry o nic ▁gene ▁programs ▁in ▁heart ▁failure .
▁Epidemi ology ▁and ▁treatment ▁of ▁chronic ▁heart ▁failure ; ▁use ▁of ▁bis o pro lol .
▁The ▁prevale nce ▁of ▁chronic ▁heart ▁failure ▁in ▁Hungary ▁is ▁1. 6% ▁in ▁the ▁adult ▁population , ▁but ▁it ▁occur s ▁in ▁15-20 % ▁of ▁subject s ▁over ▁80 ▁years ▁of ▁age .
▁The ▁base ▁of ▁treatment ▁of ▁heart ▁failure ▁is ▁the ▁block ade ▁of ▁the ▁neuro - hormon al ▁system , ▁which ▁includes ▁the ▁use ▁of ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁( angi oten sin ▁receptor ▁block ers ▁in ▁case ▁of ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁in tolerance ), ▁beta ▁receptor ▁block ers ▁and ▁mineral o cor tico id ▁receptor ▁anta gon ists .
▁Because ▁of ▁their ▁negative ▁in o tropi c ▁effect , ▁beta ▁block ers ▁were ▁negle cted ▁for ▁a ▁long ▁time ▁from ▁the ▁treatment ▁of ▁heart ▁failure .
▁However , ▁during ▁the ▁past ▁de cade s ▁several ▁studies ▁have ▁demonstrat ed ▁that ▁beta ▁block ers ▁decrease ▁mortal ity ▁in ▁patients ▁with ▁heart ▁failure .
▁The ▁effective ness ▁of ▁bis o pro lol ▁in ▁ reducing ▁mortal ity ▁has ▁also ▁also ▁been ▁document ed ▁in ▁a ▁number ▁of ▁studies .
▁My o card ial ▁loss ▁of ▁I RS 1 ▁and ▁I RS 2 ▁causes ▁heart ▁failure ▁and ▁is ▁control led ▁by ▁p 38 al pha ▁MA PK ▁during ▁insulin ▁resist ance .
▁Card iac ▁failure ▁is ▁a ▁major ▁cause ▁of ▁death ▁in ▁patients ▁with ▁type ▁2 ▁diabetes , ▁but ▁the ▁molecular ▁mechanism ▁that ▁links ▁diabetes ▁to ▁heart ▁failure ▁remain s ▁un clear .
▁In s ulin ▁resist ance ▁is ▁a ▁hall mark ▁of ▁type ▁2 ▁diabetes , ▁and ▁insulin ▁receptor ▁substrat es ▁1 ▁and ▁2 ▁( IR S 1 ▁and ▁I RS 2) ▁are ▁the ▁major ▁insulin - signal ing ▁component s ▁regula ting ▁cel lular ▁metabolism ▁and ▁survival .
▁To ▁determine ▁the ▁role ▁of ▁I RS 1 ▁and ▁I RS 2 ▁in ▁the ▁heart ▁and ▁examine ▁whether ▁hyper insu line mia ▁causes ▁my o card ial ▁insulin ▁resist ance ▁and ▁cel lular ▁dys function ▁via ▁I RS 1 ▁and ▁I RS 2 , ▁we ▁generate d ▁heart - specific ▁I RS 1 ▁and ▁I RS 2 ▁gene ▁double - k no ckou t ▁( H - D KO ) ▁mi ce ▁and ▁ liver - specific ▁I RS 1 ▁and ▁I RS 2 ▁double - k no ckou t ▁( L - D KO ) ▁mi ce .
▁H - D KO ▁mi ce ▁had ▁reduce d ▁vent ri cular ▁mass ; ▁developed ▁cardiac ▁apo pto sis , ▁fibro sis , ▁and ▁failure ; ▁and ▁showed ▁di minis hed ▁Akt → for k head ▁box ▁class ▁O -1 ▁signal ing ▁that ▁was ▁ac com pani ed ▁by ▁im pair ed ▁cardiac ▁metabol ic ▁gene ▁expression ▁and ▁reduce d ▁ATP ▁content .
▁L - D KO ▁mi ce ▁had ▁decrease d ▁cardiac ▁I RS 1 ▁and ▁I RS 2 ▁protein s ▁and ▁exhibi ted ▁features ▁of ▁heart ▁failure , ▁with ▁im pair ed ▁cardiac ▁energy ▁metabolism ▁gene ▁expression ▁and ▁activa tion ▁of ▁p 38 α ▁mit ogen - activa ted ▁protein ▁kina se ▁( p 38) .
▁U sing ▁ne ona tal ▁rat ▁vent ri cular ▁cardio my o cy tes , ▁we ▁further ▁found ▁that ▁chronic ▁insulin ▁exposure ▁reduce d ▁I RS 1 ▁and ▁I RS 2 ▁protein s ▁and ▁prevent ed ▁insulin ▁action ▁through ▁activa tion ▁of ▁p 38 , ▁reveal ing ▁a ▁fundamental ▁mechanism ▁of ▁cardiac ▁dys function ▁during ▁insulin ▁resist ance ▁and ▁type ▁2 ▁diabetes .
▁Practic e - level ▁variation ▁in ▁use ▁of ▁recommended ▁medication s ▁among ▁out patient s ▁with ▁heart ▁failure : ▁Insight s ▁from ▁the ▁NC DR ▁PIN NA CLE ▁program .
▁BA CK GRO UND : ▁The ▁objective ▁of ▁this ▁study ▁is ▁to ▁examine ▁practice - level ▁variation ▁in ▁rates ▁of ▁guide line - re com mend ed ▁treatment ▁for ▁out patient s ▁with ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction , ▁and ▁to ▁examine ▁the ▁association ▁between ▁treatment ▁variation ▁and ▁practice ▁site , ▁independent ▁of ▁patient ▁factors .
▁ MET HOD S ▁AND ▁RESULT S : ▁Card i ology ▁practice s ▁participat ing ▁in ▁the ▁National ▁Card io vas cular ▁Disease ▁Registr y ▁Practic e ▁Innovation ▁and ▁Clinic al ▁Excellence ▁registr y ▁from ▁July ▁2008 ▁to ▁December ▁2010 ▁were ▁evaluat ed .
▁Practic e ▁rates ▁of ▁treatment ▁with ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors / angi oten sin ▁receptor ▁block ers ▁and ▁β - block ers ▁and ▁an ▁optimal ▁combine d ▁treatment ▁measure ▁were ▁determine d ▁for ▁patients ▁with ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction ▁and ▁no ▁document ed ▁contra indica tions .
▁Multi vari able ▁hier archi cal ▁re gression ▁models ▁were ▁adjust ed ▁for ▁demo graphic s , ▁insurance ▁status , ▁and ▁como rbi di ties .
▁A ▁media n ▁rate ▁ratio ▁was ▁calcula ted ▁for ▁each ▁ therapy , ▁which ▁describe s ▁the ▁like li hood ▁that ▁the ▁treatment ▁of ▁a ▁patient ▁with ▁given ▁como rbi di ties ▁would ▁differ ▁at ▁2 ▁random ly ▁selected ▁practice s .
▁We ▁identified ▁12 ▁ 556 ▁patients ▁from ▁45 ▁practice s .
▁The ▁una d just ed ▁practice - level ▁pre scription ▁rates ▁range d ▁from ▁4 4% ▁to ▁100% ▁for ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors / angi oten sin ▁receptor ▁block ers ▁( media n , ▁85% ; ▁inter quart ile ▁range , ▁75% -8 9% ), ▁from ▁4 9% ▁to ▁100% ▁for ▁β - block ers ▁( media n , ▁9 2% ; ▁inter quart ile ▁range , ▁8 3% - 95% ), ▁and ▁from ▁3 7% ▁to ▁100% ▁for ▁optimal ▁combine d ▁treatment ▁( media n , ▁7 9% ; ▁inter quart ile ▁range , ▁6 6% - 85% ).
▁The ▁adjust ed ▁media n ▁rate ▁ratio ▁was ▁1. 11 ▁( 95% ▁confidence ▁interval , ▁1. 08 -1 . 18) ▁for ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors / angi oten sin ▁receptor ▁block ers ▁ therapy , ▁1. 08 ▁( 95% ▁confidence ▁interval , ▁1.0 5-1 . 15) ▁for ▁β - block ers ▁ therapy , ▁and ▁1. 17 ▁( 1.1 3-1 . 26) ▁for ▁optimal ▁combine d ▁treatment .
▁CON CL USI ONS : ▁Varia tion ▁in ▁the ▁use ▁of ▁guide line - re com mend ed ▁medication s ▁for ▁patients ▁with ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction ▁exist s ▁in ▁the ▁out patient ▁setting .
▁Address ing ▁practice - level ▁difference s ▁may ▁be ▁an ▁important ▁component ▁of ▁improving ▁quality ▁of ▁care ▁for ▁patients ▁with ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction .
▁Tras tuz um ab - related ▁cardio toxic ity ▁among ▁older ▁patients ▁with ▁breast ▁cancer .
▁The ▁use ▁of ▁tras tuz um ab ▁in ▁the ▁ad ju vant ▁setting ▁improve s ▁outcome s ▁but ▁is ▁associated ▁with ▁cardio toxic ity ▁manifest ed ▁as ▁con ges tive ▁heart ▁failure ▁( CH F ).
▁The ▁rates ▁and ▁risk ▁factors ▁associated ▁with ▁tras tuz um ab - related ▁CHF ▁among ▁older ▁patients ▁are ▁un know n .
▁Breast ▁cancer ▁patients ▁at ▁least ▁66 ▁years ▁old ▁with ▁full ▁Medica re ▁coverage , ▁diagnose d ▁with ▁stage ▁I - III ▁breast ▁cancer ▁between ▁2005 ▁and ▁2009, ▁and ▁treated ▁with ▁che mo therapy ▁were ▁identified ▁in ▁the ▁S EER - Medic are ▁and ▁in ▁the ▁Texas ▁Cancer ▁Registr y – Medic are ▁database s .
▁The ▁rates ▁and ▁risk ▁factors ▁associated ▁with ▁CHF ▁were ▁evaluat ed .
▁Che mo therapy , ▁tras tuz um ab ▁use , ▁como rbi di ties , ▁and ▁CHF ▁were ▁identified ▁using ▁International ▁Classifica tion ▁of ▁Disease s , ▁version ▁9 , ▁and ▁Health care ▁Common ▁Procedur e ▁Co ding ▁System ▁code s .
▁Analyse s ▁included ▁de script ive ▁statistic s ▁and ▁Co x ▁proportion al ▁hazard s ▁models .
▁In ▁total , ▁ 9,5 35 ▁patients ▁were ▁included , ▁of ▁whom ▁2,2 03 ▁(23 . 1%) ▁received ▁tras tuz um ab .
▁Media n ▁age ▁of ▁the ▁entire ▁co hor t ▁was ▁71 ▁years ▁old .
▁Am ong ▁tras tuz um ab ▁users , ▁the ▁rate ▁of ▁CHF ▁was ▁29. 4% ▁compared ▁with ▁18. 9% ▁in ▁non tras tuz um ab ▁users ▁( P ▁< ▁ . 001 ).
▁Tras tuz um ab ▁users ▁were ▁more ▁likely ▁to ▁develop ▁CHF ▁than ▁non tras tuz um ab ▁users ▁( haz ard ▁ratio ▁[ HR ] , ▁1. 95 ; ▁95% ▁CI , ▁1. 75 ▁to ▁2. 17) .
▁Am ong ▁tras tuz um ab - tre ated ▁patients , ▁older ▁age ▁( age ▁> ▁80 ▁years ; ▁HR , ▁1.5 3 ; ▁95% ▁CI , ▁1. 16 ▁to ▁2. 10) , ▁corona ry ▁arter y ▁disease ▁( HR , ▁1. 82 ; ▁95% ▁CI , ▁1. 34 ▁to ▁2. 48) , ▁hyper tension ▁( HR , ▁1. 24 ; ▁95% ▁CI , ▁1. 02 ▁to ▁1. 50 ), ▁and ▁week ly ▁tras tuz um ab ▁administration ▁( HR , ▁1. 33 ; ▁95% ▁CI , ▁1. 05 ▁to ▁1. 68) ▁increased ▁the ▁risk ▁of ▁CHF .
▁In ▁this ▁large ▁co hor t ▁of ▁older ▁breast ▁cancer ▁patients , ▁the ▁rates ▁of ▁tras tuz um b - related ▁CHF ▁are ▁higher ▁than ▁those ▁reported ▁in ▁clinic al ▁trial s .
▁Am ong ▁patients ▁treated ▁with ▁tras tuz um ab , ▁those ▁with ▁cardiac ▁como rbi di ties ▁and ▁older ▁age ▁may ▁be ▁at ▁higher ▁risk .
▁Fur ther ▁studies ▁need ▁to ▁confirm ▁the ▁role ▁that ▁the ▁fre que ncy ▁of ▁administration ▁play s ▁in ▁the ▁development ▁of ▁tras tuz um ab - related ▁CHF .
▁Mediterrane an ▁and ▁DAS H ▁die t ▁score s ▁and ▁mortal ity ▁in ▁women ▁with ▁heart ▁failure : ▁The ▁Women ' s ▁Health ▁Initiative .
▁BA CK GRO UND : ▁Current ▁dieta ry ▁recommendations ▁for ▁patients ▁with ▁heart ▁failure ▁( HF ) ▁are ▁large ly ▁based ▁on ▁data ▁from ▁non - HF ▁population s ; ▁evidence ▁on ▁associations ▁of ▁dieta ry ▁pattern s ▁with ▁outcome s ▁in ▁ HF ▁is ▁limited .
▁We ▁therefore ▁evaluat ed ▁associations ▁of ▁Mediterrane an ▁and ▁Diet ary ▁App ro ach es ▁to ▁Stop ▁Hyper tension ▁( DAS H ) ▁die t ▁score s ▁with ▁mortal ity ▁among ▁post meno paus al ▁women ▁with ▁ HF .
▁ MET HOD S ▁AND ▁RESULT S : ▁Women ' s ▁Health ▁Initiative ▁participants ▁were ▁followed ▁up ▁from ▁the ▁date ▁of ▁ HF ▁hospital ization ▁through ▁the ▁date ▁of ▁death ▁or ▁last ▁participant ▁contact ▁before ▁August ▁2009.
▁Mediterrane an ▁and ▁DAS H ▁die t ▁score s ▁were ▁calcula ted ▁from ▁food - fre que ncy ▁quest ionnaires .
▁Co x ▁proportion al ▁hazard s ▁models ▁adjust ed ▁for ▁demo graphic s , ▁health ▁behavior s , ▁and ▁health ▁status ▁were ▁used ▁to ▁calcula te ▁hazard ▁ratio s ▁and ▁95% ▁confidence ▁interval s ▁( CI ).
▁For ▁a ▁media n ▁of ▁ 4.6 ▁years ▁of ▁follow - up , ▁13 85 ▁of ▁32 15 ▁( 43 . 1%) ▁participants ▁who ▁experienced ▁a ▁ HF ▁hospital ization ▁die d .
▁Multi vari able - ad just ed ▁hazard ▁ratio s ▁were ▁1 ▁( reference ), ▁1. 05 ▁( 95% ▁CI , ▁ 0.8 9-1 . 24) , ▁0 . 97 ▁( 95% ▁CI , ▁ 0.8 1-1 . 17) , ▁and ▁0 . 85 ▁( 95% ▁CI , ▁ 0.7 0-1 . 02) ▁across ▁quart ile s ▁of ▁the ▁Mediterrane an ▁die t ▁score ▁( P ▁trend =0 . 08) ▁and ▁1 ▁( reference ), ▁1. 04 ▁( 95% ▁CI , ▁ 0.8 9-1 . 21) , ▁0 . 83 ▁( 95% ▁CI , ▁0 . 70 -0 . 98) , ▁and ▁0 . 84 ▁( 95% ▁CI , ▁0 . 70 - 1.00 ) ▁across ▁quart ile s ▁of ▁the ▁DAS H ▁die t ▁score ▁( P ▁trend = 0.01 ).
▁Diet ▁score ▁component s , ▁vegetables , ▁nu ts , ▁and ▁whole ▁grain ▁in take , ▁were ▁invers ely ▁associated ▁with ▁mortal ity .
▁CON CL USI ONS : ▁High er ▁DAS H ▁die t ▁score s ▁were ▁associated ▁with ▁modest ly ▁lower ▁mortal ity ▁in ▁women ▁with ▁ HF , ▁and ▁there ▁was ▁a ▁non signif i cant ▁trend ▁toward ▁an ▁in verse ▁association ▁with ▁Mediterrane an ▁die t ▁score s .
▁These ▁data ▁provide ▁support ▁for ▁the ▁concept ▁that ▁dieta ry ▁recommendations ▁developed ▁for ▁other ▁cardiovascular ▁conditions ▁or ▁general ▁population s ▁may ▁also ▁be ▁appropriate ▁in ▁patients ▁with ▁ HF .
▁Solu ble ▁ST 2 ▁in ▁ambula tory ▁patients ▁with ▁heart ▁failure : ▁Association ▁with ▁functional ▁capacity ▁and ▁long - term ▁outcome s .
▁BA CK GRO UND : ▁ST 2 ▁is ▁involved ▁in ▁cardio protec tive ▁signal ing ▁in ▁the ▁my o car dium ▁and ▁has ▁been ▁identified ▁as ▁a ▁potential ly ▁promis ing ▁bio mark er ▁in ▁heart ▁failure ▁( HF ).
▁We ▁evaluat ed ▁ST 2 ▁levels ▁and ▁their ▁association ▁with ▁functional ▁capacity ▁and ▁long - term ▁clinic al ▁outcome s ▁in ▁a ▁co hor t ▁of ▁ambula tory ▁patients ▁with ▁ HF ▁en roll ed ▁in ▁the ▁Heart ▁Fail ure : ▁A ▁Control led ▁Tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁( HF - AC TION ) ▁study - a ▁multi center , ▁random ized ▁study ▁of ▁exercise ▁training ▁in ▁ HF .
▁ MET HOD S ▁AND ▁RESULT S : ▁ HF - AC TION ▁random ized ▁23 31 ▁patients ▁with ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁< 0.3 5 ▁and ▁New ▁York ▁Heart ▁Association ▁class ▁II ▁to ▁IV ▁ HF ▁to ▁either ▁exercise ▁training ▁or ▁usual ▁care .
▁ST 2 ▁was ▁anal y zed ▁in ▁a ▁sub set ▁of ▁9 10 ▁patients ▁with ▁ evalua ble ▁plasma ▁sample s .
▁Corre lation s ▁and ▁Co x ▁models ▁were ▁used ▁to ▁assess ▁the ▁relationship ▁among ▁ST 2 , ▁functional ▁capacity , ▁and ▁long - term ▁outcome s .
▁The ▁media n ▁base line ▁ST 2 ▁level ▁was ▁23. 7 ▁ng / m L ▁( inter quart ile ▁range , ▁18. 6 -3 1.8 ).
▁ST 2 ▁was ▁modest ly ▁associated ▁with ▁measure s ▁of ▁functional ▁capacity .
▁In ▁uni vari able ▁analysis , ▁ST 2 ▁was ▁significantly ▁associated ▁with ▁death ▁or ▁hospital ization ▁( haz ard ▁ratio , ▁1. 48 ; ▁P < 0.00 01) , ▁cardiovascular ▁death ▁or ▁ HF ▁hospital ization ▁( haz ard ▁ratio , ▁2. 14 ; ▁P < 0.00 01) , ▁and ▁all - ca use ▁mortal ity ▁( haz ard ▁ratio , ▁2. 33 ; ▁P < 0.00 01 ; ▁all ▁hazard ▁ratio s ▁for ▁log 2 ▁ng / m L ).
▁In ▁multi vari able ▁models , ▁ST 2 ▁remain ed ▁independent ly ▁associated ▁with ▁outcome s ▁after ▁adjust ment ▁for ▁clinic al ▁variable s ▁and ▁amino - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de .
▁However , ▁ST 2 ▁did ▁not ▁add ▁significantly ▁to ▁re class ification ▁of ▁risk ▁as ▁assess ed ▁by ▁changes ▁in ▁the ▁C ▁statistic , ▁net ▁re class ification ▁improvement , ▁and ▁integrat ed ▁discrimina tion ▁improvement .
▁CON CL USI ONS : ▁ST 2 ▁was ▁modest ly ▁associated ▁with ▁functional ▁capacity ▁and ▁was ▁significantly ▁associated ▁with ▁outcome s ▁in ▁a ▁well - tre ated ▁co hor t ▁of ▁ambula tory ▁patients ▁with ▁ HF ▁although ▁it ▁did ▁not ▁significantly ▁affect ▁re class ification ▁of ▁risk .
▁Ten - year ▁experience ▁with ▁extend ed ▁criteri a ▁cardiac ▁transplant ation .
▁BA CK GRO UND : ▁Ex tende d ▁criteri a ▁cardiac ▁transplant ▁( EC CT ) ▁programs ▁expand ▁the ▁transplant ▁pool ▁by ▁match ing ▁donor s ▁and ▁recipient s ▁typically ▁exclu ded ▁from ▁the ▁transplant ▁process ▁because ▁of ▁age ▁or ▁como r bid ity .
▁There ▁is ▁a ▁pau city ▁of ▁data ▁exam ining ▁long - term ▁outcome s ▁with ▁this ▁strategy .
▁ MET HOD S ▁AND ▁RESULT S : ▁Bet we en ▁January ▁2000 ▁and ▁December ▁2009, ▁adult ▁patients ▁under go ing ▁isola ted ▁heart ▁transplant ▁were ▁prospect ive ly ▁class ified ▁as ▁EC CT ▁based ▁on ▁pre spec ified ▁criteri a .
▁Base line ▁character istic s ▁and ▁outcome s ▁were ▁compared ▁between ▁EC CT ▁and ▁standard ▁criteri a ▁cardiac ▁transplant ▁recipient s .
▁Two ▁Co x ▁proportion al ▁hazard s ▁models ▁were ▁developed .
▁The ▁first ▁to ▁identify ▁clinic al ▁variable s ▁contribu ting ▁to ▁survival ▁between ▁the ▁2 ▁groups , ▁and ▁the ▁second ▁to ▁determine ▁the ▁additional ▁risk ▁associated ▁with ▁assign ment ▁to ▁EC CT .
▁Am ong ▁the ▁ 454 ▁patients ▁who ▁under went ▁heart ▁transplant , ▁84 ▁(18 . 5% ) ▁were ▁EC CT .
▁Compar ed ▁with ▁the ▁patients ▁who ▁under went ▁standard ▁criteri a ▁cardiac ▁transplant , ▁EC CT ▁patients ▁were ▁older ▁( media n , ▁6 6.6 ▁years ▁versus ▁5 3.2 ▁years ; ▁P < 0.00 1) , ▁with ▁higher ▁fre que ncy ▁of ▁diabetes ▁mell itus ▁( 46 . 4% ▁versus ▁24. 6% ; ▁P < 0.00 1) ▁and ▁chronic ▁ki dne y ▁disease ▁( media n ▁estima ted ▁glo mer ular ▁filtr ation ▁rate , ▁55 ▁versus ▁6 1.6 ▁m L / min ; ▁P = 0.00 1) .
▁After ▁adjust ment ▁for ▁base line ▁character istic s , ▁standard ▁criteri a ▁cardiac ▁transplant ▁survival ▁was ▁higher ▁than ▁EC CT ▁at ▁1 ▁(8 9% ▁versus ▁8 6% ; ▁P =0 . 18) ▁and ▁5 ▁(7 7% ▁versus ▁6 6% ; ▁P = 0.0 35) ▁years .
▁In ▁a ▁multi varia te ▁model ▁that ▁included ▁list ing ▁criteri a , ▁creati nine ▁( haz ard ▁ratio , ▁1. 05 ▁per ▁0.1 ▁mg / d L ; ▁95% ▁confidence ▁interval , ▁1.0 2-1 . 09 ; ▁P = 0.00 1) ▁was ▁a ▁significant ▁predict or ▁of ▁post - trans plant ▁mortal ity .
▁CON CL USI ONS : ▁EC CT ▁is ▁an ▁acceptable ▁alternative ▁for ▁advanced ▁heart ▁failure ▁ therapy ▁in ▁select ▁patients .
▁Age ▁and ▁renal ▁dys function ▁are ▁important ▁determina nts ▁of ▁long - term ▁survival ▁and ▁post - trans plant ▁morbi d ity .
▁Change ▁in ▁read missions ▁and ▁follow - up ▁visit s ▁as ▁part ▁of ▁a ▁heart ▁failure ▁read mission ▁quality ▁improvement ▁initiative .
▁OB JE C TIVE S : ▁The ▁study ▁objective s ▁were ▁to ▁quanti fy ▁the ▁change ▁in ▁7- day ▁follow - up ▁visit s ▁and ▁30- day ▁read missions ▁as ▁part ▁of ▁a ▁hospital ▁quality ▁improvement ▁initiative ▁and ▁to ▁character ize ▁events ▁at ▁7- day ▁follow - up ▁visit s .
▁Some ▁data ▁suggest ▁that ▁out patient ▁assessment s ▁of ▁patients ▁with ▁heart ▁failure ▁within ▁7 ▁days ▁of ▁hospital ▁dis charge ▁may ▁prevent ▁read missions , ▁although ▁little ▁is ▁known ▁about ▁patient ▁needs ▁at ▁7- day ▁follow - up ▁visit s .
▁ MET HOD S : ▁We ▁perform ed ▁a ▁single - center , ▁retro spec tive ▁chart ▁review ▁of ▁all ▁heart ▁failure ▁dis charge s ▁at ▁the ▁University ▁of ▁Connect i cut ▁Health ▁Center ▁( 398 ▁patients ) ▁the ▁year ▁before ▁(2008) ▁and ▁the ▁year ▁after ▁(2011) ▁a ▁quality ▁improvement ▁initiative ▁that ▁included ▁mandato ry ▁7- day ▁follow - up ▁visit s .
▁We ▁quant ified ▁the ▁change ▁in ▁30- day ▁read mission ▁rate ▁after ▁the ▁initiative , ▁fre que ncy ▁of ▁7- day ▁follow - up ▁visit s , ▁and ▁events ▁at ▁follow - up ▁visit s .
▁RESULT S : ▁The ▁average ▁age ▁of ▁patients ▁with ▁heart ▁failure ▁was ▁7 9.9 ▁years ▁in ▁2011, ▁with ▁45 . 9% ▁having ▁sy sto lic ▁heart ▁failure .
▁Thi r ty - day ▁all - ca use ▁read missions ▁decrease d ▁from ▁27. 5% ▁to ▁19. 1% ▁after ▁our ▁quality ▁improvement ▁initiative ▁( P ▁= ▁ . 0 24) .
▁Fre que ncy ▁of ▁7- day ▁follow - up ▁visit s ▁increased ▁from ▁19. 6% ▁to ▁46 . 9% ▁( P ▁< ▁ . 01) .
▁E ight y - one ▁percent ▁of ▁7- day ▁visit s ▁occur red ▁in ▁the ▁University ▁of ▁Connect i cut ▁Heart ▁Fail ure ▁Center ▁with ▁a ▁cardio logist ▁or ▁heart ▁failure ▁nurse ▁prac ti tioner .
▁Fi ft y - one ▁percent ▁of ▁patients ▁had ▁blood ▁work ▁draw n , ▁and ▁2 6% ▁had ▁a ▁medication ▁dose ▁changed .
▁Only ▁13% ▁of ▁patients ▁had ▁no ▁disc re pan cy ▁between ▁the ▁dis charge ▁and ▁follow - up ▁medication ▁list s .
▁CON CL USI ONS : ▁Our ▁hospital ' s ▁30- day ▁read mission ▁rate ▁for ▁patients ▁with ▁heart ▁failure ▁decrease d ▁in ▁parallel ▁with ▁an ▁increase ▁in ▁7- day ▁follow - up ▁visit s .
▁Patient s ▁with ▁heart ▁failure ▁were ▁complex ▁and ▁often ▁had ▁diagnostic ▁testing ▁and ▁medication ▁changes ▁at ▁follow - up ▁visit s .
▁Card iac ▁magnetic ▁res on ance ▁post contra st ▁T 1 ▁time ▁is ▁associated ▁with ▁outcome ▁in ▁patients ▁with ▁heart ▁failure ▁and ▁pres er ved ▁e je ction ▁ fraction .
▁BA CK GRO UND : ▁The ▁under ly ing ▁pat ho phy si ology ▁of ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( H FP EF ) ▁is ▁incomp le tely ▁understood , ▁but ▁my o card ial ▁extra cel lular ▁matri x ▁accumula tion ▁is ▁thought ▁to ▁play ▁a ▁major ▁role .
▁Our ▁aims ▁were ▁to ▁estima te ▁my o card ial ▁extra cel lular ▁matri x ▁using ▁cardiac ▁magnetic ▁res on ance ▁T 1 ▁ma pping ▁and ▁to ▁assess ▁the ▁relationship ▁between ▁path obi ology / pat ho phy si ology ▁and ▁prognos is .
▁ MET HOD S ▁AND ▁RESULT S : ▁Patient s ▁with ▁suspect ed ▁H FP EF ▁( n = 100 ) ▁were ▁en roll ed ▁in ▁this ▁prospect ive , ▁observation al ▁study .
▁Con firma tory ▁diagnostic ▁tests , ▁cardiac ▁magnetic ▁res on ance ▁imagin g ▁including ▁T 1 ▁ma pping , ▁and ▁invasi ve ▁hem o dynamic ▁assessment s ▁were ▁perform ed ▁at ▁base line .
▁Six ty - one ▁patients ▁with ▁confirm ed ▁H FP EF ▁enter ed ▁a ▁longitud in al ▁outcome - monitor ing ▁phase ▁( me an , ▁22. 9 ± 5.0 ▁months ), ▁during ▁which ▁16 ▁had ▁a ▁cardiac ▁event .
▁Card iac ▁magnetic ▁res on ance ▁T 1 ▁time ▁( haz ard ▁ratio , ▁0 . 99 ; ▁95% ▁confidence ▁interval , ▁0 . 98 -0 . 99 ; ▁P = 0.0 46) , ▁left ▁at rial ▁area ▁( haz ard ▁ratio , ▁1. 08 ; ▁95% ▁confidence ▁interval , ▁1.0 3-1 . 13 ; ▁P < 0.01 ), ▁and ▁pulmonar y ▁vas cular ▁resist ance ▁( haz ard ▁ratio , ▁1. 01 ; ▁95% ▁confidence ▁interval , ▁1.0 0-1 . 01 ; ▁P =0 . 03) ▁were ▁significantly ▁associated ▁with ▁cardiac ▁events .
▁Patient s ▁with ▁T 1 ▁times ▁below ▁the ▁media n ▁( < 388 . 3 ▁ms ) ▁were ▁at ▁greater ▁risk ▁of ▁cardiac ▁events ▁than ▁the ▁rest ▁of ▁the ▁group ▁( P < 0.01 ).
▁Extra cel lular ▁matri x ▁of ▁left ▁vent ri cular ▁bio psi es ▁( n = 9 ), ▁quant ified ▁by ▁T issue FAX S ▁technology ▁cor related ▁with ▁T 1 ▁time ▁( R =0 . 98 ; ▁P < 0.01 ).
▁T 1 ▁time ▁also ▁cor related ▁with ▁right ▁vent ri cular - pul mon ary ▁arterial ▁coup ling ▁( pul mon ary ▁vas cular ▁resist ance : ▁R = -0 . 36 ; ▁P < 0.01 ; ▁right ▁vent ri cular ▁e je ction ▁ fraction : ▁R =0 . 28 ; ▁P = 0.01 ).
▁CON CL USI ONS : ▁In ▁the ▁present ▁preliminar y ▁study , ▁cardiac ▁magnetic ▁res on ance ▁post contra st ▁T 1 ▁time ▁is ▁associated ▁with ▁prognos is ▁in ▁H FP EF , ▁suggest ing ▁post contra st ▁T 1 ▁as ▁possible ▁bio mark er ▁for ▁H FP EF .
▁Impact ▁of ▁heart ▁magnetic ▁res on ance ▁imagin g ▁on ▁che lation ▁choice s , ▁compliance ▁with ▁treatment ▁and ▁risk ▁of ▁heart ▁disease ▁in ▁patients ▁with ▁tha lassa emia ▁major .
▁This ▁study ▁ai med ▁to ▁ver ify ▁the ▁impact ▁of ▁heart ▁magnetic ▁res on ance ▁imagin g ▁on ▁che lation ▁choice s ▁and ▁patient ▁compliance ▁in ▁a ▁single - institution ▁co hor t ▁as ▁well ▁as ▁its ▁predict ive ▁value ▁for ▁heart ▁failure ▁and ▁ar rhythm ias .
▁Ab normal ▁cardiac ▁T 2 * ▁values ▁determine d ▁changes ▁in ▁treatment ▁in ▁most ▁subject s .
▁Heart ▁T 2 * ▁was ▁confirm ed ▁to ▁be ▁highly ▁predict ive ▁over ▁1 ▁year ▁for ▁heart ▁failure ▁and ▁ar rhythm ias .
▁The ▁choice ▁of ▁che lation ▁regime ns ▁known ▁to ▁remove ▁heart ▁ir on ▁efficient ly ▁was ▁not ▁ sufficient ▁by ▁itself ▁to ▁influence ▁the ▁risk .
▁Comp liance ▁with ▁treatment ▁had ▁a ▁more ▁re mark able ▁role .
▁Impact ▁of ▁e je ction ▁ fraction ▁on ▁the ▁clinic al ▁response ▁to ▁cardiac ▁re syn chron ization ▁ therapy ▁in ▁mild ▁heart ▁failure .
▁BA CK GRO UND : ▁Current ▁guidelines ▁recommend ▁cardiac ▁re syn chron ization ▁ therapy ▁( C RT ) ▁in ▁mild ▁heart ▁failure ▁( HF ) ▁patients ▁with ▁QR S ▁prolong ation ▁and ▁e je ction ▁ fraction ▁( EF ) ▁ ≤ 30% .
▁To ▁assess ▁the ▁effect ▁of ▁C RT ▁in ▁less ▁severe ▁sy sto lic ▁dys function , ▁outcome s ▁in ▁the ▁RE syn chron ization ▁re VE rse s ▁Re model ing ▁in ▁Sy sto lic ▁left ▁v En tri cular ▁dys function ▁( RE VERS E ) ▁study ▁were ▁evaluat ed ▁in ▁which ▁patients ▁with ▁left ▁vent ri cular ▁( LV ) ▁e je ction ▁ fraction ▁( LV EF ) ▁> 30% ▁were ▁included .
▁ MET HOD S ▁AND ▁RESULT S : ▁The ▁results ▁of ▁patients ▁with ▁base line ▁EF ▁> 30% ▁( n = 177 ) ▁and ▁those ▁with ▁EF ▁ ≤ 30% ▁( n =4 31) , ▁as ▁determine d ▁by ▁a ▁blind ed ▁core ▁laborator y , ▁were ▁compared .
▁In ▁the ▁LV EF ▁> 30% ▁sub group , ▁there ▁was ▁a ▁trend ▁for ▁improvement ▁in ▁the ▁clinic al ▁com posit e ▁response ▁with ▁C RT ▁ON ▁versus ▁C RT ▁OFF ▁( P =0 . 06) ▁and ▁significant ▁reduc tions ▁in ▁LV ▁end ▁sy sto lic ▁volume ▁index ▁( - 6.7 ▁ ± ▁21. 1 ▁versus ▁2.1 ▁ ± ▁17. 6 ▁m L / m (2) ; ▁P = 0.01 ) ▁and ▁LV ▁mass ▁( -20 . 6 ▁ ± ▁5 0.5 ▁versus ▁5.0 ▁ ± ▁4 2.4 ▁g ; ▁P =0 . 04) ▁after ▁12 ▁months .
▁The ▁time ▁to ▁death ▁or ▁first ▁ HF ▁hospital ization ▁was ▁significantly ▁prolong ed ▁with ▁C RT ▁( haz ard ▁ratio , ▁0.2 6 ; ▁P = 0.01 2) .
▁In ▁the ▁LV EF ▁< 30% ▁sub group , ▁significant ▁improvement s ▁in ▁clinic al ▁com posit e ▁response ▁( P =0 . 02) , ▁rever se ▁remodel ing ▁parameter s , ▁and ▁time ▁to ▁death ▁or ▁first ▁ HF ▁hospital ization ▁( haz ard ▁ratio , ▁0.5 8 ; ▁P = 0.0 47) ▁were ▁observe d .
▁After ▁adjust ing ▁for ▁important ▁co varia tes , ▁the ▁C RT ▁ON ▁assign ment ▁remain ed ▁independent ly ▁associated ▁with ▁improve d ▁time ▁to ▁death ▁or ▁first ▁ HF ▁hospital ization ▁( haz ard ▁ratio , ▁0.5 4 ; ▁P = 0.0 35) , ▁where as ▁there ▁was ▁no ▁significant ▁interaction ▁with ▁LV EF .
▁CON CL USI ONS : ▁Am ong ▁subject s ▁with ▁mild ▁ HF , ▁QR S ▁prolong ation , ▁and ▁LV EF ▁> 30% , ▁C RT ▁produced ▁rever se ▁remodel ing ▁and ▁similar ▁clinic al ▁benefit ▁compared ▁with ▁subject s ▁with ▁more ▁severe ▁LV ▁sy sto lic ▁dys function .
▁My o card ial ▁titi n ▁hypo phos phor y lation ▁important ly ▁contribute s ▁to ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁in ▁a ▁rat ▁metabol ic ▁risk ▁model .
▁BA CK GRO UND : ▁Ob es ity ▁and ▁diabetes ▁mell itus ▁are ▁important ▁metabol ic ▁risk ▁factors ▁and ▁frequent ▁como rbi di ties ▁in ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction .
▁They ▁contribute ▁to ▁my o card ial ▁dia sto lic ▁dys function ▁( DD ) ▁through ▁collage n ▁de position ▁or ▁titi n ▁modification .
▁The ▁relative ▁importance ▁for ▁my o card ial ▁ DD ▁of ▁collage n ▁de position ▁and ▁titi n ▁modification ▁was ▁investiga ted ▁in ▁obes e , ▁diabet ic ▁Z SF 1 ▁rat s ▁after ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁development ▁at ▁20 ▁weeks .
▁ MET HOD S ▁AND ▁RESULT S : ▁Four ▁groups ▁of ▁rat s ▁( Wi star - K yo to , ▁n = 11 ; ▁lean ▁Z SF 1 , ▁n = 11 ; ▁obes e ▁Z SF 1 , ▁n = 11 , ▁and ▁obes e ▁Z SF 1 ▁with ▁high - fat ▁die t , ▁n = 11) ▁were ▁followed ▁up ▁for ▁20 ▁weeks ▁with ▁repeat ▁metabol ic , ▁renal , ▁and ▁e cho car dio graphic ▁evaluation s ▁and ▁hem o dynamic ally ▁assess ed ▁at ▁eu than ization .
▁My o card ial ▁collage n , ▁collage n ▁cross - link ing , ▁titi n ▁iso form s , ▁and ▁ phos phor y lation ▁were ▁also ▁determine d .
▁Rest ing ▁tension ▁( F pass ive ) - sar com ere ▁length ▁relations ▁were ▁obtain ed ▁in ▁small ▁muscle ▁strip s ▁before ▁and ▁after ▁K C l - KI ▁treatment , ▁which ▁un an chor s ▁titi n ▁and ▁allows ▁contribution s ▁of ▁titi n ▁and ▁extra cel lular ▁matri x ▁to ▁F pass ive ▁to ▁be ▁discern ed .
▁At ▁20 ▁weeks , ▁the ▁lean ▁Z SF 1 ▁group ▁was ▁hyper tensi ve , ▁where as ▁both ▁obes e ▁Z SF 1 ▁groups ▁were ▁hyper tensi ve ▁and ▁diabet ic .
▁Only ▁the ▁obes e ▁Z SF 1 ▁groups ▁had ▁developed ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction , ▁which ▁was ▁evident ▁from ▁increased ▁lung ▁weight , ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction , ▁and ▁left ▁vent ri cular ▁ DD .
▁The ▁under ly ing ▁my o card ial ▁ DD ▁was ▁obvious ▁from ▁high ▁muscle ▁strip ▁sti ff ness , ▁which ▁was ▁large ly ▁( ± 80% ) ▁attribut able ▁to ▁titi n ▁hypo phos phor y lation .
▁The ▁la tter ▁occur red ▁specifically ▁at ▁the ▁S 39 91 ▁site ▁of ▁the ▁elastic ▁N 2 Bu s ▁segment ▁and ▁at ▁the ▁S 12 884 ▁site ▁of ▁the ▁PE V K ▁segment .
▁CON CL USI ONS : ▁Ob ese ▁Z SF 1 ▁rat s ▁developed ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁during ▁a ▁20- week ▁time ▁span .
▁Tit in ▁hypo phos phor y lation ▁important ly ▁contribute d ▁to ▁the ▁under ly ing ▁my o card ial ▁ DD .
▁Safe , ▁effective ▁off - pump ▁ster nal ▁spar ing ▁approach ▁for ▁Heart Mate ▁II ▁exchange .
▁As ▁left ▁vent ri cular ▁assist ▁devices ▁( L VAD s ) ▁have ▁become ▁more ▁wide ly ▁used ▁for ▁treat ing ▁patients ▁with ▁advanced ▁heart ▁failure , ▁the ▁incide nce ▁of ▁pump ▁dys function ▁requiri ng ▁pump ▁replace ment ▁has ▁increased .
▁When ▁dys function ▁is ▁due ▁to ▁pump ▁failure ▁or ▁drive line ▁injury , ▁isola ted ▁pump ▁replace ment ▁can ▁be ▁cura tive .
▁We ▁have ▁developed ▁a ▁quick , ▁safe ▁pump - ex change ▁technique ▁that ▁avoid s ▁a ▁redo ▁ster no to my ▁and ▁cardio pul mon ary ▁by pass .
▁We ▁have ▁used ▁this ▁technique ▁to ▁exchange ▁mal function ing ▁Heart Mate ▁II ▁L VAD s ▁in ▁14 ▁consecutiv e ▁patients .
▁The ▁patients ▁were ▁ex tuba ted ▁within ▁3 ▁to ▁6 ▁hours , ▁and ▁blood ▁loss ▁and ▁trans fusion ▁requirements ▁were ▁nominal .
▁There ▁were ▁no ▁per i pro ced ural ▁death s ▁or ▁stroke s .
▁Compar able ▁performance ▁of ▁the ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁in ▁patients ▁with ▁heart ▁failure ▁with ▁pres er ved ▁and ▁reduce d ▁e je ction ▁ fraction .
▁BA CK GRO UND : ▁De spite ▁the ▁growing ▁epidemi c ▁of ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ), ▁no ▁valid ▁measure ▁of ▁patients ' ▁health ▁status ▁( sy mp tom s , ▁function , ▁and ▁quality ▁of ▁life ) ▁exist s .
▁We ▁evaluat ed ▁the ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁( K CC Q ), ▁a ▁valida ted ▁measure ▁of ▁ HF ▁with ▁reduce d ▁EF , ▁in ▁patients ▁with ▁ HF p EF .
▁ MET HOD S ▁AND ▁RESULT S : ▁U sing ▁a ▁prospect ive ▁ HF ▁registr y , ▁we ▁dicho tom ized ▁patients ▁into ▁ HF ▁with ▁reduce d ▁EF ▁( EF ≤ ▁40 ) ▁and ▁ HF p EF ▁( EF ≥ 50 ).
▁The ▁associations ▁between ▁New ▁York ▁Heart ▁Association ▁class , ▁a ▁common ly ▁used ▁criterio n ▁standard , ▁and ▁K CC Q ▁Over all ▁Summa ry ▁and ▁Total ▁Symptom ▁domain s ▁were ▁evaluat ed ▁using ▁Spe ar man ▁corre lation s ▁and ▁2- way ▁A NOVA ▁with ▁difference s ▁between ▁patients ▁with ▁ HF ▁with ▁reduce d ▁EF ▁and ▁ HF p EF ▁test ed ▁with ▁interaction ▁terms .
▁Pred ic tive ▁valid ity ▁of ▁the ▁K CC Q ▁Over all ▁Summa ry ▁score s ▁was ▁assess ed ▁with ▁Ka plan - Me ier ▁cur ves ▁for ▁death ▁and ▁all - ca use ▁hospital ization .
▁Co varia te ▁adjust ment ▁was ▁made ▁using ▁Co x ▁proportion al ▁hazard s ▁models .
▁Interna l ▁reli ability ▁was ▁assess ed ▁with ▁Cro n bach ' s ▁α .
▁Am ong ▁ 849 ▁patients , ▁200 ▁(24 %) ▁had ▁ HF p EF .
▁K CC Q ▁summary ▁score s ▁were ▁strong ly ▁associated ▁with ▁New ▁York ▁Heart ▁Association ▁class ▁in ▁both ▁patients ▁with ▁ HF p EF ▁( r = -0 . 62 ; ▁P < 0.00 1) ▁and ▁ HF ▁with ▁reduce d ▁EF ▁( r = -0 . 55 ; ▁P =0 . 27 ▁for ▁interaction ).
▁One - year ▁event - free ▁rates ▁by ▁K CC Q ▁category ▁among ▁patients ▁with ▁ HF p EF ▁were ▁0 ▁to ▁25 =1 3.8 %, ▁26 ▁to ▁50 = 59 . 1% , ▁51 ▁to ▁75 = 73 . 8% , ▁and ▁76 ▁to ▁100 = 77 . 8% ▁( log ▁rank ▁P < 0.00 1) , ▁with ▁no ▁significant ▁interaction ▁by ▁EF ▁( P =0 . 37) .
▁The ▁K CC Q ▁domain s ▁demonstrat ed ▁high ▁internal ▁consiste ncy ▁among ▁patients ▁with ▁ HF p EF ▁( C ron bach ' s ▁α =0 . 96 ▁for ▁overall ▁summary ▁and ▁ ≥ 0.6 9 ▁in ▁all ▁sub doma ins ).
▁CON CL USI ONS : ▁Am ong ▁patients ▁with ▁ HF p EF , ▁the ▁K CC Q ▁seems ▁to ▁be ▁a ▁valid ▁and ▁reliable ▁measure ▁of ▁health ▁status ▁and ▁offers ▁excellent ▁prognos tic ▁ability .
▁Future ▁studies ▁should ▁extend ▁and ▁replica te ▁our ▁finding s , ▁including ▁the ▁establish ment ▁of ▁its ▁responsive ness ▁to ▁clinic al ▁change .
▁With in - day ▁test - re test ▁reli ability ▁of ▁the ▁Time d ▁Up ▁& ▁Go ▁test ▁in ▁patients ▁with ▁advanced ▁chronic ▁organ ▁failure .
▁OB JE C TIVE : ▁To ▁investiga te ▁the ▁within - day ▁test - re test ▁reli ability ▁of ▁the ▁Time d ▁Up ▁& ▁Go ▁( TU G ) ▁test ▁in ▁patients ▁with ▁advanced ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁( CO PD ), ▁chronic ▁heart ▁failure ▁( CH F ), ▁and ▁chronic ▁renal ▁failure ▁( CR F ).
▁DESIGN : ▁Cross - sec tional .
▁SET TING : ▁Patient s ' ▁home ▁environment .
▁PARTI CI PAN TS : ▁Subject s ▁( N =23 5 , ▁6 4% ▁men ; ▁media n ▁age , ▁70 y ▁[ inter quart ile ▁range , ▁61 - 77 y ] ; ▁media n ▁body ▁mass ▁index , ▁25. 6 kg / m (2) ▁[ inter quart ile ▁range , ▁22. 8 -29 . 4 kg / m (2) ] ) ▁with ▁advanced ▁COP D ▁( n = 95) , ▁CHF ▁( n = 68) , ▁or ▁C RF ▁( n = 72 ).
▁INTER VEN TIONS : ▁Not ▁applicable .
▁M AIN ▁O UTC OME ▁ME AS URE : ▁Time ▁to ▁complete ▁the ▁TU G ▁test .
▁Three ▁trial s ▁were ▁perform ed ▁on ▁the ▁same ▁day ▁and ▁by ▁the ▁same ▁assessor s .
▁The ▁intra class ▁corre lation ▁co e ffi cient ▁( IC C ), ▁ka ppa ▁co e ffi cient , ▁standard ▁error ▁of ▁measure ment , ▁and ▁absolute ▁and ▁relative ▁minimal ▁detect able ▁change ▁( M DC ) ▁values ▁were ▁calcula ted .
▁RESULT S : ▁Good ▁agreement ▁was ▁observe d , ▁in ▁general , ▁for ▁both ▁the ▁total ▁sample ▁and ▁sub group s ▁( CO PD , ▁CHF , ▁C RF ), ▁with ▁ICC ▁values ▁rang ing ▁from ▁ . 85 ▁to ▁ . 98 , ▁and ▁ka ppa ▁co ef fici ents ▁from ▁ . 49 ▁to ▁ 1.00 .
▁However , ▁statistic al ▁improvement ▁occur red ▁in ▁the ▁total ▁sample ▁from ▁the ▁first ▁to ▁the ▁second ▁trial ▁with ▁large ▁limit s ▁of ▁agreement ▁( me an ▁difference , ▁- . 97 s ; ▁95% ▁confidence ▁interval , ▁ 3.00 ▁to ▁- 4.9 4 s ; ▁P < . 01) .
▁The ▁third ▁trial ▁added ▁little ▁or ▁no ▁information ▁to ▁the ▁first ▁2 ▁trial s .
▁For ▁the ▁total ▁sample , ▁a ▁standard ▁error ▁of ▁measure ment ▁value ▁of ▁approximately ▁1.6 ▁seconds , ▁an ▁absolute ▁value ▁of ▁M DC ▁at ▁the ▁95% ▁confidence ▁level ▁( M DC 95% ) ▁of ▁approximately ▁4.5 ▁seconds , ▁and ▁a ▁relative ▁value ▁of ▁M DC ▁at ▁the ▁95% ▁confidence ▁level ▁( M DC 95% %) ▁of ▁approximately ▁35% ▁were ▁found ▁between ▁the ▁first ▁2 ▁trial s , ▁with ▁similar ▁values ▁found ▁for ▁the ▁sub group s .
▁CON CL USI ONS : ▁The ▁TU G ▁test ▁is ▁reliable ▁in ▁patients ▁with ▁advanced ▁COP D , ▁CHF , ▁or ▁C RF ▁after ▁2 ▁trial s .
▁Value s ▁of ▁standard ▁error ▁of ▁measure ment ▁and ▁M DC ▁may ▁be ▁used ▁in ▁daily ▁clinic al ▁practice ▁with ▁these ▁population s ▁to ▁define ▁what ▁is ▁expected ▁and ▁what ▁represent s ▁true ▁change ▁in ▁repeat ed ▁measure s .
▁Global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁as ▁a ▁major ▁predict or ▁of ▁cardiovascular ▁events ▁in ▁patients ▁with ▁at rial ▁fi bril lation .
▁OB JE C TIVE : ▁Although ▁global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁( G LS ) ▁is ▁a ▁sensitive ▁measure ▁of ▁left ▁vent ri cular ▁mechanic s , ▁its ▁relationship ▁with ▁advers e ▁cardiovascular ▁( CV ) ▁events ▁in ▁at rial ▁fi bril lation ▁( AF ) ▁has ▁not ▁been ▁evaluat ed .
▁This ▁study ▁so ught ▁to ▁examine ▁the ▁ability ▁of ▁G LS ▁in ▁predict ing ▁CV ▁events ▁in ▁AF .
▁DESIGN : ▁Observa tional ▁co hor t ▁study .
▁SET TING : ▁Department ▁of ▁card i ology ▁in ▁a ▁university ▁hospital .
▁PAT IEN TS : ▁196 ▁persist ent ▁AF ▁patients ▁refer red ▁for ▁e cho car dio graphic ▁examina tion .
▁M AIN ▁O UTC OME ▁ME A SU RES : ▁The ▁risk ▁of ▁G LS ▁measure d ▁by ▁index ▁beat ▁method ▁for ▁CV ▁events ▁was ▁assess ed ▁by ▁Co x ▁proportion al ▁hazard s ▁analyse s .
▁CV ▁events ▁were ▁define d ▁as ▁CV ▁death , ▁non - fa tal ▁stroke ▁and ▁hospital isation ▁for ▁heart ▁failure .
▁RESULT S : ▁There ▁were ▁19 ▁CV ▁death s , ▁12 ▁non - fa tal ▁stroke ▁and ▁28 ▁hospital isation s ▁for ▁heart ▁failure ▁during ▁an ▁average ▁follow - up ▁of ▁21 ▁ ± ▁10 ▁months .
▁Multi varia te ▁analysis ▁showed ▁worse ning ▁G LS ▁( HR ▁1. 121 ; ▁95% ▁CI ▁1.0 23 ▁to ▁1. 228 , ▁p = 0.0 14) ▁was ▁independent ly ▁associated ▁with ▁increased ▁CV ▁events .
▁In ▁direct ▁comparison , ▁G LS ▁out per form ed ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁( LV EF ) ▁and ▁sy sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁( Sa ) ▁in ▁predict ing ▁advers e ▁CV ▁events ▁both ▁in ▁uni varia te ▁and ▁multi varia te ▁models ▁( p ▁ ≤ ▁0.0 43) .
▁Besi des , ▁the ▁addition ▁of ▁G LS ▁to ▁a ▁Co x ▁model ▁contain ing ▁chronic ▁heart ▁failure , ▁hyper tension , ▁age ▁ ≥ ▁75 ▁years , ▁diabetes , ▁prior ▁stroke ▁score , ▁estima ted ▁glo mer ular ▁filtr ation ▁rate , ▁LV EF ▁and ▁Sa ▁provided ▁an ▁additional ▁benefit ▁in ▁the ▁predict ion ▁of ▁advers e ▁CV ▁events ▁( p = 0.0 22) .
▁CON CL USI ONS : ▁G LS ▁was ▁a ▁major ▁parameter ▁and ▁strong er ▁than ▁LV EF ▁and ▁Sa ▁in ▁predict ing ▁advers e ▁CV ▁events ▁and ▁could ▁offer ▁an ▁additional ▁prognos tic ▁benefit ▁over ▁convention al ▁clinic al ▁and ▁e cho car dio graphic ▁sy sto lic ▁parameter s ▁in ▁AF .
▁Assessment ▁and ▁prognos tic ▁relevan ce ▁of ▁right ▁vent ri cular ▁contract ile ▁reserve ▁in ▁patients ▁with ▁severe ▁pulmonar y ▁hyper tension .
▁BA CK GRO UND : ▁This ▁study ▁so ught ▁to ▁anal y ze ▁a ▁new ▁approach ▁to ▁assess ▁exercise - indu ced ▁pulmonar y ▁arter y ▁sy sto lic ▁pressure ▁( PAS P ) ▁increase ▁by ▁means ▁of ▁stress ▁Do pp ler ▁e cho card i ography ▁as ▁a ▁possible ▁measure ▁of ▁right ▁vent ri cular ▁contract ile ▁reserve ▁in ▁patients ▁with ▁severe ▁pulmonar y ▁hyper tension ▁and ▁right ▁heart ▁failure .
▁ MET HOD S ▁AND ▁RESULT S : ▁In ▁this ▁prospect ive ▁study , ▁patients ▁with ▁invasi ve ly ▁diagnose d ▁pulmonar y ▁arterial ▁hyper tension ▁or ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y ▁hyper tension ▁and ▁im pair ed ▁right ▁vent ri cular ▁pump ▁function ▁de spite ▁a ▁stable ▁target ed ▁pulmonar y ▁arterial ▁hyper tension ▁medication ▁under went ▁a ▁broad ▁panel ▁of ▁non in va sive ▁assessment s , ▁including ▁stress ▁e cho card i ography ▁and ▁cardio pul mon ary ▁exercise ▁testing .
▁On ▁the ▁basis ▁of ▁the ▁assumption ▁that ▁exercise - indu ced ▁PAS P ▁is ▁a ▁measure ▁of ▁right ▁vent ri cular ▁contract ile ▁reserve , ▁patients ▁were ▁class ified ▁into ▁2 ▁groups ▁according ▁to ▁an ▁exercise - indu ced ▁PAS P ▁increase ▁above ▁or ▁below ▁the ▁media n .
▁Patient s ▁were ▁followed ▁up ▁for ▁3.0 ▁ ± ▁1.8 ▁years .
▁Uni varia te ▁and ▁multi varia te ▁analyse s ▁were ▁used ▁for ▁factors ▁predict ing ▁survival .
▁Of ▁124 ▁patients , ▁66 ▁were ▁below ▁the ▁media n ▁exercise - indu ced ▁PAS P ▁increase ▁of ▁30 ▁mm ▁H g ▁( low ▁PAS P ), ▁and ▁58 ▁patients ▁were ▁above ▁the ▁media n ▁( high ▁PAS P ).
▁These ▁groups ▁were ▁not ▁significantly ▁different ▁in ▁terms ▁of ▁medication ▁and ▁rest ing ▁hem o dynamic s .
▁Low ▁PAS P ▁was ▁associated ▁with ▁a ▁significantly ▁lower ▁6- minut e ▁walking ▁distance , ▁pe ak ▁o 2 ▁per ▁kilogram , ▁and ▁1- , ▁3- , ▁and ▁4- year ▁survival ▁rates ▁(9 2% , ▁6 9% , ▁and ▁4 8% , ▁respective ly , ▁versus ▁9 6% , ▁9 2% , ▁and ▁89 %) .
▁In ▁the ▁multi varia te ▁Co x ▁model ▁analysis ▁adjust ed ▁for ▁age ▁and ▁sex , ▁PAS P ▁increase ▁during ▁exercise ▁and ▁pe ak ▁o 2 ▁per ▁kilogram ▁remain ed ▁independent ▁prognos tic ▁marker s ▁( haz ard ▁ratio , ▁2. 56 ▁for ▁pe ak ▁o 2 ▁per ▁kilogram ▁and ▁2. 84 ▁for ▁PAS P ▁increase ).
▁CON CL USI ONS : ▁Exerci se - indu ced ▁PAS P ▁increase ▁is ▁of ▁high ▁clinic al ▁and ▁prognos tic ▁relevan ce ▁in ▁pulmonar y ▁hyper tension ▁patients ▁and ▁may ▁indicate ▁right ▁vent ri cular ▁contract ile ▁reserve .
▁Stress ▁Do pp ler ▁e cho card i ography ▁may ▁be ▁a ▁useful ▁tool ▁for ▁prognos tic ▁assessment ▁in ▁pulmonar y ▁hyper tension ▁patients .
▁Hem o glob in , ▁exercise ▁training , ▁and ▁health ▁status ▁in ▁patients ▁with ▁chronic ▁heart ▁failure ▁( from ▁the ▁ HF - AC TION ▁random ized ▁control led ▁trial ).
▁An emia ▁is ▁common ▁in ▁patients ▁with ▁chronic ▁heart ▁failure ▁( HF ), ▁with ▁a ▁prevale nce ▁rang ing ▁from ▁10% ▁to ▁ 56% , ▁and ▁may ▁be ▁a ▁risk ▁factor ▁for ▁poor ▁outcome s .
▁An emia ▁in ▁ HF ▁remain s ▁poor ly ▁understood , ▁with ▁significant ▁gap s ▁in ▁its ▁impact ▁on ▁health - related ▁quality ▁of ▁life ▁( HR Qo L ), ▁with ▁most ▁studies ▁in ▁ HF ▁being ▁retro spec tive ▁or ▁from ▁registri es .
▁The ▁purpose ▁of ▁this ▁study ▁was ▁to ▁explore ▁the ▁relation ▁of ▁hem o glob in ▁( H gb ) ▁with ▁HR Qo L ▁and ▁training - indu ced ▁changes ▁in ▁HR Qo L ▁in ▁a ▁co hor t ▁of ▁patients ▁in ▁Heart ▁Fail ure : ▁A ▁Control led ▁Tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁( HF - AC TION ).
▁U sing ▁data ▁from ▁ HF - AC TION , ▁a ▁random ized ▁control led ▁trial ▁of ▁exercise ▁training ▁in ▁patients ▁with ▁ HF ▁and ▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction s , ▁HR Qo L ▁was ▁measure d ▁using ▁the ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁( K CC Q ) ▁at ▁base line , ▁3 ▁and ▁12 ▁months , ▁and ▁annual ly ▁up ▁to ▁4 ▁years .
▁Treatment ▁group ▁effects ▁on ▁HR Qo L ▁were ▁estima ted ▁using ▁linear ▁mix ed ▁models ▁according ▁to ▁the ▁intention - to - tre at ▁princip le .
▁It ▁was ▁hypothe s ized ▁that ▁base line ▁H gb ▁would ▁be ▁cor related ▁with ▁base line ▁K CC Q ▁scale s ▁and ▁that ▁H gb ▁would ▁moderat e ▁the ▁beneficia l ▁effect ▁of ▁exercise ▁training ▁on ▁HR Qo L .
▁H gb ▁level ▁was ▁not ▁significantly ▁cor related ▁with ▁base line ▁HR Qo L .
▁Base line ▁H gb ▁did ▁not ▁moderat e ▁the ▁beneficia l ▁effect ▁of ▁exercise ▁training ▁on ▁K CC Q ▁overall ▁or ▁sub sca les ▁relative ▁to ▁usual ▁care .
▁In ▁conclusion , ▁in ▁the ▁ HF - AC TION ▁co hor t , ▁there ▁was ▁no ▁corre lation ▁with ▁base line ▁H gb ▁and ▁base line ▁HR Qo L ▁as ▁measure d ▁by ▁the ▁K CC Q .
▁In ▁addition , ▁the ▁beneficia l ▁effects ▁of ▁HR Qo L ▁from ▁exercise ▁training ▁were ▁not ▁modul ated ▁by ▁base line ▁H gb .
▁Card iac - re syn chron ization ▁ therapy ▁in ▁heart ▁failure ▁with ▁a ▁n arrow ▁QR S ▁complex .
▁BA CK GRO UND : ▁Card iac - re syn chron ization ▁ therapy ▁( C RT ) ▁reduce s ▁morbi d ity ▁and ▁mortal ity ▁in ▁chronic ▁sy sto lic ▁heart ▁failure ▁with ▁a ▁wide ▁QR S ▁complex .
▁Mechanic al ▁dys syn chron y ▁also ▁occur s ▁in ▁patients ▁with ▁a ▁n arrow ▁QR S ▁complex , ▁which ▁suggest s ▁the ▁potential ▁useful ness ▁of ▁C RT ▁in ▁such ▁patients .
▁ MET HOD S : ▁We ▁conduct ed ▁a ▁random ized ▁trial ▁in vol ving ▁115 ▁center s ▁to ▁evaluat e ▁the ▁effect ▁of ▁C RT ▁in ▁patients ▁with ▁New ▁York ▁Heart ▁Association ▁class ▁III ▁or ▁IV ▁heart ▁failure , ▁a ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁of ▁35% ▁or ▁less , ▁a ▁QR S ▁du ration ▁of ▁less ▁than ▁130 ▁m sec , ▁and ▁e cho car dio graphic ▁evidence ▁of ▁left ▁vent ri cular ▁dys syn chron y .
▁All ▁patients ▁under went ▁device ▁implant ation ▁and ▁were ▁random ly ▁assign ed ▁to ▁have ▁C RT ▁cap ability ▁turned ▁on ▁or ▁off .
▁The ▁primary ▁ef fica cy ▁outcome ▁was ▁the ▁com posit e ▁of ▁death ▁from ▁any ▁cause ▁or ▁first ▁hospital ization ▁for ▁worse ning ▁heart ▁failure .
▁RESULT S : ▁On ▁March ▁13, ▁2013, ▁the ▁study ▁was ▁stopped ▁for ▁fut ility ▁on ▁the ▁recommend ation ▁of ▁the ▁data ▁and ▁safety ▁monitoring ▁board .
▁At ▁study ▁ closure , ▁the ▁8 09 ▁patients ▁who ▁had ▁under go ne ▁random ization ▁had ▁been ▁followed ▁for ▁a ▁mean ▁of ▁19. 4 ▁months .
▁The ▁primary ▁outcome ▁occur red ▁in ▁116 ▁of ▁40 4 ▁patients ▁in ▁the ▁C RT ▁group , ▁as ▁compared ▁with ▁102 ▁of ▁40 5 ▁in ▁the ▁control ▁group ▁(28 . 7% ▁vs . ▁25. 2% ; ▁hazard ▁ratio , ▁1. 20 ; ▁95% ▁confidence ▁interval ▁[ CI ] , ▁0 . 92 ▁to ▁1. 57 ; ▁P =0 . 15) .
▁There ▁were ▁45 ▁death s ▁in ▁the ▁C RT ▁group ▁and ▁26 ▁in ▁the ▁control ▁group ▁(11 . 1% ▁vs . ▁6. 4% ; ▁hazard ▁ratio , ▁1. 81 ; ▁95% ▁CI , ▁1. 11 ▁to ▁2. 93 ; ▁P =0 . 02) .
▁CON CL USI ONS : ▁In ▁patients ▁with ▁sy sto lic ▁heart ▁failure ▁and ▁a ▁QR S ▁du ration ▁of ▁less ▁than ▁130 ▁m sec , ▁C RT ▁does ▁not ▁reduce ▁the ▁rate ▁of ▁death ▁or ▁hospital ization ▁for ▁heart ▁failure ▁and ▁may ▁increase ▁mortal ity .
▁Impact ▁of ▁car vedi lol ▁and ▁met o pro lol ▁on ▁in appropria te ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy : ▁the ▁MAD IT - C RT ▁trial ▁( Mul ti center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁With ▁Card iac ▁Re syn chron ization ▁Therapy ).
▁OB JE C TIVE S : ▁The ▁goal ▁of ▁this ▁study ▁was ▁to ▁evaluat e ▁the ▁effects ▁of ▁car vedi lol ▁and ▁met o pro lol ▁on ▁the ▁end point ▁of ▁in appropria te ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁in ▁the ▁MAD IT - C RT ▁( Mul ti center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁With ▁Card iac ▁Re syn chron ization ▁Therapy ) ▁study .
▁BA CK GRO UND : ▁The ▁impact ▁of ▁car vedi lol ▁and ▁met o pro lol ▁on ▁in appropria te ▁ therapy ▁in ▁heart ▁failure ▁patients ▁with ▁devices ▁has ▁not ▁yet ▁been ▁investiga ted .
▁ MET HOD S : ▁All ▁patients ▁in ▁the ▁MAD IT - C RT ▁study ▁who ▁received ▁a ▁device ▁( N ▁= ▁1,7 90) ▁were ▁identified .
▁U sing ▁time - dependent ▁Co x ▁re gression ▁analysis , ▁we ▁compared ▁patients ▁treated ▁with ▁different ▁types ▁of ▁beta - block ers ▁or ▁no ▁beta - block ers ▁on ▁the ▁primary ▁end point ▁of ▁in appropria te ▁ therapy , ▁deliver ed ▁as ▁anti ta chy car dia ▁pa cing ▁( A TP ) ▁or ▁shock ▁ therapy .
▁Second ary ▁end point s ▁were ▁in appropria te ▁ therapy ▁due ▁to ▁at rial ▁fi bril lation ▁and ▁at rial ▁ta chy ar rhythm ias , ▁also ▁evaluat ed ▁as ▁ATP ▁or ▁shock ▁ therapy .
▁RESULT S : ▁In appropria te ▁ therapy ▁occur red ▁in ▁25 3 ▁(14 %) ▁of ▁1,7 90 ▁patients ▁during ▁a ▁follow - up ▁period ▁of ▁3.4 ▁ ± ▁1.1 ▁years .
▁Treatment ▁with ▁car vedi lol ▁was ▁associated ▁with ▁a ▁significantly ▁decrease d ▁risk ▁of ▁in appropria te ▁ therapy ▁compared ▁with ▁met o pro lol ▁( haz ard ▁ratio ▁[ HR ] : ▁0 . 64 ▁[ 95% ▁confidence ▁interval ▁( CI ): ▁0 . 48 ▁to ▁0 . 85 ] ; ▁p ▁= ▁0.0 02) .
▁The ▁re duction ▁in ▁risk ▁was ▁consistent ▁for ▁in appropria te ▁ATP ▁( HR : ▁0 . 66 ▁[ 95% ▁CI : ▁0 . 48 ▁to ▁0 . 90 ] ; ▁p ▁= ▁0.0 09) ▁and ▁in appropria te ▁shock ▁ therapy ▁( HR : ▁0.5 4 ▁[ 95% ▁CI : ▁0.3 6 ▁to ▁0 . 80 ] ; ▁p ▁= ▁0.0 02) .
▁The ▁risk ▁of ▁in appropria te ▁ therapy ▁caused ▁by ▁at rial ▁fi bril lation ▁was ▁also ▁reduce d ▁in ▁patients ▁receiving ▁car vedi lol ▁compared ▁with ▁met o pro lol ▁( HR : ▁0 . 50 ▁[ 95% ▁CI : ▁0.3 2 ▁to ▁ 0.8 1] ; ▁p ▁= ▁0.0 04) .
▁General ▁use ▁of ▁beta - block ers ▁(9 3% ) ▁and ▁ad her ence ▁in ▁this ▁study ▁was ▁high .
▁CON CL USI ONS : ▁In ▁heart ▁failure ▁patients ▁under go ing ▁either ▁cardiac ▁re syn chron ization ▁ therapy ▁with ▁a ▁de fi br illa tor ▁or ▁with ▁an ▁implant able ▁cardio ver ter - de fi br illa tor ▁device , ▁car vedi lol ▁was ▁associated ▁with ▁a ▁3 6% ▁lower ▁rate ▁of ▁in appropria te ▁ATP ▁and ▁shock ▁ therapy ▁compared ▁with ▁met o pro lol .
▁In appropria te ▁ therapy ▁due ▁to ▁at rial ▁fi bril lation ▁was ▁associated ▁with ▁a ▁50% ▁lower ▁rate ▁in ▁patients ▁receiving ▁car vedi lol ▁compared ▁with ▁those ▁receiving ▁met o pro lol .
▁( M ADI T - C RT : ▁Multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁With ▁Card iac ▁Re syn chron ization ▁Therapy ; ▁N CT 001 80 2 71) .
▁Global ▁prote o mics ▁and ▁path way ▁analysis ▁of ▁pressure - over load - indu ced ▁heart ▁failure ▁and ▁its ▁att en u ation ▁by ▁mito cho ndri al - tar get ed ▁pe pti des .
▁BA CK GRO UND : ▁We ▁investiga ted ▁the ▁protect ive ▁effects ▁of ▁mito cho ndri al - tar get ed ▁antioxidant ▁and ▁protect ive ▁pe pti des , ▁Sze to - Sch iller ▁( SS ) ▁31 ▁and ▁SS 20 , ▁on ▁cardiac ▁function , ▁prote om ic ▁remodel ing , ▁and ▁signal ing ▁path ways .
▁ MET HOD S ▁AND ▁RESULT S : ▁We ▁applied ▁an ▁improve d ▁label - free ▁shot gun ▁prote o mics ▁approach ▁to ▁evaluat e ▁the ▁global ▁prote o mics ▁changes ▁in ▁trans verse ▁a or tic ▁con stri ction ▁( TAC ) - indu ced ▁heart ▁failure ▁and ▁the ▁associated ▁signal ing ▁path way ▁changes ▁using ▁ingen u ity ▁path way ▁analysis .
▁We ▁found ▁that ▁ 538 ▁protein s ▁significantly ▁changed ▁after ▁ TAC , ▁which ▁ma pped ▁to ▁53 ▁path ways .
▁The ▁top ▁path ways ▁were ▁in ▁the ▁categorie s ▁of ▁act in ▁cy tos kelet on , ▁mito cho ndri al ▁function , ▁intermedi ate ▁metabolism , ▁gly col ysis / glu cone ogen es is , ▁and ▁cit rate ▁cycle .
▁Con com i tant ▁treatment ▁with ▁SS 31 ▁a meli orat ed ▁the ▁con ges tive ▁heart ▁failure ▁ph eno type s ▁and ▁mito cho ndri al ▁damage ▁induc ed ▁by ▁ TAC , ▁in ▁parallel ▁with ▁global ▁att en u ation ▁of ▁mito cho ndri al ▁prote ome ▁changes , ▁with ▁an ▁average ▁of ▁8 4% ▁protection ▁of ▁mito cho ndri al ▁and ▁6 9% ▁of ▁non mi to cho ndri al ▁protein ▁changes .
▁This ▁included ▁significant ▁am elio ration ▁of ▁all ▁the ▁ingen u ity ▁path way ▁analysis ▁not ed ▁above .
▁SS 20 ▁had ▁only ▁modest ▁effects ▁on ▁heart ▁failure ▁and ▁this ▁track ed ▁with ▁only ▁parti al ▁att en u ation ▁of ▁global ▁prote o mics ▁changes ; ▁further more , ▁act in ▁cy tos kelet on ▁path ways ▁were ▁significantly ▁protected ▁in ▁SS 20 , ▁where as ▁mito cho ndri al ▁and ▁metabol ic ▁path ways ▁essential ly ▁were ▁not .
▁CON CL USI ONS : ▁This ▁study ▁elu cida tes ▁the ▁signal ing ▁path ways ▁significantly ▁changed ▁in ▁pressure - over load - indu ced ▁heart ▁failure .
▁The ▁global ▁att en u ation ▁of ▁ TAC - indu ced ▁prote om ic ▁altera tions ▁by ▁the ▁mito cho ndri al - tar get ed ▁pe pti de ▁SS 31 ▁suggest s ▁that ▁per tur bed ▁mito cho ndri al ▁function ▁may ▁be ▁an ▁up stream ▁signal ▁to ▁many ▁of ▁the ▁path way ▁altera tions ▁in ▁ TAC ▁and ▁support s ▁the ▁potential ▁clinic al ▁application ▁of ▁mito cho ndri al - tar get ed ▁pe pti de ▁drugs ▁for ▁the ▁treatment ▁heart ▁failure .
▁Impact ▁of ▁QR S ▁ morph ology ▁and ▁du ration ▁on ▁outcome s ▁after ▁cardiac ▁re syn chron ization ▁ therapy : ▁Results ▁from ▁the ▁Re syn chron ization - Def i bril lation ▁for ▁Amb ulator y ▁Heart ▁Fail ure ▁Tri al ▁( RAF T ).
▁BA CK GRO UND : ▁The ▁impact ▁of ▁QR S ▁ morph ology ▁and ▁du ration ▁on ▁the ▁effective ness ▁of ▁cardiac ▁re syn chron ization ▁ therapy ▁( C RT ) ▁has ▁been ▁usually ▁assess ed ▁separate ly .
▁The ▁interaction ▁between ▁these ▁2 ▁simple ▁E CG ▁parameter s ▁and ▁their ▁effect ▁on ▁C RT ▁has ▁not ▁been ▁systematic ally ▁assess ed ▁in ▁a ▁large - s cale ▁clinic al ▁trial .
▁ MET HOD S ▁AND ▁RESULT S : ▁The ▁Re syn chron ization - Def i bril lation ▁for ▁Amb ulator y ▁Heart ▁Fail ure ▁Tri al ▁showed ▁that ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT ▁was ▁associated ▁with ▁a ▁significant ▁re duction ▁in ▁the ▁primary ▁end ▁point ▁of ▁all - ca use ▁mortal ity ▁or ▁heart ▁failure ▁hospital ization .
▁For ▁this ▁sub stu dy , ▁we ▁exclu ded ▁patients ▁in ▁at rial ▁fi bril lation ▁and ▁those ▁with ▁a ▁previous ▁pace maker .
▁All ▁base line ▁E CG s ▁were ▁review ed ▁by ▁a ▁panel ▁of ▁3 ▁experienced ▁electro car dio graph ers .
▁A ▁total ▁of ▁14 83 ▁patients ▁were ▁included ▁in ▁this ▁study .
▁Of ▁these , ▁11 75 ▁had ▁left ▁bund le - bran ch ▁block ▁( LB BB ) ▁and ▁30 8 ▁had ▁non - LB BB .
▁In ▁patients ▁with ▁ LB BB ▁receiving ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT , ▁there ▁was ▁a ▁re duction ▁in ▁the ▁primary ▁outcome ▁and ▁in ▁each ▁individual ▁component ▁of ▁the ▁primary ▁outcome .
▁Fur ther more , ▁there ▁was ▁continuo us ▁relationship ▁between ▁QR S ▁du ration ▁and ▁extent ▁of ▁benefit .
▁In ▁patients ▁with ▁non - LB BB ▁and ▁QR S ▁ ≥ 160 ▁ms , ▁the ▁hazard ▁ratio ▁for ▁the ▁primary ▁outcome ▁was ▁0.5 2 ▁(0 . 29 -0 . 96 ; ▁P = 0.0 33) ; ▁in ▁patients ▁with ▁QR S ▁< 160 ▁ms , ▁the ▁hazard ▁ratio ▁was ▁1. 38 ▁(0 . 88 -2 . 14 ; ▁P =0 . 155 ).
▁CON CL USI ONS : ▁In ▁patients ▁with ▁ LB BB , ▁there ▁was ▁a ▁continuo us ▁relationship ▁between ▁broad er ▁QR S ▁and ▁greater ▁benefit ▁from ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT .
▁However , ▁our ▁data ▁do ▁not ▁support ▁the ▁use ▁of ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT ▁in ▁patients ▁with ▁non - LB BB , ▁especially ▁when ▁the ▁QR S ▁du ration ▁is ▁< 160 ▁ms .
▁There ▁may ▁be ▁some ▁de lay ed ▁benefit ▁when ▁the ▁QR S ▁is ▁ ≥ 160 ▁ms , ▁but ▁this ▁needs ▁further ▁investigation .
▁Red u ced ▁hospital ization s ▁in ▁severe , ▁re frac tory ▁con ges tive ▁heart ▁failure ▁with ▁per ito ne al ▁di al ysis : ▁a ▁consecutiv e ▁case ▁series .
▁BA CK GRO UND : ▁Peri tone al ▁di al ysis ▁( PD ) ▁for ▁long - term ▁management ▁of ▁di ure tic ▁resist ant ▁volume ▁over load ▁in ▁heart ▁failure ▁( HF ) ▁may ▁provide ▁potential ▁benefit ▁with ▁few ▁advers e ▁consequences .
▁We ▁examine d ▁the ▁impact ▁of ▁PD ▁on ▁clinic al ▁status ▁hospital ization s , ▁and ▁complica tions ▁of ▁ therapy ▁in ▁severe ▁end - s tage ▁ HF .
▁ MET HOD S : ▁A ▁consecutiv e ▁case ▁series ▁of ▁10 ▁transplant ▁in elig ible ▁patients ▁receiving ▁PD ▁sole ly ▁for ▁ HF ▁volume ▁management ▁between ▁2007 ▁and ▁2011 ▁was ▁evaluat ed ▁with ▁clinic al ▁data ▁review ed ▁pre - ▁and ▁post - PD ▁initiat ion .
▁RESULT S : ▁The ▁mean ▁e je ction ▁ fraction ▁( EF ) ▁pre - PD ▁was ▁24. 5 ▁ ± ▁6. 0% ▁with ▁the ▁majority ▁of ▁patients ▁having ▁NY HA ▁class ▁III B ▁symptoms ▁and ▁moderat e - sever e ▁right ▁vent ri cular ▁dys function .
▁9 /10 ▁patients ▁were ▁Stage ▁3 ▁chronic ▁ki dne y ▁disease ▁( CK D ) ▁or ▁worse .
▁After ▁PD ▁initiat ion , ▁average ▁weight ▁loss ▁was ▁almost ▁7 ▁kg ▁( p ▁= ▁0.0 16) ▁with ▁improvement ▁in ▁di ure tic ▁response , ▁per i pher al ▁ed ema , ▁and ▁functional ▁class .
▁There ▁was ▁a ▁significant ▁decrease ▁in ▁re - hospital ization ▁from ▁an ▁average ▁of ▁3.2 ▁ ± ▁2.5 ▁to ▁0.1 ▁ ± ▁0.3 ▁ad missions ▁per ▁patient ▁( p ▁= ▁0.0 07) ▁and ▁reduce d ▁average ▁length ▁of ▁stay ▁from ▁37 ▁ ± ▁3 6.7 ▁to ▁0 . 78 ▁ ± ▁2.3 ▁days ▁( p ▁= ▁0.0 19) .
▁SU MMA RY : ▁Object ive ▁criteri a based ▁institution ▁of ▁PD ▁for ▁the ▁treatment ▁of ▁di ure tic ▁re frac tory ▁severe - end - s tage ▁ HF ▁was ▁well ▁to ler ated ▁and ▁demonstrat ed ▁favorable ▁outcome s ; ▁these ▁included ▁improve d ▁clinic al ▁status , ▁reduce d ▁hospital ization s ▁and ▁length ▁of ▁stay , ▁with ▁very ▁few ▁and ▁easily ▁treat able ▁PD related ▁complica tions .
▁PD ▁appears ▁to ▁be ▁a ▁vi able ▁option ▁in ▁re frac tory , ▁end - s tage ▁con ges tive ▁heart ▁failure ▁( CH F ).
▁Use ful ness ▁and ▁consequences ▁of ▁cardiac ▁re syn chron ization ▁ therapy ▁in ▁di al ysis - dependent ▁patients ▁with ▁heart ▁failure .
▁Card iac ▁re syn chron ization ▁ therapy ▁( C RT ) ▁is ▁often ▁de fer red ▁in ▁di al ysis - dependent ▁patients ▁with ▁heart ▁failure ▁( HF ) ▁because ▁of ▁a ▁perc ei ved ▁lack ▁of ▁benefit ▁and ▁potential ly ▁higher ▁risk s , ▁although ▁the ▁outcome s ▁associated ▁with ▁C RT ▁in ▁di al ysis ▁have ▁not ▁been ▁reported .
▁We ▁therefore ▁studie d ▁our ▁center ' s ▁experience ▁with ▁C RT ▁in ▁di al ysis - dependent ▁patients .
▁We ▁construct ed ▁a ▁de script ive ▁assessment ▁of ▁these ▁patients ▁( n ▁= ▁15 ) ▁and ▁perform ed ▁a ▁case - control ▁analysis ▁match ing ▁for ▁age , ▁gender , ▁bund le ▁bran ch ▁ morph ology , ▁diabetes ▁mell itus , ▁cardio my o pathy ▁origin , ▁and ▁β - block er ▁and ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tor ▁or ▁ang io ten sin ▁II ▁receptor ▁block er ▁use .
▁Base line ▁and ▁6- mont h ▁e cho card i ogram s ▁were ▁assess ed ▁for ▁evidence ▁of ▁rever se ▁remodel ing .
▁No ▁per i pro ced ural ▁or ▁long - term ▁complica tions ▁were ▁observe d ▁among ▁di al ysis ▁patients .
▁Het e rogen ous ▁improvement ▁in ▁e je ction ▁ fraction ▁(+ 3.1 ▁ ± ▁9. 2%) ▁was ▁not ed ▁and ▁2 ▁patients ▁deri ved ▁absolute ▁improvement s ▁of ▁8% ▁and ▁22% , ▁respective ly .
▁Dia lys is ▁patients ▁demonstrat ed ▁the ▁following ▁3- year ▁event ▁rates : ▁ HF ▁hospital ization , ▁3 1% ; ▁all - ca use ▁hospital ization , ▁100% ; ▁mortal ity , ▁7 3% ; ▁and ▁ HF ▁hospital ization ▁or ▁death , ▁8 2% .
▁In ▁the ▁case - control ▁analysis , ▁control s ▁demonstrat ed ▁superior ▁rever se ▁remodel ing ▁(+ 9.2 ▁ ± ▁9. 5% ▁increase ▁in ▁e je ction ▁ fraction ), ▁decrease d ▁mortal ity ▁(7 3% ▁vs ▁4 4% , ▁p ▁= ▁0.0 38) , ▁and ▁all - ca use ▁hospital ization s ▁(7 6% ▁vs ▁100% , ▁p ▁= ▁0.0 47) , ▁with ▁no ▁difference ▁in ▁ HF ▁hospital ization s ▁( p ▁= ▁0 . 39) , ▁compared ▁with ▁di al ysis ▁patients .
▁In ▁conclusion , ▁at ▁our ▁center , ▁the ▁di al ysis - dependent ▁patients ▁with ▁ HF ▁who ▁under went ▁C RT ▁implant ation ▁did ▁so ▁safe ly ▁and ▁no ▁serious ▁complica tions ▁were ▁observe d .
▁Cer tain ▁di al ysis ▁patients ▁demonstrat ed ▁comp e lling ▁improvement ▁after ▁device ▁implant ation .
▁Compar ed ▁with ▁match ed ▁control s , ▁di al ysis ▁patients ▁were ▁at ▁increased ▁risk ▁for ▁advers e ▁events ▁and ▁worse ned ▁e cho car dio graphic ▁outcome s .
▁Low - so dium ▁DAS H ▁die t ▁improve s ▁dia sto lic ▁function ▁and ▁vent ri cular - arte rial ▁coup ling ▁in ▁hyper tensi ve ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction .
▁BA CK GRO UND : ▁Heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( H FP EF ) ▁involve s ▁failure ▁of ▁cardiovascular ▁reserve ▁in ▁multiple ▁domain s .
▁In ▁H FP EF ▁animal ▁models , ▁dieta ry ▁so dium ▁restriction ▁improve s ▁vent ri cular ▁and ▁vas cular ▁sti ff ness ▁and ▁function .
▁We ▁hypothe s ized ▁that ▁the ▁so dium - re strict ed ▁dieta ry ▁approach es ▁to ▁stop ▁hyper tension ▁die t ▁( DAS H / S RD ) ▁would ▁improve ▁left ▁vent ri cular ▁dia sto lic ▁function , ▁arterial ▁elastan ce , ▁and ▁vent ri cular - arte rial ▁coup ling ▁in ▁hyper tensi ve ▁H FP EF .
▁ MET HOD S ▁AND ▁RESULT S : ▁Thi r teen ▁patients ▁with ▁treated ▁hyper tension ▁and ▁compensa ted ▁H FP EF ▁consum ed ▁the ▁DAS H / S RD ▁( tar get ▁so dium , ▁50 ▁mm ol /2 100 ▁kcal ) ▁for ▁21 ▁days .
▁We ▁measure d ▁base line ▁and ▁post - DAS H / S RD ▁bra chi al ▁and ▁central ▁blood ▁pressure ▁( via ▁radi al ▁arterial ▁ton ometr y ) ▁and ▁cardiovascular ▁function ▁with ▁e cho car dio graphic ▁measure s ▁( all ▁previously ▁invasi ve ly ▁valida ted ).
▁Dia sto lic ▁function ▁was ▁quant ified ▁via ▁the ▁parametr ized ▁dia sto lic ▁fill ing ▁formal ism ▁that ▁yi eld s ▁relax ation / vis co ela stic ▁( c ) ▁and ▁passiv e / sti ff ness ▁( k ) ▁constant s ▁through ▁the ▁analysis ▁of ▁Do pp ler ▁mit ral ▁in flow ▁veloci ty ▁( E - wa ve ) ▁conto urs .
▁Effective ▁arterial ▁elastan ce ▁( E a ) ▁end - sy sto lic ▁elastan ce ▁( E es ) ▁and ▁vent ri cular - arte rial ▁coup ling ▁( de fin ed ▁as ▁the ▁ratio ▁E es : E a ) ▁were ▁determine d ▁using ▁previously ▁published ▁techniques .
▁Wil co xon ▁match ed - pair s ▁signed - rank ▁tests ▁were ▁used ▁for ▁pre - post ▁comparison s .
▁The ▁DAS H / S RD ▁reduce d ▁clinic ▁and ▁24- ho ur ▁bra chi al ▁sy sto lic ▁pressure ▁( 155 ▁ ± ▁35 ▁to ▁138 ▁ ± ▁30 ▁and ▁130 ▁ ± ▁16 ▁to ▁123 ▁ ± ▁18 ▁mm ▁H g ; ▁both ▁P =0 . 02) , ▁and ▁central ▁end - sy sto lic ▁pressure ▁trend ed ▁lower ▁( 116 ▁ ± ▁18 ▁to ▁111 ▁ ± ▁16 ▁mm ▁H g ; ▁P =0 . 12) .
▁In ▁con jun ction , ▁dia sto lic ▁function ▁improve d ▁( c =2 4.3 ▁ ± ▁5.3 ▁to ▁22. 7 ▁ ± ▁8.1 ▁g / s ; ▁P =0 . 03 ; ▁k =2 52 ▁ ± ▁115 ▁to ▁170 ▁ ± ▁37 ▁g / s (2) ; ▁P =0 . 03) , ▁Ea ▁decrease d ▁( 2.0 ▁ ± ▁ 0.4 ▁to ▁1.7 ▁ ± ▁ 0.4 ▁mm ▁H g / m L ; ▁P = 0.00 7) , ▁and ▁vent ri cular - arte rial ▁coup ling ▁improve d ▁( E es : E a = 1.5 ▁ ± ▁0.3 ▁to ▁1.7 ▁ ± ▁ 0.4 ; ▁P =0 . 04) .
▁CON CL USI ONS : ▁In ▁patients ▁with ▁hyper tensi ve ▁H FP EF , ▁the ▁so dium - re strict ed ▁DAS H ▁die t ▁was ▁associated ▁with ▁favorable ▁changes ▁in ▁vent ri cular ▁dia sto lic ▁function , ▁arterial ▁elastan ce , ▁and ▁vent ri cular - arte rial ▁coup ling .
▁Human ▁resist in ▁in ▁che mo therapy - indu ced ▁heart ▁failure ▁in ▁human ized ▁male ▁mi ce ▁and ▁in ▁women ▁treated ▁for ▁breast ▁cancer .
▁Res istin ▁is ▁a ▁circula ting ▁media tor ▁of ▁insulin ▁resist ance ▁main ly ▁express ed ▁in ▁human ▁mono cy tes ▁and ▁responsive ▁to ▁infla mma tory ▁stimul i .
▁Recent ▁clinic al ▁studies ▁have ▁connected ▁eleva ted ▁resist in ▁levels ▁with ▁the ▁development ▁and ▁sever ity ▁of ▁heart ▁failure .
▁To ▁further ▁our ▁understanding ▁of ▁the ▁role ▁of ▁human ▁resist in ▁in ▁heart ▁failure , ▁we ▁studie d ▁a ▁human ized ▁mouse ▁model ▁la cking ▁mur ine ▁resist in ▁but ▁trans ge nic ▁for ▁the ▁human ▁Ret n ▁gene ▁( H um - Re t n ▁mi ce ), ▁which ▁exhibi ts ▁bas al ▁and ▁ inflammation - stimul ated ▁resist in ▁levels ▁similar ▁to ▁humans .
▁Specific ally , ▁we ▁explore d ▁whether ▁resist in ▁under lies ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic ity .
▁Re mark ably , ▁do xor ubi cin ▁(25 mg / kg ▁i p ) ▁led ▁to ▁a ▁4- fold ▁in duction ▁of ▁se rum ▁resist in ▁levels ▁in ▁Hum - Re t n ▁mi ce .
▁More over , ▁do xor ubi cin - indu ced ▁cardio toxic ity ▁was ▁greater ▁in ▁the ▁Hum - Re t n ▁mi ce ▁than ▁in ▁litt er mate ▁control s ▁not ▁express ing ▁human ▁resist in ▁( Re t n ( - / - ) ).
▁Hum - Re t n ▁mi ce ▁showed ▁increased ▁cardiac ▁m RNA ▁levels ▁of ▁infla mma tory ▁and ▁cell ▁a dhe sion ▁gene s ▁compared ▁with ▁Ret n ( - / - ) ▁mi ce .
▁Mac rop hage s , ▁but ▁not ▁cardio my o cy tes , ▁from ▁Hum - Re t n ▁mi ce ▁treated ▁with ▁do xor ubi cin ▁in ▁vi tro ▁showed ▁dramatic ▁in duction ▁of ▁h Re t n ▁( human ▁resist in ) ▁m RNA ▁and ▁protein ▁expression .
▁We ▁also ▁examine d ▁resist in ▁levels ▁in ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁patients ▁with ▁and ▁without ▁cardio toxic ity .
▁Intr igu ing ly , ▁se rum ▁resist in ▁levels ▁in ▁women ▁under go ing ▁an thra cycli ne - conta ining ▁che mo therapy ▁increased ▁significantly ▁at ▁3 ▁months ▁and ▁remain ed ▁eleva ted ▁at ▁6 ▁months ▁in ▁those ▁with ▁subsequent ▁cardio toxic ity .
▁Fur ther , ▁eleva tion ▁in ▁resist in ▁cor related ▁with ▁decline ▁in ▁e je ction ▁ fraction ▁in ▁these ▁women .
▁These ▁results ▁suggest ▁that ▁eleva ted ▁resist in ▁is ▁a ▁bio mark er ▁of ▁an thra cycli ne - indu ced ▁cardio toxic ity ▁and ▁may ▁contribute ▁in ▁the ▁development ▁of ▁heart ▁failure ▁via ▁its ▁direct ▁effects ▁on ▁macro pha ges .
▁These ▁results ▁further ▁implica te ▁resist in ▁as ▁a ▁link ▁between ▁ inflammation , ▁metabolism , ▁and ▁heart ▁disease .
▁Ef fica cy , ▁safety , ▁and ▁outcome s ▁of ▁cat heter ▁ab lation ▁of ▁at rial ▁fi bril lation ▁in ▁patients ▁with ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction .
▁OB JE C TIVE S : ▁This ▁study ▁so ught ▁to ▁investiga te ▁the ▁ef fica cy ▁and ▁safety ▁of ▁cat heter ▁ab lation ▁for ▁at rial ▁fi bril lation ▁( AF ) ▁in ▁patients ▁with ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( H FP EF ).
▁BA CK GRO UND : ▁AF ▁is ▁a ▁precipit ating ▁factor ▁for ▁clinic al ▁deteriora tion ▁of ▁H FP EF .
▁ MET HOD S : ▁Cat heter ▁ab lation ▁for ▁AF ▁was ▁perform ed ▁in ▁a ▁consecutiv e ▁74 ▁patients ▁with ▁compensa ted ▁H FP EF ▁( le ft ▁vent ri cular ▁[ LV ] ▁e je ction ▁ fraction ▁> 50% ).
▁AF - free ▁probabil ity ▁after ▁cat heter ▁ab lation ▁and ▁factors ▁relat ing ▁to ▁maintenance ▁of ▁sinus ▁ rhythm ▁were ▁investiga ted .
▁LV ▁strain ▁and ▁strain ▁rate ▁were ▁assess ed ▁by ▁e cho card i ography ▁at ▁base line ▁and ▁over ▁12 ▁months ▁after ▁ab lation .
▁RESULT S : ▁During ▁a ▁34 ▁ ± ▁16- mont h ▁follow - up ▁period , ▁single - ▁and ▁multiple - procedure ▁drug - free ▁success ▁rates ▁were ▁2 7% ▁( n ▁= ▁20 ) ▁and ▁45% ▁( n ▁= ▁33 ), ▁respective ly .
▁Multi ple ▁procedure s ▁and ▁ pharma ce ut ically ▁assist ed ▁success ▁rate ▁was ▁7 3% ▁( n ▁= ▁54 ).
▁No ▁major ▁complica tions ▁occur red ▁during ▁follow - up .
▁Multi varia te ▁Co x ▁re gression ▁analyse s ▁reveal ed ▁that ▁AF ▁type ▁( other ▁than ▁long - standing ▁persist ent ▁AF ) ▁and ▁lack ▁of ▁hyper tension ▁were ▁independent ly ▁associated ▁with ▁maintenance ▁of ▁sinus ▁ rhythm ▁( haz ard ▁ratio ▁[ HR ] : ▁1. 81 , ▁95% ▁confidence ▁interval ▁[ CI ] : ▁1. 03 ▁to ▁3. 17 , ▁p ▁= ▁0.0 4 ; ▁HR : ▁0 . 49 , ▁95% ▁CI : ▁0.2 4 ▁to ▁0 . 96 , ▁p ▁= ▁0.0 4 , ▁respective ly ).
▁LV ▁sy sto lic ▁indice s ▁( LV ▁e je ction ▁ fraction , ▁LV ▁strain / stra in ▁rate ▁at ▁sy stol e ) ▁and ▁dia sto lic ▁indice s ▁( E / E ' , ▁ratio ▁of ▁LV ▁strain ▁rate ▁at ▁dia stol e ▁with ▁early ▁transmit ral ▁flow ) ▁were ▁improve d ▁only ▁in ▁patients ▁maintain ing ▁sinus ▁ rhythm ▁at ▁follow - up .
▁CON CL USI ONS : ▁Our ▁results ▁suggest ▁that ▁AF ▁can ▁be ▁effectively ▁and ▁safe ly ▁treated ▁with ▁a ▁com posit e ▁of ▁repeat ▁procedure s ▁and ▁ pharma ce u tical s ▁in ▁patients ▁with ▁H FP EF .
▁However , ▁the ▁current ▁study ▁was ▁a ▁single - arm ▁analysis ; ▁therefore , ▁larger ▁random ized ▁control ▁studies ▁are ▁needed ▁to ▁ver ify ▁the ▁benefit ▁of ▁AF ▁ab lation ▁in ▁this ▁co hor t .
▁Nico rand il ▁a meli orat es ▁mito cho ndri al ▁dys function ▁in ▁do xor ubi cin - indu ced ▁heart ▁failure ▁in ▁rat s : ▁possible ▁mechanism ▁of ▁cardio protec tion .
▁De spite ▁of ▁its ▁known ▁cardio toxic ity , ▁do xor ubi cin ▁is ▁still ▁a ▁highly ▁effective ▁anti - neo plast ic ▁agent ▁in ▁the ▁treatment ▁of ▁several ▁cancer s .
▁In ▁the ▁present ▁study , ▁the ▁cardio protec tive ▁effect ▁of ▁nic oran dil ▁was ▁investiga ted ▁on ▁hem o dynamic ▁altera tions ▁and ▁mito cho ndri al ▁dys function ▁induc ed ▁by ▁cum ul ative ▁administration ▁of ▁do xor ubi cin ▁in ▁rat s .
▁Do xor ubi cin ▁was ▁inject ed ▁i . p .
▁over ▁2 ▁weeks ▁to ▁obtain ▁a ▁cum ul ative ▁dose ▁of ▁18 ▁mg / kg .
▁Nico rand il ▁(3 ▁mg / kg / day ) ▁was ▁given ▁oral ly ▁with ▁or ▁without ▁do xor ubi cin ▁treatment .
▁Heart ▁rate ▁and ▁a or tic ▁blood ▁flow ▁were ▁record ed ▁24 ▁h ▁after ▁receiving ▁the ▁last ▁dose ▁of ▁do xor ubi cin .
▁Rat s ▁were ▁then ▁sacrifice d ▁and ▁heart s ▁were ▁rapid ly ▁ex ci sed ▁for ▁estima tion ▁of ▁cas pas e -3 ▁activity , ▁ phos pho creati ne ▁and ▁a den ine ▁nucleo ti des ▁content s ▁in ▁addition ▁to ▁cy to ch rom e ▁c , ▁B cl 2 , ▁Bax ▁and ▁cas pas e ▁3 ▁expression .
▁More over , ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity , ▁creati ne ▁kina se ▁activity ▁and ▁oxid ative ▁stress ▁marker s ▁were ▁measure d ▁together ▁with ▁the ▁examina tion ▁of ▁DNA ▁fragment ation ▁and ▁ultra struct ural ▁changes .
▁Nico rand il ▁was ▁effective ▁in ▁alle via ting ▁the ▁de cre ment ▁of ▁heart ▁rate ▁and ▁a or tic ▁blood ▁flow ▁and ▁the ▁state ▁of ▁mito cho ndri al ▁oxid ative ▁stress ▁induc ed ▁by ▁do xor ubi cin ▁cardio toxic ity .
▁Nico rand il ▁also ▁pres er ved ▁ phos pho creati ne ▁and ▁a den ine ▁nucleo ti des ▁content s ▁by ▁resto ring ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁and ▁creati ne ▁kina se ▁activity .
▁More over , ▁nic oran dil ▁provided ▁a ▁significant ▁cardio protec tion ▁via ▁inhibi tion ▁of ▁apo pto tic ▁signal ing ▁path way , ▁DNA ▁fragment ation ▁and ▁mito cho ndri al ▁ultra struct ural ▁changes .
▁Interes ting ly , ▁nic oran dil ▁did ▁not ▁interfere ▁with ▁cy to toxic ▁effect ▁of ▁do xor ubi cin ▁against ▁the ▁growth ▁of ▁solid ▁Eh r lich ▁car cino ma .
▁In ▁conclusion , ▁nic oran dil ▁was ▁effective ▁against ▁the ▁development ▁of ▁do xor ubi cin - indu ced ▁heart ▁failure ▁in ▁rat s ▁as ▁indicate d ▁by ▁improvement ▁of ▁hem o dynamic ▁perturba tions , ▁mito cho ndri al ▁dys function ▁and ▁ultra struct ural ▁changes ▁without ▁affect ing ▁its ▁anti tum or ▁activity .
▁Relation ▁between ▁pre operativ e ▁renal ▁dys function ▁and ▁cardiovascular ▁events ▁( stro ke , ▁my o card ial ▁in far ction , ▁or ▁heart ▁failure ▁or ▁death ) ▁within ▁three ▁months ▁of ▁isola ted ▁corona ry ▁arter y ▁by pass ▁graf ting .
▁Ren al ▁dys function ▁is ▁related ▁to ▁long - term ▁mortal ity ▁and ▁my o card ial ▁in far ction ▁after ▁corona ry ▁arter y ▁by pass ▁graf ting ▁( CA BG ).
▁We ▁ai med ▁to ▁investiga te ▁the ▁association ▁between ▁pre operativ e ▁renal ▁dys function ▁and ▁early ▁risk ▁of ▁stroke , ▁my o card ial ▁in far ction , ▁or ▁heart ▁failure ▁after ▁CA BG .
▁From ▁the ▁Swedish ▁Web - system ▁for ▁En han ce ment ▁and ▁Development ▁of ▁E viden ce - based ▁care ▁in ▁Heart ▁disease ▁Evalua ted ▁According ▁to ▁Reco mmende d ▁Therapie s ▁registr y , ▁we ▁included ▁all ▁36 , 28 4 ▁patients ▁who ▁under went ▁primary ▁isola ted ▁CA BG ▁from ▁2000 ▁to ▁2008 ▁in ▁Sweden .
▁The ▁Swedish ▁National ▁In patient ▁Registr y ▁was ▁used ▁to ▁obtain ▁the ▁primary ▁end ▁point , ▁which ▁was ▁re hospital ization ▁for ▁stroke , ▁my o card ial ▁in far ction , ▁or ▁heart ▁failure ▁ ≤ 90 ▁days ▁after ▁CA BG .
▁Log istic ▁re gression ▁models ▁were ▁used ▁to ▁estima te ▁the ▁risk ▁for ▁the ▁primary ▁outcome ▁and ▁the ▁seconda ry ▁outcome ▁of ▁death ▁from ▁any ▁cause , ▁while ▁adjust ing ▁for ▁con found ers .
▁During ▁90 ▁days ▁of ▁follow - up , ▁there ▁were ▁2,4 62 ▁cardiovascular ▁events ▁and ▁6 17 ▁death s .
▁In ▁total , ▁17% ▁of ▁patients ▁developed ▁a cute ▁ki dne y ▁injury ▁post operativ ely .
▁Odd s ▁ratio s ▁with ▁95% ▁confidence ▁interval s ▁for ▁cardiovascular ▁events ▁after ▁adjust ment ▁for ▁age , ▁gender , ▁at rial ▁fi bril lation , ▁left ▁vent ri cular ▁e je ction ▁ fraction , ▁diabetes ▁mell itus , ▁per i pher al ▁vas cular ▁disease , ▁and ▁history ▁of ▁my o card ial ▁in far ction , ▁heart ▁failure , ▁or ▁stroke ▁was ▁1. 24 ▁(1 . 06 ▁to ▁1. 45) ▁in ▁patients ▁with ▁an ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁of ▁15 ▁to ▁45 ▁ml / min /1 . 73 ▁m (2) ▁but ▁became ▁non signif i cant ▁after ▁a cute ▁ki dne y ▁injury ▁was ▁introduce d ▁into ▁the ▁statistic al ▁model .
▁The ▁risk ▁of ▁death ▁was ▁significantly ▁increased ▁in ▁patients ▁with ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁of ▁15 ▁to ▁45 ▁ml / min /1 . 73 ▁m (2) ▁( odd s ▁ratio ▁1. 76 , ▁95% ▁confidence ▁interval ▁1. 38 ▁to ▁2. 25) ▁even ▁after ▁adjust ment ▁for ▁all ▁con found ers .
▁Ren al ▁dys function ▁was ▁associated ▁with ▁all - ca use ▁mortal ity ▁but ▁not ▁with ▁cardiovascular ▁events ▁during ▁the ▁first ▁3 ▁post operativ e ▁months ▁after ▁primary ▁isola ted ▁CA BG .
▁Heart ▁failure ▁in ▁the ▁young .
▁Heart ▁failure ▁is ▁an ▁enorm ous ▁clinic al ▁burde n ▁in ▁adult ▁medicine , ▁large ly ▁because ▁of ▁the ▁prevale nce ▁of ▁a ther omat ous ▁corona ry ▁disease .
▁In ▁children , ▁where ▁corona ry ▁disease ▁is ▁not ▁the ▁leading ▁cause ▁of ▁heart ▁failure , ▁it ▁is ▁less ▁common .
▁It ▁is , ▁however , ▁an ▁important ▁disease , ▁account ing ▁for ▁10% ▁of ▁pa e dia tric ▁cardiac ▁transplant s ▁in ▁children .
▁Card iac ▁symptoms ▁in ▁children ▁are ▁usually ▁the ▁result ▁of ▁con geni tal ▁les ions .
▁Most ▁of ▁these ▁les ions , ▁such ▁as ▁sept al ▁defect s , ▁are ▁amen able ▁to ▁sur g ical ▁intervention .
▁It ▁is ▁not ▁appropriate ▁to ▁expand ▁on ▁the ▁management ▁of ▁con geni tal ▁heart ▁les ions ▁in ▁this ▁review .
▁There ▁is ▁a ▁small ▁sub group ▁of ▁children ▁that ▁have ▁dia sto lic ▁failure ▁from ▁cardio my o pathi c ▁restriction ▁to ▁flow .
▁The ▁remain ing ▁patients , ▁which ▁will ▁be ▁focused ▁on ▁below , ▁have ▁heart ▁failure ▁that ▁is ▁principal ly ▁related ▁to ▁poor ▁my o card ial ▁function ▁and ▁large ly ▁compris e ▁those ▁children ▁with ▁dil ated ▁poor ly ▁contract ing ▁vent ric les , ▁which ▁can ▁be ▁related ▁to ▁specific ▁a eti ologie s ▁in ▁some ▁cases .
▁Parti cular ▁topic s ▁of ▁debate ▁in ▁pa e dia tric ▁heart ▁failure ▁concern : ▁the ▁ diagnos is ▁and ▁management ▁of ▁my o card itis ▁versus ▁dil ated ▁cardio my o pathy ▁the ▁most ▁appropriate ▁investigation s ▁for ▁new ▁ons et ▁heart ▁failure ▁cel lular ▁response s ▁to ▁heart ▁failure ▁the ▁increasing ▁population ▁of ▁an thra cycli ne ▁treated ▁sur viv ors ▁of ▁child hood ▁malign ant ▁disease ▁treatment ▁strategie s .
▁Key ▁role ▁of ▁E RK 1/2 ▁molecular ▁sc af fold s ▁in ▁heart ▁path ology .
▁The ▁ability ▁of ▁cardio my o cy tes ▁to ▁detect ▁mechanic al ▁and ▁humor al ▁stimul i ▁is ▁critical ▁for ▁ adaptation ▁of ▁the ▁my o car dium ▁in ▁response ▁to ▁new ▁conditions ▁and ▁for ▁sustain ing ▁the ▁increased ▁work load ▁during ▁stress .
▁While ▁certain ▁stimul i ▁media te ▁a ▁beneficia l ▁ adaptation ▁to ▁stress ▁conditions , ▁others ▁result ▁in ▁mal adapt ive ▁remodel ling , ▁ultima tely ▁leading ▁to ▁heart ▁failure .
▁Specific ▁signal ling ▁path ways ▁activa ting ▁either ▁adapt ive ▁or ▁mal adapt ive ▁cardiac ▁remodel ling ▁have ▁been ▁identified .
▁Paradox ically , ▁however , ▁in ▁a ▁number ▁of ▁cases , ▁the ▁trans duction ▁path ways ▁involved ▁in ▁such ▁opp os ing ▁response s ▁engage ▁the ▁same ▁signal ling ▁protein s .
▁A ▁notable ▁example ▁is ▁the ▁Raf - MEK 1/2 - ER K 1/2 ▁signal ling ▁path way ▁that ▁can ▁control ▁both ▁adapt ive ▁and ▁mal adapt ive ▁remodel ling .
▁E RK 1/2 ▁signal ling ▁requires ▁a ▁signal o some ▁complex ▁where ▁a ▁sc af fold ▁protein ▁drive s ▁the ▁a ssem bly ▁of ▁these ▁three ▁kina ses ▁into ▁a ▁linear ▁path way ▁to ▁facilita te ▁their ▁sequenti al ▁ phos phor y lation , ▁ultima tely ▁target ing ▁specific ▁effect or ▁mole cules .
▁Interes ting ly , ▁a ▁number ▁of ▁different ▁Raf - MEK 1/2 - ER K 1/2 ▁sc af fold ▁protein s ▁have ▁been ▁identified , ▁and ▁their ▁role ▁in ▁determin ing ▁the ▁adapt ive ▁or ▁mal adapt ive ▁cardiac ▁remodel ling ▁is ▁a ▁promis ing ▁field ▁of ▁investigation ▁for ▁the ▁development ▁of ▁ therapeut ic ▁strategie s ▁capable ▁of ▁select ive ly ▁potentia ting ▁the ▁adapt ive ▁response .
▁Card iac ▁a my lo idos is , ▁about ▁an ▁a typ ical ▁case .
▁The ▁described ▁report ▁de als ▁with ▁the ▁case ▁of ▁a ▁patient ▁with ▁ diagnos is ▁of ▁ ische mic - hy per tensi ve ▁cardio my io pathy ▁based ▁on ▁the ▁history ▁of ▁ang ina ▁and ▁induc ible ▁my o card ial ▁ ische mia ▁with ▁normal ▁corona ry ▁arteri es .
▁However , ▁after ▁cardiac ▁magnetic ▁res on ance , ▁the ▁typical ▁a my lo ido tic ▁pattern ▁is ▁found ▁and ▁the ▁final ▁ diagnos is ▁of ▁multiple ▁mye loma ▁is ▁made ▁at ▁osteo me dulla ry ▁bio psy .
▁Me as uring ▁fra il ty ▁in ▁heart ▁failure : ▁a ▁community ▁perspective .
▁BA CK GRO UND : ▁Fra il ty , ▁an ▁important ▁prognos tic ▁indicator ▁in ▁heart ▁failure ▁( HF ), ▁may ▁be ▁define d ▁as ▁a ▁bi ological ▁ph eno type ▁or ▁an ▁accumula tion ▁of ▁deficit s .
▁Each ▁method ▁has ▁strength s ▁and ▁limitation s , ▁but ▁their ▁utili ty ▁has ▁never ▁been ▁evaluat ed ▁in ▁the ▁same ▁community ▁ HF ▁co hor t .
▁ MET HOD S : ▁South e a stern ▁Minnesota ▁residents ▁with ▁ HF ▁were ▁recruit ed ▁from ▁2007 ▁to ▁2011.
▁Fra il ty ▁according ▁to ▁the ▁bi ological ▁ph eno type ▁was ▁define d ▁as ▁3 ▁or ▁more ▁of : ▁we ak ▁grip ▁strength , ▁physical ▁exhaust ion , ▁slow ness , ▁low ▁activity ▁and ▁un inten tional ▁weight ▁loss ▁> 10 ▁l b ▁in ▁1 ▁year .
▁Inter media te ▁fra il ty ▁was ▁define d ▁as ▁1 ▁to ▁2.
▁The ▁deficit ▁index ▁was ▁define d ▁as ▁the ▁proportion ▁of ▁deficit s ▁present ▁out ▁of ▁32 ▁deficit s .
▁RESULT S : ▁Am ong ▁223 ▁patients ▁( me an ▁age ▁71 ▁ ± ▁14 , ▁6 1% ▁male ), ▁21% ▁were ▁fra il ▁and ▁4 8% ▁intermedi ate ▁fra il ▁according ▁to ▁the ▁bi ological ▁ph eno type .
▁The ▁deficit ▁index ▁range d ▁from ▁0.0 2-0 . 75 , ▁with ▁a ▁mean ▁( SD ) ▁of ▁0.2 5 ▁(0 . 13) .
▁Over ▁a ▁mean ▁follow - up ▁of ▁2.4 ▁years , ▁63 ▁patients ▁die d .
▁After ▁adjust ment ▁for ▁age , ▁sex ▁and ▁e je ction ▁ fraction , ▁patients ▁categori zed ▁as ▁fra il ▁by ▁the ▁bi ological ▁ph eno type ▁had ▁a ▁2- fold ▁increased ▁risk ▁of ▁death ▁compared ▁to ▁those ▁with ▁no ▁fra il ty , ▁where as ▁a ▁0.1 ▁unit ▁increase ▁in ▁the ▁deficit ▁index ▁was ▁associated ▁with ▁a ▁4 4% ▁increased ▁risk ▁of ▁death .
▁Both ▁measure s ▁predict ed ▁death ▁equal ly ▁( C - stat istic s : ▁0 . 687 ▁for ▁bi ological ▁ph eno type ▁and ▁0 . 700 ▁for ▁deficit ▁index ).
▁CON C LU SION : ▁The ▁deficit ▁index ▁and ▁the ▁bi ological ▁ph eno type ▁equal ly ▁predict ▁mortal ity .
▁As ▁the ▁bi ological ▁ph eno type ▁is ▁not ▁routine ly ▁assess ed ▁clinic ally , ▁the ▁deficit ▁index , ▁which ▁can ▁be ▁as cert ained ▁from ▁medical ▁records , ▁is ▁a ▁fe a sible ▁alternative ▁to ▁as certa in ▁fra il ty .
▁Learning ▁from ▁recent ▁trial s ▁and ▁sha ping ▁the ▁future ▁of ▁a cute ▁heart ▁failure ▁trial s .
▁The ▁last ▁de cade ▁of ▁a cute ▁heart ▁failure ▁( HF ) ▁research ▁is ▁character ized ▁by ▁dis appoint ments ▁in ▁large ▁phase ▁2 ▁and ▁3 ▁ pharma c ologic ▁studies ▁of ▁ therapeut ics ▁including ▁calci um - sensi t izing ▁agents ▁and ▁anta gon ists ▁of ▁en do the lin , ▁vaso press in , ▁and ▁ad enos ine .
▁As ▁a ▁result , ▁ pharma c ologic ▁management ▁for ▁a cute ▁ HF ▁has ▁changed ▁little ▁in ▁recent ▁years , ▁and ▁advers e ▁event ▁rates ▁remain ▁higher ▁than ▁in ▁chronic ▁ HF .
▁De spite ▁neutral ▁results ▁in ▁many ▁a cute ▁ HF ▁trial s , ▁recent ▁studies ▁including ▁RELA X - A HF , ▁ AST RON AUT , ▁and ▁PR ONTO ▁have ▁highlight ed ▁the ▁role ▁of ▁appropriate ▁tim ing ▁of ▁patient ▁en roll ment , ▁target ing ▁the ▁" right " ▁patients , ▁and ▁select ing ▁appropriate ▁end ▁points ▁and ▁sites .
▁We ▁describe ▁lessons ▁learned ▁from ▁recent ▁trial s ▁in ▁a cute ▁ HF ▁and ▁out line ▁strategie s ▁to ▁improve ▁the ▁potential ▁for ▁success ▁in ▁future ▁trial s .
▁Me a sure ment ▁of ▁na tri ure tic ▁pe pti des ▁at ▁the ▁point ▁of ▁care ▁in ▁the ▁emergency ▁and ▁ambula tory ▁setting : ▁current ▁status ▁and ▁future ▁perspective s .
▁The ▁measure ment ▁of ▁na tri ure tic ▁pe pti des ▁( NP s ), ▁B - type ▁ NP ▁or ▁N - termin al ▁pro - B - type ▁ NP , ▁can ▁be ▁an ▁important ▁tool ▁in ▁the ▁ diagnos is ▁of ▁a cute ▁heart ▁failure ▁in ▁patients ▁present ing ▁to ▁an ▁Emer gen cy ▁Department ▁( ED ) ▁with ▁a cute ▁dys pne a , ▁according ▁to ▁international ▁guidelines .
▁Studies ▁and ▁subsequent ▁meta - analyse s ▁are ▁mix ed ▁on ▁the ▁absolute ▁value ▁of ▁routine ▁ NP ▁assessment ▁of ▁ED ▁patients .
▁However , ▁levels ▁of ▁ NP s ▁are ▁likely ▁to ▁be ▁used ▁also ▁to ▁guide ▁treatment ▁and ▁to ▁assess ▁risk ▁of ▁advers e ▁outcome s ▁in ▁other ▁patients ▁at ▁risk ▁of ▁developing ▁heart ▁failure , ▁including ▁those ▁with ▁pulmonar y ▁e mbol ism ▁or ▁diabetes , ▁or ▁receiving ▁che mo therapy .
▁Na tri ure tic ▁pe pti de ▁levels , ▁like ▁other ▁bio mark ers , ▁can ▁now ▁be ▁measure d ▁at ▁the ▁point ▁of ▁care ▁( PO C ).
▁We ▁have ▁review ed ▁the ▁current ▁status ▁of ▁ NP ▁measure ment ▁together ▁with ▁the ▁potential ▁contribution ▁of ▁PO C ▁measure ment ▁of ▁ NP s ▁to ▁clinic al ▁care ▁delivery ▁in ▁the ▁emergency ▁and ▁other ▁setting s .
▁Sever al ▁PO C ▁systems ▁for ▁me as uring ▁ NP ▁levels ▁are ▁now ▁available : ▁these ▁produce ▁test ▁results ▁within ▁15 ▁minutes ▁and ▁appear ▁ sufficient ly ▁sensitive ▁and ▁robust ▁to ▁be ▁used ▁routine ly ▁in ▁diagnostic ▁evaluation s .
▁Point - of - care ▁systems ▁could ▁be ▁used ▁to ▁assess ▁ NP ▁levels ▁in ▁the ▁ED ▁and ▁community ▁out patient ▁setting s ▁to ▁monitor ▁the ▁risk ▁of ▁a cute ▁heart ▁failure .
▁Fur ther more , ▁the ▁use ▁of ▁protocol - driv en ▁PO C ▁testing ▁of ▁ NP ▁within ▁the ▁time ▁frame ▁of ▁a ▁patient ▁consultation ▁in ▁the ▁ED ▁may ▁facilita te ▁and ▁accelerat e ▁the ▁through put ▁and ▁disposition ▁of ▁at - risk ▁patients .
▁Ap propria tely ▁designed ▁clinic al ▁trial s ▁will ▁be ▁needed ▁to ▁confirm ▁these ▁potential ▁benefits .
▁It ▁is ▁also ▁important ▁that ▁process es ▁of ▁care ▁delivery ▁are ▁re design ed ▁to ▁take ▁full ▁advantage ▁of ▁the ▁fast er ▁turn a round ▁times ▁provided ▁by ▁PO C ▁technology .
▁Me as uring ▁heart ▁failure ▁care ▁by ▁30- day ▁read mission : ▁Re think ing ▁the ▁quality ▁of ▁outcome ▁measure s .
▁The ▁Center s ▁for ▁Medica re ▁and ▁Medica id ▁Services ▁( C MS ) ▁has ▁operation al ized ▁hospital ▁quality ▁of ▁care ▁outcome s ▁through ▁public ly ▁reported ▁30- day ▁risk - standard ized ▁mortal ity ▁and ▁read mission ▁rates ▁and ▁associated ▁penal ties ▁for ▁higher - than - exp e cted ▁rates .
▁The ▁objective ▁of ▁the ▁measure ▁is ▁to ▁motiva te ▁hospital s ▁to ▁improve ▁the ▁quality ▁of ▁care ▁they ▁provide ▁patients ▁hospital ized ▁for ▁heart ▁failure ▁( HF ) ▁and ▁other ▁conditions ▁such ▁as ▁a cute ▁my o card ial ▁in far ction , ▁pneu monia , ▁with ▁expected ▁future ▁exp an sion ▁to ▁other ▁conditions .
▁Card i ology : ▁Bro modo main ▁inhibi tion ▁halt s ▁heart ▁failure .
▁Heart ▁failure ▁( HF ) ▁is ▁the ▁leading ▁cause ▁of ▁mortal ity ▁in ▁modern ▁society .
▁It ▁is ▁a ▁consequ ence ▁of ▁path ological ▁remodel ling ▁of ▁the ▁heart , ▁which ▁involve s ▁cardiac ▁hyper trop hy ▁( a ▁robust ▁predict or ▁of ▁subsequent ▁ HF ▁and ▁death ), ▁fibro sis ▁and ▁ inflammation .
▁At ▁the ▁molecular ▁level , ▁ HF ▁has ▁been ▁associated ▁with ▁chr omat in ▁hyper ace ty lation .
▁Now , ▁report ing ▁in ▁Cell , ▁Anand ▁et ▁al .
▁show ▁that ▁the ▁ BET ▁family ▁bro modo main ▁protein s ▁( BET s ), ▁a ▁family ▁of ▁a ce tyl - ly sine ▁reader ▁protein s , ▁are ▁central ▁to ▁ HF ▁path ogen es is ▁and ▁that ▁they ▁are ▁promis ing ▁target s ▁for ▁the ▁pre vention ▁of ▁ HF .
▁The ▁remodel ling ▁that ▁preced es ▁ HF ▁is ▁induc ed ▁by ▁ha emo dynamic ▁and ▁neuron al ▁stress ors .
▁These ▁activa te ▁a ▁signal ▁trans duction ▁casca de ▁that ▁con verge s ▁on ▁a ▁define d ▁set ▁of ▁tran scription ▁factors , ▁and ▁path ological ▁changes ▁in ▁cardio my o cy tes ▁occur ▁through ▁an ▁inter play ▁between ▁these ▁tran scription ▁factors ▁and ▁epi gene tic ▁changes ▁in ▁chr omat in ▁structure .
▁Both ▁epi gene tic ▁' writer ' ▁protein s ▁( hi stone ▁a ce tyl transfer as es ) ▁and ▁epi gene tic ▁' eras ers ' ▁( hi stone ▁de ace ty las es ) ▁have ▁been ▁implica ted ▁in ▁cardiac ▁development ▁and ▁disease .
▁However , ▁the ▁role ▁of ▁' rea ders ' ▁( bro modo main ▁protein s ) ▁was ▁less ▁well ▁define d .
▁The ▁group ▁utilize d ▁the ▁recently ▁developed ▁first - in - class ▁inhibi tor ▁J Q 1 , ▁which ▁dis place s ▁ BET s ▁from ▁chr omat in , ▁result ing ▁in ▁the ▁sup pression ▁of ▁down stream ▁signal ling ▁to ▁ RNA ▁poly mera se ▁II ▁( Pol ▁II ).
▁Investiga ting ▁the ▁role ▁of ▁ BET s ▁in ▁an ▁in ▁vi tro ▁model ▁of ▁neuro hormon ally ▁induc ed ▁heart ▁disease , ▁the ▁author s ▁showed ▁that ▁na nomo lar ▁dos es ▁of ▁J Q 1 ▁significantly ▁block ed ▁ phen yle ph rine - media ted ▁hyper trop hy ▁of ▁cardio my o cy tes ▁and ▁path ological ▁gene ▁in duction .
▁Similar ▁results ▁were ▁achieve d ▁through ▁knock down ▁of ▁the ▁ BET ▁bro modo main - conta ining ▁protein ▁4 ▁( BR D 4) , ▁which ▁is ▁highly ▁express ed ▁in ▁cardiac ▁tissu es .
▁Gene ▁expression ▁profil ing ▁of ▁culture d ▁cardio my o cy tes ▁in ▁the ▁presence ▁or ▁ absence ▁of ▁J Q 1 ▁showed ▁that ▁the ▁drug ▁ab roga ted ▁the ▁in duction ▁of ▁a ▁substantial ▁sub set ▁of ▁ phen yle ph rine - indu ced ▁gene s .
▁In ▁vivo ▁experiment s ▁of ▁ HF ▁induc ed ▁in ▁mi ce ▁via ▁ phen yle ph rine ▁or ▁ha emo dynamic ▁stress ▁( us ing ▁the ▁sur g ical ▁method ▁of ▁trans verse ▁a or tic ▁con stri ction ▁( TAC ) ) ▁showed ▁that ▁J Q 1 ▁protected ▁against ▁several ▁path ological ▁changes , ▁including ▁cardiac ▁hyper trop hy .
▁Important ly , ▁no ▁ toxic ity ▁or ▁effects ▁on ▁system ic ▁blood ▁pressure ▁were ▁observe d .
▁Detail ed ▁tran scription al ▁analysis ▁of ▁cardiac ▁tissu e ▁from ▁mi ce ▁that ▁were ▁either ▁ TAC - ▁or ▁sham - opera ted ▁and ▁treated ▁with ▁either ▁J Q 1 ▁or ▁vehicle ▁reveal ed ▁that ▁ BET ▁inhibi tion ▁sup press es ▁a ▁path ological ▁cardiac ▁gene ▁expression ▁programme .
▁Important ly , ▁the ▁target s ▁of ▁ BET s ▁in ▁the ▁mouse ▁ TAC ▁model ▁were ▁also ▁found ▁to ▁be ▁relevant ▁in ▁human ▁ HF .
▁Fur ther ▁molecular ▁analysis ▁reveal ed ▁that ▁ BET s ▁play ▁a ▁crucial ▁role ▁in ▁chr omat in - media ted ▁signal ▁trans duction ▁to ▁Pol ▁II , ▁co - activa ting ▁tran scription ▁factor ▁network s ▁that ▁are ▁known ▁to ▁be ▁causa l ▁in ▁ HF ▁path ogen es is , ▁including ▁nuclear ▁factor ▁of ▁activa ted ▁T ▁cell s ▁( N FAT ), ▁nuclear ▁factor - κ B ▁( NF - κ B ) ▁and ▁the ▁tran scription ▁factor ▁G ATA 4 .
▁More over , ▁ BET s ▁were ▁found ▁to ▁function , ▁in ▁part , ▁by ▁promo ting ▁tran scription al ▁pause ▁release ▁( and ▁there by ▁re - activa ting ▁tran scription ) ▁during ▁path ological ▁stress .
▁This ▁study ▁implica tes ▁epi gene tic ▁readers ▁in ▁cardiac ▁bi ology ▁and ▁suggest s ▁that ▁the ▁manipula tion ▁of ▁cardiac ▁gene ▁control ▁via ▁the ▁target ing ▁of ▁chr omat in - dependent ▁signal ▁trans duction ▁could ▁potential ly ▁a bro gate ▁path ological ▁gene ▁expression ▁and ▁ HF ▁progression .
▁Multi acquisition ▁T 1- ma pping ▁M RI ▁during ▁tid al ▁respira tion ▁for ▁quant ification ▁of ▁my o card ial ▁T 1 ▁in ▁s win e ▁with ▁heart ▁failure .
▁OB JE C TIVE : ▁The ▁purpose ▁of ▁this ▁article ▁is ▁to ▁evaluat e ▁a ▁free - bre a thing ▁puls e ▁se que nce ▁to ▁quanti fy ▁my o card ial ▁T 1 ▁changes ▁in ▁a ▁s win e ▁model ▁of ▁ta chy car dia - indu ced ▁heart ▁failure .
▁MAT ERIA LS ▁AND ▁ MET HOD S : ▁York shire ▁s win e ▁were ▁implant ed ▁with ▁pace makers ▁and ▁were ▁vent ri cular ly ▁pace d ▁at ▁200 ▁beat s / min ▁to ▁induc e ▁heart ▁failure .
▁Animal s ▁were ▁scan ned ▁twice ▁with ▁a ▁1.5 - T ▁M RI ▁scanner , ▁once ▁at ▁base line ▁and ▁once ▁at ▁heart ▁failure .
▁A ▁T 1- ma pping ▁se que nce ▁was ▁perform ed ▁during ▁tid al ▁respira tion ▁before ▁and ▁5 ▁minutes ▁after ▁the ▁administration ▁of ▁a ▁ gado lini um - che late ▁contrast ▁agent .
▁T 1- ma pping ▁values ▁were ▁compared ▁between ▁the ▁base line ▁and ▁heart ▁failure ▁scan s .
▁The ▁percentage ▁of ▁fibro sis ▁of ▁heart ▁failure ▁my o card ial ▁tissu e ▁was ▁compared ▁with ▁similar ▁left ▁vent ri cular ▁tissu e ▁from ▁control ▁animals ▁using ▁tri ch rom e ▁blue ▁his t ologic ▁analysis .
▁RESULT S : ▁In ▁the ▁study ▁co hor t , ▁difference s ▁were ▁found ▁between ▁the ▁base line ▁and ▁heart ▁failure ▁T 1- ma pping ▁values ▁before ▁the ▁administration ▁of ▁contrast ▁agent ▁( 960 ▁ ± ▁96 ▁and ▁7 26 ▁ ± ▁94 ▁ms , ▁respective ly ; ▁p ▁= ▁0.0 2) ▁and ▁after ▁contrast ▁agent ▁administration ▁( 546 ▁ ± ▁180 ▁and ▁300 ▁ ± ▁171 ▁ms , ▁respective ly ; ▁p ▁= ▁0.0 05) .
▁The ▁animals ▁with ▁heart ▁failure ▁also ▁had ▁a ▁difference ▁his t ological ly ▁in ▁the ▁percentage ▁of ▁my o card ial ▁collage n ▁compared ▁with ▁tissu e ▁from ▁healthy ▁control ▁animals ▁( control , ▁5. 4% ▁ ± ▁1. 0% ; ▁heart ▁failure , ▁9. 4% ▁ ± ▁1. 6% ; ▁p ▁< ▁0.0 01) .
▁CON C LU SION : ▁The ▁propose d ▁T 1- ma pping ▁technique ▁can ▁quanti fy ▁diffuse ▁my o card ial ▁changes ▁associated ▁with ▁heart ▁failure ▁without ▁the ▁use ▁of ▁a ▁contrast ▁agent ▁and ▁without ▁breath - hold ing .
▁These ▁T 1 ▁changes ▁appear ▁to ▁be ▁associated ▁with ▁increase s ▁in ▁the ▁percentage ▁of ▁my o card ial ▁collage n ▁that ▁in ▁this ▁study ▁were ▁not ▁detect ed ▁by ▁traditional ▁my o card ial ▁de lay ed ▁enhance ment ▁imagin g .
▁T 1 ▁ma pping ▁may ▁be ▁a ▁useful ▁technique ▁for ▁detect ing ▁early ▁but ▁clinic ally ▁significant ▁my o card ial ▁fibro sis .
▁Con tempor ary ▁use ▁of ▁devices ▁in ▁heart ▁failure .
▁Device s ▁have ▁become ▁a ▁corner stone ▁of ▁heart ▁failure ▁( HF ) ▁ therapy .
▁Implant able ▁cardio ver ter - de fi br illa tors ▁( IC D s ) ▁decrease ▁mortal ity , ▁and ▁cardiac ▁re syn chron ization ▁ therapy ▁( C RT ) ▁improve s ▁symptoms ▁and ▁mortal ity .
▁Most ▁data ▁have ▁been ▁collect ed ▁in ▁patients ▁with ▁sy sto lic ▁dys function .
▁Data ▁in ▁patients ▁with ▁pres er ved ▁sy sto lic ▁function ▁are ▁scar ce , ▁but ▁interesting ▁ therapeut ic ▁concept s ▁are ▁e vol ving .
▁Besi des ▁ therapeut ic ▁function s , ▁devices ▁can ▁have ▁add - on ▁diagnostic ▁features ▁such ▁as ▁early ▁det ection ▁of ▁fluid ▁over load .
▁In ▁addition , ▁stand - a lone ▁diagnostic ▁devices ▁are ▁now ▁also ▁being ▁developed ▁for ▁ HF .
▁Heart ▁failure : ▁a ▁disease ▁complex ▁with ▁challenging ▁ therapeut ics .
▁Heart ▁failure ▁( HF ) ▁is ▁the ▁most ▁common ▁cause ▁of ▁cardiovascular ▁hospital ization , ▁especially ▁among ▁the ▁el der ly .
▁It ▁has ▁a ▁higher ▁mortal ity ▁and ▁morbi d ity ▁than ▁several ▁cancer s ▁and ▁consum es ▁a ▁significant ▁portion ▁of ▁the ▁health - care ▁budget .
▁ HF ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ) ▁is ▁common er ▁among ▁women ▁who ▁may ▁have ▁under ly ing ▁hyper tension .
▁Sign ific ant ▁progress ▁has ▁been ▁achieve d ▁in ▁the ▁development ▁of ▁life sa ving ▁drugs ▁for ▁ HF ▁with ▁reduce d ▁e je ction ▁ fraction ▁( HF r EF ).
▁However , ▁treatment ▁of ▁ HF p EF ▁still ▁poses ▁significant ▁challenges .
▁Un fold ed ▁protein ▁response ▁regula tes ▁cardiac ▁so dium ▁current ▁in ▁sy sto lic ▁human ▁heart ▁failure .
▁BA CK GRO UND : ▁Human ▁heart ▁failure ▁( HF ) ▁increase s ▁alternative ▁m RNA ▁s plic ing ▁of ▁the ▁type ▁V , ▁volta ge - ga ted ▁cardiac ▁Na + ▁channel ▁α - sub un it ▁( S CN 5 A ), ▁genera ting ▁variant s ▁en co ding ▁tru nca ted , ▁non function al ▁channel s ▁that ▁are ▁trapp ed ▁in ▁the ▁en do plas mic ▁reti culum .
▁In ▁this ▁work , ▁we ▁test ed ▁whether ▁tru nca ted ▁Na + ▁channel s ▁activa te ▁the ▁un fold ed ▁protein ▁response ▁( U PR ), ▁contribu ting ▁to ▁S CN 5 A ▁electric ▁remodel ing ▁in ▁ HF .
▁ MET HOD S ▁AND ▁RESULT S : ▁U PR ▁and ▁S CN 5 A ▁were ▁anal y zed ▁in ▁human ▁vent ri cular ▁sy sto lic ▁ HF ▁tissu e ▁sample s ▁and ▁human ▁induc ed ▁pluri potent ▁stem ▁cell - der i ved ▁cardio my o cy tes ▁( hi PS C - CM s ).
▁Cell s ▁were ▁expose d ▁to ▁ang io ten sin ▁II ▁( Ang II ) ▁and ▁hypo xia , ▁known ▁activa tors ▁of ▁ab normal ▁S CN 5 A ▁m RNA ▁s plic ing , ▁or ▁were ▁induc ed ▁to ▁over express ▁S CN 5 A ▁variant s .
▁U PR ▁effect ors , ▁protein ▁kina se ▁R - like ▁ER ▁kina se ▁( PER K ), ▁cal ret icul in , ▁and ▁CHO P , ▁were ▁increased ▁in ▁human ▁ HF ▁tissu es .
▁In duction ▁of ▁S CN 5 A ▁variant s ▁with ▁Ang II ▁or ▁hypo xia ▁or ▁the ▁expression ▁of ▁ex ogen ous ▁variant s ▁induc ed ▁the ▁U PR ▁with ▁con com i tant ▁down regul ation ▁of ▁Na + ▁current .
▁PER K ▁activa tion ▁destabiliz ed ▁S CN 5 A ▁and , ▁surprising ly , ▁Kv 4.3 ▁channel ▁m RNA s ▁but ▁not ▁trans ient ▁receptor ▁potential ▁ cation ▁channel ▁M 7 ▁( TR PM 7) ▁channel ▁m RNA .
▁PER K ▁inhibi tion ▁prevent ed ▁the ▁loss ▁of ▁full - leng th ▁S CN 5 A ▁and ▁Kv 4.3 ▁m RNA ▁levels ▁result ing ▁from ▁express ing ▁Na + ▁channel ▁m RNA ▁sp lice ▁variant s .
▁CON CL USI ONS : ▁U PR ▁can ▁be ▁initiat ed ▁by ▁Na + ▁channel ▁m RNA ▁sp lice ▁variant s ▁and ▁is ▁involved ▁in ▁the ▁re duction ▁of ▁cardiac ▁Na + ▁current ▁during ▁human ▁ HF .
▁Because ▁the ▁effect ▁is ▁not ▁entirely ▁specific ▁to ▁the ▁S CN 5 A ▁tran script , ▁the ▁U PR ▁may ▁play ▁an ▁important ▁role ▁in ▁down regul ation ▁of ▁multiple ▁cardiac ▁gene s ▁in ▁ HF .
▁A cute ▁right ▁heart ▁failure ▁in ▁pulmonar y ▁hyper tension .
▁The ▁right ▁vent ric le ▁( RV ) ▁is ▁integral ▁to ▁normal ▁cardiac ▁function , ▁but ▁receive s ▁little ▁attention ▁in ▁the ▁medical ▁literature .
▁The ▁et i ologic ▁causes ▁of ▁a cute ▁ RV ▁failure ▁often ▁differ ▁from ▁those ▁encounter ed ▁in ▁left ▁vent ri cular ▁dys function .
▁Thu s , ▁ RV ▁failure ▁frequently ▁requires ▁diagnostic ▁procedure s ▁and ▁management ▁strategie s ▁that ▁differ ▁from ▁those ▁routine ly ▁used ▁in ▁the ▁management ▁of ▁intr in sic ▁left ▁vent ri cular ▁dys function .
▁In ▁this ▁summary , ▁the ▁structure ▁and ▁function ▁of ▁the ▁ RV ▁will ▁be ▁review ed , ▁concentrat ing ▁on ▁the ▁pat ho phy si ologic ▁mechanism s ▁behind ▁the ▁development ▁of ▁ RV ▁dys function .
▁We ▁will ▁then ▁focus ▁on ▁two ▁distinct ▁population s ▁of ▁patients ▁who ▁are ▁at ▁risk ▁for ▁a cute ▁ RV ▁failure : ▁those ▁with ▁chronic ▁pulmonar y ▁arterial ▁hyper tension ▁( PA H ) ▁and ▁those ▁with ▁a cute ▁pulmonar y ▁e mbol ism .
▁In ▁chronic ▁P AH , ▁we ▁will ▁examine ▁clinic al ▁circumstances ▁common ▁to ▁hospital ized ▁patients ▁that ▁may ▁provok e ▁a cute ▁ RV ▁de com pensa tion , ▁as ▁well ▁as ▁ pharma c ologic ▁ therapie s ▁that ▁are ▁unique ▁to ▁ RV ▁failure ▁management ▁in ▁P AH .
▁Individual s ▁with ▁a cute ▁ RV ▁failure ▁in ▁the ▁setting ▁of ▁pulmonar y ▁e mbol ism ▁represent ▁a ▁group ▁with ▁particularly ▁high ▁mortal ity , ▁and ▁the ▁specific ▁diagnostic ▁and ▁management ▁strategie s ▁that ▁are ▁important ▁for ▁improve d ▁survival ▁will ▁be ▁discuss ed .
▁Con tempor ary ▁trend s ▁in ▁heart ▁failure ▁with ▁reduce d ▁and ▁pres er ved ▁e je ction ▁ fraction ▁after ▁my o card ial ▁in far ction : ▁a ▁community ▁study .
▁Major ▁changes ▁have ▁recently ▁occur red ▁in ▁the ▁epidemi ology ▁of ▁my o card ial ▁in far ction ▁( MI ) ▁that ▁could ▁possibly ▁affect ▁outcome s ▁such ▁as ▁heart ▁failure ▁( HF ).
▁Data ▁descri bing ▁trend s ▁in ▁ HF ▁after ▁MI ▁are ▁scar ce ▁and ▁conflict ing ▁and ▁do ▁not ▁distingui sh ▁between ▁pres er ved ▁and ▁reduce d ▁e je ction ▁ fraction ▁( EF ).
▁We ▁evaluat ed ▁temporal ▁trend s ▁in ▁ HF ▁after ▁MI .
▁All ▁residents ▁of ▁Ol m sted ▁County , ▁Minnesota ▁( n ▁= ▁2,5 96) ▁who ▁had ▁a ▁first - ever ▁MI ▁diagnose d ▁in ▁1990- 2010 ▁and ▁no ▁prior ▁ HF ▁were ▁followed - up ▁through ▁2012.
▁Fram ing ham ▁Heart ▁Study ▁criteri a ▁were ▁used ▁to ▁define ▁ HF , ▁which ▁was ▁further ▁class ified ▁according ▁to ▁EF .
▁Both ▁early - ons et ▁(0 -7 ▁days ▁after ▁MI ) ▁and ▁late - ons et ▁(8 ▁days ▁to ▁5 ▁years ▁after ▁MI ) ▁ HF ▁were ▁examine d .
▁Change s ▁in ▁patient ▁presentation ▁were ▁not ed , ▁including ▁few er ▁ST - seg ment - elevat ion ▁MI s , ▁lower ▁Kill ip ▁class , ▁and ▁more ▁como r bid ▁conditions .
▁Over ▁the ▁5- year ▁follow - up ▁period , ▁7 15 ▁patients ▁developed ▁ HF , ▁4 75 ▁of ▁whom ▁developed ▁it ▁during ▁the ▁first ▁week .
▁The ▁age - ▁and ▁sex - ad just ed ▁risk ▁decline d ▁from ▁1990- 1996 ▁to ▁2004 -2010 , ▁with ▁hazard ▁ratio s ▁of ▁0 . 67 ▁( 95% ▁confidence ▁interval ▁( CI ): ▁0.5 4 , ▁0 . 85) ▁for ▁early - ons et ▁ HF ▁and ▁0 . 63 ▁( 95% ▁CI : ▁0 . 45 , ▁0 . 86) ▁for ▁late - ons et ▁ HF .
▁Fur ther ▁adjust ment ▁for ▁patient ▁and ▁MI ▁character istic s ▁yi eld ed ▁hazard ▁ratio s ▁of ▁0 . 86 ▁( 95% ▁CI : ▁0 . 66 , ▁1. 11) ▁and ▁0 . 63 ▁( 95% ▁CI : ▁0 . 45 , ▁0 . 88) ▁for ▁early - ▁and ▁late - ons et ▁ HF , ▁respective ly .
▁Dec lines ▁in ▁early - ons et ▁and ▁late - ons et ▁ HF ▁were ▁observe d ▁for ▁ HF ▁with ▁reduce d ▁EF ▁( < 50% ) ▁but ▁not ▁for ▁ HF ▁with ▁pres er ved ▁EF , ▁indicat ing ▁a ▁change ▁in ▁the ▁case ▁mix ▁of ▁ HF ▁after ▁MI ▁that ▁requires ▁new ▁pre vention ▁strategie s .
▁Different ial ▁effects ▁of ▁non sel ective ▁versus ▁select ive ▁beta - block ers ▁on ▁cardiac ▁sympa the tic ▁activity ▁and ▁hemos tas is ▁in ▁patients ▁with ▁heart ▁failure .
▁Car vedi lol , ▁a ▁non sel ective ▁β - block er , ▁may ▁be ▁more ▁effective ▁than ▁the ▁select ive ▁β - block er ▁met o pro lol ▁in ▁ reducing ▁the ▁risk ▁of ▁ thro mbo e mbol ic ▁events ▁in ▁heart ▁failure .
▁The ▁a im ▁of ▁this ▁study ▁was , ▁first , ▁to ▁assess ▁whether ▁there ▁is ▁a ▁differenti al ▁response ▁in ▁cardiac ▁sympa the tic ▁activity ▁by ▁(1 23) I - meta - i odob enz yl guan i dine ▁(( 123 ) I - MI BG ) ▁imagin g ▁when ▁either ▁β - block er ▁is ▁used .
▁Second , ▁we ▁assess ed ▁whether ▁that ▁response ▁corre late s ▁with ▁levels ▁of ▁various ▁se rum ▁factors ▁that ▁serve ▁as ▁marker s ▁for ▁coa gul ability .
▁ MET HOD S : ▁In ▁this ▁prospect ive , ▁random ized , ▁open - label ▁cross over ▁study ▁with ▁mask ed ▁outcome ▁assessment s , ▁stable ▁heart ▁failure ▁patients ▁( le ft ▁vent ri cular ▁e je ction ▁ fraction ▁< ▁40% ) ▁homo zy go us ▁for ▁the ▁Ar g 16 / G l n 27 ▁( n ▁= ▁13 ) ▁or ▁G ly 16 / G lu 27 ▁ha plo type ▁( n ▁= ▁8) ▁of ▁the ▁β 2- recept or ▁were ▁random ized ▁to ▁equipo tent ▁dos ages ▁of ▁car vedi lol ▁or ▁met o pro lol ▁for ▁two ▁6- w k ▁period s .
▁Prima ry ▁outcome ▁was ▁sympa the tic ▁activity ▁as ▁measure d ▁by ▁(1 23) I - MI BG ▁my o card ial ▁was hout .
▁Second ary ▁outcome s ▁included ▁marker s ▁of ▁hemos tas is .
▁RESULT S : ▁(1 23) I - MI BG ▁cardiac ▁was hout ▁was ▁lower ▁during ▁car vedi lol ▁than ▁met o pro lol ▁treatment ▁(12 . 9% ▁ ± ▁3. 9% ▁vs . ▁22. 1% ▁ ± ▁2. 8% , ▁respective ly , ▁P ▁= ▁0.0 03) , ▁ir respect ive ▁of ▁β 2- ad r energi c ▁receptor ▁ha plo type .
▁In ▁addition , ▁treatment ▁with ▁car vedi lol ▁result ed ▁in ▁a ▁lower ▁von ▁Will e brand ▁factor ▁than ▁did ▁met o pro lol ▁(14 9% ▁ ± ▁13% ▁vs . ▁15 7% ▁ ± ▁13% , ▁respective ly , ▁P ▁= ▁ 0.01 ), ▁ir respect ive ▁of ▁β 2- ad r energi c ▁receptor ▁ha plo type .
▁CON C LU SION : ▁Compar ed ▁with ▁met o pro lol , ▁car vedi lol ▁result ed ▁in ▁greater ▁re duction ▁of ▁sympa the tic ▁activity ▁after ▁6 ▁w k ▁of ▁treatment ▁and ▁lower ▁von ▁Will e brand ▁factor ▁concentration s ▁in ▁both ▁Ar g 16 / G l n 27 ▁and ▁G ly 16 / G lu 27 ▁individuals .
▁Therefore , ▁car vedi lol ▁may ▁reduce ▁the ▁risk ▁of ▁ thro mbo e mbol ic ▁events ▁in ▁patients ▁with ▁heart ▁failure , ▁ir respect ive ▁of ▁β 2- recept or ▁ha plo type ▁status .
▁Reason s ▁for ▁not ▁pre scribi ng ▁guide line - re com mend ed ▁medication s ▁to ▁adults ▁with ▁heart ▁failure .
▁BA CK GRO UND : ▁Little ▁is ▁known ▁about ▁how ▁often ▁context ual ▁factors ▁such ▁as ▁patient ▁preference s ▁and ▁competi ng ▁priorit ies ▁impact ▁pre scribi ng ▁of ▁guide line - re com mend ed ▁medication s , ▁or ▁about ▁the ▁extent ▁to ▁which ▁these ▁factors ▁are ▁document ed ▁in ▁medical ▁records ▁and ▁available ▁to ▁performance ▁measure ment ▁systems .
▁ MET HOD S : ▁Mix ed - met hod s ▁study ▁of ▁2 95 ▁veteran s ▁a ged ▁50 ▁years ▁and ▁older ▁in ▁4 ▁VA ▁health ▁care ▁systems ▁who ▁had ▁sy sto lic ▁heart ▁failure ▁and ▁were ▁not ▁pre scribe d ▁a ▁β - block er ▁and / or ▁an ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁or ▁ang io ten sin - recept or ▁block er .
▁Reason s ▁for ▁non tre at ment ▁were ▁identified ▁from ▁clinic ▁notes ▁and ▁from ▁interview s ▁with ▁62 ▁primary ▁care ▁clinic ians ▁car ing ▁for ▁these ▁patients .
▁These ▁reasons ▁were ▁class ified ▁using ▁a ▁published ▁tax ono my .
▁RESULT S : ▁Am ong ▁2 95 ▁patients ▁not ▁receiving ▁guide line - re com mend ed ▁drugs ▁for ▁heart ▁failure , ▁chart ▁review ▁identified ▁bio medic al ▁reasons ▁for ▁non pre scribi ng ▁in ▁4 2% -5 8% ▁of ▁patients ▁and ▁context ual ▁reasons ▁in ▁11% -17 % .
▁Clinic ian ▁interview s ▁identified ▁twice ▁as ▁many ▁reasons ▁for ▁non pre scribi ng ▁as ▁chart ▁review ▁( me an ▁1.6 ▁vs . ▁ 0.8 ▁reasons ▁per ▁patient , ▁P < 0.00 1) .
▁In ▁these ▁interview s , ▁bio medic al ▁reasons ▁for ▁non pre scribi ng ▁were ▁ci ted ▁in ▁50% - 70% ▁of ▁patients , ▁and ▁context ual ▁reasons ▁in ▁6 4% - 70% .
▁The ▁most ▁common ▁context ual ▁reasons ▁were ▁co management ▁with ▁other ▁clinic ians ▁(3 2% -3 5% ▁of ▁patients ), ▁patient ▁preference s ▁and ▁non adh er ence ▁( 15% -24 %) , ▁and ▁clinic ian ▁belief ▁that ▁the ▁medication ▁is ▁not ▁indicate d ▁in ▁the ▁patient ▁(1 2% - 20% ).
▁CON CL USI ONS : ▁Con text ual ▁reasons ▁for ▁not ▁pre scribi ng ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁/ ▁ang io ten sin - recept or ▁block ers ▁and ▁β - block ers ▁are ▁present ▁in ▁two ▁third s ▁of ▁patients ▁with ▁heart ▁failure ▁who ▁did ▁not ▁receive ▁these ▁medication s , ▁yet ▁are ▁poor ly ▁document ed ▁in ▁medical ▁records .
▁The ▁structure ▁of ▁medical ▁records ▁should ▁be ▁improve d ▁to ▁facilita te ▁documentation ▁of ▁context ual ▁reasons ▁for ▁not ▁providing ▁guide line - re com mend ed ▁care .
▁Inc rea se ▁in ▁para sy mpa the tic ▁tone ▁by ▁py rido stig mine ▁prevent s ▁vent ri cular ▁dys function ▁during ▁the ▁ons et ▁of ▁heart ▁failure .
▁Heart ▁failure ▁( HF ) ▁is ▁character ized ▁by ▁eleva ted ▁sympa the tic ▁activity ▁and ▁reduce d ▁para sy mpa the tic ▁control ▁of ▁the ▁heart .
▁Experiment al ▁evidence ▁suggest s ▁that ▁the ▁increase ▁in ▁para sy mpa the tic ▁function ▁can ▁be ▁a ▁ therapeut ic ▁alternative ▁to ▁slow ▁ HF ▁e volution .
▁The ▁para sy mpa the tic ▁neuro trans mission ▁can ▁be ▁improve d ▁by ▁a ce tyl cho line ster ase ▁inhibi tion .
▁We ▁investiga ted ▁the ▁long - term ▁(4 ▁w k ) ▁effects ▁of ▁the ▁a ce tyl cho line ster ase ▁inhibi tor ▁py rido stig mine ▁on ▁sympa t hova gal ▁balance , ▁cardiac ▁remodel ing , ▁and ▁cardiac ▁function ▁in ▁the ▁ons et ▁of ▁ HF ▁following ▁my o card ial ▁in far ction .
▁My o card ial ▁in far ction ▁was ▁e licit ed ▁in ▁adult ▁male ▁Wi star ▁rat s .
▁After ▁4 ▁w k ▁of ▁py rido stig mine ▁administration , ▁per ▁os , ▁met hy la tropi ne ▁and ▁propra no lol ▁were ▁used ▁to ▁evaluat e ▁the ▁cardiac ▁sympa t hova gal ▁balance .
▁The ▁ta chy car dic ▁response ▁caused ▁by ▁met hy la tropi ne ▁was ▁considered ▁to ▁be ▁the ▁va gal ▁tone , ▁where as ▁the ▁bra dy car dic ▁response ▁caused ▁by ▁propra no lol ▁was ▁considered ▁to ▁be ▁the ▁sympa the tic ▁tone .
▁In ▁ conscious ▁ HF ▁rat s , ▁py rido stig mine ▁reduce d ▁the ▁bas al ▁heart ▁rate , ▁increased ▁va gal , ▁and ▁reduce d ▁sympa the tic ▁control ▁of ▁heart ▁rate .
▁Pyr ido stig mine ▁reduce d ▁the ▁my o cy te ▁diameter ▁and ▁collage n ▁den s ity ▁of ▁the ▁sur vi ving ▁left ▁vent ric le .
▁Pyr ido stig mine ▁also ▁increased ▁vas cular ▁en dot heli al ▁growth ▁factor ▁protein ▁in ▁the ▁left ▁vent ric le , ▁suggest ing ▁my o card ial ▁ang io gene sis .
▁Card iac ▁function ▁was ▁assess ed ▁by ▁means ▁of ▁the ▁pressure - volu me ▁conduct ance ▁cat heter ▁system .
▁ HF ▁rat s ▁treated ▁with ▁py rido stig mine ▁exhibi ted ▁a ▁higher ▁stroke ▁volume , ▁e je ction ▁ fraction , ▁cardiac ▁output , ▁and ▁contract ility ▁of ▁the ▁left ▁vent ric le .
▁It ▁was ▁demonstrat ed ▁that ▁the ▁long - term ▁administration ▁of ▁py rido stig mine ▁started ▁right ▁after ▁corona ry ▁arter y ▁liga tion ▁aug mente d ▁cardiac ▁va gal ▁and ▁reduce d ▁sympa the tic ▁tone , ▁att en u ating ▁cardiac ▁remodel ing ▁and ▁left ▁vent ri cular ▁dys function ▁during ▁the ▁progression ▁of ▁ HF ▁in ▁rat s .
▁Me chan istic ▁insight ▁into ▁prolong ed ▁electro me chan ical ▁de lay ▁in ▁dys syn chron ous ▁heart ▁failure : ▁a ▁computa tional ▁study .
▁In ▁addition ▁to ▁the ▁left ▁bund le ▁bran ch ▁block ▁type ▁of ▁electric al ▁activa tion , ▁there ▁are ▁further ▁remodel ing ▁aspects ▁associated ▁with ▁dys syn chron ous ▁heart ▁failure ▁( HF ) ▁that ▁affect ▁the ▁electro me chan ical ▁behavior ▁of ▁the ▁heart .
▁Am ong ▁the ▁most ▁important ▁are ▁alter ed ▁vent ri cular ▁structure ▁( bo th ▁ge ometr y ▁and ▁fiber / she et ▁ orientation ), ▁ab normal ▁Ca (2 +) ▁handling , ▁slow ed ▁con duction , ▁and ▁reduce d ▁wall ▁sti ff ness .
▁In ▁dys syn chron ous ▁ HF , ▁the ▁electro me chan ical ▁de lay ▁( EM D ), ▁the ▁time ▁interval ▁between ▁local ▁my o cy te ▁de po lar ization ▁and ▁my o fi ber ▁short en ing ▁ons et , ▁is ▁prolong ed .
▁However , ▁the ▁contribution s ▁of ▁the ▁four ▁major ▁ HF ▁remodel ing ▁aspects ▁in ▁extend ing ▁EM D ▁in ▁the ▁dys syn chron ous ▁fail ing ▁heart ▁remain ▁un know n .
▁The ▁goal ▁of ▁this ▁study ▁was ▁to ▁determine ▁the ▁individual ▁and ▁combine d ▁contribution s ▁of ▁ HF - indu ced ▁remodel ing ▁aspects ▁to ▁EM D ▁prolong ation .
▁We ▁used ▁M RI - based ▁models ▁of ▁dys syn chron ous ▁non fail ing ▁and ▁ HF ▁can ine ▁electro me chan ics ▁and ▁construct ed ▁additional ▁models ▁in ▁which ▁var ying ▁combination s ▁of ▁the ▁four ▁remodel ing ▁aspects ▁were ▁represent ed .
▁A ▁left ▁bund le ▁bran ch ▁block ▁electric al ▁activa tion ▁se que nce ▁was ▁simula ted ▁in ▁all ▁models .
▁The ▁simula tion ▁results ▁reveal ed ▁that ▁de rang ed ▁Ca (2 +) ▁handling ▁is ▁the ▁primary ▁cul pri t ▁in ▁extend ing ▁EM D ▁in ▁dys syn chron ous ▁ HF , ▁with ▁the ▁other ▁aspects ▁of ▁remodel ing ▁contribu ting ▁insigni fica nt ly .
▁Me chan ist ically , ▁we ▁found ▁that ▁ab normal ▁Ca (2 +) ▁handling ▁in ▁dys syn chron ous ▁ HF ▁slow s ▁my o fi ber ▁short en ing ▁veloci ty ▁at ▁the ▁early - activa ted ▁sept um ▁and ▁de press es ▁both ▁my o fi ber ▁short en ing ▁and ▁stretch ▁rate ▁at ▁the ▁late - activa ted ▁lateral ▁wall .
▁These ▁changes ▁in ▁my o fi ber ▁dynamic s ▁de lay ▁the ▁ons et ▁of ▁my o fi ber ▁short en ing , ▁thu s ▁giving ▁ rise ▁to ▁prolong ed ▁EM D ▁in ▁dys syn chron ous ▁ HF .
▁Relation ship s ▁between ▁right ▁vent ri cular ▁function , ▁body ▁composition , ▁and ▁prognos is ▁in ▁advanced ▁heart ▁failure .
▁OB JE C TIVE S : ▁This ▁study ▁so ught ▁to ▁examine ▁the ▁relationships ▁between ▁right ▁vent ri cular ▁( RV ) ▁function , ▁body ▁composition , ▁and ▁prognos is ▁in ▁patients ▁with ▁advanced ▁heart ▁failure ▁( HF ).
▁BA CK GRO UND : ▁Previous ▁studies ▁investiga ting ▁ HF - related ▁cache xia ▁have ▁not ▁examine d ▁the ▁impact ▁of ▁ RV ▁function ▁on ▁body ▁composition .
▁We ▁hypothe s ized ▁that ▁ RV ▁dys function ▁is ▁link ed ▁to ▁weight ▁loss , ▁ab normal ▁body ▁composition , ▁and ▁worse ned ▁prognos is ▁in ▁advanced ▁ HF .
▁ MET HOD S : ▁Subject s ▁with ▁advanced ▁ HF ▁( n ▁= ▁4 08) ▁under went ▁prospect ive ▁assessment ▁of ▁body ▁composition ▁( s kin fold ▁thi ck ness , ▁dual - ener gy ▁X - ray ▁ab sor pti ometr y ), ▁comprehensive ▁e cho card i ography , ▁and ▁blood ▁testing .
▁Subject s ▁were ▁followed ▁up ▁for ▁advers e ▁events ▁( de fin ed ▁as ▁death , ▁transplant ation , ▁or ▁circula tory ▁assist ▁device ).
▁RESULT S : ▁Subject s ▁with ▁ RV ▁dys function ▁(5 1%) ▁had ▁lower ▁body ▁mass ▁index , ▁lower ▁fat ▁mass ▁index , ▁and ▁were ▁more ▁likely ▁to ▁display ▁cache xia ▁(19 %) .
▁The ▁extent ▁of ▁ RV ▁dys function ▁cor related ▁with ▁greater ▁antecede nt ▁weight ▁loss ▁and ▁a ▁lower ▁fat / lean ▁body ▁mass ▁ratio .
▁Over ▁a ▁media n ▁follow - up ▁of ▁5 41 ▁days , ▁there ▁were ▁150 ▁events ▁(3 7% ).
▁Risk ▁of ▁event ▁was ▁greater ▁in ▁subject s ▁with ▁ RV ▁dys function ▁( haz ard ▁ratio : ▁3. 09 ▁[ 95% ▁confidence ▁interval ▁( CI ): ▁2. 18 ▁to ▁4. 45 ] ) ▁and ▁cache xia ▁( haz ard ▁ratio : ▁2. 90 ▁[ 95% ▁CI : ▁ 2.00 ▁to ▁4.1 2] ) ▁in ▁uni varia te ▁and ▁multi varia te ▁analyse s .
▁Inc rea sed ▁body ▁mass ▁index ▁was ▁associated ▁with ▁a ▁lower ▁event ▁rate ▁( HR ▁per ▁kg / m (2) : ▁0 . 92 ▁[ 95% ▁CI : ▁0 . 88 ▁to ▁0 . 96 ] ), ▁and ▁this ▁protection ▁was ▁media ted ▁by ▁a ▁higher ▁fat ▁mass ▁(0 . 91 ▁[ 95% ▁CI : ▁0 . 87 ▁to ▁0 . 96 ] ) ▁but ▁not ▁a ▁fat - free ▁mass ▁index ▁(0 . 97 ▁[ 95% ▁CI : ▁0 . 92 ▁to ▁1.0 3] ).
▁CON CL USI ONS : ▁ RV ▁dys function ▁and ▁cardiac ▁cache xia ▁often ▁co exist , ▁have ▁addit ive ▁advers e ▁impact , ▁and ▁might ▁be ▁mechan ist ically ▁inter related .
▁Was ting ▁of ▁fat ▁but ▁not ▁of ▁lean ▁mass ▁was ▁predict ive ▁of ▁advers e ▁outcome , ▁suggest ing ▁that ▁fat ▁loss ▁is ▁either ▁a ▁sur roga te ▁of ▁enhance d ▁cata bol ism ▁or ▁adi pose ▁tissu e ▁is ▁cardio protec tive ▁in ▁the ▁context ▁of ▁ HF .
▁Effect ▁of ▁If - chan nel ▁inhibi tion ▁on ▁hem o dynamic ▁status ▁and ▁exercise ▁ tolerance ▁in ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction : ▁a ▁random ized ▁trial .
▁OB JE C TIVE S : ▁The ▁a im ▁of ▁this ▁study ▁was ▁to ▁test ▁the ▁effects ▁of ▁treatment ▁with ▁i va bra dine ▁on ▁exercise ▁capacity ▁and ▁left ▁vent ri cular ▁fill ing ▁in ▁patients ▁with ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ).
▁BA CK GRO UND : ▁Because ▁symptoms ▁of ▁ HF p EF ▁are ▁typically ▁ex er tional , ▁optimiza tion ▁of ▁dia sto lic ▁fill ing ▁time ▁by ▁control ling ▁heart ▁rate ▁may ▁de lay ▁the ▁ons et ▁of ▁symptoms .
▁ MET HOD S : ▁Six ty - one ▁patients ▁with ▁ HF p EF ▁were ▁random ly ▁assign ed ▁to ▁i va bra dine ▁5 ▁mg ▁twice ▁daily ▁( n ▁= ▁30 ) ▁or ▁place bo ▁( n ▁= ▁31 ) ▁for ▁7 ▁days ▁in ▁this ▁double - blind ▁trial .
▁Card io pul mon ary ▁exercise ▁testing ▁with ▁e cho car dio graphic ▁assessment ▁of ▁my o card ial ▁function ▁and ▁left ▁vent ri cular ▁fill ing ▁were ▁under tak en ▁at ▁rest ▁and ▁after ▁exercise .
▁RESULT S : ▁The ▁i va bra dine ▁group ▁demonstrat ed ▁significant ▁improvement ▁between ▁base line ▁and ▁follow - up ▁exercise ▁capacity ▁( 4.2 ▁ ± ▁1.8 ▁ MET s ▁vs . ▁ 5.7 ▁ ± ▁1.9 ▁ MET s , ▁p ▁= ▁0.0 01) ▁and ▁pe ak ▁oxygen ▁up take ▁(1 4.0 ▁ ± ▁6.1 ▁ml / min / kg ▁vs . ▁1 7.0 ▁ ± ▁3.3 ▁ml / min / kg , ▁p ▁= ▁0.0 01) , ▁with ▁simultan e ous ▁re duction ▁in ▁exercise - indu ced ▁increase ▁in ▁the ▁ratio ▁of ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁to ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty ▁( 3.1 ▁ ± ▁2. 7 ▁vs . ▁1.3 ▁ ± ▁2.0 , ▁p ▁= ▁0.0 04) .
▁Work ▁load - corre cted ▁chr ono tropi c ▁response ▁( the ▁difference ▁in ▁heart ▁rate ▁at ▁the ▁same ▁exercise ▁time ▁at ▁the ▁base line ▁and ▁follow - up ▁tests ) ▁showed ▁a ▁slow er ▁increase ▁in ▁heart ▁rate ▁during ▁exercise ▁than ▁in ▁the ▁place bo - tre ated ▁group .
▁Therapy ▁with ▁i va bra dine ▁( β ▁= ▁0.3 4 , ▁p ▁= ▁0.0 4) ▁and ▁change ▁with ▁treatment ▁in ▁ex er tional ▁increase ▁in ▁the ▁ratio ▁of ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁to ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty ▁( β ▁= ▁ -0 . 30 , ▁p ▁= ▁0.0 2) ▁were ▁independent ▁corre late s ▁of ▁increase ▁in ▁exercise ▁capacity , ▁and ▁ therapy ▁with ▁i va bra dine ▁( β ▁= ▁0.3 2 , ▁p ▁= ▁0.0 07) ▁was ▁independent ly ▁cor related ▁with ▁increase ▁in ▁pe ak ▁oxygen ▁up take .
▁CON CL USI ONS : ▁In ▁patients ▁with ▁ HF p EF , ▁short - term ▁treatment ▁with ▁i va bra dine ▁increased ▁exercise ▁capacity , ▁with ▁a ▁contribution ▁from ▁improve d ▁left ▁vent ri cular ▁fill ing ▁pressure ▁response ▁to ▁exercise ▁as ▁reflect ed ▁by ▁the ▁ratio ▁of ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁to ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty .
▁Because ▁this ▁patient ▁population ▁is ▁symptom a tic ▁on ▁ex er tion , ▁ therapeut ic ▁treatment s ▁target ing ▁ab normal ▁exercise ▁hem o dynamic ▁status ▁may ▁prove ▁useful .
▁( U se ▁of ▁Exerci se ▁and ▁Medical ▁Therapie s ▁to ▁Im prove ▁Card iac ▁Fun ction ▁Am ong ▁Patient s ▁With ▁Ex er tional ▁Short ness ▁of ▁Breath ▁Du e ▁to ▁Lung ▁Con gestion ; ▁ ACT RN 126 1000 10 870 44) .
▁A ▁simple ▁valida ted ▁clinic al ▁tool ▁to ▁predict ▁the ▁ absence ▁of ▁corona ry ▁arter y ▁disease ▁in ▁patients ▁with ▁sy sto lic ▁heart ▁failure ▁of ▁un clear ▁et i ology .
▁Corona ry ▁arter y ▁disease ▁( CAD ) ▁is ▁a ▁major ▁cause ▁of ▁sy sto lic ▁heart ▁failure ▁( HF ).
▁Ident ifying ▁CAD ▁as ▁a ▁cause ▁of ▁sy sto lic ▁ HF ▁has ▁prognos tic ▁and ▁treatment ▁implica tions .
▁Whether ▁all ▁patients ▁with ▁sy sto lic ▁ HF ▁of ▁un clear ▁et i ology ▁should ▁under go ▁corona ry ▁ang i ography ▁has ▁been ▁controversia l .
▁We ▁so ught ▁to ▁der ive ▁and ▁valida te ▁a ▁clinic al ▁predict ion ▁rule ▁to ▁exclu de ▁CAD ▁as ▁a ▁cause ▁of ▁sy sto lic ▁ HF .
▁A ▁deriva tion ▁co hor t ▁was ▁for med ▁of ▁consecutiv e ▁patients ▁who ▁had ▁under go ne ▁corona ry ▁ang i ography ▁with ▁a ▁primary ▁ diagnos is ▁of ▁sy sto lic ▁ HF ▁of ▁un clear ▁et i ology ▁( ej ection ▁ fraction ▁< 50% ).
▁U sing ▁multi varia te ▁logistic ▁re gression ▁analysis , ▁we ▁deri ved ▁a ▁predict ion ▁rule ▁for ▁severe ▁CAD ▁( ≥ 50% ▁diameter ▁sten osis ▁in ▁the ▁left ▁main , ▁3- ves sel ▁CAD , ▁and ▁2- ves sel ▁CAD ▁in vol ving ▁the ▁proxima l ▁left ▁anterior ▁descend ing ▁arter y ).
▁The ▁diagnostic ▁performance ▁of ▁the ▁define d ▁predict ion ▁rule ▁was ▁prospect ive ly ▁valida ted ▁in ▁a ▁separate ▁co hor t ▁recruit ed ▁from ▁2 ▁institution s .
▁Of ▁the ▁124 ▁patients ▁in ▁the ▁deriva tion ▁co hor t , ▁2 7% ▁had ▁CAD , ▁including ▁15% ▁with ▁severe ▁CAD .
▁The ▁independent ▁predict ors ▁of ▁severe ▁CAD ▁included ▁diabetes ▁( odd s ▁ratio ▁5.1 , ▁p ▁= ▁0.0 05) , ▁electro car dio graphic ▁Q ▁wa ves ▁or ▁left ▁bund le ▁bran ch ▁block ▁( odd s ▁ratio ▁ 3.8 , ▁p ▁= ▁0.0 2) , ▁and ▁ ≥ 2 ▁non dia bete s ▁risk ▁factors : ▁age ▁( men ▁ ≥ 55 ▁or ▁women ▁ ≥ 65 ▁years ), ▁dys li pide mia , ▁hyper tension , ▁and ▁to ba cco ▁use ▁( odd s ▁ratio ▁4. 8 , ▁p ▁= ▁0.0 2) .
▁A ▁predict ion ▁rule ▁of ▁having ▁ ≥ 1 ▁independent ▁predict or ▁identified ▁9 7% ▁of ▁the ▁patients ▁with ▁CAD ▁and ▁100% ▁of ▁the ▁patients ▁with ▁severe ▁CAD .
▁In ▁the ▁prospect ive ▁valida tion ▁co hor t ▁of ▁143 ▁patients , ▁the ▁predict ion ▁rule ▁had ▁98% ▁ sensitiv ity ▁and ▁18% ▁specific ity ▁for ▁CAD ▁but ▁100% ▁ sensitiv ity ▁for ▁severe ▁CAD .
▁In ▁conclusion , ▁a ▁simple ▁clinic al ▁predict ion ▁rule ▁can ▁accurate ly ▁identify ▁patients ▁with ▁CAD ▁and ▁elimina te ▁the ▁need ▁for ▁ang i ography ▁in ▁a ▁substantial ▁proportion ▁of ▁patients ▁with ▁sy sto lic ▁ HF , ▁with ▁potential ly ▁significant ▁cost ▁sav ings ▁and ▁risk ▁avoid ance .
▁Experience ▁of ▁a ▁vaso press in ▁receptor ▁anta gon ist , ▁to lv ap tan , ▁under ▁the ▁unique ▁indica tion ▁in ▁Japanese ▁heart ▁failure ▁patients .
▁Tol va p tan ▁is ▁a ▁vaso press in ▁type ▁2 ▁receptor ▁anta gon ist .
▁Current ly , ▁to lv ap tan ▁is ▁indicate d ▁for ▁the ▁treatment ▁of ▁severe ▁hypo na trem ia ▁in ▁most ▁countries , ▁including ▁the ▁United ▁States , ▁but ▁in ▁Japan ▁the ▁indica tion ▁is ▁broad er ; ▁it ▁can ▁be ▁used ▁in ▁con ges tive ▁heart ▁failure ▁patients ▁in ▁addition ▁to ▁standard ▁or ▁optimal ▁di ure tic ▁ therapy , ▁regardless ▁of ▁their ▁se rum ▁so dium ▁levels ▁or ▁sy sto lic ▁function .
▁Our ▁review ▁of ▁this ▁new ly ▁introduce d ▁drug ▁is ▁based ▁on ▁our ▁experience ▁in ▁Japan .
▁Di ure tic ▁use ▁in ▁heart ▁failure ▁and ▁outcome s .
▁Di ure tics ▁are ▁frequently ▁ad minister ed ▁to ▁reli eve ▁con ges tive ▁symptoms ▁in ▁patients ▁with ▁heart ▁failure ▁( HF ).
▁De spite ▁their ▁wide spre ad ▁use , ▁prospect ive ▁data ▁on ▁the ▁potential ▁of ▁di ure tics ▁to ▁modul ate ▁ HF - related ▁morbi d ity ▁and ▁mortal ity ▁are ▁scar ce .
▁Di ure tic ▁ef fica cy ▁may ▁be ▁limited ▁by ▁advers e ▁neuro hormon al ▁activa tion ▁and ▁by ▁" con gestion - like " ▁symptoms ▁that ▁may ▁occur ▁in ▁the ▁ absence ▁of ▁fluid ▁over load .
▁Here in , ▁we ▁review ▁the ▁current ▁knowledge ▁on ▁di ure tic ▁use ▁and ▁outcome s ▁in ▁ HF .
▁The ▁high - risk ▁patient ▁with ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction : ▁treatment ▁options ▁and ▁challenges .
▁An ▁estima ted ▁5.1 ▁million ▁American s ▁a ged ▁20 ▁years ▁and ▁older ▁have ▁heart ▁failure .
▁(1) ▁With ▁ therapie s ▁rang ing ▁from ▁medication ▁and ▁physical ▁ therapy ▁to ▁implant able ▁de fi br illa tors ▁and ▁circula tory ▁support , ▁and ▁possibly ▁transplant ation , ▁accurate ▁risk ▁strat ification ▁of ▁patient ▁with ▁heart ▁failure ▁and ▁delivery ▁of ▁ therapie s ▁appropriate ▁to ▁the ▁level ▁of ▁their ▁disease ▁sever ity ▁is ▁becoming ▁increasing ly ▁important .
▁Determina tion ▁of ▁risk ▁and ▁associated ▁treatment ▁strategie s ▁is ▁the ▁subject ▁of ▁this ▁brief ▁review .
▁Pho s pho dies tera se -2 ▁is ▁up - regula ted ▁in ▁human ▁fail ing ▁heart s ▁and ▁blu nts ▁beta - ad r energi c ▁response s ▁in ▁cardio my o cy tes .
▁OB JE C TIVE S : ▁This ▁study ▁investiga ted ▁whether ▁my o card ial ▁ phos pho dies tera se -2 ▁( P DE 2) ▁is ▁alter ed ▁in ▁heart ▁failure ▁( HF ) ▁and ▁determine d ▁P DE 2- media ted ▁effects ▁on ▁beta - ad r energi c ▁receptor ▁( β - AR ) ▁signal ing ▁in ▁healthy ▁and ▁disease d ▁cardio my o cy tes .
▁BA CK GRO UND : ▁Di minis hed ▁ cycli c ▁ad enos ine ▁mono phos pha te ▁( c AMP ) ▁and ▁aug mente d ▁ cycli c ▁gua no sine ▁mono phos pha te ▁( c G MP ) ▁signal ing ▁is ▁character istic ▁for ▁fail ing ▁heart s .
▁Am ong ▁the ▁P DE ▁super family , ▁P DE 2 ▁has ▁the ▁unique ▁property ▁of ▁being ▁able ▁to ▁be ▁stimula ted ▁by ▁c G MP , ▁thu s ▁leading ▁to ▁a ▁re mark able ▁increase ▁in ▁c AMP ▁hydro lys is ▁media ting ▁a ▁negative ▁cross ▁talk ▁between ▁c G MP ▁and ▁c AMP ▁signal ing .
▁However , ▁the ▁role ▁of ▁P DE 2 ▁in ▁ HF ▁is ▁poor ly ▁understood .
▁ MET HOD S : ▁Immun o blo tting , ▁radio en zy matic - ▁and ▁fluor esc ence ▁res on ance ▁energy ▁transfer - based ▁as say s , ▁video ▁edge ▁det ection , ▁epi flu o resc ence ▁micro s copy , ▁and ▁L - type ▁Ca 2 ( +) ▁current ▁measure ments ▁were ▁perform ed ▁in ▁my o card ial ▁tissu es ▁and / or ▁isola ted ▁cardio my o cy tes ▁from ▁human ▁and / or ▁experimental ▁ HF , ▁respective ly .
▁RESULT S : ▁My o card ial ▁P DE 2 ▁expression ▁and ▁activity ▁were ▁~ 2- fold ▁higher ▁in ▁advanced ▁human ▁ HF .
▁Chro nic ▁β - AR ▁stimul ation ▁via ▁cate chol amine ▁in fusion s ▁in ▁rat s ▁enhance d ▁P DE 2 ▁expression ▁~ 2- fold ▁and ▁c AMP ▁hydro ly tic ▁activity ▁~ 4- fold , ▁which ▁cor related ▁with ▁blu n ted ▁cardiac ▁β - AR ▁responsive ness .
▁In ▁disease d ▁cardio my o cy tes , ▁higher ▁P DE 2 ▁activity ▁could ▁be ▁further ▁enhance d ▁by ▁stimul ation ▁of ▁c G MP ▁synth es is ▁via ▁ni tric ▁oxid e ▁donor s , ▁where as ▁specific ▁P DE 2 ▁inhibi tion ▁parti ally ▁resto red ▁β - AR ▁responsive ness .
▁According ly , ▁P DE 2 ▁over expression ▁in ▁healthy ▁cardio my o cy tes ▁reduce d ▁the ▁ rise ▁in ▁c AMP ▁levels ▁and ▁L - type ▁Ca 2 ( +) ▁current ▁amplitud e , ▁and ▁a boli shed ▁the ▁in o tropi c ▁effect ▁following ▁a cute ▁β - AR ▁stimul ation , ▁without ▁affect ing ▁bas al ▁contract ility .
▁Important ly , ▁P DE 2- over express ing ▁cardio my o cy tes ▁showed ▁marked ▁protection ▁from ▁no re pine ph rine - indu ced ▁hyper trop hic ▁response s .
▁CON CL USI ONS : ▁P DE 2 ▁is ▁marked ly ▁up - regula ted ▁in ▁fail ing ▁heart s ▁and ▁desen siti zes ▁against ▁a cute ▁β - AR ▁stimul ation .
▁This ▁may ▁constitu te ▁an ▁important ▁defense ▁mechanism ▁during ▁cardiac ▁stress , ▁for ▁example , ▁by ▁anta gon izing ▁excessive ▁β - AR ▁drive .
▁Thu s , ▁activa ting ▁my o card ial ▁P DE 2 ▁may ▁represent ▁a ▁novel ▁intra cel lular ▁anti ad r energi c ▁ therapeut ic ▁strategy ▁in ▁ HF .
▁Safety ▁and ▁ef fica cy ▁of ▁e pler en one ▁in ▁patients ▁at ▁high ▁risk ▁for ▁hyper kal emia ▁and / or ▁worse ning ▁renal ▁function : ▁analyse s ▁of ▁the ▁EM PHA SIS - HF ▁study ▁sub group s ▁( E pler en one ▁in ▁Mil d ▁Patient s ▁Hospital ization ▁And ▁Sur v I val ▁Study ▁in ▁Heart ▁Fail ure ).
▁OB JE C TIVE S : ▁The ▁study ▁so ught ▁to ▁investiga te ▁the ▁safety ▁and ▁ef fica cy ▁of ▁e pler en one ▁in ▁patients ▁at ▁high ▁risk ▁for ▁hyper kal emia ▁or ▁worse ning ▁renal ▁function ▁( W RF ) ▁in ▁EM PHA SIS - HF , ▁a ▁trial ▁that ▁en roll ed ▁patients ▁at ▁least ▁55 ▁years ▁old ▁with ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction ▁( HF - RE F ), ▁in ▁New ▁York ▁Heart ▁Association ▁( NY HA ) ▁functional ▁class ▁II ▁and ▁with ▁an ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁( e G FR ) ▁> 30 ▁ml / min /1 . 73 ▁m (2) ▁and ▁se rum ▁po tas s ium ▁< 5.0 ▁mm ol / l .
▁Patient s ▁were ▁receiving ▁optimal ▁ therapy ▁and ▁most ▁had ▁been ▁hospital ized ▁for ▁a ▁cardiovascular ▁reason ▁within ▁180 ▁days ▁of ▁inclusi on .
▁BA CK GRO UND : ▁Under use ▁of ▁e pler en one ▁in ▁patients ▁with ▁ HF - RE F ▁may ▁be ▁due ▁to ▁fear ▁of ▁induc ing ▁hyper kal emia ▁or ▁W RF ▁in ▁high - risk ▁patients .
▁ MET HOD S : ▁This ▁was ▁a ▁pre - spec ified ▁analysis ▁of ▁sub group s ▁of ▁patients ▁at ▁high ▁risk ▁of ▁hyper kal emia ▁or ▁W RF ▁( patient s ▁ ≥ ▁75 ▁years ▁of ▁age , ▁with ▁diabetes , ▁with ▁e G FR ▁< 60 ▁ml / min /1 . 73 ▁m (2) , ▁and ▁with ▁sy sto lic ▁blood ▁pressure ▁< ▁media n ▁of ▁123 ▁mm ▁H g ), ▁exam ining ▁the ▁major ▁safety ▁measure s ▁( po tas s ium ▁> 5.5 , ▁> 6 . 0 , ▁and ▁< 3.5 ▁mm ol / l ; ▁hyper kal emia ▁leading ▁to ▁study - drug ▁dis continu ation ▁or ▁hospital ization ; ▁and ▁hospital ization ▁for ▁W RF ) ▁as ▁well ▁as ▁the ▁primary ▁outcome ▁( hospital ization ▁for ▁ HF ▁or ▁cardiovascular ▁mortal ity ).
▁RESULT S : ▁In ▁all ▁high - risk ▁sub group s , ▁patients ▁treated ▁with ▁e pler en one ▁had ▁an ▁increased ▁risk ▁of ▁po tas s ium ▁> 5.5 ▁mm ol / l ▁but ▁not ▁of ▁po tas s ium ▁> 6 . 0 ▁mm ol / l , ▁and ▁of ▁hospital ization ▁for ▁hyper kal emia ▁or ▁dis continu ation ▁of ▁study ▁medication ▁due ▁to ▁advers e ▁events .
▁E pler en one ▁was ▁effective ▁in ▁ reducing ▁the ▁primary ▁com posit e ▁end point ▁in ▁all ▁sub group s .
▁CON CL USI ONS : ▁In ▁patients ▁with ▁chronic ▁ HF - RE F , ▁in ▁NY HA ▁functional ▁class ▁II , ▁and ▁meeting ▁specific ▁inclusi on ▁and ▁exclu sion ▁criteri a , ▁including ▁an ▁e G FR ▁> 30 ▁ml / min /1 . 73 ▁m (2) ▁and ▁po tas s ium ▁< 5.0 ▁mm ol / l , ▁e pler en one ▁was ▁both ▁efficaci ous ▁and ▁safe ▁when ▁carefully ▁monitor ed , ▁even ▁in ▁sub group s ▁at ▁high ▁risk ▁of ▁developing ▁hyper kal emia ▁or ▁W RF .
▁( A ▁Compar ison ▁Of ▁Out com es ▁In ▁Patient s ▁In ▁New ▁York ▁Heart ▁Association ▁[ NY HA ] ▁Class ▁II ▁Heart ▁Fail ure ▁When ▁Tre ated ▁With ▁E pler en one ▁Or ▁Place bo ▁In ▁Add i tion ▁To ▁Standard ▁Heart ▁Fail ure ▁Medicine s ▁[ EMP HA SIS - HF ▁Study ] ; ▁N CT 002 321 80) .
▁At rial ▁fi bril lation ▁and ▁con ges tive ▁heart ▁failure : ▁a ▁cost ▁analysis ▁of ▁ rhythm - control ▁vs . ▁rate - control ▁strategie s .
▁BA CK GRO UND : ▁At rial ▁fi bril lation ▁( AF ) ▁is ▁common ▁in ▁patients ▁with ▁heart ▁failure .
▁ Rhythm - ▁and ▁rate - control ▁strategie s ▁are ▁associated ▁with ▁similar ▁ef fica cy ▁outcome s .
▁We ▁compared ▁the ▁economic ▁impact ▁of ▁the ▁2 ▁treatment ▁strategie s ▁in ▁patients ▁with ▁AF ▁and ▁heart ▁failure ▁from ▁the ▁province ▁of ▁Québec , ▁Canada .
▁ MET HOD S : ▁In ▁a ▁sub stu dy ▁of ▁the ▁At rial ▁Fi bril lation ▁and ▁Con ges tive ▁Heart ▁Fail ure ▁trial , ▁health ▁care ▁ex pendi tures ▁of ▁patients ▁from ▁Québec ▁random ized ▁to ▁ rhythm ▁and ▁rate - control ▁treatment ▁strategie s ▁were ▁compared ▁from ▁a ▁single - pay er ▁perspective ▁using ▁a ▁cost - mini m ization ▁approach .
▁In - t rial ▁resource ▁utiliza tion ▁and ▁unit ▁costs ▁were ▁estima ted ▁from ▁Québec ▁Health ▁Insurance ▁Board ▁database s ▁supplement ed ▁by ▁disease - specific ▁costs ▁from ▁the ▁Ontario ▁Case ▁Cost ing ▁Initiative .
▁RESULT S : ▁In ▁all , ▁304 ▁patients ▁were ▁included , ▁a ged ▁68 ▁ ± ▁9 ▁years ; ▁8 6% ▁male ; ▁e je ction ▁ fraction , ▁2 6% ▁ ± ▁6% .
▁Base line ▁character istic s ▁were ▁similar ▁in ▁ rhythm - control ▁( n ▁= ▁149 ) ▁and ▁rate - control ▁( n ▁= ▁155 ) ▁groups .
▁Ar rhythm ia - related ▁costs ▁account ed ▁for ▁45% ▁of ▁total ▁ex pendi tures .
▁Rate - control ▁patients ▁had ▁few er ▁cardiac ▁procedure s ▁( 146 ▁vs . ▁23 8 , ▁P ▁< ▁0.0 01) , ▁drive n ▁by ▁few er ▁cardio version s , ▁and ▁lower ▁costs ▁related ▁to ▁anti ar rhythm ic ▁drugs ▁( CAD ▁$ 48 ▁per ▁patient ▁[ 95% ▁confidence ▁interval ▁{ CI } , ▁$2 1- $ 96 ] ▁vs . ▁$ 13 19 ▁per ▁patient ▁[ 95% ▁CI , ▁$1 124 - $ 152 2] ).
▁However , ▁these ▁difference s ▁were ▁off set ▁by ▁higher ▁ex pendi tures ▁due ▁to ▁hospital ization s ▁for ▁non car dio vas cular ▁diagnose s , ▁implant able ▁cardiac ▁ar rhythm ia ▁devices , ▁and ▁non car dio vas cular ▁drugs ▁in ▁the ▁rate - control ▁group .
▁The ▁total ▁cost ▁per ▁patient ▁was ▁not ▁significantly ▁different ▁between ▁ rhythm - control ▁( $ 72 , 764 ▁[ 95% ▁CI , ▁$ 6 1,5 75 - $ 85 , 145 ] ) ▁and ▁rate - control ▁( $ 78 , 767 ▁[ 95% ▁CI , ▁$ 67 , 101 - $ 92 , 139 ] ) ▁strategie s .
▁CON C LU SION : ▁In ▁the ▁study ▁population , ▁the ▁ therapeut ic ▁strategy ▁used ▁to ▁manage ▁AF ▁in ▁patients ▁with ▁severe ▁heart ▁failure ▁appears ▁to ▁have ▁little ▁influence ▁on ▁the ▁overall ▁financial ▁burde n , ▁which ▁remain s ▁substantial .
▁Per tur ba tions ▁in ▁skelet al ▁muscle ▁sar com ere ▁structure ▁in ▁patients ▁with ▁heart ▁failure ▁and ▁type ▁2 ▁diabetes : ▁resto ra tive ▁effects ▁of ▁( - ) - e pica tech in - rich ▁coco a .
▁ HF ▁( heart ▁failure ) ▁and ▁T 2 D ▁( Type ▁2 ▁diabetes ) ▁associa te ▁with ▁detriment al ▁altera tions ▁in ▁Sk M ▁( s kelet al ▁muscle ) ▁structure / function .
▁We ▁have ▁demonstrat ed ▁recently ▁that ▁( - ) - ERC ▁( e pica tech in - rich ▁coco a ) ▁improve s ▁Sk M ▁mito cho ndri al ▁structure ▁[ Ta ub , ▁Ram i rez - S anche z , ▁Ci ar aldi , ▁Per kin s , ▁Murphy , ▁Na vi aux , ▁Hoga n , ▁Ce ball os , ▁Mais el , ▁Henry ▁et ▁al .
▁(2012) ▁C lin .
▁Trans .
▁Sci .
▁5 , ▁43 -47 ] .
▁We ▁hypothe s ized ▁that ▁an ▁improve d ▁mito cho ndri al ▁structure ▁may ▁facilita te ▁the ▁rever sal ▁of ▁detriment al ▁altera tions ▁in ▁sar come ric ▁micro structure .
▁In ▁a ▁pilot ▁study , ▁five ▁patients ▁with ▁ HF ▁and ▁T 2 D ▁consum ed ▁ ERC ▁for ▁3 ▁months ; ▁tre ad m ill ▁testing ▁[ VO 2 max ▁( ma xim um ▁oxygen ▁consum p tion ) ] ▁and ▁Sk M ▁bio psi es ▁were ▁perform ed .
▁Western ▁blot ▁analysis , ▁immun oh isto che mist ry ▁and ▁electro n ▁micro s copy ▁were ▁used .
▁We ▁report ▁severe ▁perturba tions ▁in ▁component s ▁of ▁the ▁DAP C ▁( dys trop hin - as soci ated ▁protein ▁complex ) ▁as ▁well ▁as ▁sar come ric ▁micro structure ▁at ▁base line .
▁ ERC ▁induc ed ▁recovery / en han ce ment ▁of ▁DAP C ▁protein ▁levels , ▁sar come ric ▁micro structure ▁and , ▁in ▁a ▁co - ordina ted ▁fashion , ▁altera tions ▁in ▁marker s ▁of ▁Sk M ▁growth / different i ation ▁consistent ▁with ▁my o fi bre ▁regenera tion .
▁VO 2 max ▁increased ▁( ~ 24 %) ▁but ▁did ▁not ▁reach ▁statistic al ▁significa nce .
▁These ▁initial ▁results ▁warrant ▁further ▁rigor ous ▁investigation , ▁since ▁the ▁use ▁of ▁ ERC ▁( or ▁pure ▁epi cate chin ) ▁may ▁represent ▁a ▁safe ▁and ▁novel ▁means ▁of ▁improving ▁muscle ▁function .
▁Effective ness ▁of ▁Chinese ▁herbal ▁medicine ▁as ▁an ▁ad ju nc tive ▁treatment ▁for ▁dil ated ▁cardio my o pathy ▁in ▁patients ▁with ▁heart ▁failure .
▁OB JE C TIVE S : ▁To ▁evaluat e ▁the ▁effective ness ▁and ▁safety ▁of ▁Chinese ▁herbal ▁medicine ▁( CH M ) ▁as ▁an ▁ad ju nc tive ▁treatment ▁for ▁patients ▁with ▁dil ated ▁cardio my o pathy ▁( DC M ) ▁and ▁heart ▁failure .
▁DESIGN : ▁Studies ▁on ▁bio medic al ▁treatment ▁plus ▁CH M ▁versus ▁bio medic al ▁treatment ▁alone ▁in ▁treat ing ▁patients ▁with ▁D CM ▁and ▁heart ▁failure ▁were ▁re trie ved ▁from ▁Pub Med ▁and ▁other ▁major ▁database s ▁( 1980 -2011 ).
▁Meta - analys is ▁was ▁perform ed ▁on ▁the ▁overall ▁effects ▁on ▁effective ▁rate , ▁left ▁vent ri cular ▁e je ction ▁ fraction , ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter , ▁and ▁other ▁outcome ▁measure s .
▁RESULT S : ▁T went y - s even ▁studies ▁with ▁1887 ▁patients ▁were ▁included .
▁Compar ed ▁with ▁bio medic al ▁treatment ▁alone , ▁bio medic al ▁treatment ▁plus ▁CH M ▁showed ▁significant ▁improvement ▁in ▁effective ▁rate ▁( rela tive ▁risk , ▁1. 26 ; ▁95% ▁confidence ▁interval ▁[ CI ] , ▁1.1 9-1 . 34) , ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁( %) ▁( me an ▁difference , ▁5. 88 ; ▁95% ▁CI , ▁3. 92 -7 . 85) , ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter ▁( mm ) ▁( me an ▁difference , ▁- 2. 78 ; ▁95% ▁CI , ▁- 5 . 15 ▁to ▁- 0.4 2) , ▁and ▁other ▁outcome ▁measure s .
▁Most ▁advers e ▁events ▁observe d ▁in ▁the ▁studies ▁were ▁not ▁severe ▁and ▁resolve d ▁without ▁special ▁treatment .
▁CON CL USI ONS : ▁This ▁meta - analys is ▁indicate d ▁that ▁bio medic al ▁treatment ▁plus ▁CH M ▁is ▁more ▁effective ▁than ▁bio medic al ▁treatment ▁alone ▁in ▁treat ing ▁patients ▁with ▁D CM ▁and ▁heart ▁failure .
▁However , ▁further ▁studies ▁with ▁long - term ▁follow - up , ▁system ic ▁advers e ▁events ▁evaluation , ▁and ▁other ▁et h nic ▁groups ▁are ▁still ▁required ▁to ▁ver ify ▁the ▁ef fica cy ▁and ▁safety ▁of ▁CH M ▁as ▁an ▁ad ju nc tive ▁treatment ▁in ▁all ▁patients ▁with ▁D CM ▁and ▁heart ▁failure .
▁Base line ▁and ▁6- We ek ▁follow - up ▁levels ▁of ▁PA F ▁and ▁activity ▁of ▁its ▁metabol ic ▁enzym es ▁in ▁patients ▁with ▁heart ▁failure ▁and ▁healthy ▁volunteer s - - a ▁pilot ▁study .
▁This ▁study ▁ai med ▁at ▁evaluat ing ▁the ▁changes ▁in ▁plate let - activa ting ▁factor ▁( PA F ) ▁and ▁its ▁metabol ic ▁enzym es ▁over ▁a ▁6- week ▁follow - up ▁period ▁in ▁patients ▁with ▁new ly ▁diagnose d ▁heart ▁failure ▁( [ HF ] ▁n ▁= ▁12 ) ▁compared ▁with ▁age - , ▁sex - , ▁and ▁B MI - match ed ▁apparently ▁healthy ▁volunteer s ▁( n ▁= ▁10 ).
▁The ▁PA F , ▁its ▁key ▁bio syn the tic ▁enzym es ▁( lys o - PA F ▁a ce tyl transfer ase ▁[ lys o - PA F - AT ] ▁and ▁di thi oth rei tol ▁[ D TT ] - in sensitiv e ▁CD P ▁cho line : ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁cho line phos pho transfer ase ▁[ PA F - C PT ] ), ▁and ▁its ▁cata bo lic ▁iso en zy mes ▁( PA F - ace tyl hydro lase ▁[ PA F - AH ] ▁and ▁lipo prote in - as soci ated ▁ phos pho lipa se ▁A 2 ▁[ L p - PLA 2] ) ▁were ▁measure d ▁in ▁se rum ▁and ▁leuk o cy tes ▁of ▁participants .
▁At ▁base line , ▁patients ▁with ▁ HF ▁had ▁lower ▁media n ▁activities ▁of ▁lys o - PA F - AT ▁( P ▁< ▁ . 001 ) ▁and ▁PA F - C PT ▁( P ▁= ▁ . 07) ▁in ▁parallel ▁with ▁PA F ▁levels ▁( P ▁= ▁ . 05) ▁and ▁higher ▁activities ▁of ▁PA F - AH ▁( P ▁= ▁ . 02) ▁and ▁L p - PLA 2 ▁( P ▁< ▁ . 001 ) ▁than ▁control s .
▁At ▁follow - up , ▁PA F - C PT ▁and ▁PA F ▁levels ▁marginal ly ▁increased ▁( P ▁= ▁ . 1) , ▁lys o - PA F - AT ▁( P ▁< ▁ . 001 ) ▁remain ed ▁down regula ted , ▁while ▁PA F - AH ▁( P ▁= ▁ . 004 ) ▁and ▁L p - PLA 2 ▁( P ▁< ▁ . 001 ) ▁remain ed ▁eleva ted ▁compared ▁with ▁the ▁control s .
▁New ly ▁diagnose d ▁patients ▁with ▁ HF ▁under ▁drug ▁treatment ▁have ▁an ▁affected ▁profile ▁of ▁PA F ▁bio syn the tic ▁enzym es ▁and ▁especially ▁lys o - PA F - AT .
▁Exerci se ▁in tolerance ▁in ▁heart ▁failure : ▁update ▁on ▁exercise ▁parameter s ▁for ▁ diagnos is , ▁prognos is ▁and ▁ therapeut ic ▁intervention s .
▁Exerci se ▁in tolerance ▁is ▁a ▁hall mark ▁feature ▁of ▁chronic ▁heart ▁failure ▁and ▁is ▁associated ▁with ▁poor ▁prognos is .
▁This ▁review ▁provides ▁an ▁update ▁on ▁cardio pul mon ary ▁exercise ▁variable s , ▁proven ▁to ▁be ▁prognos t ically ▁important ▁in ▁heart ▁failure .
▁Besi des ▁the ▁wide ly ▁accepte d ▁pe ak ▁oxygen ▁consum p tion ▁( pe ak ▁VO 2) ▁and ▁ VEN / V CO 2 ▁s lope , ▁other ▁exercise ▁variable s ▁- ▁exercise ▁os cilla tory ▁ventilation ▁( E OV ) ▁and ▁parti al ▁pressure ▁of ▁end - ti dal ▁CO 2 , ▁( PET CO 2) ▁- ▁should ▁gain ▁attention ▁in ▁the ▁interpretation ▁of ▁cardio pul mon ary ▁exercise ▁testing .
▁In ▁addition ▁to ▁prognos is , ▁the ▁pat ho phy si ological ▁origin ▁is ▁also ▁discuss ed .
▁Different ▁mechanism s ▁under lie ▁these ▁exercise ▁variable s ▁with ▁an ▁important ▁contribution ▁of ▁ha emo dynamic , ▁pulmonar y ▁and ▁per i pher al ▁ab normal ities .
▁Give n ▁the ▁different ▁pat ho phy si ological ▁origin , ▁a ▁multi varia te ▁assessment ▁with ▁the ▁inclusi on ▁of ▁all ▁the ▁a for ement ion ed ▁parameter s ▁should ▁be ▁encourage d , ▁not ▁only ▁for ▁diagnostic ▁and ▁prognos tic ▁purpose s ▁but ▁also ▁for ▁evaluat ing ▁the ▁effect ▁of ▁intervention s .
▁A cute ▁care ▁surgery ▁in ▁heart ▁transplant ▁recipient s .
▁Ort ho topic ▁heart ▁transplant ation ▁( O HT ) ▁is ▁the ▁optimal ▁treatment ▁for ▁end - s tage ▁heart ▁failure .
▁We ▁review ed ▁our ▁institution al ▁experience ▁between ▁2008 ▁and ▁2012 ▁with ▁a cute ▁care ▁surgery ▁( AC S ) ▁consultation s ▁and ▁procedure s ▁within ▁1 ▁year ▁of ▁O HT ▁in ▁recipient s ▁ bridge d ▁to ▁transplant ation ▁with ▁medical ▁ therapy ▁( MT , ▁n ▁= ▁169 ), ▁including ▁intra ven ous ▁in o trop es , ▁and ▁vent ri cular ▁assist ▁devices ▁( VAD s , ▁n ▁= ▁74 ).
▁In ▁total , ▁28 ▁consultation s ▁were ▁required ▁in ▁21 ▁patients ▁( 9% ) ▁and ▁16 ▁procedure s ▁were ▁perform ed ▁in ▁11 ▁patients ▁( 5% ).
▁The ▁interval ▁from ▁transplant ation ▁to ▁consultation ▁was ▁short er ▁for ▁the ▁MT ▁group ▁(50 ▁vs ▁82 ▁days ; ▁P ▁= ▁0.0 15) , ▁where as ▁the ▁interval ▁from ▁consultation ▁to ▁operation ▁was ▁longer ▁(5 ▁vs ▁1 ▁day ; ▁P ▁= ▁0.0 3) .
▁Patient s ▁under go ing ▁MT ▁were ▁more ▁likely ▁to ▁require ▁consultation ▁for ▁abdominal ▁problems ▁( 88 ▁vs ▁2 7% ; ▁P ▁= ▁0.0 04) .
▁All ▁but ▁one ▁of ▁the ▁seven ▁ ische mic / in flam ma tory ▁abdominal ▁problems ▁occur red ▁in ▁the ▁MT ▁group .
▁Com plication s ▁occur red ▁after ▁five ▁A CS ▁procedure s ▁(3 1%) ▁in ▁two ▁patients ▁under go ing ▁MT ▁and ▁three ▁patients ▁under go ing ▁ VAD .
▁Mor t ality ▁was ▁24 ▁per ▁cent ▁with ▁five ▁death s ▁occur ring ▁within ▁30 ▁days ▁of ▁A CS ▁consultation ▁and / or ▁operation .
▁In ▁summary , ▁this ▁is ▁one ▁of ▁the ▁largest ▁series ▁of ▁A CS ▁problems ▁in ▁patients ▁under go ing ▁O HT ▁ bridge d ▁to ▁transplant ▁with ▁MT ▁or ▁ VAD .
▁With ▁similar ▁incide nce ▁in ▁MT ▁and ▁ VAD ▁groups , ▁A CS ▁consultation s ▁and ▁operation s ▁are ▁in fre quen t ▁with ▁high ▁mortal ity ▁and ▁morbi d ity .
▁Extra corp o real ▁membran e ▁oxygen ation ▁as ▁ bridge ▁to ▁recovery ▁in ▁in far ction - related ▁re frac tory ▁right ▁heart ▁failure .
▁HIS TORY ▁AND ▁CL INI CAL ▁FIN DING S : ▁We ▁present ▁a ▁41 - year - old ▁man ▁with ▁cardiac ▁arrest ▁in ▁need ▁of ▁cardio pul mon ary ▁res uscita tion ▁( C PR ) ▁with ▁the ▁ diagnos is ▁of ▁a ▁posterior ▁wall ▁in far ction , ▁who ▁was ▁hospital ized ▁in ▁our ▁cardiac ▁centre .
▁INVEST IGA TIONS : ▁The ▁cardiac ▁cat heter ization ▁showed ▁a ▁ thro mbo tic ▁ob struct ion ▁of ▁the ▁right ▁corona ry ▁arter y .
▁After ▁per cuta ne ous ▁corona ry ▁re vas cular ization ▁a ▁hem o dynamic ally ▁stable ▁situation ▁could ▁be ▁achieve d ▁and ▁the ▁patient ▁was ▁admit ted ▁to ▁the ▁intensiv e ▁care ▁unit ▁( ICU ).
▁TRE AT MENT ▁AND ▁CL INI CAL ▁C OUR SE : ▁The ▁patient ▁became ▁again ▁hem o dynamic ally ▁uns table ▁and ▁a ▁C PR ▁was ▁required .
▁Base d ▁on ▁the ▁a cute ▁right ▁heart ▁failure ▁with ▁ therapy ▁re frac tory ▁cardio ge nic ▁shock ▁we ▁decided ▁within ▁our ▁heart ▁team ▁for ▁an ▁extra ▁corpore al ▁membran e ▁oxygen ation ▁( EC MO ) ▁applied ▁during ▁C PR ▁in ▁the ▁ ICU .
▁The ▁extra corp o real ▁support ▁was ▁needed ▁for ▁three ▁days .
▁Seven ▁days ▁after ▁the ▁emergency ▁cardiac ▁cat heter ization ▁the ▁patient ▁was ▁ex tuba ted ▁and ▁transfer red ▁to ▁our ▁intermedi ate ▁care .
▁CON C LU SION : ▁Extra corp o real ▁life ▁support ▁is ▁fe a sible ▁und ▁effective ▁for ▁ brid ging ▁ therapy ▁in ▁patients ▁with ▁a cute ▁ ische mic ▁right ▁heart ▁failure ▁with ▁re frac tory ▁cardio ge nic ▁shock ▁and ▁successful ▁reper fusion ▁ therapy .
▁Heart ▁failure ▁with ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction .
▁Half ▁of ▁patients ▁with ▁heart ▁failure ▁( HF ) ▁have ▁a ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁( HF p EF ).
▁Morbi d ity ▁and ▁mortal ity ▁in ▁ HF p EF ▁are ▁similar ▁to ▁values ▁observe d ▁in ▁patients ▁with ▁ HF ▁and ▁reduce d ▁EF , ▁yet ▁no ▁effective ▁treatment ▁has ▁been ▁identified .
▁While ▁early ▁research ▁focused ▁on ▁the ▁importance ▁of ▁dia sto lic ▁dys function ▁in ▁the ▁pat ho phy si ology ▁of ▁ HF p EF , ▁recent ▁studies ▁have ▁reveal ed ▁that ▁multiple ▁non - dia sto lic ▁ab normal ities ▁in ▁cardiovascular ▁function ▁also ▁contribute .
▁ Diagnos is ▁of ▁ HF p EF ▁is ▁frequently ▁challenging ▁and ▁reli es ▁upon ▁care ful ▁clinic al ▁evaluation , ▁e cho - D opp ler ▁card i ography , ▁and ▁invasi ve ▁ha emo dynamic ▁assessment .
▁In ▁this ▁review , ▁the ▁principal ▁mechanism s , ▁diagnostic ▁approach es , ▁and ▁clinic al ▁trial s ▁are ▁review ed , ▁along ▁with ▁a ▁discussion ▁of ▁novel ▁treatment ▁strategie s ▁that ▁are ▁currently ▁under ▁investigation ▁or ▁hold ▁promise ▁for ▁the ▁future .
▁Trend s ▁from ▁1996 ▁to ▁2007 ▁in ▁incide nce ▁and ▁mortal ity ▁outcome s ▁of ▁heart ▁failure ▁after ▁a cute ▁my o card ial ▁in far ction : ▁a ▁population - based ▁study ▁of ▁20 , 8 12 ▁patients ▁with ▁first ▁a cute ▁my o card ial ▁in far ction ▁in ▁Western ▁Australia .
▁BA CK GRO UND : ▁Advance s ▁in ▁treatment ▁for ▁a cute ▁my o card ial ▁in far ction ▁( AMI ) ▁are ▁likely ▁to ▁have ▁had ▁a ▁beneficia l ▁impact ▁on ▁the ▁incide nce ▁of ▁and ▁death s ▁attribut able ▁to ▁heart ▁failure ▁( HF ) ▁complicat ing ▁ AMI , ▁although ▁limited ▁data ▁are ▁available ▁to ▁support ▁this ▁con tention .
▁ MET HOD S ▁AND ▁RESULT S : ▁Western ▁Australian ▁link ed ▁administrative ▁health ▁data ▁were ▁used ▁to ▁identify ▁20 ▁8 12 ▁consecutiv e ▁patients , ▁a ged ▁40 ▁to ▁84 ▁years , ▁without ▁prior ▁ HF ▁hospital ized ▁with ▁an ▁index ▁( fir st ) ▁ AMI ▁between ▁1996 ▁and ▁2007.
▁We ▁assess ed ▁the ▁temporal ▁incide nce ▁of ▁and ▁adjust ed ▁odds ▁ratio / haz ard ▁ratio ▁for ▁death ▁associated ▁with ▁ HF ▁concurrent ▁with ▁ AMI ▁ad mission ▁and ▁within ▁1 ▁year ▁after ▁dis charge .
▁Con current ▁ HF ▁compris ed ▁75% ▁of ▁incident ▁ HF ▁cases .
▁Bet we en ▁the ▁period s ▁1996 - 1998 ▁and ▁2005 -2007 , ▁the ▁prevale nce ▁of ▁ HF ▁after ▁ AMI ▁decline d ▁from ▁28. 1% ▁to ▁16. 5% , ▁with ▁an ▁adjust ed ▁odds ▁ratio ▁of ▁0 . 50 ▁( 95% ▁CI , ▁0 . 44 ▁to ▁0.5 5) .
▁The ▁cru de ▁28- day ▁case - fat ality ▁rate ▁for ▁patients ▁with ▁concurrent ▁ HF ▁decline d ▁marginal ly ▁from ▁20. 5% ▁to ▁15. 9% ▁( P ▁< ▁0.0 5) ▁compared ▁with ▁those ▁without ▁concurrent ▁ HF , ▁in ▁whom ▁the ▁case - fat ality ▁rate ▁decline d ▁from ▁11. 0% ▁to ▁4. 8% ▁( P ▁< ▁0.0 01) .
▁Con current ▁ HF ▁was ▁associated ▁with ▁a ▁multi varia te - ad just ed ▁odds ▁ratio ▁of ▁2.2 ▁for ▁28- day ▁mortal ity ▁and ▁a ▁hazard ▁ratio ▁of ▁2.2 ▁for ▁1- year ▁mortal ity ▁in ▁28- day ▁sur viv ors .
▁O c curr ence ▁of ▁ HF ▁within ▁90 ▁days ▁of ▁the ▁index ▁ AMI ▁was ▁associated ▁with ▁an ▁adjust ed ▁hazard ▁ratio ▁of ▁2. 7 ▁for ▁1- year ▁mortal ity ▁in ▁90- day ▁sur viv ors .
▁CON CL USI ONS : ▁De spite ▁en cour aging ▁decline s ▁in ▁the ▁incide nce ▁of ▁ HF ▁complicat ing ▁ AMI , ▁it ▁remain s ▁a ▁common ▁problem ▁with ▁high ▁mortal ity .
▁Inc rea sed ▁attention ▁to ▁these ▁high - risk ▁patients ▁is ▁needed ▁given ▁the ▁lack ▁of ▁improvement ▁in ▁their ▁long - term ▁prognos is .
▁Test o ster one ▁ therapy ▁during ▁exercise ▁rehabilita tion ▁in ▁male ▁patients ▁with ▁chronic ▁heart ▁failure ▁who ▁have ▁low ▁testosteron e ▁status : ▁a ▁double - blind ▁random ized ▁control led ▁fe asi bility ▁study .
▁BA CK GRO UND : ▁This ▁study ▁assess ed ▁the ▁fe asi bility ▁of ▁a ▁12- week ▁program ▁of ▁exercise , ▁with ▁and ▁without ▁intra mus cular ▁testosteron e ▁supplement ation , ▁in ▁male ▁patients ▁with ▁chronic ▁heart ▁failure ▁( CH F ) ▁and ▁low ▁testosteron e ▁status ▁and ▁collect ed ▁preliminar y ▁data ▁for ▁key ▁health ▁outcome s .
▁ MET HOD S : ▁Male ▁patients ▁with ▁CHF ▁( n ▁= ▁41 , ▁age ▁6 7.2 ▁years , ▁range ▁51 - 84 ▁years ) ▁with ▁mean ▁ ± ▁SD ▁testosteron e ▁levels ▁of ▁10. 7 ▁ ± ▁2.6 ▁n mol / L ▁(30 9 ▁ ± ▁76 ▁ng / d L ) ▁were ▁random ly ▁al locat ed ▁to ▁exercise ▁with ▁testosteron e ▁or ▁place bo ▁groups .
▁Fe asi bility ▁was ▁assess ed ▁in ▁terms ▁of ▁recruit ment , ▁intervention ▁compliance , ▁and ▁att ri tion .
▁Out com es ▁included ▁an ▁incrementa l ▁shu ttle ▁walk ▁test , ▁pe ak ▁oxygen ▁up take , ▁muscular ▁strength , ▁e cho car dio graphic ▁measure s , ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de , ▁infla mma tory ▁marker s , ▁depression ▁( Be ck ▁De pression ▁In ven tory ), ▁and ▁health - related ▁quality ▁of ▁life ▁( Min nes ota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁and ▁Medical ▁Out com es ▁Study ▁Short - Form ).
▁RESULT S : ▁Att ri tion ▁was ▁30% ▁but ▁with ▁100% ▁compliance ▁to ▁exercise ▁and ▁inject ions ▁in ▁patients ▁who ▁completed ▁the ▁study .
▁Similar ▁improvement s ▁in ▁shu ttle ▁walk ▁test ▁(18 % ▁vs ▁19% ), ▁body ▁mass ▁( - 1.3 ▁kg ▁vs ▁- 1.0 ▁kg ), ▁and ▁hand ▁grip ▁strength ▁( 2.1 ▁kg ▁vs ▁2.5 ▁kg ) ▁from ▁base line ▁were ▁observe d ▁in ▁both ▁groups .
▁The ▁exercise ▁with ▁testosteron e ▁group ▁showed ▁improvement s ▁from ▁base line ▁in ▁pe ak ▁oxygen ▁up take ▁( P ▁< ▁ . 01) , ▁Beck ▁De pression ▁In ven tory ▁( P ▁< ▁ . 05) , ▁leg ▁strength ▁( P ▁< ▁ . 05) , ▁and ▁several ▁Medical ▁Out com es ▁Study ▁Short - Form ▁quality ▁of ▁life ▁domain s ▁( P ▁< ▁ . 05) , ▁which ▁were ▁generally ▁not ▁apparent ▁in ▁the ▁exercise ▁with ▁place bo ▁group .
▁E cho car dio graphic ▁measure s , ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de , ▁and ▁infla mma tory ▁marker s ▁were ▁mostly ▁un change d .
▁CON CL USI ONS : ▁This ▁study ▁shows ▁for ▁the ▁first ▁time ▁that ▁testosteron e ▁supplement ation ▁during ▁a ▁program ▁of ▁exercise ▁rehabilita tion ▁is ▁fe a sible ▁and ▁can ▁positive ly ▁impact ▁on ▁a ▁range ▁of ▁key ▁health ▁outcome s ▁in ▁el der ly ▁male ▁patients ▁with ▁CHF ▁who ▁have ▁a ▁low ▁testosteron e ▁status .
▁Fun ction al ▁electric al ▁stimul ation ▁of ▁per i pher al ▁muscle s ▁improve s ▁en dot heli al ▁function ▁and ▁clinic al ▁and ▁emotional ▁status ▁in ▁heart ▁failure ▁patients ▁with ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction .
▁BA CK GRO UND : ▁Fun ction al ▁electric al ▁stimul ation ▁( F ES ) ▁improve s ▁exercise ▁capacity , ▁quality ▁of ▁life , ▁emotional ▁stress , ▁and ▁en dot heli al ▁function ▁in ▁chronic ▁heart ▁failure ▁with ▁im pair ed ▁sy sto lic ▁function .
▁We ▁so ught ▁to ▁investiga te ▁the ▁effects ▁of ▁F ES ▁on ▁the ▁above ▁parameter s ▁in ▁patients ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ).
▁ MET HOD S : ▁Thi r ty ▁ HF p EF ▁patients , ▁18 ▁female ▁and ▁12 ▁male , ▁a ged ▁69 ▁ ± ▁8 ▁years , ▁in ▁New ▁York ▁Heart ▁Association ▁class ▁II ▁or ▁III ▁and ▁with ▁mean ▁e je ction ▁ fraction ▁6 3% ▁ ± ▁6% , ▁were ▁random ly ▁(1 :1) ▁assign ed ▁to ▁a ▁6- week ▁F ES ▁program ▁or ▁place bo .
▁Assessment ▁was ▁perform ed ▁at ▁base line ▁and ▁after ▁complet ion ▁of ▁training ▁protocol ▁and ▁included ▁6- minut e ▁walked ▁distance , ▁quality ▁of ▁life ▁( Kan sas ▁City ▁Card i om yo pathy ▁Question naire ▁and ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ), ▁ depressiv e ▁symptoms ▁( Be ck ▁De pression ▁In ven tory ▁and ▁Z ung ▁self - rat ed ▁depression ▁score s ), ▁B - type ▁na tri ure tic ▁pe pti de , ▁en dot heli al ▁function ▁( flow - media ted ▁di la tation ), ▁and ▁left ▁vent ri cular ▁dia sto lic ▁function .
▁RESULT S : ▁A ▁significant ▁improvement ▁in ▁6- minut e ▁walked ▁distance ▁( F ▁= ▁21. 61 , ▁P ▁= ▁ . 001 ), ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁summary ▁( F ▁= ▁8. 68 , ▁P ▁= ▁ . 006 ), ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁( F ▁= ▁6. 43 , ▁P ▁= ▁ . 0 17) , ▁Beck ▁De pression ▁In ven tory ▁( F ▁= ▁6. 66 , ▁P ▁= ▁ . 0 15) , ▁Z ung ▁( F ▁= ▁6. 25 , ▁P ▁= ▁ . 0 19) , ▁and ▁flow - media ted ▁di la tation ▁diameter ▁( F ▁= ▁11. 98 , ▁P ▁= ▁ . 002 ) ▁was ▁observe d ▁in ▁the ▁F ES ▁group ▁compared ▁with ▁place bo ▁group ; ▁B - type ▁na tri ure tic ▁pe pti de ▁also ▁decline d ▁but ▁not ▁significantly ▁( F ▁= ▁0.2 49 , ▁P ▁= ▁ . 622 ), ▁and ▁there ▁was ▁a ▁tende ncy ▁toward ▁lower ▁mit ral ▁E / e ' ▁wa ve ▁ratio ▁( F ▁= ▁3.0 66 , ▁P ▁= ▁ . 09 1) .
▁CON C LU SION : ▁As ▁in ▁heart ▁failure ▁and ▁reduce d ▁left ▁vent ri cular ▁e je ction ▁ fraction , ▁F ES ▁also ▁improve s ▁exercise ▁capacity , ▁quality ▁of ▁life , ▁emotional ▁status , ▁and ▁en dot heli al ▁function ▁in ▁ HF p EF .
▁Give n ▁the ▁lack ▁of ▁effective ▁evidence - based ▁ therapie s ▁in ▁these ▁patients , ▁F ES ▁warrant s ▁further ▁investigation .
▁Chro nic ▁heart ▁failure ▁is ▁associated ▁with ▁transform ing ▁growth ▁factor ▁beta - dependent ▁yi eld ▁and ▁functional ▁decline ▁in ▁at rial ▁ex plant - der i ved ▁c - K it + ▁cell s .
▁BA CK GRO UND : ▁Card iac ▁c - K it + ▁cell s ▁isola ted ▁from ▁cardiac ▁ex plant - der i ved ▁cell s ▁modest ly ▁improve ▁cardiac ▁function s ▁after ▁my o card ial ▁in far ction ; ▁however , ▁their ▁full ▁potential ▁has ▁not ▁yet ▁been ▁realized .
▁For ▁instance , ▁the ▁majority ▁of ▁potential ▁candidat es ▁for ▁cell ▁ therapy ▁suffer ▁from ▁chronic ▁heart ▁failure ▁( CH F ), ▁and ▁it ▁is ▁un clear ▁how ▁this ▁disease ▁affect s ▁the ▁ex plant - der i ved ▁pro gen itor ▁cell s .
▁Therefore , ▁the ▁objective ▁of ▁this ▁study ▁was ▁to ▁determine ▁the ▁effect ▁of ▁CHF ▁on ▁the ▁number ▁and ▁ph eno type ▁of ▁cardiac ▁ex plant ▁c - K it + ▁pro geni tors ▁and ▁e luci date ▁mechanism s ▁of ▁their ▁regula tion .
▁ MET HOD S ▁AND ▁RESULT S : ▁My o card ial ▁in far ction ▁was ▁created ▁by ▁left ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on .
▁Sham - opera ted ▁animals ▁were ▁used ▁as ▁a ▁control ▁group .
▁CHF - develop ed ▁in far cted ▁animals ▁were ▁selected ▁on ▁the ▁basis ▁of ▁left ▁vent ric le ▁end - dia sto lic ▁pressure ▁ ≥ ▁20 ▁mm ▁H g ▁and ▁scar ▁size ▁ ≥ ▁30% .
▁Here , ▁we ▁found ▁that ▁CHF ▁at rial ▁ex plant s ▁produced ▁less ▁c - K it + ▁cell s ▁than ▁sham ▁ex plant s .
▁CHF - der i ved ▁c - K it + ▁cell s ▁exhibi ted ▁up regula ted ▁transform ing ▁growth ▁factor - β ▁( T GF - β ) ▁signal ing , ▁increased ▁level ▁of ▁epi the li al ▁to ▁mes en chy mal ▁transition ▁marker s , ▁and ▁di minis hed ▁expression ▁of ▁pluri pote ncy ▁marker s ▁compared ▁with ▁sham s .
▁We ▁show ▁that ▁intervention ▁with ▁T GF - β ▁signal ing ▁by ▁inhibi ting ▁T GF - β ▁receptor ▁type ▁I ▁or ▁S mad ▁2/3 ▁using ▁small - mo le cule ▁inhibi tors ▁improve d ▁c - K it + ▁cell ▁yi eld , ▁att en u ated ▁epi the li al ▁to ▁mes en chy mal ▁transition ▁marker s , ▁stimula ted ▁the ▁pluri pote ncy ▁marker ▁Na nog , ▁and ▁improve d ▁efficiency ▁of ▁c - K it + ▁cell ▁differenti ation ▁toward ▁cardio my o cy te - like ▁cell s ▁in ▁vi tro .
▁CON CL USI ONS : ▁Tak en ▁together , ▁our ▁finding s ▁suggest ▁that ▁T GF - β ▁inhibi tion ▁positive ly ▁modul ates ▁c - K it + ▁cell ▁ph eno type ▁and ▁function ▁in ▁vi tro , ▁and ▁this ▁strategy ▁may ▁be ▁considered ▁in ▁optim izing ▁cardiac ▁pro gen itor ▁function ▁and ▁cell ▁exp an sion ▁protocol s ▁for ▁clinic al ▁application .
▁Period ic ▁breath ing ▁with ▁no ▁heart ▁beat .
▁A ▁protocol ▁was ▁original ly ▁designed ▁to ▁study ▁breath ing ▁control ▁during ▁and ▁following ▁cardiac ▁arrest ▁in ▁humans , ▁taking ▁advantage ▁of ▁the ▁period ▁of ▁puls e less ▁vent ri cular ▁fi bril lation ▁( PV F ) ▁produced ▁while ▁testing ▁a ▁new ly ▁implant ed ▁cardio ver ter - de fi br illa tor ▁device .
▁A ▁patient ▁a ged ▁in ▁his ▁60 s ▁with ▁New ▁York ▁Heart ▁Association ▁class ▁III ▁heart ▁failure ▁( HF ) ▁( le ft ▁vent ri cular ▁e je ction ▁ fraction ▁of ▁25% ) ▁who ▁was ▁original ly ▁part ▁of ▁this ▁study ▁display ed ▁permanent ▁periodic ▁breath ing ▁( PB ) ▁and ▁was ▁then ▁exclu ded ▁from ▁the ▁final ▁data ▁analysis ; ▁his ▁response ▁is ▁presente d ▁in ▁this ▁report .
▁The ▁8- ▁to ▁9- s ▁PV F ▁was ▁incident ally ▁produced ▁during ▁the ▁ascend ing ▁phase ▁of ▁a ▁ PB ▁cycle , ▁followed ▁by ▁another ▁12- s ▁recovery ▁period ▁of ▁low ▁BP .
▁PV F ▁and ▁its ▁recovery ▁had ▁no ▁effect ▁on ▁ PB ▁character istic s ▁( period ▁or ▁amplitud e ).
▁This ▁occur red ▁de spite ▁a ▁pro found ▁change ▁in ▁Paco 2 , ▁cerebral ▁blood ▁flow , ▁and ▁per fusion ▁of ▁the ▁caro tid ▁bo dies .
▁It ▁is ▁conclude d ▁that ▁ PB ▁in ▁patients ▁with ▁ HF ▁could ▁be ▁produced ▁by ▁primary ▁os cilla tions ▁origina ting ▁from ▁the ▁central ▁pattern ▁generator .
▁Do ▁antico a gul ants ▁or ▁anti plate let ▁drugs ▁have ▁a ▁role ▁in ▁treat ing ▁heart ▁failure ▁in ▁the ▁ absence ▁of ▁at rial ▁fi bril lation ?
▁Patient s ▁with ▁at rial ▁fi bril lation ▁( AF ) ▁and ▁heart ▁failure ▁( HF ) ▁are ▁at ▁risk ▁for ▁stroke , ▁and ▁progress ▁in ▁antico ag ulation ▁has ▁led ▁to ▁new ▁options ▁for ▁these ▁patients .
▁Patient s ▁in ▁sinus ▁ rhythm ▁may ▁benefit ▁from ▁anti plate let ▁agents ▁or ▁antico a gul ants , ▁but ▁much ▁work ▁remain s ▁to ▁establish ▁ef fica cy ▁and ▁safety .
▁Add i tional ▁progress ▁is ▁needed , ▁including ▁better ▁tools ▁for ▁risk ▁strat ification ▁and ▁clar ity ▁regarding ▁the ▁need ▁for ▁anti plate let ▁agents ▁in ▁combination ▁with ▁antico a gul ants ▁for ▁those ▁with ▁other ▁vas cular ▁disease s .
▁Nutrition ▁in ▁heart ▁failure : ▁an ▁update .
▁ PUR POS E ▁OF ▁RE VIEW : ▁Chro nic ▁heart ▁failure ▁( CH F ) ▁is ▁increasing ly ▁recognize d ▁as ▁a ▁multi system ▁disease ▁with ▁important ▁como rbi di ties ▁such ▁as ▁an emia , ▁insulin ▁resist ance , ▁autonomi c ▁dys balance , ▁or ▁cardiac ▁cache xia .
▁REC ENT ▁FIN DING S : ▁Apart ▁from ▁these ▁perturba tions , ▁increasing ▁evidence ▁points ▁to ▁altera tions ▁in ▁intestinal ▁ morph ology , ▁per me ability , ▁and ▁ab sor p tion ▁function ▁in ▁patients ▁with ▁CHF .
▁This ▁review ▁provides ▁an ▁over view ▁of ▁the ▁sono graphic , ▁his t ological , ▁and ▁functional ▁ab normal ities ▁of ▁different ▁gastro inte stin al ▁region s .
▁This ▁intestinal ▁dys function ▁and ▁disturb ed ▁intestinal ▁barrier ▁may ▁lead ▁to ▁both ▁the ▁chronic ▁infla mma tory ▁state ▁and ▁cata bo lic / ana bo lic ▁im balance ▁as ▁seen ▁in ▁cardiac ▁cache xia , ▁as ▁a ▁terminal ▁stage ▁of ▁CHF , ▁which ▁car ries ▁a ▁particularly ▁poor ▁prognos is .
▁This ▁review ▁highlight s ▁the ▁current ▁knowledge ▁of ▁nutrition al ▁ab normal ities ▁that ▁may ▁occur ▁in ▁CHF , ▁including ▁fat , ▁car bo hydrat es , ▁protein s , ▁water , ▁and ▁micro nutri ents .
▁The ▁regula tion ▁of ▁feed ing ▁is ▁discuss ed , ▁as ▁are ▁nutrition al ▁strategie s ▁with ▁potential ly ▁anti - in flam ma tory ▁effects ▁in ▁the ▁treatment ▁of ▁CHF .
▁SU MMA RY : ▁The ▁gut ▁and ▁its ▁role ▁for ▁ inflammation ▁and ▁dieta ry ▁intervention s ▁in ▁heart ▁failure ▁patients ▁are ▁a ▁crucial ▁target ▁of ▁further ▁heart ▁failure ▁research .
▁B - type ▁na tri ure tic ▁pe pti de ▁and ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁– ▁ Diagnos tic ▁role ▁in ▁stable ▁corona ry ▁arter y ▁disease ▁B - type ▁na tri ure tic ▁pe pti de ▁( B NP ) ▁and ▁its ▁N - termin al ▁fragment ▁( NT - pro B NP ) ▁are ▁released ▁from ▁vent ri cular ▁cardio my o cy tes ▁in ▁response ▁to ▁an ▁increase ▁in ▁vent ri cular ▁wall ▁stress ▁and ▁to ▁my o card ial ▁ ische mia .
▁Both ▁B NP ▁and ▁NT - pro B NP ▁have ▁proven ▁to ▁be ▁reliable ▁diagnostic ▁and ▁prognos tic ▁bio mark ers ▁in ▁patients ▁with ▁heart ▁failure .
▁Recent ly , ▁the ▁diagnostic ▁role s ▁of ▁B NP ▁and ▁NT - pro B NP ▁in ▁patients ▁with ▁corona ry ▁arter y ▁disease ▁( CAD ) ▁have ▁been ▁investiga ted .
▁For ▁patients ▁with ▁a cute ▁corona ry ▁syndrome s , ▁data ▁have ▁been ▁deri ved ▁from ▁a ▁great ▁number ▁of ▁studies , ▁where as ▁in ▁patients ▁with ▁stable ▁CAD , ▁only ▁a ▁limited ▁amount ▁of ▁recent ▁data ▁is ▁available ; ▁although ▁limited , ▁these ▁data ▁show ▁that ▁eleva tions ▁in ▁B NP ▁and ▁NT - pro B NP ▁levels ▁are ▁associated ▁with ▁the ▁extent ▁of ▁CAD , ▁thu s ▁providing ▁prognos tic ▁information ▁for ▁an ▁un f avour able ▁clinic al ▁outcome .
▁However , ▁clinic al ▁and ▁ therapeut ic ▁implica tions ▁are ▁indi stin ct ▁and ▁need ▁to ▁be ▁elu cida ted ▁in ▁further ▁studies .
▁Uni lateral ▁renal ▁den er va tion ▁improve s ▁autonomi c ▁balance ▁in ▁ conscious ▁rabbi ts ▁with ▁chronic ▁heart ▁failure .
▁A ▁hall mark ▁of ▁chronic ▁heart ▁failure ▁( CH F ) ▁is ▁an ▁increased ▁sympa the tic ▁tone ▁result ing ▁in ▁autonomi c ▁im balance .
▁Ren al ▁den er va tion ▁( DN x ) ▁in ▁CHF ▁patients ▁has ▁result ed ▁in ▁symptom a tic ▁improvement , ▁but ▁the ▁protect ive ▁mechanism s ▁remain ▁un clear .
▁We ▁hypothe s ized ▁in ▁CHF , ▁unilateral ▁renal ▁DN x ▁would ▁improve ▁cardiac ▁autonomi c ▁balance .
▁The ▁present ▁study ▁used ▁ conscious , ▁chronic ally ▁instrument ed ▁New ▁Zealand ▁White ▁rabbi ts ▁under go ing ▁renal ▁DN x ▁prior ▁to ▁pa cing - indu ced ▁CHF .
▁Four ▁treatment ▁groups ▁were ▁used : ▁non pa ce , ▁non - DN x ▁[ S ham - I nner vat ed ▁( S ham - IN V ) ] , ▁non pa ce ▁DN x ▁( s ham - DN x ), ▁pace ▁non - DN x ▁( CH F - IN V ) ▁or ▁pace ▁DN x ▁( CH F - DN x ).
▁We ▁examine d ▁several ▁marker s ▁indicati ve ▁of ▁autonomi c ▁balance .
▁Baro re flex ▁ sensitiv ity ▁and ▁time ▁domain ▁heart ▁rate ▁variabil ity ▁( HR V ) ▁were ▁both ▁decrease d ▁in ▁the ▁CHF - IN V ▁group ▁compared ▁with ▁sham - IN V ▁and ▁were ▁resto red ▁to ▁sham ▁levels ▁by ▁renal ▁DN x .
▁Power ▁spec tral ▁analysis ▁indicate d ▁an ▁increase ▁in ▁low - fre que ncy / high - fre que ncy ▁( LF / HF ) ▁ratio ▁in ▁the ▁CHF - IN V ▁compared ▁with ▁the ▁sham - IN V , ▁which ▁was ▁normal ized ▁to ▁sham ▁levels ▁by ▁DN x .
▁To ▁assess ▁whether ▁this ▁was ▁due ▁to ▁a ▁withdraw al ▁of ▁sympa the tic ▁tone ▁or ▁an ▁increase ▁in ▁para sy mpa the tic ▁tone , ▁the ▁heart ▁rate ▁response ▁was ▁measure d ▁after ▁an ▁intra ven ous ▁bol us ▁of ▁met o pro lol ▁or ▁a tropi ne .
▁Brad y car dia ▁induc ed ▁by ▁intra ven ous ▁met o pro lol ▁( indica tive ▁of ▁cardiac ▁sympa the tic ▁tone ) ▁was ▁ex a cer bat ed ▁in ▁CHF - IN V ▁rabbi ts ▁compared ▁with ▁sham - IN V ▁but ▁was ▁normal ized ▁in ▁CHF - DN x .
▁Con verse ly , ▁the ▁ta chy car dia ▁in ▁response ▁to ▁intra ven ous ▁a tropi ne ▁( indica tive ▁of ▁cardiac ▁va gal ▁tone ) ▁was ▁not ▁improve d ▁in ▁CHF - DN x ▁vs . ▁CHF - IN V ▁animals .
▁Ren al ▁DN x ▁also ▁prevent ed ▁the ▁increase ▁in ▁circula ting ▁plasma ▁NE ▁seen ▁in ▁CHF - IN V ▁rabbi ts .
▁These ▁results ▁suggest ▁renal ▁DN x ▁improve s ▁cardiac ▁autonomi c ▁balance ▁in ▁CHF ▁by ▁a ▁re duction ▁of ▁sympa the tic ▁tone .
▁Compar ative ▁effects ▁of ▁vent ri cular ▁assist ▁device ▁and ▁extra corp o real ▁membran e ▁oxygen ation ▁on ▁renal ▁function ▁in ▁pediatr ic ▁heart ▁failure .
▁BA CK GRO UND : ▁Effect s ▁of ▁mechanic al ▁cardiac ▁support ▁on ▁renal ▁function ▁in ▁children ▁with ▁end - s tage ▁heart ▁failure ▁are ▁un know n .
▁The ▁objective ▁of ▁this ▁study ▁was ▁to ▁investiga te ▁the ▁impact ▁of ▁vent ri cular ▁assist ▁device ▁( VAD ) ▁and ▁extra corp o real ▁membran e ▁oxygen ation ▁( EC MO ) ▁on ▁renal ▁function ▁in ▁children .
▁ MET HOD S : ▁We ▁perform ed ▁a ▁single ▁center ▁retro spec tive ▁observation al ▁study ▁in ▁children ▁with ▁end - s tage ▁heart ▁failure ▁support ed ▁on ▁pediatr ic ▁mechanic al ▁cardiac ▁support .
▁The ▁patient ▁population ▁was ▁divide d ▁into ▁three ▁groups : ▁the ▁ VAD ▁group ▁included ▁patients ▁receiving ▁vent ri cular ▁assist ▁device ▁support ; ▁the ▁EC MO ▁group ▁included ▁patients ▁receiving ▁extra corp o real ▁membran e ▁oxygen ation ▁membran e ▁support ▁for ▁more ▁than ▁14 ▁days ; ▁and ▁the ▁EC MO + VAD ▁group ▁included ▁patients ▁receiving ▁EC MO ▁followed ▁by ▁ VAD ▁support .
▁Compar ison ▁of ▁base line ▁character istic s , ▁du ration ▁of ▁mechanic al ▁cardiac ▁support , ▁and ▁renal ▁function ▁was ▁made ▁between ▁the ▁three ▁groups .
▁RESULT S : ▁During ▁the ▁study ▁period , ▁there ▁were ▁23 ▁patients ▁in ▁the ▁ VAD ▁group , ▁16 ▁patients ▁in ▁the ▁EC MO + VAD ▁group , ▁and ▁37 ▁patients ▁in ▁the ▁EC MO ▁group .
▁The ▁patients ▁in ▁the ▁EC MO ▁group ▁were ▁significantly ▁young er ▁and ▁smaller ▁than ▁the ▁patients ▁in ▁the ▁ VAD ▁and ▁EC MO + VAD ▁groups .
▁There ▁was ▁a ▁stea dy ▁improvement ▁in ▁e G FR ▁in ▁the ▁ VAD ▁group ▁and ▁the ▁EC MO + VAD ▁group ▁until ▁day ▁7 ▁after ▁which ▁there ▁was ▁a ▁decline ▁in ▁renal ▁function .
▁In ▁the ▁EC MO ▁group , ▁the ▁improvement ▁in ▁e G FR ▁continued ▁until ▁day ▁28 ▁after ▁which ▁there ▁was ▁a ▁stea dy ▁decline ▁in ▁e G FR .
▁Im prove ment ▁in ▁e G FR ▁in ▁the ▁ VAD ▁group ▁and ▁the ▁EC MO + VAD ▁group ▁was ▁much ▁higher ▁than ▁in ▁the ▁EC MO ▁group ▁in ▁the ▁first ▁7 ▁days .
▁CON CL USI ONS : ▁On ▁the ▁basis ▁of ▁these ▁data , ▁we ▁demonstrat e ▁that ▁renal ▁dys function ▁improve s ▁early ▁after ▁mechanic al ▁cardiac ▁support .
▁Nur sing - sensitiv e ▁outcome ▁change ▁score s ▁for ▁hospital ized ▁older ▁adults ▁with ▁heart ▁failure : ▁a ▁preliminar y ▁de script ive ▁study .
▁Nur sing ▁has ▁a ▁social ▁mandat e ▁to ▁ensure ▁effective ▁practice ▁within ▁its ▁domain ▁and ▁to ▁be ▁account able ▁for ▁the ▁outcome s ▁of ▁nur sing ▁care .
▁U sing ▁standard ized ▁nur sing ▁terminologi es ▁makes ▁it ▁possible ▁to ▁measure ▁aspects ▁of ▁nur sing ▁care .
▁The ▁purpose ▁of ▁this ▁study ▁was ▁to ▁determine ▁whether ▁a ▁significant ▁difference ▁in ▁outcome ▁rating s ▁exist s ▁from ▁ad mission ▁to ▁dis charge ▁for ▁hospital ized ▁older ▁adults ▁with ▁heart ▁failure ▁( HF ) ▁using ▁Nur sing ▁Out com es ▁Classifica tion ▁( NO C ).
▁A ▁retro spec tive ▁de script ive ▁research ▁design ▁was ▁used .
▁Data ▁were ▁obtain ed ▁from ▁26 8 ▁in patient ▁records ▁of ▁patients ▁dis charge d ▁with ▁ HF ▁during ▁a ▁1- year ▁period .
▁All ▁top ▁10 ▁NO C ▁outcome s ▁demonstrat ed ▁statistic ally ▁significant ▁improvement ▁in ▁outcome ▁rating s ▁from ▁ad mission ▁to ▁dis charge .
▁Find ings ▁from ▁this ▁study ▁provide ▁insight ▁on ▁the ▁possible ▁contribution ▁of ▁nur sing ▁to ▁outcome s ▁of ▁hospital ized ▁older ▁adults ▁with ▁ HF .
▁Vali dating ▁and ▁incorpora ting ▁nur sing - sensitiv e ▁outcome ▁measure s ▁in ▁future ▁prospect ive ▁experimental ▁research ▁can ▁contribute ▁to ▁the ▁advance ment ▁of ▁science ▁regarding ▁effective ▁treatment ▁of ▁older ▁adults ▁hospital ized ▁with ▁ HF , ▁while ▁highlight ing ▁the ▁contribution ▁of ▁nur sing ▁care ▁to ▁outcome s .
▁beta 1- ad r energi c ▁receptor ▁and ▁sp hing os ine -1 - phos pha te ▁receptor ▁1 ▁( S 1 PR 1) ▁reciproc al ▁down regul ation ▁influence s ▁cardiac ▁hyper trop hic ▁response ▁and ▁progression ▁to ▁heart ▁failure : ▁protect ive ▁role ▁of ▁S 1 PR 1 ▁cardiac ▁gene ▁ therapy .
▁BA CK GRO UND : ▁The ▁sp hing os ine -1 - phos pha te ▁receptor ▁1 ▁( S 1 PR 1) ▁and ▁β 1- ad r energi c ▁receptor ▁( β 1 AR ) ▁are ▁G - prote in - co up led ▁receptor s ▁express ed ▁in ▁the ▁heart .
▁These ▁2 ▁receptor s ▁have ▁opp os ing ▁actions ▁on ▁a den yl yl ▁cy cla se ▁because ▁of ▁differenti al ▁G - prote in ▁coup ling .
▁Important ly , ▁both ▁of ▁these ▁receptor s ▁can ▁be ▁regula ted ▁by ▁the ▁actions ▁of ▁G - prote in - co up led ▁receptor ▁kina se -2 , ▁which ▁trigger s ▁desen sit ization ▁and ▁down regul ation ▁process es .
▁Although ▁classic ▁signal ing ▁paradigm s ▁suggest ▁that ▁simultan e ous ▁activa tion ▁of ▁β 1 AR s ▁and ▁S 1 PR 1 s ▁in ▁a ▁my o cy te ▁would ▁simply ▁result ▁in ▁opp os ing ▁action ▁on ▁c AMP ▁production , ▁in ▁this ▁report ▁we ▁have ▁un cover ed ▁a ▁direct ▁interaction ▁between ▁these ▁2 ▁receptor s , ▁with ▁regulator y ▁involve ment ▁of ▁G - prote in - co up led ▁receptor ▁kina se -2 .
▁ MET HOD S ▁AND ▁RESULT S : ▁In ▁H EK ▁( human ▁em bry o nic ▁ki dne y ) ▁29 3 ▁cell s ▁over express ing ▁both ▁β 1 AR ▁and ▁S 1 PR 1 , ▁we ▁demonstrat ed ▁that ▁β 1 AR ▁down regul ation ▁can ▁occur ▁after ▁stimul ation ▁with ▁sp hing os ine -1 - phos pha te ▁( an ▁S 1 PR 1 ▁ago nist ), ▁where as ▁S 1 PR 1 ▁down regul ation ▁can ▁be ▁trigger ed ▁by ▁iso prot eren ol ▁( a ▁β - ad r energi c ▁receptor ▁ago nist ) ▁treatment .
▁This ▁cross ▁talk ▁between ▁these ▁2 ▁distinct ▁G - prote in - co up led ▁receptor s ▁appears ▁to ▁have ▁physio logic al ▁significa nce , ▁because ▁they ▁interact ▁and ▁show ▁reciproc al ▁regula tion ▁in ▁mouse ▁heart s ▁under go ing ▁chronic ▁β - ad r energi c ▁receptor ▁stimul ation ▁and ▁in ▁a ▁rat ▁model ▁of ▁post ische mic ▁heart ▁failure .
▁CON CL USI ONS : ▁We ▁demonstrat e ▁that ▁resto ration ▁of ▁cardiac ▁plasma ▁membran e ▁levels ▁of ▁S 1 PR 1 ▁produce s ▁beneficia l ▁effects ▁that ▁counter balance ▁the ▁delete rious ▁β 1 AR ▁over stimul ation ▁in ▁heart ▁failure .
▁Impact ▁of ▁physician ▁continu ity ▁on ▁death ▁or ▁urgent ▁read mission ▁after ▁dis charge ▁among ▁patients ▁with ▁heart ▁failure .
▁BA CK GRO UND : ▁E ar ly ▁physician ▁follow - up ▁after ▁dis charge ▁is ▁associated ▁with ▁lower ▁rates ▁of ▁death ▁and ▁read mission ▁among ▁patients ▁with ▁heart ▁failure .
▁We ▁explore d ▁whether ▁physician ▁continu ity ▁further ▁influence s ▁outcome s ▁after ▁dis charge .
▁ MET HOD S : ▁We ▁used ▁data ▁from ▁link ed ▁administrative ▁database s ▁for ▁all ▁adults ▁a ged ▁20 ▁years ▁or ▁more ▁in ▁the ▁province ▁of ▁Albert a ▁who ▁were ▁dis charge d ▁ali ve ▁from ▁hospital ▁between ▁January ▁1999 ▁and ▁June ▁2009 ▁with ▁a ▁first - time ▁ diagnos is ▁of ▁heart ▁failure .
▁We ▁used ▁Co x ▁proportion al ▁hazard ▁models ▁with ▁time - dependent ▁co varia tes ▁to ▁anal y ze ▁the ▁effect ▁of ▁follow - up ▁with ▁a ▁familiar ▁physician ▁within ▁the ▁first ▁month ▁after ▁dis charge ▁on ▁the ▁primary ▁outcome ▁of ▁death ▁or ▁urgent ▁all - ca use ▁read mission ▁over ▁6 ▁months .
▁A ▁familiar ▁physician ▁was ▁define d ▁as ▁one ▁who ▁had ▁seen ▁the ▁patient ▁at ▁least ▁twice ▁in ▁the ▁year ▁before ▁the ▁index ▁ad mission ▁or ▁once ▁during ▁the ▁index ▁ad mission .
▁RESULT S : ▁In ▁the ▁first ▁month ▁after ▁dis charge , ▁53 36 ▁(21 . 9% ) ▁of ▁the ▁24 ▁37 3 ▁identified ▁patients ▁had ▁no ▁follow - up ▁visit s , ▁16 ▁ 855 ▁( 69 . 2%) ▁saw ▁a ▁familiar ▁physician , ▁and ▁21 82 ▁(9 . 0% ) ▁saw ▁un fa milia r ▁physician ( s ) ▁exclusive ly .
▁The ▁risk ▁of ▁death ▁or ▁un plan ned ▁read mission ▁during ▁the ▁6- mont h ▁observation ▁period ▁was ▁lower ▁among ▁patients ▁who ▁saw ▁a ▁familiar ▁physician ▁( 43 . 6% ; ▁adjust ed ▁hazard ▁ratio ▁[ HR ] ▁0 . 87 , ▁95% ▁confidence ▁interval ▁[ CI ] ▁0 . 83 -0 . 91) ▁or ▁an ▁un fa milia r ▁physician ▁( 43 . 6% ; ▁adjust ed ▁HR ▁0 . 90 , ▁95% ▁CI ▁0 . 83 -0 . 97) ▁for ▁early ▁follow - up ▁visit s , ▁as ▁compared ▁with ▁patients ▁who ▁had ▁no ▁follow - up ▁visit s ▁( 62 . 9% ).
▁Tak ing ▁into ▁account ▁all ▁follow - up ▁visit s ▁over ▁the ▁6- mont h ▁period , ▁we ▁found ▁that ▁the ▁risk ▁of ▁death ▁or ▁urgent ▁read mission ▁was ▁lower ▁among ▁patients ▁who ▁had ▁all ▁of ▁their ▁visit s ▁with ▁a ▁familiar ▁physician ▁than ▁among ▁those ▁followed ▁by ▁un fa milia r ▁physician s ▁( ad just ed ▁HR ▁0 . 91 , ▁95% ▁CI ▁0 . 85 -0 . 98) .
▁INTER P RET ATION : ▁E ar ly ▁physician ▁follow - up ▁after ▁dis charge ▁and ▁physician ▁continu ity ▁were ▁both ▁associated ▁with ▁better ▁outcome s ▁among ▁patients ▁with ▁heart ▁failure .
▁Research ▁is ▁needed ▁to ▁explore ▁whether ▁physician ▁continu ity ▁is ▁important ▁for ▁other ▁conditions ▁and ▁in ▁setting s ▁other ▁than ▁recent ▁hospital ▁dis charge .
▁Human ▁heart ▁failure ▁is ▁ac com pani ed ▁by ▁alter ed ▁protein ▁kina se ▁A ▁sub un it ▁expression ▁and ▁post - trans la tional ▁state .
▁β - Ad r energi c ▁receptor ▁block ade ▁reduce s ▁total ▁mortal ity ▁and ▁all - ca use ▁hospital ization s ▁in ▁patients ▁with ▁heart ▁failure ▁( HF ).
▁No ne the less , ▁β - block ade ▁does ▁not ▁halt ▁disease ▁progression , ▁suggest ing ▁that ▁c AMP - dependent ▁protein ▁kina se ▁( P KA ) ▁signal ing ▁down stream ▁of ▁β - ad r energi c ▁receptor ▁activa tion ▁may ▁persist ▁through ▁unique ▁post - trans la tional ▁states .
▁In ▁this ▁study , ▁human ▁my o card ial ▁tissu e ▁was ▁used ▁to ▁examine ▁the ▁state ▁of ▁P KA ▁sub un its .
▁As ▁expected , ▁total ▁my os in ▁ binding ▁protein - C ▁ phos phor y lation ▁and ▁Ser 23 /24 ▁trop onin ▁I ▁ phos phor y lation ▁significantly ▁decrease d ▁in ▁ HF .
▁Ex a mination ▁of ▁P KA ▁sub un its ▁demonstrat ed ▁no ▁change ▁in ▁type ▁II ▁regulator y ▁( RI I α ) ▁or ▁cata ly tic ▁( C α ) ▁sub un it ▁expression , ▁although ▁site ▁specific ▁R II α ▁( Ser 96) ▁and ▁C α ▁( Th r 1 97) ▁ phos phor y lation ▁were ▁increased ▁in ▁ HF .
▁Fur ther , ▁the ▁expression ▁of ▁type ▁I ▁regulator y ▁sub un it ▁( RI ) ▁was ▁increased ▁in ▁ HF .
▁Iso electric ▁focus ing ▁of ▁RI α ▁demonstrat ed ▁up ▁to ▁three ▁variant s , ▁consistent ▁with ▁reports ▁that ▁Ser 77 ▁and ▁Ser 83 ▁are ▁in ▁vivo ▁ phos phor y lation ▁sites .
▁Western ▁blot s ▁with ▁site - specific ▁mono clo nal ▁anti bo dies ▁showed ▁increased ▁Ser 83 ▁ phos phor y lation ▁in ▁ HF .
▁8- flu o - c AMP ▁ binding ▁by ▁wild ▁type ▁and ▁ phos pho mi mic ▁Ser 77 ▁and ▁Ser 83 ▁mu tant ▁RI α ▁protein s ▁demonstrat ed ▁reduce d ▁K d ▁for ▁the ▁double ▁mu tant ▁as ▁compared ▁to ▁ WT ▁RI α .
▁Therefore , ▁fail ing ▁my o car dium ▁display s ▁alter ed ▁expression ▁and ▁post - trans la tional ▁modification ▁of ▁P KA ▁sub un its ▁that ▁may ▁impact ▁down stream ▁signal ing .
▁Auto no mic ▁modul ation ▁of ▁repo lar ization ▁in st ability ▁in ▁patients ▁with ▁heart ▁failure ▁pro ne ▁to ▁vent ri cular ▁ta chy car dia .
▁ QT ▁variabil ity ▁( Q TV ) ▁signifi es ▁repo lar ization ▁la bility , ▁and ▁increased ▁Q TV ▁is ▁a ▁risk ▁predict or ▁for ▁sud den ▁cardiac ▁death .
▁The ▁a im ▁of ▁the ▁present ▁study ▁was ▁to ▁investiga te ▁the ▁role ▁of ▁autonomi c ▁ner vous ▁system ▁activity ▁on ▁Q TV .
▁This ▁study ▁was ▁perform ed ▁in ▁29 ▁subject s : ▁10 ▁heart ▁failure ▁( HF ) ▁patients ▁with ▁spontane ous ▁vent ri cular ▁ta chy car dia ▁[ HF VT ( +) ] , ▁10 ▁ HF ▁patients ▁without ▁spontane ous ▁ VT ▁[ HF VT ( - ) ] , ▁and ▁9 ▁subject s ▁with ▁structura lly ▁normal ▁heart s ▁( H Nor m ).
▁The ▁beat - to - beat ▁ QT ▁interval ▁was ▁measure d ▁on ▁3- min ▁records ▁of ▁surface ▁E CG s ▁at ▁base line ▁and ▁during ▁intervention s ▁( at rial ▁pa cing ▁and ▁es mol ol , ▁iso pren a line , ▁and ▁a tropi ne ▁in fusion ).
▁Vari ability ▁in ▁ QT ▁interval s ▁was ▁express ed ▁as ▁the ▁SD ▁of ▁all ▁ QT ▁interval s ▁( SD QT ).
▁The ▁ratio ▁of ▁the ▁SD QT ▁to ▁SD ▁of ▁ RR ▁interval s ▁( SD RR ) ▁was ▁calcula ted ▁as ▁an ▁index ▁of ▁Q TV ▁normal ized ▁to ▁heart ▁rate ▁variabil ity .
▁There ▁was ▁a ▁trend ▁toward ▁a ▁higher ▁base line ▁SD QT - to - SD RR ▁ratio ▁in ▁the ▁ HF VT ( +) ▁group ▁compared ▁with ▁the ▁ HF VT ( - ) ▁and ▁H Nor m ▁groups ▁( P ▁= ▁0 . 09) .
▁SD QT ▁increased ▁significantly ▁in ▁the ▁ HF VT ( +) ▁and ▁ HF VT ( - ) ▁groups ▁compared ▁with ▁the ▁H Nor m ▁group ▁during ▁fixed - rate ▁at rial ▁pa cing ▁( P ▁= ▁0.0 08) .
▁Compar ed ▁with ▁base line , ▁iso pren a line ▁in fusion ▁increased ▁SD QT ▁in ▁H Nor m ▁subject s ▁( P ▁= ▁0.0 2) ▁but ▁not ▁in ▁ HF ▁patients .
▁SD QT ▁remain ed ▁eleva ted ▁in ▁the ▁ HF VT ( +) ▁group ▁relative ▁to ▁the ▁H Nor m ▁group ▁de spite ▁a cute ▁β - ad re no cept or ▁block ade ▁with ▁es mol ol ▁( P ▁= ▁0.0 2) .
▁In ▁conclusion , ▁patients ▁with ▁ HF ▁and ▁spontane ous ▁ VT ▁have ▁larger ▁flu ctu ations ▁in ▁beat - to - beat ▁ QT ▁interval s .
▁This ▁appears ▁to ▁be ▁a ▁genuin e ▁effect ▁that ▁is ▁not ▁sole ly ▁a ▁consequ ence ▁of ▁heart ▁rate ▁variation .
▁The ▁effect ▁of ▁a cute ▁autonomi c ▁ner vous ▁system ▁modul ation ▁on ▁Q TV ▁appears ▁to ▁be ▁limited ▁in ▁ HF ▁patients .
▁Gene tic ▁sus cept i bility ▁to ▁an thra cycli ne - related ▁con ges tive ▁heart ▁failure ▁in ▁sur viv ors ▁of ▁ha e mato po ie tic ▁cell ▁transplant ation .
▁Ha e mato po ie tic ▁cell ▁transplant ation ▁( H CT ) ▁sur viv ors ▁are ▁at ▁increased ▁risk ▁for ▁developing ▁con ges tive ▁heart ▁failure ▁( CH F ), ▁primari ly ▁due ▁to ▁pre - H CT ▁exposure ▁to ▁an thra cycli nes .
▁We ▁examine d ▁the ▁association ▁between ▁the ▁development ▁of ▁CHF ▁after ▁H CT ▁and ▁poly morph ism s ▁in ▁16 ▁candidat e ▁gene s ▁involved ▁in ▁an thra cycli ne ▁metabolism , ▁ir on ▁home osta sis , ▁anti - oxid ant ▁de fen ce , ▁and ▁my o card ial ▁remodel ling .
▁A ▁neste d ▁case - control ▁study ▁design ▁was ▁used .
▁Case s ▁( post - H CT ▁CHF ) ▁were ▁identified ▁from ▁29 50 ▁patients ▁who ▁under went ▁H CT ▁between ▁1988 ▁and ▁2007 ▁at ▁City ▁of ▁Hope ▁and ▁had ▁survive d ▁ ≥ 1 ▁year .
▁This ▁co hor t ▁for med ▁the ▁sa mp ling ▁frame ▁for ▁select ing ▁control s ▁( with out ▁CHF ) ▁match ed ▁on : ▁age , ▁race / eth nici ty , ▁cum ul ative ▁an thra cycli ne ▁exposure , ▁stem ▁cell ▁source ▁( allo gene ic , ▁auto logo us ), ▁and ▁length ▁of ▁follow - up .
▁Seven ty - s even ▁cases ▁with ▁pre - H CT ▁germ line ▁DNA ▁and ▁178 ▁control s ▁were ▁geno type d .
▁Multi varia te ▁analysis ▁reveal ed ▁that ▁the ▁odds ▁of ▁CHF ▁was ▁higher ▁in ▁female s ▁[ Od ds ▁Ra tio ▁( OR ) ▁= ▁2 · 9 , ▁P ▁< ▁0 · 01 ] , ▁individuals ▁with ▁pre - H CT ▁che st ▁radi ation ▁( OR ▁= ▁4 · 7 , ▁P ▁= ▁0 · 05) , ▁hyper tension ▁( OR ▁= ▁2 · 9 , ▁P ▁= ▁0 · 01) , ▁and ▁with ▁variant s ▁of ▁gene s ▁co ding ▁for ▁the ▁ NAD ( P ) H - oxid ase ▁sub un it ▁ RAC 2 ▁( rs 130 58 338 , ▁750 8 T → A ; ▁OR ▁= ▁2 · 8 , ▁P ▁< ▁0 · 01) , ▁H FE ▁( rs 17 999 45 , ▁63 C → G ; ▁OR ▁= ▁2 · 5 , ▁P ▁= ▁0 · 05) ▁or ▁the ▁do xor ubi cin ▁ eff lux ▁transporter ▁ABC C 2 ▁( rs 81 877 10 , ▁15 15 G → A ; ▁OR ▁= ▁4 · 3 , ▁P ▁< ▁0 · 01) .
▁A ▁combine d ▁( clin ical ▁and ▁genetic ) ▁CHF ▁predict ive ▁model ▁perform ed ▁better ▁[ area ▁under ▁the ▁cur ve ▁( AU C ), ▁0 · 79 ] ▁than ▁the ▁genetic ▁( AU C ▁= ▁0 · 67) ▁or ▁the ▁clinic al ▁( AU C ▁= ▁0 · 69) ▁models ▁alone .
▁Fat , ▁cache xia , ▁and ▁the ▁right ▁vent ric le ▁in ▁heart ▁failure : ▁a ▁web ▁of ▁complici ty .
▁In ▁this ▁guide line , ▁the ▁International ▁Right ▁Heart ▁Foundation ▁Work ing ▁Group ▁move s ▁a ▁step ▁forward ▁to ▁develop ▁a ▁common ▁language ▁to ▁describe ▁the ▁development ▁and ▁defect s ▁that ▁exempli fy ▁the ▁common ▁syndrome ▁of ▁right ▁heart ▁failure .
▁We ▁first ▁propose ▁fundamental ▁definition s ▁of ▁the ▁distinct ive ▁component s ▁of ▁the ▁right ▁heart ▁circulation ▁and ▁provide ▁consensu s ▁on ▁a ▁universal ▁definition ▁of ▁right ▁heart ▁failure .
▁These ▁definition s ▁will ▁form ▁the ▁foundation ▁for ▁descri bing ▁a ▁uniform ▁nomen cla ture ▁for ▁right ▁heart ▁circula tory ▁failure ▁with ▁a ▁view ▁to ▁fost er ▁collabora tive ▁research ▁initiative s ▁and ▁con jo int ▁education ▁in ▁an ▁effort ▁to ▁provide ▁insight ▁into ▁mechanism s ▁of ▁disease ▁unique ▁to ▁the ▁right ▁heart .
▁First - in - class ▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁in ▁heart ▁failure .
▁Ne pri ly sin ▁inhibi tors ▁aug ment ▁the ▁na tri ure tic ▁pe pti de ▁system ▁by ▁prevent ing ▁the ▁break down ▁of ▁at rial ▁na tri ure tic ▁pe pti de ▁and ▁B - type ▁na tri ure tic ▁pe pti de .
▁L CZ 696 , ▁an ▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁compose d ▁of ▁a ▁nepri ly sin ▁inhibi tor ▁pro drug ▁and ▁the ▁ang io ten sin ▁receptor ▁anta gon ist ▁val sar tan , ▁has ▁proven ▁effective ▁in ▁hyper tension , ▁has ▁shown ▁promise ▁in ▁a ▁pilot ▁trial ▁of ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction , ▁and ▁is ▁being ▁test ed ▁in ▁a ▁large ▁outcome s ▁trial ▁of ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction .
▁A ▁pres er ved ▁e je ction ▁ fraction ▁outcome s ▁trial ▁is ▁beginning .
▁Pharma c ological ▁treatment ▁of ▁a cute ▁heart ▁failure : ▁current ▁treatment ▁and ▁new ▁target s .
▁A cute ▁heart ▁failure ▁( A HF ) ▁is ▁define d ▁as ▁the ▁rapid ▁ons et ▁of , ▁or ▁changes ▁in , ▁the ▁symptoms ▁and ▁sign s ▁of ▁heart ▁failure ▁( HF ).
▁It ▁is ▁a ▁life - th rea te ning ▁situation ▁in ▁which ▁ diagnos is ▁and ▁initiat ion ▁of ▁ therapy ▁are ▁crucial .
▁The ▁treatment ▁aims ▁are ▁to ▁stabili ze ▁the ▁patient , ▁improve ▁clinic al ▁symptoms , ▁and ▁increase ▁long - term ▁survival ▁rates .
▁Fe w ▁treatment s ▁have ▁been ▁investiga ted ▁in ▁clinic al ▁trial s .
▁This ▁review ▁summa riz es ▁the ▁princip les ▁of ▁ pharma c ologic ▁treatment , ▁the ▁under ly ing ▁clinic al ▁trial s , ▁and ▁new ▁ pharma c ologic ▁target s .
▁The rap eu tic ▁implica tions ▁of ▁bio mark ers ▁in ▁chronic ▁heart ▁failure .
▁Under standing ▁of ▁chronic ▁heart ▁failure ▁( HF ) ▁has ▁progress ed ▁from ▁the ▁concept ▁of ▁a ▁pure ly ▁hem o dynamic ▁disorder ▁to ▁that ▁of ▁a ▁syndrome ▁that ▁results ▁from ▁dys function ▁in ▁inter connect ed ▁molecular ▁path ways .
▁As ▁a ▁result , ▁the ▁focus ▁of ▁research ▁investigation s ▁and ▁clinic al ▁care ▁has ▁shift ed ▁to ▁measure ment ▁and ▁modification ▁of ▁mal adapt ive ▁molecular ▁process es .
▁Acc u mula ting ▁evidence ▁shows ▁that ▁molecular ▁bio mark ers ▁provide ▁a ▁window ▁into ▁the ▁pat ho phy si ology ▁of ▁chronic ▁ HF ▁and ▁therefore ▁have ▁important ▁ therapeut ic ▁implica tions .
▁However , ▁the ▁use ▁of ▁bio mark ers ▁in ▁the ▁treatment ▁of ▁ HF ▁remain s ▁in ▁its ▁in fan cy .
▁This ▁is ▁part ly ▁a ▁result ▁of ▁short com ings ▁in ▁research ▁studies ▁and ▁a ▁de arth ▁of ▁bio mark er - guide d ▁clinic al ▁trial s .
▁In ▁this ▁review , ▁we ▁summa riz e ▁the ▁potential ▁ therapeut ic ▁implica tions ▁of ▁promis ing ▁bio mark ers ▁that ▁unique ly ▁capture ▁the ▁molecular ▁dys function ▁that ▁occur s ▁in ▁chronic ▁ HF .
▁We ▁discuss ▁the ▁need ▁for ▁strict ▁statistic al ▁standard s ▁in ▁bio mark er ▁studies , ▁provide ▁an ▁over view ▁of ▁bio mark er - guide d ▁clinic al ▁trial ▁design , ▁and ▁discuss ▁the ▁ therapeut ic ▁potential ▁of ▁a ▁multi mark er - based ▁strategy .
▁Micro RNA s ▁in ▁heart ▁failure : ▁new ▁target s ▁in ▁disease ▁management .
▁Heart ▁failure ▁is ▁the ▁leading ▁cause ▁of ▁mortal ity ▁in ▁Western ▁society ▁and ▁represent s ▁the ▁fast est ▁growing ▁sub class ▁of ▁cardiovascular ▁disease s .
▁An ▁increasing ▁body ▁of ▁evidence ▁indicate s ▁an ▁important ▁role ▁for ▁micro RNA s ▁( mi RNA s ) ▁in ▁the ▁path ogen es is ▁and ▁progression ▁of ▁heart ▁failure .
▁mi RNA s ▁are ▁small ▁non co ding ▁ RNA s ▁that ▁regula te ▁expression ▁of ▁target ▁gene s ▁by ▁se que nce - specific ▁ binding ▁to ▁the ▁3 ' ▁un trans la ted ▁region ▁of ▁messenger ▁ RNA , ▁which ▁results ▁in ▁degrada tion ▁or ▁translation al ▁re pression .
▁To ▁date , ▁many ▁mi RNA s ▁( and ▁their ▁target s ) ▁that ▁play ▁a ▁role ▁in ▁diverse ▁aspects ▁of ▁cardiac ▁remodel ing ▁and ▁heart ▁failure ▁development ▁have ▁been ▁identified .
▁Here , ▁we ▁give ▁an ▁over view ▁of ▁these ▁mi RNA s ▁and ▁their ▁role ▁in ▁cardiac ▁path ogen es is .
▁In ▁addition , ▁we ▁provide ▁brief ▁insight ▁into ▁the ▁potential ▁of ▁mi RNA s ▁as ▁novel ▁ therapeut ic ▁target s ▁for ▁heart ▁failure .
▁Re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁in ▁heart ▁failure .
▁Heart ▁failure ▁( HF ) ▁is ▁a ▁very ▁common ▁condition ▁that , ▁de spite ▁advance s ▁in ▁treatment , ▁car ries ▁significant ▁morbi d ity ▁and ▁mortal ity .
▁Although ▁there ▁is ▁good ▁evidence ▁for ▁the ▁treatment ▁of ▁ HF ▁with ▁reduce d ▁e je ction ▁ fraction ▁( HF r EF ), ▁the ▁treatment ▁for ▁ HF ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ) ▁is ▁not ▁well ▁define d .
▁The ▁re nin - angi oten sin - al do ster one ▁system ▁( RA AS ) ▁has ▁been ▁shown ▁to ▁be ▁an ▁effective ▁target ▁in ▁the ▁treatment ▁of ▁H Fr EF ▁using ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors , ▁ang io ten sin ▁receptor ▁block ers , ▁and ▁al do ster one ▁block ade , ▁although ▁the ▁evidence ▁in ▁ HF p EF ▁is ▁less ▁clear .
▁This ▁review ▁aims ▁to ▁look ▁first ▁at ▁the ▁evidence ▁for ▁these ▁drugs , ▁and ▁second ▁at ▁the ▁new er ▁drugs ▁that ▁act ▁on ▁the ▁RA AS , ▁na mely , ▁direct ▁re nin ▁inhibi tors , ▁neutral ▁en dop ep tida se ▁inhibi tors , ▁vaso pe pti das e ▁inhibi tors , ▁and ▁ang io ten sin ▁receptor ▁block ers .
▁S kelet al ▁muscle ▁ab normal ities ▁and ▁exercise ▁capacity ▁in ▁adults ▁with ▁a ▁Font an ▁circulation .
▁OB JE C TIVE S : ▁The ▁per i pher al ▁muscle ▁pump ▁is ▁key ▁in ▁promo ting ▁cardiac ▁fill ing ▁during ▁exercise , ▁especially ▁in ▁subject s ▁who ▁lack ▁a ▁sub pul mon ary ▁vent ric le ▁( the ▁Font an ▁circulation ).
▁A ▁muscle - was ting ▁syndrome ▁exist s ▁in ▁acquire d ▁heart ▁failure ▁but ▁has ▁not ▁been ▁assess ed ▁in ▁Font an ▁subject s .
▁We ▁so ught ▁to ▁investiga te ▁whether ▁adults ▁with ▁the ▁Font an ▁circulation ▁exhibi t ▁reduce d ▁skelet al ▁muscle ▁mass ▁and / or ▁metabol ic ▁ab normal ities .
▁DESIGN ▁AND ▁PAT IEN TS : ▁Six teen ▁New ▁York ▁Heart ▁Association ▁Class ▁I / II ▁Font an ▁adults ▁(30 ± 2 ▁years ) ▁under went ▁cardio pul mon ary ▁exercise ▁testing ▁and ▁lean ▁mass ▁quant ification ▁with ▁dual ▁x - ray ▁ab sor pti ometr y ▁( D XA ); ▁eight ▁had ▁cal f ▁muscle ▁(31) P ▁magnetic ▁res on ance ▁spec tros copy ▁as ▁did ▁eight ▁healthy ▁age - match ed ▁and ▁sex - match ed ▁control s .
▁D XA ▁results ▁were ▁compared ▁with ▁Australian ▁reference ▁data .
▁SET TING : ▁Single ▁tertia ry ▁refer ral ▁centre .
▁RESULT S : ▁Peak ▁VO 2 ▁was ▁1.9 ± 0.1 ▁L / min ▁( 66 ± 3% ▁of ▁predict ed ▁values ).
▁S kelet al ▁muscle ▁mass ▁assess ed ▁by ▁relative ▁appen di cular ▁lean ▁mass ▁index ▁was ▁significantly ▁reduce d ▁compared ▁with ▁age - match ed ▁and ▁sex - match ed ▁reference ▁values ▁( Z - s core ▁-1 . 46 ± 0.2 2 , ▁p < 0.00 01) .
▁Low ▁skelet al ▁muscle ▁mass ▁cor related ▁with ▁poor er ▁VO 2 ▁max ▁( r =0 . 67 , ▁p = 0.00 4) .
▁Over all , ▁skelet al ▁muscle ▁mass ▁T - s core ▁( der i ved ▁from ▁comparison ▁with ▁young ▁normal ▁reference ▁mean ) ▁was ▁-1 . 47 ± 0.2 1 ; ▁4 /16 ▁Font an ▁subject s ▁had ▁sar co pen ic ▁range ▁muscle ▁was ting ▁( T - s core ▁< - 2.0 ) ▁and ▁9 /16 ▁had ▁less ▁marked , ▁but ▁clinic ally ▁significant ▁was ting ▁( T - s core ▁< - 1.0 ▁but ▁ ≥ - 2.0 ).
▁Mus cle ▁aero bic ▁capacity , ▁measure d ▁by ▁the ▁rate ▁constant ▁( k ) ▁of ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis , ▁was ▁significantly ▁im pair ed ▁in ▁Font an ▁adults ▁versus ▁control s ▁(1 . 48 ± 0.1 3 ▁vs ▁2. 40 ± 0.3 3 ▁min ( -1) , ▁p =0 . 02) .
▁Psycho metric ▁testing ▁of ▁the ▁Self - Car e ▁of ▁Heart ▁Fail ure ▁Index ▁Version ▁6.2 .
▁The ▁Self - Car e ▁of ▁Heart ▁Fail ure ▁Index ▁Version ▁6.2 ▁( SCH FI ▁v . 6.2 ) ▁is ▁wide ly ▁used , ▁but ▁its ▁psycho metric ▁profile ▁is ▁still ▁question ed .
▁In ▁a ▁sample ▁of ▁ 659 ▁heart ▁failure ▁patients ▁from ▁Italy , ▁we ▁perform ed ▁confirma tory ▁factor ▁analysis ▁( C FA ) ▁to ▁test ▁the ▁original ▁construct ▁of ▁the ▁ SCH FI ▁v . 6.2 ▁scale s ▁( Sel f - Car e ▁Main ten ance , ▁Self - Car e ▁Management , ▁and ▁Self - Car e ▁Confi den ce ), ▁with ▁limited ▁success .
▁We ▁then ▁used ▁explora tory ▁factor ▁analysis ▁to ▁determine ▁the ▁presence ▁of ▁separate ▁scale ▁dimensions , ▁followed ▁by ▁C FA ▁in ▁a ▁separate ▁sub - sa mple .
▁Con struct ▁valid ity ▁of ▁individual ▁scale s ▁showed ▁excellent ▁fit ▁indice s : ▁C FI ▁= ▁ . 92 , ▁RM SE A ▁= ▁ . 05 ▁for ▁the ▁Self - Car e ▁Main ten ance ▁Scal e ; ▁C FI ▁= ▁ . 95 , ▁RM SE A ▁= ▁ . 07 ▁for ▁the ▁Self - Car e ▁Management ▁Scal e ; ▁C FI ▁= ▁ . 99 , ▁RM SE A ▁= ▁ . 02 ▁for ▁the ▁Self - Car e ▁Confi den ce ▁scale .
▁Contra s ting ▁groups ▁valid ity , ▁internal ▁consiste ncy , ▁and ▁test - re test ▁reli ability ▁were ▁support ed ▁as ▁well .
▁This ▁evidence ▁provides ▁a ▁new ▁understanding ▁of ▁the ▁structure ▁of ▁the ▁ SCH FI ▁v . 6.2 ▁and ▁support s ▁its ▁use ▁in ▁clinic al ▁practice ▁and ▁research .
▁Circula ting ▁fragment s ▁of ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti des ▁in ▁plasma ▁of ▁heart ▁failure ▁patients .
▁BA CK GRO UND : ▁The ▁use ▁of ▁non standard ized ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁( NT - pro B NP ) ▁as say s ▁can ▁contribute ▁to ▁the ▁mis diagnos is ▁of ▁heart ▁failure ▁( HF ).
▁More over , ▁there ▁is ▁yet ▁to ▁be ▁established ▁a ▁common ▁consensu s ▁regarding ▁the ▁circula ting ▁form s ▁of ▁NT - pro B NP ▁being ▁used ▁in ▁current ▁as say s .
▁We ▁ai med ▁to ▁character ize ▁and ▁quanti fy ▁the ▁various ▁form s ▁of ▁NT - pro B NP ▁in ▁the ▁circulation ▁of ▁ HF ▁patients .
▁ MET HOD S : ▁Plas ma ▁sample s ▁were ▁collect ed ▁from ▁ HF ▁patients ▁( n ▁= ▁20 ) ▁at ▁rest ▁and ▁store d ▁at ▁- 80 ▁° C .
▁NT - pro B NP ▁was ▁en rich ed ▁from ▁ HF ▁patient ▁plasma ▁by ▁use ▁of ▁immun o preci pit ation ▁followed ▁by ▁mass ▁spec tro metric ▁analysis .
▁Custom ized ▁homo gene ous ▁sandwich ▁Alpha LIS A ® ▁immun o assa ys ▁were ▁developed ▁and ▁valida ted ▁to ▁quanti fy ▁6 ▁fragment s ▁of ▁NT - pro B NP .
▁RESULT S : ▁Mass ▁spec tro met ry ▁identified ▁the ▁presence ▁of ▁several ▁N - ▁and ▁C - termin ally ▁process ed ▁form s ▁of ▁circula ting ▁NT - pro B NP , ▁with ▁physio logic al ▁prote ol ysis ▁between ▁Pro 2- Le u 3 , ▁Le u 3- G ly 4 , ▁Pro 6 - G ly 7 , ▁and ▁Pro 75 - Ar g 76 .
▁Cons isten t ▁with ▁this ▁result , ▁Alpha LIS A ▁immun o assa ys ▁demonstrat ed ▁that ▁anti bo dies ▁target ing ▁the ▁extreme ▁N ▁or ▁C ▁termini ▁measure d ▁a ▁low ▁apparent ▁concentration ▁of ▁circula ting ▁NT - pro B NP .
▁The ▁apparent ▁circula ting ▁NT - pro B NP ▁concentration ▁was ▁increased ▁with ▁anti bo dies ▁target ing ▁non gly cos yla ted ▁and ▁non termin al ▁e pito pes ▁( P ▁< ▁0.0 5) .
▁CON CL USI ONS : ▁In ▁plasma ▁collect ed ▁from ▁ HF ▁patients , ▁immun ore active ▁NT - pro B NP ▁was ▁present ▁as ▁multiple ▁N - ▁and ▁C - termin ally ▁tru nca ted ▁fragment s ▁of ▁the ▁full ▁length ▁NT - pro B NP ▁mole cule .
▁Immun o det ection ▁of ▁NT - pro B NP ▁was ▁significantly ▁improve d ▁with ▁the ▁use ▁of ▁anti bo dies ▁that ▁did ▁not ▁target ▁these ▁terminal ▁region s .
▁These ▁finding s ▁support ▁the ▁development ▁of ▁a ▁next ▁generation ▁NT - pro B NP ▁as say ▁target ing ▁non termin al ▁e pito pes ▁as ▁well ▁as ▁avoid ing ▁the ▁central ▁gly cos yla ted ▁region ▁of ▁this ▁mole cule .
▁Pre val ence , ▁clinic al ▁character istic s , ▁and ▁outcome s ▁associated ▁with ▁ecce n tric ▁versus ▁concentr ic ▁left ▁vent ri cular ▁hyper trop hy ▁in ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction .
▁Although ▁concentr ic ▁remodel ing ▁( CR ) ▁and ▁concentr ic ▁hyper trop hy ▁( CH ) ▁are ▁common ▁form s ▁of ▁left ▁vent ri cular ▁( LV ) ▁remodel ing ▁in ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ), ▁ecce n tric ▁hyper trop hy ▁( EH ) ▁can ▁also ▁occur ▁in ▁these ▁patients .
▁However , ▁clinic al ▁character istic s ▁and ▁outcome s ▁of ▁EH ▁have ▁not ▁been ▁well ▁described ▁in ▁ HF p EF .
▁We ▁prospect ive ly ▁studie d ▁40 2 ▁patients ▁with ▁ HF p EF , ▁divide d ▁into ▁4 ▁groups ▁based ▁on ▁LV ▁structure : ▁normal ▁ge ometr y ▁( no ▁LV ▁hyper trop hy ▁[ LV H ] ▁and ▁relative ▁wall ▁thi ck ness ▁[ RW T ] ▁ ≤ 0.4 2) ; ▁CR ▁( no ▁LV H ▁and ▁R WT ▁> 0.4 2) ; ▁CH ▁( LV H ▁and ▁R WT ▁> 0.4 2) ; ▁and ▁EH ▁( LV H ▁and ▁R WT ▁ ≤ 0.4 2) .
▁We ▁compared ▁clinic al , ▁laborator y , ▁e cho car dio graphic , ▁invasi ve ▁hem o dynamic , ▁and ▁outcome ▁data ▁among ▁groups .
▁Of ▁40 2 ▁patients , ▁48 ▁(1 2%) ▁had ▁EH .
▁Compar ed ▁with ▁CH , ▁patients ▁with ▁EH ▁had ▁lower ▁sy sto lic ▁blood ▁pressure ▁and ▁less ▁renal ▁im pair ment ▁de spite ▁similar ▁rates ▁of ▁hyper tension .
▁After ▁adjust ment ▁for ▁co varia tes , ▁EH ▁was ▁associated ▁with ▁reduce d ▁LV ▁contract ility ▁compared ▁with ▁CH : ▁lower ▁LV EF ▁( β ▁co e ffi cient ▁= ▁- 3.2 ; ▁95% ▁confidence ▁interval ▁[ CI ] ▁- 5 . 4 ▁to ▁-1 . 1%) ▁and ▁ratio ▁of ▁sy sto lic ▁blood ▁pressure ▁to ▁end - sy sto lic ▁volume ▁( β ▁co e ffi cient ▁= ▁- 1.0 ; ▁95% ▁CI ▁- 1.5 ▁to ▁- 0.5 ▁mm ▁H g / ml ).
▁EH ▁was ▁also ▁associated ▁with ▁increased ▁LV ▁compliance ▁compared ▁with ▁CH ▁( LV ▁end - dia sto lic ▁volume ▁at ▁an ▁ideal ized ▁LV ▁end - dia sto lic ▁pressure ▁of ▁20 ▁mm ▁H g ▁β ▁co e ffi cient ▁= ▁14. 2 ; ▁95% ▁CI ▁9. 4 ▁to ▁19. 1 ▁ml ).
▁De spite ▁these ▁difference s , ▁EH ▁and ▁CH ▁had ▁similar ly ▁eleva ted ▁cardiac ▁fill ing ▁pressure s ▁and ▁equivalent ▁advers e ▁outcome s .
▁In ▁conclusion , ▁the ▁presence ▁of ▁EH ▁de no tes ▁a ▁distinct ▁sub set ▁of ▁ HF p EF ▁that ▁is ▁pat ho phy si ological ly ▁similar ▁to ▁ HF ▁with ▁reduce d ▁EF ▁( HF r EF ) ▁and ▁may ▁benefit ▁from ▁H Fr EF ▁ therapy .
▁Heart ▁failure ▁in ▁patients ▁treated ▁with ▁bis phos phon ates .
▁OB JE C TIVE S : ▁The ▁a im ▁of ▁this ▁study ▁was ▁to ▁investiga te ▁the ▁occur r ence ▁of ▁heart ▁failure ▁in ▁patients ▁treated ▁with ▁bis phos phon ates .
▁DESIGN : ▁In ▁this ▁nation wide ▁retro spec tive ▁co hor t ▁study ▁from ▁Denmark , ▁all ▁users ▁of ▁bis phos phon ates ▁and ▁ra lo xi fen e ▁between ▁1996 ▁and ▁2006 ▁( n ▁= ▁102 ▁34 2) ▁were ▁included ▁in ▁the ▁' ex posed ' ▁group ▁and ▁three ▁age - ▁and ▁gender - match ed ▁subject s ▁( n ▁= ▁30 7.0 26) ▁from ▁the ▁general ▁population ▁compris ed ▁the ▁control ▁group .
▁The ▁risk ▁of ▁heart ▁failure ▁was ▁estima ted ▁by ▁Co x ▁proportion al ▁hazard ▁analyse s .
▁RESULT S : ▁The ▁mean ▁follow - up ▁times ▁were ▁ 2.8 , ▁5.5 ▁and ▁ 4.9 ▁years ▁for ▁ale ndr onate - , ▁et id rona te - ▁and ▁ra lo xi fen e - tre ated ▁patients , ▁respective ly .
▁The ▁absolute ▁risk ▁of ▁heart ▁failure ▁was ▁4. 4% ▁in ▁the ▁expose d ▁group ▁and ▁3. 7% ▁in ▁the ▁control ▁group ▁( P ▁< ▁ 0.01 ).
▁The ▁relative ▁risk ▁( RR ) ▁of ▁heart ▁failure ▁was ▁significantly ▁increased ▁in ▁users ▁of ▁bis pho phon ates : ▁cru de ▁ RR ▁1. 71 ▁[ 95% ▁confidence ▁interval ▁( CI ) ▁1.6 3-1 . 79 ] ; ▁adjust ed ▁hazard ▁ratio ▁( HR ) ▁1. 41 ▁( 95% ▁CI ▁1.3 4-1 . 48) .
▁By ▁comparison , ▁ra lo xi fen e , ▁which ▁is ▁used ▁for ▁the ▁same ▁indica tion ▁but ▁has ▁a ▁different ▁mechanism ▁of ▁action , ▁was ▁not ▁associated ▁with ▁an ▁increased ▁risk ▁of ▁heart ▁failure : ▁adjust ed ▁HR ▁1. 07 ▁( 95% ▁CI ▁ 0.7 6-1 . 50 ).
▁When ▁the ▁two ▁most ▁common ly ▁used ▁bis phos phon ates , ▁ale ndr onate ▁and ▁et id rona te , ▁were ▁analyse d ▁separate ly , ▁significant ▁trend s ▁in ▁the ▁risk ▁of ▁heart ▁failure ▁were ▁observe d ▁across ▁re fill ▁compliance ▁strat a .
▁The ▁risk ▁of ▁heart ▁failure ▁increased ▁significantly ▁with ▁increasing ▁re fill ▁compliance ▁for ▁et id rona te ▁( P ▁for ▁trend ▁< ▁ 0.01 ), ▁where as ▁it ▁decrease d ▁for ▁ale ndr onate ▁( P ▁for ▁trend ▁< ▁ 0.01 ).
▁CON CL USI ONS : ▁Bis phos phon ate ▁users ▁were ▁at ▁increased ▁risk ▁of ▁heart ▁failure ▁compared ▁to ▁age - ▁and ▁gender - match ed ▁control ▁subject s .
▁However , ▁users ▁of ▁ale ndr onate ▁showed ▁a ▁dose - dependent ▁re duction ▁in ▁this ▁risk , ▁suggest ing ▁that ▁ale ndr onate ▁may ▁reduce ▁the ▁risk ▁of ▁heart ▁failure .
▁Re ver sal ▁of ▁cardiac ▁dys function ▁and ▁sub cel lular ▁altera tions ▁by ▁met o pro lol ▁in ▁heart ▁failure ▁due ▁to ▁my o card ial ▁in far ction .
▁In ▁order ▁to ▁examine ▁the ▁rever si bility ▁of ▁heart ▁failure ▁due ▁to ▁my o card ial ▁in far ction ▁( MI ) ▁by ▁β - ad re no cept or ▁block ade , ▁12 ▁weeks ▁in far cted ▁rat s ▁were ▁treated ▁with ▁or ▁without ▁met o pro lol ▁(50 ▁mg / kg / day ) ▁for ▁8 ▁weeks .
▁The ▁de press ed ▁left ▁vent ri cular ▁( LV ) ▁sy sto lic ▁pressure , ▁positive ▁and ▁negative ▁rates ▁of ▁changes ▁in ▁pressure ▁development , ▁e je ction ▁ fraction , ▁ fraction al ▁short en ing ▁and ▁cardiac ▁output , ▁as ▁well ▁as ▁increased ▁LV ▁end - dia sto lic ▁pressure ▁in ▁20 ▁weeks ▁MI ▁animals ▁were ▁parti ally ▁rever sed ▁by ▁met o pro lol .
▁MI - indu ced ▁decrease s ▁in ▁sept um ▁( sy sto lic ) ▁thi ck ness ▁as ▁well ▁as ▁increase ▁in ▁LV ▁posterior ▁wall ▁thi ck ness ▁and ▁LV ▁internal ▁diameter ▁were ▁parti ally ▁or ▁fully ▁rever sible ▁by ▁met o pro lol .
▁Treatment ▁of ▁MI ▁animals ▁with ▁met o pro lol ▁parti ally ▁rever sed ▁the ▁eleva ted ▁levels ▁of ▁plasma ▁no re pine ph rine ▁and ▁dop amine ▁without ▁affect ing ▁the ▁eleva ted ▁levels ▁of ▁e pine ph rine .
▁Although ▁sar co plas mic ▁reti cular ▁( SR ) ▁Ca (2 +) - up take , ▁as ▁well ▁as ▁protein ▁content ▁for ▁SR ▁Ca (2 +) - pump ▁and ▁ phos pho lam ban , ▁were ▁reduce d ▁in ▁the ▁in far cted ▁heart s ; ▁these ▁changes ▁were ▁parti ally ▁rever sible ▁with ▁met o pro lol .
▁De press ed ▁my o fi bril lar ▁Ca (2 +) - stimul ated ▁ATP ase ▁activity , ▁as ▁well ▁as ▁m RNA ▁levels ▁for ▁SR ▁Ca (2 +) - pump , ▁ phos pho lam ban ▁and ▁α - my os in ▁heavy ▁chain , ▁were ▁una ffe cted ▁where as ▁increased ▁m RNA ▁level ▁for ▁β - my os in ▁heavy ▁chain ▁was ▁parti ally ▁rever sed ▁by ▁met o pro lol .
▁The ▁results ▁suggest ▁that ▁parti al ▁improvement ▁of ▁cardiac ▁performance ▁by ▁β - ad re no cept or ▁block ade ▁at ▁advanced ▁stage s ▁of ▁heart ▁failure ▁may ▁be ▁due ▁to ▁parti al ▁rever sal ▁of ▁changes ▁in ▁SR ▁Ca (2 +) - pump ▁function ▁where as ▁parti al ▁to ▁complete ▁rever se ▁cardiac ▁remodel ing ▁may ▁be ▁due ▁to ▁parti al ▁re duction ▁in ▁the ▁eleva ted ▁levels ▁of ▁plasma ▁cate chol amine s .
▁P sori asis ▁is ▁not ▁associated ▁with ▁at hero sc ler osis ▁and ▁incident ▁cardiovascular ▁events : ▁the ▁Rotterdam ▁Study .
▁P sori asis ▁has ▁been ▁suggest ed ▁to ▁be ▁an ▁independent ▁risk ▁factor ▁for ▁cardiovascular ▁disease ▁( CV D ); ▁however , ▁available ▁studies ▁have ▁shown ▁in cons isten t ▁results .
▁In ▁this ▁study , ▁ embe dded ▁within ▁the ▁population - based ▁Rotterdam ▁Study , ▁we ▁ai med ▁to ▁assess ▁the ▁association ▁between ▁psoriasis ▁and ▁cardiovascular ▁outcome s .
▁Ad just ed ▁means ▁were ▁calcula ted ▁for ▁sub clin ical ▁at hero sc ler osis ▁using ▁general ▁linear ▁models .
▁U sing ▁Co x ▁re gression , ▁the ▁hazard s ▁of ▁cardiovascular ▁events ▁for ▁psoriasis , ▁as ▁a ▁time - dependent ▁variable , ▁were ▁calcula ted .
▁A ▁total ▁of ▁26 2 ▁psoriasis ▁(2 4% ▁system ic / UV ▁treatment ) ▁and ▁8 , 009 ▁reference ▁subject s ▁were ▁followed ▁up ▁for ▁a ▁mean ▁of ▁11 ▁years .
▁P sori asis ▁patients ▁were ▁significantly ▁young er , ▁smo ked ▁more , ▁and ▁had ▁higher ▁dia sto lic ▁blood ▁pressure ▁and ▁body ▁mass ▁index ▁levels .
▁The ▁adjust ed ▁caro tid ▁intim a - media ▁thi ck ness ▁was ▁1. 02 ± 0.1 8 ▁mm ▁for ▁psoriasis ▁and ▁1. 02 ± 0.1 6 ▁mm ▁for ▁reference ▁subject s .
▁Similar ly , ▁cru de ▁and ▁adjust ed ▁an kle - bra chi al ▁index , ▁puls e - wa ve ▁veloci ty , ▁and ▁corona ry ▁arter y ▁calci um ▁score s ▁did ▁not ▁differ ▁between ▁the ▁two ▁groups .
▁The ▁risk ▁of ▁incident ▁CV D ▁was ▁not ▁increased ▁in ▁psoriasis ▁( ad just ed ▁hazard ▁ratio ▁0 . 73 , ▁95% ▁confidence ▁interval ▁0.5 0-1 . 06) .
▁The ▁results ▁were ▁similar ▁when ▁corona ry ▁heart ▁disease , ▁stroke , ▁and ▁heart ▁failure ▁were ▁anal y zed ▁separate ly .
▁P sori asis ▁patients ▁with ▁predomina nt ly ▁mild ▁disease ▁from ▁the ▁general ▁population ▁are ▁as ▁likely ▁to ▁develop ▁at hero sc ler osis ▁and ▁cardiovascular ▁events ▁as ▁subject s ▁without ▁psoriasis .
▁Pres ence ▁of ▁dia sto lic ▁dys function ▁in ▁patients ▁with ▁per i pher al ▁arter y ▁disease .
▁Peri pher al ▁arter y ▁disease ▁( PAD ) ▁and ▁heart ▁failure ▁( HF ) ▁share ▁many ▁risk ▁factors ; ▁however , ▁the ▁prevale nce ▁and ▁character istic s ▁of ▁ HF ▁in ▁patients ▁with ▁ PAD ▁have ▁not ▁been ▁fully ▁examine d .
▁We ▁investiga ted ▁120 ▁consecutiv e ▁patients ▁with ▁ PAD , ▁define d ▁by ▁an ▁an kle - bra chi al ▁index ▁ ≤ ▁ 0.9 .
▁In ▁all , ▁36 ▁(30 %) ▁patients ▁had ▁brain ▁na tri ure tic ▁pe pti de ▁( B NP ) ▁levels ▁ ≥ ▁100 ▁p g / m L ▁( high ▁B NP ▁group ), ▁and ▁84 ▁( 70% ) ▁patients ▁had ▁B NP ▁levels ▁< ▁100 ▁p g / m L ▁( low ▁B NP ▁group ).
▁Uni varia te ▁analysis ▁showed ▁that ▁high ▁B NP ▁was ▁associated ▁with ▁age , ▁estima ted ▁glo mer ular ▁filtr ation ▁rate , ▁hyper tension , ▁and ▁transmit ral ▁E - wa ve / ear ly ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty ▁( E / e ' ) ▁ratio .
▁Multi varia te ▁logistic ▁re gression ▁analysis ▁established ▁that ▁a ▁high ▁B NP ▁was ▁strong ly ▁and ▁independent ly ▁associated ▁with ▁the ▁highest ▁quart ile ▁of ▁E / e ' , ▁highlight ing ▁these ▁patients ' ▁dia sto lic ▁dys function .
▁The ▁prevale nce ▁of ▁high ▁B NP ▁levels ▁in ▁patients ▁with ▁ PAD ▁suggest s ▁that ▁routine ▁B NP ▁measure ments ▁might ▁be ▁useful ▁to ▁detect ▁ HF .
▁Hospital - to - Home : ▁a ▁hospital ▁read mission ▁re duction ▁program ▁for ▁con ges tive ▁heart ▁failure .
▁OB JE C TIVE : ▁To ▁decrease ▁the ▁30- day ▁read mission ▁rate ▁following ▁hospital ▁stay ▁for ▁con ges tive ▁heart ▁failure , ▁which ▁in ▁the ▁United ▁States ▁approach es ▁30 ▁percent ▁national ly .
▁In ▁addition ▁to ▁indicat ing ▁possible ▁sub optimal ▁care ▁of ▁patients ▁with ▁this ▁condition , ▁there ▁are ▁significant ▁economic ▁consideration s .
▁DESIGN : ▁Pro spec tive , ▁non - rando m ized , ▁two - center ▁pilot ▁project .
▁SET TING : ▁General ▁hospital ▁and ▁cardiac ▁special ty ▁hospital , ▁both ▁located ▁in ▁a ▁community ▁of ▁1 50,000 ▁population ▁in ▁predomina nt ly ▁rural ▁South ▁Da kota .
▁PARTI CI PAN TS : ▁All ▁patients ▁admit ted ▁between ▁June ▁7 , ▁2010 ▁and ▁June ▁6 , ▁2011 ▁with ▁a ▁ diagnos is ▁of ▁con ges tive ▁heart ▁failure .
▁INTER VEN TION : ▁An ▁intensiv e ▁transition s ▁of ▁care ▁program ▁was ▁implement ed ▁to ▁ensure ▁adequat e ▁self - management ▁training ▁of ▁patients ▁and ▁appropriate ▁out - patient ▁follow - up ▁and ▁monitoring ▁of ▁the ▁patient ▁by ▁the ▁health ▁care ▁system .
▁M AIN ▁O UTC OME ▁ME AS URE : ▁30- day ▁all - ca use ▁read missions .
▁RESULT S : ▁A ▁statistic ally ▁significant ▁42 ▁percent ▁relative ▁re duction ▁in ▁30- day ▁read mission ▁rate ▁was ▁document ed ▁for ▁those ▁patients ▁participat ing ▁in ▁the ▁pilot ▁program .
▁This ▁represent ed ▁a ▁net ▁economic ▁sav ings , ▁even ▁account ing ▁for ▁the ▁added ▁cost ▁of ▁the ▁intervention .
▁CON CL USI ONS : ▁An ▁intensiv e ▁transition s ▁of ▁care ▁program ▁decrease s ▁the ▁30- day ▁read mission ▁rate ▁for ▁patients ▁with ▁con ges tive ▁heart ▁failure ▁in ▁a ▁non - urban ized ▁Mid we stern ▁state ▁like ▁South ▁Da kota .
▁Heart ▁rate ▁variabil ity ▁in ▁risk ▁strat ification ▁of ▁cardiac ▁patients .
▁Heart ▁rate ▁( HR ) ▁variabil ity ▁has ▁been ▁ex tensi ve ly ▁studie d ▁in ▁cardiac ▁patients , ▁especially ▁in ▁patients ▁sur vi ving ▁an ▁a cute ▁my o card ial ▁in far ction ▁( AMI ) ▁and ▁also ▁in ▁patients ▁with ▁con ges tive ▁heart ▁failure ▁( CH F ) ▁or ▁left ▁vent ri cular ▁( LV ) ▁dys function .
▁The ▁majority ▁of ▁studies ▁have ▁shown ▁that ▁patients ▁with ▁reduce d ▁or ▁ab normal ▁HR ▁variabil ity ▁have ▁an ▁increased ▁risk ▁of ▁mortal ity ▁within ▁a ▁few ▁years ▁after ▁an ▁ AMI ▁or ▁after ▁a ▁ diagnos is ▁of ▁CHF / LV ▁dys function .
▁Vario us ▁measure s ▁of ▁HR ▁dynamic s , ▁such ▁as ▁time - doma in , ▁spec tral , ▁and ▁non - line ar ▁measure s ▁of ▁HR ▁variabil ity ▁have ▁been ▁used ▁in ▁risk ▁strat ification .
▁The ▁prognos tic ▁power ▁of ▁various ▁measure s , ▁except ▁of ▁those ▁reflect ing ▁rapid ▁R - R ▁interval ▁os cilla tions , ▁has ▁been ▁almost ▁identi cal , ▁al be it ▁some ▁non - line ar ▁HR ▁variabil ity ▁measure s , ▁such ▁as ▁short - term ▁fra c tal ▁scal ing ▁ex ponent ▁have ▁provided ▁somewhat ▁better ▁prognos tic ▁information ▁than ▁the ▁others .
▁Ab normal ▁HR ▁variabil ity ▁predict s ▁both ▁sud den ▁and ▁non - sud den ▁cardiac ▁death .
▁Because ▁of ▁remodel ing ▁of ▁the ▁ar rhythm ia ▁substrat e ▁after ▁ AMI , ▁early ▁measure ment ▁of ▁HR ▁variabil ity ▁to ▁identify ▁those ▁at ▁high ▁risk ▁should ▁likely ▁be ▁repeat ed ▁later ▁in ▁order ▁to ▁assess ▁the ▁risk ▁of ▁fatal ▁ar rhythm ia ▁events .
▁Future ▁random ized ▁trial s ▁using ▁HR ▁variabil ity / tur bul ence ▁as ▁one ▁of ▁the ▁pre - de fin ed ▁inclusi on ▁criteri a ▁will ▁show ▁whether ▁routine ▁measure ment ▁of ▁HR ▁variabil ity / tur bul ence ▁will ▁become ▁a ▁routine ▁clinic al ▁tool ▁for ▁risk ▁strat ification ▁of ▁cardiac ▁patients .
▁Ren al ▁arter y ▁sten osis ▁- ▁an ▁update .
▁Ren al ▁arter y ▁sten osis ▁( RAS ) ▁is ▁a ▁common ▁form ▁of ▁per i pher al ▁arterial ▁disease .
▁The ▁most ▁common ▁cause ▁of ▁ RAS ▁is ▁at hero sc ler osis .
▁It ▁is ▁predomina nt ly ▁unilateral .
▁The ▁pat ho phy si ologic ▁mechanism ▁stem s ▁from ▁renal ▁under per fusion ▁result ing ▁in ▁the ▁activa tion ▁of ▁the ▁re nin - ▁ang io ten sin - al do ster one ▁path way .
▁Even ▁though ▁the ▁majority ▁of ▁patients ▁with ▁ RAS ▁are ▁as ym pto matic , ▁it ▁can ▁clinic ally ▁present ▁with ▁hyper tension , ▁nep hro pathy ▁and ▁con ges tive ▁heart ▁failure .
▁This ▁progressive ▁disease ▁can ▁lead ▁to ▁resist ant ▁hyper tension ▁and ▁end ▁stage ▁ki dne y ▁failure .
▁Screen ing ▁patients ▁for ▁ RAS ▁with ▁either ▁Do pp ler ▁ultra son ography , ▁com put ed ▁to mo graphic ▁ang i ography , ▁or ▁magnetic ▁res on ance ▁ang i ography ▁is ▁prefer red .
▁Ade qua te ▁blood ▁pressure ▁control , ▁goal - direct ed ▁lipid - lo wering ▁ therapy , ▁smoking ▁ces s ation , ▁and ▁other ▁preventiv e ▁measure s ▁form ▁the ▁foundation ▁of ▁management ▁of ▁patients ▁with ▁ RAS .
▁Cat heter - based ▁per cuta ne ous ▁re vas cular ization ▁with ▁ang io plast y ▁and ▁sten ting ▁showed ▁modest ▁clinic al ▁benefit ▁for ▁patients ▁in ▁small ▁retro spec tive ▁studies , ▁but ▁data ▁from ▁random ized ▁clinic al ▁trial s ▁failed ▁to ▁confirm ▁these ▁beneficia l ▁results .
▁The ▁current ▁ongoing ▁Card io vas cular ▁Out com es ▁in ▁Ren al ▁Ath eros cle ro tic ▁Les ions ▁( CO RAL ) ▁trial ▁may ▁provide ▁more ▁concrete ▁data ▁regarding ▁the ▁role ▁of ▁sten ting ▁in ▁ RAS .
▁Sur g ical ▁re vas cular ization ▁is ▁considered ▁only ▁if ▁cat heter - based ▁re vas cular ization ▁is ▁un suit able ▁or ▁un succes s ful .
▁The ▁American ▁College ▁of ▁Card i ology / American ▁Heart ▁Association ▁guidelines ▁on ▁evaluation ▁and ▁management ▁of ▁patients ▁with ▁ RAS ▁provide ▁the ▁framework ▁for ▁determin ing ▁individual ized ▁assessment ▁and ▁treatment ▁plans ▁for ▁patients ▁with ▁ RAS .
▁Bio informati c ▁analysis ▁of ▁micro arra y ▁data ▁reveal s ▁several ▁key ▁gene s ▁related ▁to ▁heart ▁failure .
▁OB JE C TIVE S : ▁Heart ▁failure ▁is ▁a ▁major ▁public ▁health ▁problem ▁worldwide .
▁However , ▁the ▁molecular ▁mechanism ▁is ▁still ▁un clear .
▁This ▁study ▁aims ▁to ▁discover ▁differenti ally ▁express ed ▁gene s ▁( DE G s ) ▁between ▁non - ische mic ▁or ▁ ische mic ▁heart ▁failure ▁sample s ▁and ▁healthy ▁control , ▁which ▁may ▁be ▁used ▁for ▁ diagnos is ▁and ▁treatment ▁of ▁heart ▁failure .
▁MAT ERIA LS ▁AND ▁ MET HOD S : ▁Gene ▁expression ▁profile ▁G SE 91 28 ▁was ▁download ed ▁from ▁Gene ▁Express ion ▁Omni bus , ▁including ▁3 ▁normal ▁sample s , ▁4 ▁non - ische mic ▁heart ▁failure ▁sample s ▁and ▁4 ▁ ische mic ▁sample s .
▁Data ▁process ing ▁and ▁differenti al ▁analysis ▁were ▁carried ▁out ▁with ▁package s ▁of ▁R . ▁Clu ster ▁analysis ▁was ▁also ▁perform ed ▁for ▁all ▁the ▁sample s ▁to ▁global ly ▁observe ▁the ▁difference ▁among ▁the ▁three ▁groups ▁of ▁sample s .
▁Inter ac tors ▁of ▁the ▁DE G s ▁were ▁re trie ved ▁with ▁O spre y ▁and ▁then ▁network s ▁were ▁construct ed .
▁The ▁over la pping ▁part ▁of ▁the ▁network ▁was ▁selected ▁out ▁using ▁Cy to scape , ▁for ▁which ▁functional ▁en rich ment ▁analysis ▁was ▁applied ▁with ▁DA VID ▁tools .
▁RESULT S : ▁A ▁total ▁of ▁29 3 ▁and ▁133 ▁DE G s ▁were ▁obtain ed ▁for ▁non - ische mic ▁and ▁ ische mic ▁heart ▁failure , ▁respective ly .
▁Two ▁network s ▁were ▁established ▁and ▁then ▁functional ▁en rich ment ▁analysis ▁reveal ed ▁that ▁" regul ation ▁of ▁programme d ▁cell ▁death " ▁was ▁most ▁significantly ▁over - re present ed ▁in ▁common ▁DE G s .
▁CON CL USI ONS : ▁Gene s ▁differenti ally ▁express ed ▁in ▁non - ische mic ▁and ▁ ische mic ▁heart ▁failure ▁can ▁be ▁bio mark ers ▁to ▁distingui sh ▁the ▁two ▁types ▁of ▁heart ▁failure .
▁Besi des , ▁these ▁gene s ▁can ▁be ▁target s ▁to ▁develop ▁treatment s .
▁Effect s ▁of ▁care ▁management ▁and ▁tele health : ▁a ▁longitud in al ▁analysis ▁using ▁medica re ▁data .
▁OB JE C TIVE S : ▁To ▁evaluat e ▁mortal ity ▁and ▁health care ▁utiliza tion ▁effects ▁of ▁an ▁intervention ▁that ▁combine d ▁care ▁management ▁and ▁tele health , ▁target ing ▁individuals ▁with ▁con ges tive ▁heart ▁failure , ▁chronic ▁ob struct ive ▁pulmonar y ▁disease , ▁or ▁diabetes ▁mell itus .
▁DESIGN : ▁Retro spec tive ▁match ed ▁co hor t ▁study .
▁SET TING : ▁North west ▁United ▁States .
▁PARTI CI PAN TS : ▁High - co st ▁Medica re ▁fee - for - service ▁beneficiar ies ▁( N ▁= ▁1,7 67) ▁en roll ed ▁in ▁two ▁Center s ▁for ▁Medica re ▁and ▁Medica id ▁Services ▁demonstra tion ▁participat ing ▁clinic s ▁and ▁a ▁pro pens ity - s core ▁match ed ▁control ▁group .
▁INTER VEN TION : ▁The ▁Health ▁Budd y ▁Program , ▁which ▁integrat es ▁a ▁content - driv en ▁tele health ▁system ▁with ▁care ▁management .
▁ME AS UR EMENT S : ▁Mor t ality , ▁in patient ▁ad missions , ▁hospital ▁days , ▁and ▁emergency ▁department ▁( ED ) ▁visit s ▁during ▁the ▁2- year ▁study ▁period ▁were ▁measure d .
▁Co x - propor tional ▁hazard ▁models ▁and ▁negative ▁bi nom ial ▁re gression ▁models ▁were ▁used ▁to ▁assess ▁the ▁relationship ▁between ▁the ▁intervention ▁and ▁survival ▁and ▁utiliza tion , ▁control ling ▁for ▁demo graphic ▁and ▁health ▁character istic s ▁that ▁were ▁statistic ally ▁different ▁between ▁groups ▁after ▁match ing .
▁RESULT S : ▁At ▁2 ▁years , ▁participants ▁offered ▁the ▁Health ▁Budd y ▁Program ▁had ▁15% ▁lower ▁risk - ad just ed ▁all - ca use ▁mortal ity ▁( haz ard ▁ratio ▁( HR ) ▁= ▁0 . 85 , ▁95% ▁confidence ▁interval ▁( CI ) ▁= ▁0 . 74 -0 . 98 ; ▁P ▁= ▁ . 03) ▁and ▁had ▁reduc tions ▁in ▁the ▁number ▁of ▁quarter ly ▁in patient ▁ad missions ▁from ▁base line ▁to ▁the ▁study ▁period ▁that ▁were ▁18% ▁greater ▁than ▁those ▁of ▁match ed ▁control s ▁during ▁this ▁same ▁time ▁period ▁( - 0.0 35 ▁vs ▁- 0.00 3 ; ▁difference - in - di ffer ences ▁= ▁- 0.0 32 , ▁95% ▁CI ▁= ▁- 0.0 54 ▁to ▁- 0.0 10 , ▁P ▁= ▁ . 005 ).
▁No ▁relationship ▁was ▁found ▁between ▁the ▁Health ▁Budd y ▁Program ▁and ▁ED ▁use ▁or ▁number ▁of ▁hospital ▁days ▁for ▁participants ▁who ▁were ▁hospital ized .
▁The ▁Health ▁Budd y ▁Program ▁was ▁most ▁strong ly ▁associated ▁with ▁few er ▁ad missions ▁for ▁individuals ▁with ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁and ▁mortal ity ▁for ▁those ▁with ▁con ges tive ▁heart ▁failure .
▁CON C LU SION : ▁Care ▁management ▁couple d ▁with ▁content - driv en ▁tele health ▁technology ▁has ▁potential ▁to ▁improve ▁health ▁outcome s ▁in ▁high - co st ▁Medica re ▁beneficiar ies .
▁Race , ▁exercise ▁training , ▁and ▁outcome s ▁in ▁chronic ▁heart ▁failure : ▁finding s ▁from ▁Heart ▁Fail ure ▁- ▁a ▁Control led ▁Tri al ▁Investiga ting ▁Out com es ▁in ▁Exerci se ▁Tra i N ing ▁( HF - AC TION ).
▁BA CK GRO UND : ▁The ▁strength ▁of ▁race ▁as ▁an ▁independent ▁predict or ▁of ▁long - term ▁outcome s ▁in ▁a ▁con tempor ary ▁chronic ▁heart ▁failure ▁( HF ) ▁population ▁and ▁its ▁association ▁with ▁exercise ▁training ▁response ▁have ▁not ▁been ▁well ▁established .
▁We ▁ai med ▁to ▁investiga te ▁the ▁association ▁between ▁race ▁and ▁outcome s ▁and ▁to ▁explore ▁interaction s ▁with ▁exercise ▁training ▁in ▁patients ▁with ▁ambula tory ▁ HF .
▁ MET HOD S : ▁We ▁perform ed ▁an ▁analysis ▁of ▁ HF - AC TION , ▁which ▁random ized ▁23 31 ▁patients ▁with ▁ HF ▁having ▁an ▁e je ction ▁ fraction ▁ ≤ 3 5% ▁to ▁usual ▁care ▁with ▁or ▁without ▁exercise ▁training .
▁We ▁examine d ▁character istic s ▁and ▁outcome s ▁( mortal ity / hospital ization , ▁mortal ity , ▁and ▁cardiovascular ▁mortal ity / HF ▁hospital ization ) ▁by ▁race ▁using ▁adjust ed ▁Co x ▁models ▁and ▁explore d ▁an ▁interaction ▁with ▁exercise ▁training .
▁RESULT S : ▁There ▁were ▁ 749 ▁self - identifi ed ▁black ▁patients ▁(3 3% ).
▁Black s ▁were ▁young er ▁with ▁significantly ▁more ▁hyper tension ▁and ▁diabetes , ▁less ▁ ische mic ▁et i ology , ▁and ▁lower ▁socio economic ▁status ▁versus ▁white s .
▁Black s ▁had ▁short er ▁6- minut e ▁walk ▁distance ▁and ▁lower ▁pe ak ▁VO 2 ▁at ▁base line .
▁Over ▁a ▁media n ▁follow - up ▁of ▁2.5 ▁years , ▁black ▁race ▁was ▁associated ▁with ▁increased ▁risk ▁for ▁all ▁outcome s ▁except ▁mortal ity .
▁After ▁multi vari able ▁adjust ment , ▁black ▁race ▁was ▁associated ▁with ▁increased ▁mortal ity / hospital ization ▁( haz ard ▁ratio ▁[ HR ] ▁1. 16 , ▁95% ▁CI ▁1.0 1-1 . 33) ▁and ▁cardiovascular ▁mortal ity / HF ▁hospital ization ▁( HR ▁1. 46 , ▁95% ▁CI ▁1.2 0-1 . 77 ).
▁The ▁hazard ▁associated ▁with ▁black ▁race ▁was ▁large ly ▁caused ▁by ▁increased ▁ HF ▁hospital ization ▁( HR ▁1. 58 , ▁95% ▁CI ▁1.2 7-1 . 96) , ▁given ▁similar ▁cardiovascular ▁mortal ity .
▁There ▁was ▁no ▁interaction ▁between ▁race ▁and ▁exercise ▁training ▁on ▁outcome s ▁( P ▁> ▁ . 5) .
▁CON CL USI ONS : ▁Black ▁race ▁in ▁patients ▁with ▁chronic ▁ HF ▁was ▁associated ▁with ▁increased ▁prevale nce ▁of ▁modifi able ▁risk ▁factors , ▁lower ▁exercise ▁performance , ▁and ▁increased ▁ HF ▁hospital ization , ▁but ▁not ▁increased ▁mortal ity ▁or ▁a ▁differenti al ▁response ▁to ▁exercise ▁training .
▁Im prov ing ▁outcome s ▁in ▁patients ▁with ▁at rial ▁fi bril lation : ▁rational e ▁and ▁design ▁of ▁the ▁E ar ly ▁treatment ▁of ▁At rial ▁fi bril lation ▁for ▁Stro ke ▁pre vention ▁Tri al .
▁BA CK GRO UND : ▁Even ▁on ▁optimal ▁ therapy ▁including ▁antico ag ulation ▁and ▁rate ▁control , ▁major ▁cardiovascular ▁complica tions ▁( stro ke , ▁cardiovascular ▁death , ▁and ▁a cute ▁heart ▁failure ) ▁are ▁common ▁in ▁patients ▁with ▁at rial ▁fi bril lation ▁( AF ).
▁Concept u ally , ▁maintenance ▁of ▁sinus ▁ rhythm ▁could ▁prevent ▁advers e ▁outcome s ▁related ▁to ▁AF .
▁ Rhythm ▁control ▁ therapy ▁has ▁been ▁only ▁moderat ely ▁effective ▁in ▁published ▁trial s , ▁and ▁its ▁potential ▁benefit ▁was ▁off set ▁by ▁side ▁effects ▁of ▁repeat ed ▁intervention s .
▁R ATION ALE : ▁ Rhythm ▁control ▁ therapy ▁applied ▁early ▁after ▁the ▁first ▁ diagnos is ▁of ▁AF ▁could ▁pre serve ▁at rial ▁structure ▁and ▁function ▁and ▁maintain ▁sinus ▁ rhythm ▁more ▁effectively ▁than ▁the ▁current ▁practice ▁of ▁de lay ed ▁ rhythm ▁control ▁( w hen ▁symptoms ▁persist ▁after ▁otherwise ▁effective ▁rate ▁control ).
▁Fur ther more , ▁cat heter ▁ab lation ▁and ▁new ▁anti ar rhythm ic ▁drugs ▁have ▁enhance d ▁the ▁potential ▁effective ness ▁and ▁safety ▁of ▁ rhythm ▁control ▁ therapy .
▁The ▁E AST ▁will ▁test ▁whether ▁an ▁early , ▁modern ▁ rhythm ▁control ▁ therapy ▁can ▁reduce ▁cardiovascular ▁complica tions ▁in ▁AF .
▁DESIGN : ▁The ▁E AST ▁( E ar ly ▁treatment ▁of ▁At rial ▁fi bril lation ▁for ▁Stro ke ▁pre vention ▁Tri al ) ▁will ▁random ize ▁approximately ▁ 3,000 ▁patients ▁with ▁recent ▁ons et ▁AF ▁at ▁risk ▁for ▁stroke ▁( CHA 2 DS 2 VAS c ▁score ▁ ≥ 2) ▁to ▁either ▁guide line - manda ted ▁usual ▁care ▁or ▁to ▁usual ▁care ▁plus ▁early ▁ rhythm ▁control ▁ therapy ▁in ▁a ▁prospect ive , ▁random ized , ▁open , ▁blind ed ▁outcome ▁assessment ▁trial .
▁All ▁patients ▁will ▁be ▁followed ▁up ▁until ▁the ▁end ▁of ▁the ▁trial ▁for ▁the ▁com posit e ▁primary ▁outcome ▁of ▁cardiovascular ▁death , ▁stroke , ▁worse ning ▁of ▁heart ▁failure , ▁and ▁my o card ial ▁in far ction .
▁Night s ▁spent ▁in ▁hospital ▁will ▁be ▁count ed ▁as ▁a ▁co prima ry ▁outcome .
▁Usu al ▁care ▁will ▁consist ▁of ▁antico ag ulation , ▁ therapy ▁of ▁under ly ing ▁heart ▁disease , ▁and ▁rate ▁control ▁as ▁an ▁initial ▁approach .
▁E ar ly ▁ rhythm ▁control ▁ therapy ▁will ▁consist ▁of ▁usual ▁care ▁plus ▁ rhythm ▁control ▁ therapy ▁by ▁anti ar rhythm ic ▁drugs , ▁cat heter ▁ab lation , ▁and ▁a ▁patient - opera ted ▁electro car dio graphic ▁device ▁to ▁monitor ▁the ▁ongoing ▁ rhythm .
▁Key ▁seconda ry ▁outcome s ▁include ▁cognitive ▁function ▁and ▁quality ▁of ▁life .
▁CON C LU SION : ▁E AST ▁will ▁determine ▁whether ▁ rhythm ▁control ▁ therapy , ▁when ▁applied ▁early ▁after ▁the ▁initial ▁ diagnos is ▁of ▁AF , ▁can ▁prevent ▁cardiovascular ▁complica tions ▁associated ▁with ▁AF .
▁Gastro inte stin al ▁ble ed ing ▁in ▁patients ▁with ▁vent ri cular ▁assist ▁devices : ▁what ▁every ▁cardiac ▁nurse ▁should ▁know .
▁Patient s ▁with ▁end - s tage ▁heart ▁failure ▁are ▁increasing ly ▁being ▁treated ▁with ▁implant ation ▁of ▁a ▁long - term ▁vent ri cular ▁assist ▁device .
▁As ▁the ▁use ▁of ▁these ▁devices ▁has ▁grow n , ▁health ▁care ▁provider s ▁have ▁been ▁face d ▁with ▁man aging ▁clinic ally ▁significant ▁gastro inte stin al ▁ble ed ing ▁in ▁this ▁population .
▁Gastro inte stin al ▁ble ed ing ▁is ▁not ▁un com mon ▁and ▁is ▁reported ▁to ▁occur ▁in ▁13% ▁to ▁4 4% ▁of ▁patients ▁treated ▁with ▁vent ri cular ▁assist ▁devices .
▁Interes ting ly , ▁because ▁patients ▁with ▁vent ri cular ▁assist ▁devices ▁are ▁house d ▁on ▁unit s ▁accu sto med ▁to ▁man aging ▁the ▁device , ▁cardiac ▁nurse s ▁are ▁often ▁asked ▁about ▁the ▁management ▁of ▁gastro inte stin al ▁ble ed ing .
▁This ▁article ▁describe s ▁the ▁possible ▁causes ▁of , ▁the ▁arra y ▁of ▁diagnostic ▁procedure s ▁for , ▁and ▁treatment s ▁for ▁this ▁complica tion .
▁It ▁is ▁critical ▁to ▁develop ▁an ▁understanding ▁of ▁this ▁topic ▁so ▁cardiac ▁nurse s ▁can ▁partner ▁with ▁other ▁sub special ty ▁groups ▁to ▁manage ▁this ▁population .
▁Management ▁of ▁end ▁stage ▁heart ▁failure ▁Heart ▁failure ▁is ▁a ▁major ▁public ▁health ▁problem , ▁with ▁a ▁patient ▁population ▁of ▁at ▁least ▁10 ▁million ▁in ▁Europe ▁and ▁approximately ▁5 ▁million ▁in ▁North ▁America .
▁Because ▁of ▁its ▁age - dependent ▁increase ▁in ▁incide nce ▁and ▁prevale nce , ▁heart ▁failure ▁is ▁one ▁of ▁the ▁leading ▁causes ▁of ▁death ▁and ▁hospital isation ▁among ▁the ▁el der ly .
▁As ▁a ▁consequ ence ▁of ▁the ▁worldwide ▁increase ▁in ▁life ▁expect an cy , ▁and ▁due ▁to ▁improvement s ▁in ▁the ▁treatment ▁of ▁heart ▁failure ▁in ▁recent ▁years , ▁the ▁proportion ▁of ▁patients ▁that ▁reach ▁an ▁advanced ▁phase ▁of ▁the ▁disease , ▁so - call ed ▁end ▁stage , ▁re frac tory ▁or ▁terminal ▁heart ▁failure , ▁is ▁ste adi ly ▁growing .
▁Patient s ▁with ▁end ▁stage ▁heart ▁failure ▁fall ▁into ▁stage ▁D ▁of ▁the ▁ABC D ▁classifica tion ▁of ▁the ▁American ▁College ▁of ▁Card i ology ▁( A CC ) / American ▁Heart ▁Association ▁( AHA ), ▁and ▁class ▁III – IV ▁of ▁the ▁New ▁York ▁Heart ▁Association ▁( NY HA ) ▁functional ▁classifica tion ; ▁they ▁are ▁character ised ▁by ▁advanced ▁structura l ▁heart ▁disease ▁and ▁prono un ced ▁symptoms ▁of ▁heart ▁failure ▁at ▁rest ▁or ▁upon ▁minimal ▁physical ▁ex er tion , ▁de spite ▁maximal ▁medical ▁treatment ▁according ▁to ▁current ▁guidelines .
▁This ▁patient ▁population ▁has ▁a ▁1- year ▁mortal ity ▁rate ▁of ▁approximately ▁50% ▁and ▁requires ▁special ▁ therapeut ic ▁intervention s .
▁Every ▁attempt ▁should ▁be ▁made ▁to ▁identify ▁and ▁correct ▁rever sible ▁causes ▁for ▁a ▁worse ning ▁of ▁heart ▁failure , ▁such ▁as ▁poor ▁patient ▁compliance , ▁my o card ial ▁is cha emia , ▁ta chy - ▁or ▁bra dy ar rhythm ias , ▁val vu lar ▁re gur gi tation , ▁pulmonar y ▁e mbol ism , ▁infection , ▁or ▁renal ▁dys function .
▁In ▁this ▁article , ▁we ▁describe ▁current ▁strategie s ▁for ▁the ▁treatment ▁of ▁end ▁stage ▁heart ▁failure .
▁Po tent ▁inhibi tion ▁of ▁L - type ▁Ca 2 + ▁current s ▁by ▁a ▁Rad ▁variant ▁associated ▁with ▁con ges tive ▁heart ▁failure .
▁Ca (2 +) ▁influ x ▁via ▁L - type ▁volta ge - ga ted ▁Ca (2 +) ▁channel s ▁support s ▁the ▁plate au ▁phase ▁of ▁vent ri cular ▁action ▁potential s ▁and ▁is ▁the ▁trigger ▁for ▁excita tion - con traction ▁( EC ) ▁coup ling ▁in ▁the ▁my o car dium .
▁Rad , ▁a ▁member ▁of ▁the ▁R GK ▁( Re m , ▁Rem 2 , ▁Rad , ▁Gem / Kir ) ▁family ▁of ▁mono me ric ▁G ▁protein s , ▁regula tes ▁vent ri cular ▁action ▁potential ▁du ration ▁and ▁EC ▁coup ling ▁gain ▁through ▁its ▁ability ▁to ▁inhibi t ▁cardiac ▁L - type ▁channel ▁activity .
▁In ▁this ▁study , ▁we ▁have ▁investiga ted ▁the ▁potential ▁dys function ▁of ▁a ▁natural ly ▁occur ring ▁Rad ▁variant ▁( Q 66 P ) ▁that ▁has ▁been ▁associated ▁with ▁con ges tive ▁heart ▁failure ▁in ▁humans .
▁Specific ally , ▁we ▁have ▁test ed ▁whether ▁Rad ▁Q 66 P ▁limit s , ▁or ▁even ▁elimina tes , ▁the ▁inhibi tory ▁actions ▁of ▁Rad ▁on ▁Ca V 1.2 ▁and ▁Ca V 1.3 , ▁the ▁two ▁L - type ▁channel ▁iso form s ▁known ▁to ▁be ▁express ed ▁in ▁the ▁heart .
▁We ▁have ▁found ▁that ▁mouse ▁Rad ▁Q 65 P ▁( the ▁mur ine ▁equivalent ▁of ▁human ▁Rad ▁Q 66 P ) ▁inhibi ts ▁L - type ▁current s ▁conduct ed ▁by ▁Ca V 1.2 ▁or ▁Ca V 1.3 ▁channel s ▁as ▁ potent ly ▁as ▁wild - type ▁Rad ▁( > 95% ▁inhibi tion ▁of ▁both ▁channel s ).
▁In ▁addition , ▁Rad ▁Q 65 P ▁att en u ates ▁the ▁ga ting ▁movement ▁of ▁both ▁channel s ▁as ▁effectively ▁as ▁wild - type ▁Rad , ▁indicat ing ▁that ▁the ▁Q 65 P ▁substitut ion ▁does ▁not ▁differenti ally ▁im pair ▁any ▁of ▁the ▁three ▁described ▁mode s ▁of ▁L - type ▁channel ▁inhibi tion ▁by ▁R GK ▁protein s .
▁Thu s , ▁we ▁conclude ▁that ▁if ▁Rad ▁Q 66 P ▁contribute s ▁to ▁cardio my o pathy , ▁it ▁does ▁so ▁via ▁a ▁mechanism ▁that ▁is ▁not ▁related ▁to ▁its ▁ability ▁to ▁inhibi t ▁L - type ▁channel - dependent ▁process es ▁per ▁se .
▁However , ▁our ▁results ▁do ▁not ▁rule ▁out ▁the ▁possibility ▁that ▁decrease d ▁expression , ▁mis tar ge ting ▁or ▁alter ed ▁regula tion ▁of ▁Rad ▁Q 66 P ▁may ▁reduce ▁the ▁R GK ▁protein ' s ▁ef fica cy ▁in ▁vivo .
▁A ▁young ▁adult ▁Jehovah ' s ▁Wit ness ▁with ▁severe ▁an emia .
▁Two ▁of ▁the ▁most ▁et h ically ▁complex ▁situations ▁in ▁pediatr ics ▁are ▁those ▁in vol ving ▁families ▁whose ▁religious ▁belief s ▁pre clu de ▁the ▁provision ▁of ▁life - s usta ining ▁treatment ▁and ▁those ▁in vol ving ▁young ▁adults ▁who ▁have ▁reached ▁the ▁age ▁of ▁legal ▁majority ▁and ▁who ▁face ▁decisions ▁about ▁life - s usta ining ▁treatment .
▁This ▁month ' s ▁" E thi cs ▁Round s " ▁present s ▁a ▁case ▁in ▁which ▁these ▁2 ▁complex ities ▁over la pped .
▁An ▁18- year - old ▁Jehovah ' s ▁Wit ness ▁with ▁sick le ▁cell ▁disease ▁has ▁life - th rea te ning ▁an emia .
▁She ▁is ▁going ▁into ▁heart ▁failure .
▁Her ▁doctor s ▁urgent ly ▁recommend ▁blood ▁trans fusion s .
▁The ▁young ▁woman ▁and ▁her ▁family ▁adam ant ly ▁refuse .
▁Should ▁the ▁doctor s ▁let ▁her ▁die ?
▁Is ▁there ▁any ▁alternative ?
▁Com posit e ▁quality ▁measure s ▁for ▁common ▁in patient ▁medical ▁conditions .
▁BA CK GRO UND : ▁Public ▁report ing ▁on ▁quality ▁aims ▁to ▁help ▁patients ▁select ▁better ▁hospital s .
▁However , ▁individual ▁quality ▁measure s ▁are ▁sub optimal ▁in ▁identify ing ▁superior ▁and ▁inferior ▁hospital s ▁based ▁on ▁outcome ▁performance .
▁OB JE C TIVE : ▁To ▁combine ▁structure , ▁process , ▁and ▁outcome ▁measure s ▁into ▁an ▁em pir ically ▁deri ved ▁com posit e ▁quality ▁measure ▁for ▁heart ▁failure ▁( HF ), ▁a cute ▁my o card ial ▁in far ction ▁( AMI ), ▁and ▁pneu monia ▁( P NA ).
▁To ▁assess ▁how ▁well ▁the ▁com posit e ▁measure ▁predict s ▁future ▁high ▁and ▁low ▁perform ers , ▁and ▁explain s ▁varia nce ▁in ▁future ▁hospital ▁mortal ity .
▁RES E ARCH ▁DESIGN : ▁U sing ▁national ▁Medica re ▁data , ▁we ▁created ▁a ▁co hor t ▁of ▁older ▁patients ▁treated ▁at ▁an ▁a cute ▁care ▁hospital ▁for ▁ HF ▁( n =1 , 20 3,5 95) , ▁ AMI ▁( n = 62 5,5 95) , ▁or ▁P NA ▁( n = 1,2 34 , 2 99) .
▁We ▁rank ed ▁hospital s ▁on ▁the ▁basis ▁of ▁their ▁July ▁2005 ▁to ▁June ▁2008 ▁performance ▁on ▁the ▁com posit e .
▁We ▁then ▁estima ted ▁the ▁odds ▁of ▁future ▁( Jul y ▁to ▁December ▁2009) ▁30- day , ▁risk - ad just ed ▁mortal ity ▁at ▁the ▁worst ▁versus ▁best ▁quin tile ▁of ▁hospital s .
▁We ▁repeat ed ▁this ▁analysis ▁using ▁2005 -2008 ▁performance ▁on ▁existing ▁quality ▁indicator s , ▁including ▁mortal ity .
▁RESULT S : ▁The ▁com posit e ▁( vs . ▁Hospital ▁Compar e ) ▁explained ▁6 8% ▁( vs . ▁39 %) ▁of ▁variation ▁in ▁future ▁ AMI ▁mortal ity ▁rates .
▁In ▁2009, ▁if ▁an ▁ AMI ▁patient ▁had ▁chose n ▁a ▁hospital ▁in ▁the ▁worst ▁versus ▁best ▁quin tile ▁of ▁performance ▁using ▁2005 -2008 ▁com posit e ▁( vs . ▁Hospital ▁Compar e ) ▁ranking s , ▁he ▁or ▁she ▁would ▁have ▁had ▁1. 61 ▁( vs . ▁1. 39) ▁times ▁the ▁odds ▁of ▁dy ing ▁in ▁30 ▁days ▁( P - valu e ▁for ▁difference ▁< 0.00 1) .
▁Results ▁were ▁similar ▁for ▁ HF ▁and ▁P NA .
▁CON CL USI ONS : ▁Com posit e ▁measure s ▁of ▁quality ▁for ▁ HF , ▁ AMI , ▁and ▁P NA ▁perform ed ▁better ▁than ▁existing ▁measure s ▁at ▁explain ing ▁variation ▁in ▁future ▁mortal ity ▁and ▁predict ing ▁future ▁high ▁and ▁low ▁perform ers .
▁Race ▁influence s ▁the ▁safety ▁and ▁ef fica cy ▁of ▁spi rono lac tone ▁in ▁severe ▁heart ▁failure .
▁BA CK GRO UND : ▁The ▁incide nce ▁of ▁hyper kal emia ▁caused ▁by ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁may ▁var y ▁by ▁race , ▁but ▁whether ▁race ▁influence s ▁ef fica cy ▁of ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁in ▁heart ▁failure ▁( HF ) ▁is ▁un know n .
▁ MET HOD S ▁AND ▁RESULT S : ▁We ▁assess ed ▁hyper kal emia ▁and ▁outcome s ▁in ▁African ▁American s ▁( AA s ; ▁n =1 20) ▁and ▁non - AA s ▁( n =1 543 ; ▁white ▁93 %) ▁with ▁New ▁York ▁Heart ▁Association ▁( NY HA ) ▁class ▁III ▁or ▁IV ▁ HF ▁and ▁left ▁vent ri cular ▁dys function ▁who ▁were ▁random ized ▁to ▁spi rono lac tone , ▁ti tra ted ▁to ▁25 ▁or ▁50 ▁mg ▁daily ▁or ▁place bo , ▁in ▁the ▁Rand om ized ▁Al da cto ne ▁Evalua tion ▁Study ▁( RAL ES ).
▁AA ▁participants ▁were ▁significantly ▁young er , ▁less ▁likely ▁to ▁have ▁an ▁ ische mic ▁ HF ▁path ogen es is , ▁more ▁likely ▁to ▁be ▁NY HA ▁functional ▁class ▁IV , ▁and ▁more ▁likely ▁to ▁have ▁a ▁higher ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁and ▁heart ▁rate , ▁less ▁hyper tension , ▁diabetes ▁mell itus , ▁or ▁history ▁of ▁my o card ial ▁in far ction ▁compared ▁with ▁non - AA ▁participants .
▁Po tas s ium ▁increased ▁with ▁spi rono lac tone ▁in ▁non - AA s ▁(4 . 29 ± 0.5 -4 . 55 ± 0.4 9 ▁mm ol / L ) ▁but ▁not ▁in ▁AA s ▁(4 . 32 ± 0.5 4- 4.3 1 ± 0.4 9 ▁mm ol / L ; ▁race ▁by ▁treatment ▁interaction , ▁P =0 . 03) ▁during ▁the ▁first ▁month ▁and ▁remain ed ▁higher ▁throughout ▁the ▁trial .
▁Compar ed ▁with ▁AA s , ▁non - AA s ▁were ▁more ▁likely ▁to ▁at tain ▁maximal ▁spi rono lac tone ▁dose ▁(13 . 9% ▁versus ▁5. 8% ; ▁P =0 . 04) ▁and ▁had ▁higher ▁rates ▁of ▁hyper kal emia ▁( po tas s ium > 5.5 ▁mm ol / L ; ▁9. 7% ▁versus ▁4. 2% ; ▁P < 0.0 46) , ▁as ▁well ▁as ▁lower ▁rates ▁of ▁hypo kal emia ▁( po tas s ium < 3.5 ▁mm ol / L ; ▁5. 6% ▁versus ▁17. 9% ; ▁P < 0.00 1) .
▁After ▁adjust ment ▁for ▁difference s ▁in ▁base line ▁character istic s ▁and ▁achieve d ▁study ▁drug ▁dose , ▁spi rono lac tone ▁reduce d ▁the ▁combine d ▁end ▁point ▁of ▁death ▁or ▁hospital ization ▁for ▁ HF ▁in ▁non - AA s ▁( haz ard ▁ratio , ▁0 . 63 ; ▁95% ▁confidence ▁interval , ▁0.5 5- 0.7 3) ▁but ▁not ▁in ▁AA s ▁( haz ard ▁ratio , ▁1. 07 ; ▁95% ▁confidence ▁interval , ▁ 0.6 7-1 . 71 ; ▁P ▁value ▁for ▁interaction = 0.0 32) .
▁CON CL USI ONS : ▁AA s ▁with ▁ HF ▁exhibi ted ▁less ▁hyper kal emia ▁and ▁more ▁hypo kal emia ▁with ▁spi rono lac tone ▁compared ▁with ▁non - AA s ▁and ▁seemed ▁to ▁der ive ▁less ▁clinic al ▁benefit .
▁These ▁hypothe sis - genera ting ▁finding s ▁suggest ▁that ▁safety ▁and ▁ef fica cy ▁of ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁may ▁differ ▁by ▁race .
▁Does ▁ reducing ▁length ▁of ▁stay ▁increase ▁re hospital ization ▁of ▁medica re ▁fee - for - service ▁beneficiar ies ▁dis charge d ▁to ▁skille d ▁nur sing ▁facilities ?
▁OB JE C TIVE S : ▁To ▁anal y ze ▁the ▁relationship ▁between ▁length ▁of ▁stay ▁and ▁re hospital ization .
▁DESIGN : ▁Retro spec tive ▁co hor t ▁study .
▁SET TING : ▁Six ▁thousand ▁five ▁hundred ▁ thir ty - s even ▁hospital s ▁nation wide ▁from ▁January ▁1999 ▁through ▁September ▁2005.
▁PARTI CI PAN TS : ▁Medica re ▁fee - for - service ▁beneficiar ies ▁associated ▁with ▁2 , 101 , 481 ▁hospital ization s .
▁ME AS UR EMENT S : ▁Thi r ty - day ▁re hospital ization ▁deri ved ▁from ▁Medica re ▁hospital ▁claims ▁using ▁the ▁implementation ▁of ▁Medica re ' s ▁post - a cute ▁care ▁transfer ▁policy ▁as ▁a ▁quasi - experiment .
▁RESULT S : ▁Medica re ' s ▁post - a cute ▁care ▁transfer ▁policy ▁led ▁to ▁immediate ▁decline s ▁in ▁length ▁of ▁stay .
▁A ▁1- day ▁decrease ▁in ▁length ▁of ▁stay ▁was ▁associated ▁with ▁an ▁absolute ▁increase ▁in ▁30- day ▁re hospital ization ▁of ▁1. 56 ▁percentage ▁points ▁( 95% ▁confidence ▁interval ▁( CI ) ▁= ▁0 . 30 -2 . 82) ▁for ▁a cute ▁my o card ial ▁in far ction ▁( AMI ) ▁with ▁major ▁complica tions ▁and ▁0 . 81 ▁percentage ▁points ▁( 95% ▁CI ▁= ▁0.0 3-1 . 60) ▁for ▁ki dne y ▁infection ▁or ▁urin ary ▁tract ▁infection ▁( UTI ) ▁without ▁major ▁complica tions .
▁Individual s ▁hospital ized ▁for ▁ AMI ▁without ▁major ▁complica tions , ▁heart ▁failure , ▁or ▁ki dne y ▁infection ▁or ▁ UTI ▁with ▁major ▁complica tions ▁had ▁no ▁increase ▁in ▁30- day ▁re hospital ization .
▁CON C LU SION : ▁A ▁1- day ▁re duction ▁in ▁hospital ▁length ▁of ▁stay ▁was ▁not ▁consistent ly ▁associated ▁with ▁a ▁higher ▁rate ▁of ▁re hospital ization .
▁Physic ian ▁volume , ▁special ty , ▁and ▁outcome s ▁of ▁care ▁for ▁patients ▁with ▁heart ▁failure .
▁BA CK GRO UND : ▁There ▁is ▁an ▁urgent ▁need ▁to ▁improve ▁outcome s ▁and ▁reduce ▁costs ▁for ▁patients ▁with ▁heart ▁failure ▁( HF ).
▁Physic ian ▁volume ▁is ▁associated ▁with ▁better ▁outcome s ▁for ▁patients ▁under go ing ▁procedure s , ▁but ▁its ▁association ▁with ▁outcome s ▁for ▁med ically ▁managed ▁disease s , ▁such ▁as ▁ HF , ▁is ▁not ▁well ▁understood .
▁ MET HOD S ▁AND ▁RESULT S : ▁We ▁used ▁Medica re ▁in patient ▁data ▁in ▁2009 ▁to ▁examine ▁all ▁ HF ▁ad missions ▁to ▁a cute ▁care ▁hospital s ▁in ▁the ▁United ▁States .
▁We ▁divide d ▁physician s ▁into ▁qui nti les ▁according ▁to ▁their ▁volume ▁of ▁patients ▁with ▁ HF .
▁We ▁used ▁patient - level ▁re gression ▁to ▁compare ▁30- day ▁risk - ad just ed ▁mortal ity , ▁read missions , ▁and ▁costs ▁across ▁volume ▁groups , ▁control ling ▁for ▁patient , ▁physician , ▁and ▁hospital ▁character istic s .
▁We ▁examine d ▁physician ▁volume ▁within ▁strat a ▁of ▁hospital ▁volume ▁and ▁physician ▁special ty .
▁Patient s ▁care d ▁for ▁by ▁the ▁high - volu me ▁physician s ▁had ▁lower ▁mortal ity ▁than ▁those ▁by ▁the ▁low - volu me ▁physician s ▁(8 . 9% ▁versus ▁9. 7% ; ▁P < 0.00 1 ); ▁this ▁relationship ▁was ▁strong est ▁in ▁low - volu me ▁hospital s .
▁In ▁contrast , ▁patients ▁care d ▁for ▁by ▁high - volu me ▁physician s ▁had ▁higher ▁read mission ▁rates ▁(25 . 8% ▁versus ▁21. 5% ; ▁P < 0001 ); ▁this ▁relationship ▁was ▁similar ▁across ▁hospital ▁volume ▁groups .
▁Finally , ▁costs ▁were ▁higher ▁for ▁the ▁high - volu me ▁physician s ▁( $ 898 2 ▁versus ▁$ 87 31 ; ▁P = 0.00 2 , ▁a ▁difference ▁that ▁was ▁consistent ▁across ▁hospital ▁volume ▁groups ).
▁The ▁relationship ▁between ▁physician ▁volume ▁and ▁mortal ity ▁was ▁strong est ▁for ▁intern ists ▁(9 . 2% ▁versus ▁10. 6% ; ▁P < 0.00 1) ▁and ▁we ak est ▁for ▁cardio logist s ▁(6 . 4% ▁versus ▁6. 7% ; ▁P =0 . 485 ).
▁CON CL USI ONS : ▁Physic ian ▁volume ▁is ▁associated ▁with ▁lower ▁mortal ity ▁for ▁ HF , ▁particularly ▁in ▁low - volu me ▁institution s ▁and ▁among ▁non car dio logist ▁physician s .
▁Our ▁finding s ▁suggest ▁that ▁clinic ian ▁expertise ▁may ▁play ▁an ▁important ▁role ▁in ▁ HF ▁care .
▁Al do ster one ▁anta gon ism ▁in ▁heart ▁failure ▁Al do ster one , ▁a ▁neuro hormon e ▁known ▁to ▁affect ▁electro ly tes , ▁has ▁recently ▁been ▁implica ted ▁as ▁playing ▁a ▁major ▁role ▁in ▁the ▁progression ▁of ▁heart ▁failure , ▁particularly ▁in ▁patients ▁with ▁sy sto lic ▁dys function .
▁Major ▁clinic al ▁trial s ▁designed ▁to ▁anal y ze ▁clinic al ▁outcome s ▁using ▁an ▁al do ster one ▁anta gon ist ▁have ▁been ▁done ▁in ▁two ▁groups ▁with ▁heart ▁failure .
▁The ▁first ▁was ▁the ▁Rand om ized ▁Al da cto ne ▁Evalua tion ▁Study , ▁which ▁was ▁done ▁in ▁symptom a tic ▁chronic ▁advanced ▁heart ▁failure ▁patients ▁and ▁showed ▁that ▁an ▁al do ster one ▁anta gon ist , ▁spi rono lac tone , ▁reduce d ▁mortal ity ▁significantly ▁compared ▁with ▁place bo .
▁Very ▁few ▁of ▁these ▁patients ▁were ▁on ▁standard ▁ therapy ▁with ▁beta ▁block ade .
▁Another ▁study , ▁the ▁E pler en one ▁Post ▁my o card ial ▁in far ction ▁Heart ▁failure ▁Ef fica cy ▁and ▁SU rvi val ▁Study ▁( EP HE SUS ), ▁done ▁in ▁post - my o card ial ▁in far ction ▁patients ▁with ▁heart ▁failure , ▁demonstrat ed ▁a ▁significant ▁re duction ▁in ▁mortal ity ▁and ▁hospital ization s ▁for ▁patients ▁random ized ▁to ▁the ▁al do ster one ▁anta gon ist ▁e pler en one .
▁These ▁trial ▁results ▁provide ▁the ▁background ▁for ▁al do ster one ▁anta gon ist ▁ therapy ▁in ▁chronic ▁advanced ▁heart ▁failure ▁patients ▁as ▁well ▁as ▁post - my o card ial ▁in far ction ▁heart ▁failure ▁patients ▁with ▁reduce d ▁e je ction .
▁Im prov ing ▁survival ▁rates ▁of ▁patients ▁with ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁in ▁Tu sca ny ▁over ▁3 ▁de cade s : ▁impact ▁of ▁evidence - based ▁management .
▁BA CK GRO UND : ▁Con tempor ary ▁ therapeut ic ▁options ▁have ▁led ▁to ▁substantial ▁improvement ▁in ▁survival ▁of ▁patients ▁with ▁heart ▁failure .
▁However , ▁limited ▁evidence ▁is ▁available ▁specifically ▁on ▁ idio pathi c ▁dil ated ▁cardio my o pathy .
▁We ▁thu s ▁examine d ▁changes ▁in ▁prognos is ▁of ▁a ▁large ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁co hor t ▁systematic ally ▁followed ▁during ▁the ▁past ▁30 ▁years .
▁ MET HOD S ▁AND ▁RESULT S : ▁From ▁1977 ▁to ▁2011, ▁60 3 ▁consecutiv e ▁patients ▁( age , ▁53 ± 12 ▁years ; ▁7 3% ▁men ; ▁left ▁vent ri cular ▁e je ction ▁ fraction , ▁32 ± 10% ) ▁fulfill ing ▁World ▁Health ▁Organization ▁criteri a ▁for ▁ idio pathi c ▁dil ated ▁cardio my o pathy , ▁including ▁negative ▁corona ry ▁ang i ography , ▁were ▁followed ▁up ▁for ▁ 8.8 ± 6.3 ▁years .
▁Patient s ▁were ▁sub divi ded ▁in ▁4 ▁en roll ment ▁period s ▁on ▁the ▁basis ▁of ▁heart ▁failure ▁treatment ▁era s : ▁(1) ▁1977 - 1984 ▁( n = 66) ; ▁(2) ▁1985 - 1990 ▁( n = 102 ); ▁(3) ▁1991 -2000 ▁( n =1 97) ; ▁(4) ▁2001 -2011 ▁( n =2 38) .
▁Rate s ▁of ▁patients ▁receiving ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors / angi oten sin ▁receptor s ▁block ers , ▁β - block ers , ▁and ▁devices ▁at ▁final ▁evaluation ▁increased ▁from ▁ 56% , ▁12% , ▁8% ▁( period ▁1) ▁to ▁9 7% , ▁8 6% , ▁17% ▁( period ▁4) , ▁respective ly ▁( P < 0.0 5) .
▁There ▁was ▁a ▁trend ▁toward ▁en roll ment ▁of ▁older ▁patients ▁with ▁less ▁severe ▁left ▁vent ri cular ▁di la tation ▁and ▁dys function ▁during ▁the ▁years .
▁During ▁follow - up , ▁271 ▁patients ▁( 45 %) ▁reached ▁a ▁combine d ▁end ▁point ▁including ▁death ▁( heart ▁failure ▁related , ▁n = 142 ; ▁sud den ▁death , ▁n = 71 ; ▁and ▁non card iac , ▁n =22 ) ▁or ▁cardiac ▁transplant ▁( n = 36) .
▁A ▁more ▁recent ▁en roll ment ▁period ▁represent ed ▁the ▁most ▁powerful ▁independent ▁predict or ▁of ▁favorable ▁outcome ▁{ period ▁2 ▁versus ▁1 ▁( haz ard ▁ratio ▁[ HR ] , ▁0 . 64 ; ▁P =0 . 04) , ▁period ▁3 ▁versus ▁1 ▁( HR , ▁0.3 5 ; ▁P < 0.00 1) , ▁period ▁4 ▁versus ▁1 ▁( HR , ▁0.1 4 ; ▁P < 001 ) } .
▁Each ▁period ▁was ▁associated ▁with ▁a ▁4 2% ▁risk ▁re duction ▁versus ▁the ▁previous ▁one ▁( HR , ▁0.5 8 ; ▁95% ▁confidence ▁interval , ▁0 . 50 -0 . 67 ; ▁P < 0.00 1) , ▁reflect ing ▁marked ▁decrease s ▁in ▁heart ▁failure - related ▁mortal ity ▁and ▁sud den ▁death ▁( period ▁4 ▁versus ▁1: ▁HR , ▁0 . 10 ; ▁P < 001 ▁and ▁HR , ▁0.1 3 ; ▁P < 0.00 01 , ▁respective ly ).
▁CON CL USI ONS : ▁E viden ce - based ▁treatment ▁has ▁led ▁to ▁dramatic ▁improvement ▁in ▁the ▁prognos is ▁of ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁during ▁the ▁past ▁3 ▁de cade s .
▁The ▁benefits ▁of ▁control led ▁random ized ▁trial s ▁can ▁be ▁replica ted ▁in ▁the ▁real ▁world , ▁emp has izing ▁the ▁importance ▁of ▁ta ilor ed ▁follow - up ▁and ▁long - term ▁continu ity ▁of ▁care .
▁Pro gno stic ▁value ▁of ▁in determina ble ▁ana ero bic ▁thre s hold ▁in ▁heart ▁failure .
▁BA CK GRO UND : ▁In ▁patients ▁with ▁heart ▁failure ▁( HF ), ▁during ▁maximal ▁cardio pul mon ary ▁exercise ▁test , ▁ana ero bic ▁thre s hold ▁( AT ) ▁is ▁not ▁always ▁identified .
▁We ▁evaluat ed ▁whether ▁this ▁finding ▁has ▁a ▁prognos tic ▁meaning .
▁ MET HOD S ▁AND ▁RESULT S : ▁We ▁recruit ed ▁and ▁prospect ive ly ▁followed ▁up , ▁in ▁14 ▁dedicated ▁ HF ▁unit s , ▁30 58 ▁patients ▁with ▁sy sto lic ▁( le ft ▁vent ri cular ▁e je ction ▁ fraction ▁< 40% ) ▁ HF ▁in ▁stable ▁clinic al ▁conditions , ▁New ▁York ▁Heart ▁Association ▁class ▁I ▁to ▁III , ▁who ▁under went ▁clinic al , ▁laborator y , ▁e cho car dio graphic , ▁and ▁cardio pul mon ary ▁exercise ▁test ▁investigation s ▁at ▁study ▁en roll ment .
▁We ▁exclu ded ▁9 21 ▁patients ▁who ▁did ▁not ▁perform ▁a ▁maximal ▁exercise , ▁based ▁on ▁lack ▁of ▁achieve ment ▁of ▁ana ero bic ▁metabolism ▁( pe ak ▁respirator y ▁ quot ient ▁ ≤ 1 . 05) .
▁Prima ry ▁study ▁end ▁point ▁was ▁a ▁com posit e ▁of ▁cardiovascular ▁death ▁and ▁urgent ▁cardiac ▁transplant , ▁and ▁seconda ry ▁end ▁point ▁was ▁all - ca use ▁death .
▁Media n ▁follow - up ▁was ▁3.0 1 ▁(1 . 39 -4 . 98) ▁years .
▁AT ▁was ▁identified ▁in ▁1935 ▁out ▁of ▁21 37 ▁patients ▁(9 0.5 4% ).
▁At ▁multi vari able ▁logistic ▁analysis , ▁failure ▁in ▁detect ing ▁AT ▁result ed ▁significantly ▁in ▁reduce d ▁pe ak ▁oxygen ▁up take ▁and ▁higher ▁metabol ic ▁exercise ▁and ▁cardiac ▁and ▁ki dne y ▁index ▁score ▁value , ▁a ▁powerful ▁prognos tic ▁com posit e ▁ HF ▁index ▁( P < 0.00 1) .
▁At ▁multi vari able ▁analysis , ▁the ▁following ▁variable s ▁were ▁significantly ▁associated ▁with ▁primary ▁study ▁end ▁point : ▁pe ak ▁oxygen ▁up take ▁( % ▁pred ; ▁P < 0.00 1 ; ▁hazard ▁ratio ▁[ HR ] =0 . 977 ; ▁confidence ▁interval ▁[ CI ] =0 . 97 -0 . 98) , ▁ventilator y ▁efficiency ▁s lope ▁( P = 0.01 ; ▁HR =1 . 02 ; ▁CI = 1.0 1-1 . 03) , ▁hem o glob in ▁( P < 0.0 5 ; ▁HR = 0.9 31 ; ▁CI =0 . 87 - 1.00 ), ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁( P < 0.00 1 ; ▁HR = 0.9 48 ; ▁CI =0 . 94 -0 . 96) , ▁renal ▁function ▁( mod ification ▁of ▁die t ▁in ▁renal ▁disease ; ▁P < 0.00 1 ; ▁HR =0 . 990 ; ▁CI =0 . 98 -0 . 99) , ▁so dium ▁( P < 0.0 5 ; ▁HR =0 . 967 ; ▁CI =0 . 94 -0 . 99) , ▁and ▁AT ▁non identification ▁( P < 0.0 5 ; ▁HR =1 . 41 ; ▁CI = 1.0 6-1 . 89) .
▁Non identification ▁of ▁AT ▁remain ed ▁associated ▁to ▁prognos is ▁also ▁when ▁compared ▁with ▁metabol ic ▁exercise ▁and ▁cardiac ▁and ▁ki dne y ▁index ▁score ▁( P < 0.01 ; ▁HR =1 . 459 ; ▁CI = 1.0 9-1 . 10) .
▁Similar ▁results ▁were ▁obtain ed ▁for ▁the ▁seconda ry ▁study ▁end ▁point .
▁CON CL USI ONS : ▁The ▁in ability ▁to ▁identify ▁AT ▁most ▁often ▁occur s ▁in ▁patients ▁with ▁severe ▁ HF , ▁and ▁it ▁has ▁an ▁independent ▁prognos tic ▁role ▁in ▁ HF .
▁Card i ore spira tory ▁fitness , ▁body ▁mass ▁index , ▁and ▁heart ▁failure ▁mortal ity ▁in ▁men : ▁Cooper ▁Center ▁Long itud in al ▁Study .
▁BA CK GRO UND : ▁We ▁evaluat ed ▁the ▁individual ▁and ▁joint ▁associations ▁among ▁cardio re spira tory ▁fitness ▁( CR F ), ▁body ▁mass ▁index , ▁and ▁heart ▁failure ▁( HF ) ▁mortal ity , ▁as ▁well ▁as ▁the ▁addit ive ▁effect ▁of ▁an ▁increasing ▁number ▁of ▁cardiovascular ▁risk ▁factors ▁on ▁ HF ▁mortal ity ▁in ▁fit ▁versus ▁un fit ▁men .
▁ MET HOD S ▁AND ▁RESULT S : ▁A ▁total ▁of ▁44 ▁6 74 ▁men ▁without ▁a ▁history ▁of ▁cardiovascular ▁disease ▁under went ▁a ▁base line ▁examina tion ▁between ▁1971 ▁and ▁2010.
▁Me as ures ▁included ▁body ▁mass ▁index ▁and ▁C RF ▁quant ified ▁as ▁du ration ▁of ▁maximal ▁tre ad m ill ▁exercise ▁testing .
▁Participa nts ▁were ▁divide d ▁into ▁age - specific ▁low , ▁moderat e , ▁and ▁high ▁C RF ▁categorie s .
▁Hazard ▁ratio s ▁were ▁com put ed ▁with ▁Co x ▁re gression ▁analysis .
▁During ▁a ▁mean ▁follow - up ▁of ▁19. 8 ± 10 . 4 ▁years , ▁153 ▁ HF ▁death s ▁occur red .
▁Ad just ed ▁hazard ▁ratio s ▁across ▁high , ▁moderat e , ▁and ▁low ▁C RF ▁categorie s ▁were ▁1.0 , ▁1. 63 , ▁and ▁3. 97 , ▁respective ly , ▁where as ▁those ▁of ▁normal , ▁over weight , ▁and ▁obes e ▁body ▁mass ▁index ▁categorie s ▁were ▁1.0 , ▁1. 56 , ▁and ▁3. 71 , ▁respective ly ▁( P ▁for ▁trend ▁< 0.00 01 ▁for ▁each ).
▁When ▁groupe d ▁into ▁categorie s ▁of ▁fit ▁and ▁un fit ▁( u pper ▁80% ▁and ▁lower ▁20% ▁of ▁C RF ▁distribution , ▁respective ly ), ▁hazard ▁ratio s ▁were ▁significantly ▁lower ▁in ▁fit ▁compared ▁with ▁un fit ▁men ▁in ▁normal ▁and ▁over weight ▁body ▁mass ▁index ▁strat a ▁( P < 0.00 2) ▁but ▁not ▁in ▁obes e ▁men .
▁With in ▁men ▁match ed ▁for ▁the ▁same ▁number ▁of ▁ HF ▁risk ▁factors , ▁fit ▁men ▁had ▁significantly ▁lower ▁ HF ▁mortal ity ▁than ▁un fit ▁men ▁( P ≤ 0.0 2) .
▁CON CL USI ONS : ▁High er ▁base line ▁C RF ▁is ▁associated ▁with ▁lower ▁ HF ▁mortal ity ▁risk ▁in ▁men , ▁regardless ▁of ▁the ▁number ▁of ▁ HF ▁risk ▁factors ▁present .
▁Men ▁should ▁be ▁counsel ed ▁on ▁physical ▁activity ▁with ▁the ▁goal ▁of ▁a chie ving ▁at ▁least ▁a ▁moderat e ▁level ▁of ▁C RF , ▁there by ▁presu m ably ▁de cre as ing ▁their ▁risk ▁of ▁ HF ▁mortal ity .
▁Card iac ▁insulin - re si stance ▁and ▁decrease d ▁mito cho ndri al ▁energy ▁production ▁preced e ▁the ▁development ▁of ▁sy sto lic ▁heart ▁failure ▁after ▁pressure - over load ▁hyper trop hy .
▁BA CK GRO UND : ▁Card iac ▁hyper trop hy ▁is ▁ac com pani ed ▁by ▁significant ▁altera tions ▁in ▁energy ▁metabolism .
▁Whether ▁these ▁changes ▁in ▁energy ▁metabolism ▁preced e ▁and ▁contribute ▁to ▁the ▁development ▁of ▁heart ▁failure ▁in ▁the ▁hyper trop hi ed ▁heart ▁is ▁not ▁clear .
▁ MET HOD S ▁AND ▁RESULT S : ▁Mi ce ▁were ▁subject ed ▁to ▁cardiac ▁hyper trop hy ▁seconda ry ▁to ▁pressure - over load ▁as ▁a ▁result ▁of ▁an ▁abdominal ▁a or tic ▁con stri ction ▁( A AC ).
▁The ▁rates ▁of ▁energy ▁substrat e ▁metabolism ▁were ▁assess ed ▁in ▁isola ted ▁working ▁heart s ▁obtain ed ▁1 , ▁2 , ▁and ▁3 ▁weeks ▁after ▁A AC .
▁Mi ce ▁subject ed ▁to ▁A AC ▁demonstrat ed ▁a ▁progressive ▁development ▁of ▁cardiac ▁hyper trop hy .
▁In ▁vivo ▁assessment ▁of ▁cardiac ▁function ▁( via ▁e cho card i ography ) ▁demonstrat ed ▁dia sto lic ▁dys function ▁by ▁2 ▁weeks ▁( 20% ▁increase ▁in ▁E / E ' ), ▁and ▁sy sto lic ▁dys function ▁by ▁3 ▁weeks ▁(1 6% ▁decrease ▁in ▁% ▁e je ction ▁ fraction ).
▁Mark ed ▁cardiac ▁insulin - re si stance ▁by ▁2 ▁weeks ▁post - A AC ▁was ▁evidence d ▁by ▁a ▁significant ▁decrease ▁in ▁insulin - stimul ated ▁rates ▁of ▁gly col ysis ▁and ▁gluco se ▁oxid ation , ▁and ▁plasma ▁membran e ▁trans location ▁of ▁gluco se ▁transporter ▁4.
▁Over all ▁ATP ▁production ▁rates ▁were ▁decrease d ▁at ▁2 ▁and ▁3 ▁weeks ▁post - A AC ▁( by ▁3 7% ▁and ▁4 7% , ▁respective ly ) ▁because ▁of ▁a ▁re duction ▁in ▁mito cho ndri al ▁oxid ation ▁of ▁gluco se , ▁lac tate , ▁and ▁fa tty ▁acid s ▁that ▁was ▁not ▁ac com pani ed ▁by ▁an ▁increase ▁in ▁my o card ial ▁gly col ysis ▁rates .
▁Red u ced ▁mito cho ndri al ▁complex ▁V ▁activity ▁was ▁evident ▁at ▁3 ▁weeks ▁post - A AC , ▁con com i tant ▁with ▁a ▁re duction ▁in ▁the ▁ratio ▁of ▁ phos pho creati ne ▁to ▁ATP .
▁CON CL USI ONS : ▁The ▁development ▁of ▁cardiac ▁insulin - re si stance ▁and ▁decrease d ▁mito cho ndri al ▁oxid ative ▁metabolism ▁are ▁early ▁metabol ic ▁changes ▁in ▁the ▁development ▁of ▁cardiac ▁hyper trop hy , ▁which ▁create ▁an ▁energy ▁deficit ▁that ▁may ▁contribute ▁to ▁the ▁progression ▁from ▁hyper trop hy ▁to ▁heart ▁failure .
▁The ▁reality ▁of ▁heart ▁failure ▁in ▁Latin ▁America .
▁Heart ▁failure ▁( HF ) ▁data ▁in ▁Latin ▁America ▁( LA ) ▁were ▁review ed ▁to ▁guide ▁health ▁service ▁planning ▁in ▁the ▁pre vention ▁and ▁treatment ▁of ▁ HF .
▁The ▁ HF ▁epidemi ology ▁and ▁the ▁ adequa cy ▁of ▁relevant ▁health ▁service ▁provision ▁related ▁to ▁ HF ▁in ▁LA ▁are ▁not ▁well ▁de line ated .
▁A ▁systematic ▁search ▁of ▁the ▁electronic ▁database s ▁and ▁the ▁World ▁Health ▁Organization ▁website ▁was ▁under tak en ▁for ▁ HF ▁in ▁LA .
▁LA ▁countries ▁have ▁reduce d ▁gross ▁income ▁and ▁lower ▁total ▁ex pendi ture ▁on ▁health ▁per ▁capita .
▁LA ▁is ▁a ▁hetero gene ous ▁region ▁with ▁ HF ▁risk ▁factors ▁of ▁developed ▁and ▁non develop ed ▁countries , ▁including ▁lower ▁risk ▁of ▁raised ▁blood ▁gluco se ▁levels , ▁obes ity , ▁to ba cco , ▁and ▁ aging , ▁where as ▁system ic ▁hyper tension ▁( SH ), ▁rhe u matic ▁fe ver , ▁and ▁Cha gas ' ▁disease ▁( C ' D ) ▁are ▁higher ▁in ▁LA .
▁Main ▁et i ologie s ▁of ▁ HF ▁in ▁LA ▁are ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁( from ▁1. 3% ▁to ▁37 %) , ▁C ' D ▁( from ▁1. 3% ▁to ▁21% ), ▁ ische mic ▁( from ▁6 8% ▁to ▁17% ), ▁SH ▁( from ▁14% ▁to ▁76 %) , ▁val vu lar ▁( from ▁3% ▁to ▁22% ), ▁and ▁alcohol ▁related ▁( from ▁1. 1% ▁to ▁ 8%) .
▁The ▁prognos is ▁of ▁C ' D ▁ HF ▁is ▁worse ▁than ▁for ▁other ▁et i ologie s .
▁Chro nic ▁ HF ▁is ▁the ▁cause ▁of ▁death ▁in ▁6. 3% ▁of ▁cases .
▁De com pensa ted ▁ HF ▁is ▁the ▁main ▁cause ▁of ▁cardiovascular ▁hospital ization .
▁The ▁prevale nce ▁of ▁sy sto lic ▁ HF ▁varie s ▁from ▁6 4% ▁to ▁6 9% .
▁LA ▁is ▁under ▁the ▁a w ful ▁paradox ▁of ▁having ▁the ▁ HF ▁risk ▁factors ▁and ▁ HF ▁epidemi ology ▁of ▁developed ▁countries ▁with ▁the ▁added ▁factors ▁of ▁SH , ▁C ' D , ▁and ▁rhe u matic ▁fe ver .
▁Over all , ▁in ▁the ▁scenario ▁of ▁lower ▁total ▁ex pendi ture ▁on ▁health ▁per ▁capita ▁and ▁lower ▁gross ▁national ▁income ▁per ▁capita , ▁new ▁strategie s ▁are ▁essential ▁for ▁pre vention ▁and ▁treatment ▁of ▁ HF ▁in ▁LA .
▁A ▁CL CN KA ▁poly morph ism ▁( rs 109 27 887 ; ▁p . Ar g 83 G ly ) ▁previously ▁link ed ▁to ▁heart ▁failure ▁is ▁associated ▁with ▁the ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁in ▁the ▁RE NAS TUR ▁co hor t .
▁A ▁total ▁of ▁ 569 ▁individuals ▁a ged ▁55 - 85 ▁and ▁Cau ca sian ▁were ▁geno type d ▁for ▁S NP ▁rs 109 27 887 ▁in ▁the ▁Ka ▁renal ▁chlor ide ▁channel ▁gene ▁( CL CN KA ).
▁The ▁following ▁variable s ▁were ▁significantly ▁associated ▁with ▁an ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁of ▁( e G FR ) ▁< 60 ▁ml / min . /1 . 73 ▁m (2) : ▁age , ▁type ▁2 ▁diabetes , ▁total ▁cholesterol , ▁L DL - ch olesterol , ▁and ▁the ▁CL CN KA ▁ GG ▁geno type ▁( p =0 . 03 ; ▁OR =1 . 65 , ▁95% ▁CI =1 . 04 -2 . 62 ).
▁This ▁novel ▁finding ▁could ▁part ly ▁explain ▁the ▁reported ▁greater ▁risk ▁of ▁heart ▁failure ▁link ed ▁to ▁the ▁CL CN KA ▁S NP , ▁but ▁requires ▁confirmation ▁on ▁other ▁population s .
▁A sse ssing ▁the ▁link ▁between ▁air ▁pollution ▁and ▁heart ▁failure .
▁Ambient ▁air ▁pollution ▁is ▁a ▁well - re cogni sed ▁risk ▁factor ▁for ▁cardiovascular ▁health , ▁and ▁it ▁has ▁been ▁shown ▁to ▁be ▁an ▁important ▁trigger ▁of ▁a cute ▁my o card ial ▁in far ction .
▁In ▁The ▁Lance t , ▁Ano op ▁Shah ▁and ▁colleagues ▁provide ▁a ▁new ▁systematic ▁review ▁of ▁the ▁effects ▁of ▁air ▁pollution ▁on ▁heart ▁failure , ▁a ▁common ▁disorder ▁associated ▁with ▁high ▁morbi d ity ▁and ▁mortal ity , ▁especially ▁in ▁el der ly ▁people .
▁Physic ians ▁and ▁professionals ▁in ▁public ▁health ▁should ▁be ▁aware ▁that ▁the ▁air ▁pollution ▁experienced ▁in ▁most ▁urban ▁and ▁industrial ▁areas ▁can ▁ag grav ate ▁cardiovascular ▁health ▁and ▁lead ▁to ▁hospital isation ▁and ▁death .
▁Card iac ▁over expression ▁of ▁Mamma lian ▁enabled ▁( Men a ) ▁ex a cer bat es ▁heart ▁failure ▁in ▁mi ce .
▁Mamma lian ▁enabled ▁( Men a ) ▁is ▁a ▁key ▁regulator ▁of ▁cy tos kelet al ▁act in ▁dynamic s , ▁which ▁has ▁been ▁implica ted ▁in ▁heart ▁failure ▁( HF ).
▁We ▁have ▁previously ▁demonstrat ed ▁that ▁cardiac ▁Men a ▁dele tion ▁produced ▁cardiac ▁dys function ▁with ▁con duction ▁ab normal ities ▁and ▁hyper trop hy .
▁More over , ▁eleva ted ▁Men a ▁expression ▁corre late s ▁with ▁ HF ▁in ▁human ▁and ▁animal ▁models , ▁yet ▁the ▁precise ▁role ▁of ▁Men a ▁in ▁cardiac ▁pat ho phy si ology ▁is ▁un clear .
▁In ▁these ▁studies , ▁we ▁evaluat ed ▁mi ce ▁with ▁cardiac ▁my o cy te - specific ▁Men a ▁over expression ▁( TTA / T g T et Men a ) ▁comparable ▁to ▁that ▁observe d ▁in ▁cardiac ▁path ology .
▁We ▁found ▁that ▁the ▁heart s ▁of ▁ TTA / T g T et Men a ▁mi ce ▁were ▁functional ly ▁and ▁ morph ological ly ▁comparable ▁to ▁wild - type ▁litt er mates , ▁except ▁for ▁mild ly ▁increased ▁heart ▁mass ▁in ▁the ▁trans ge nic ▁mi ce .
▁Interes ting ly , ▁ TTA / T g T et Men a ▁mi ce ▁were ▁particularly ▁susceptible ▁to ▁cardiac ▁injury , ▁as ▁these ▁animals ▁experienced ▁prono un ced ▁decrease s ▁in ▁e je ction ▁ fraction ▁and ▁ fraction al ▁short en ing ▁as ▁well ▁as ▁heart ▁di la tation ▁and ▁hyper trop hy ▁after ▁trans verse ▁a or tic ▁con stri ction ▁( TAC ).
▁By ▁" tur ning ▁off " ▁Men a ▁over expression ▁in ▁ TTA / T g T et Men a ▁mi ce ▁either ▁immediately ▁prior ▁to ▁or ▁immediately ▁after ▁ TAC ▁surgery , ▁we ▁discovered ▁that ▁normal izing ▁Men a ▁levels ▁elimina ted ▁cardiac ▁hyper trop hy ▁in ▁ TTA / T g T et Men a ▁animals ▁but ▁did ▁not ▁pre clu de ▁post - TAC ▁cardiac ▁functional ▁deteriora tion .
▁These ▁finding s ▁indicate ▁that ▁heart s ▁with ▁increased ▁levels ▁of ▁Men a ▁fare ▁worse ▁when ▁subject ed ▁to ▁cardiac ▁injury ▁and ▁suggest ▁that ▁Men a ▁contribute s ▁to ▁ HF ▁pat ho phy si ology .
▁Future ▁of ▁advanced ▁heart ▁failure ▁and ▁mechanic al ▁support ▁devices : ▁A ▁Card i ology - Car dio vas cular ▁Sur ger y ▁Cons en sus ▁Report ▁Heart ▁failure ▁is ▁a ▁progressive ▁disease .
▁A ▁considerable ▁number ▁of ▁patients ▁eventually ▁reach ▁an ▁advanced ▁or ▁terminal ▁phase , ▁in ▁ spite ▁of ▁development s ▁in ▁diagnostic ▁procedure , ▁alternative ▁treatment s ▁that ▁can ▁slow ▁progression , ▁management , ▁and ▁follow - up .
▁In ▁addition ▁to ▁palli ative ▁care ▁of ▁patients ▁in ▁the ▁terminal ▁phase , ▁accurate ▁recognition ▁of ▁advanced ▁disease ▁is ▁vital ▁in ▁the ▁determina tion ▁of ▁ therapeut ic ▁options .
▁Over all ▁management ▁of ▁patients ▁with ▁heart ▁failure ▁requires ▁the ▁collaboration ▁of ▁professionals ▁from ▁multiple ▁discipline s .
▁Still , ▁patients ▁with ▁advanced ▁heart ▁failure ▁should ▁be ▁managed ▁by ▁a ▁" heart ▁team , " ▁as ▁indicate d ▁by ▁guidelines ; ▁communication ▁and ▁collaboration ▁among ▁cardio logist s , ▁cardiovascular ▁surge ons , ▁and ▁other ▁medical ▁staff ▁responsible ▁for ▁patient ▁care ▁is ▁necessary .
▁While ▁our ▁country ▁has ▁physician s ▁experienced ▁in ▁the ▁management ▁of ▁patients ▁with ▁advanced ▁heart ▁failure , ▁these ▁professionals ▁are ▁not ▁distribu ted ▁even ly ▁across ▁the ▁country , ▁and ▁equi table ▁access ▁to ▁ therapeut ic ▁options ▁is ▁not ▁provided .
▁H ence , ▁progress ▁has ▁yet ▁to ▁be ▁made ▁regarding ▁appropriate ▁refer ral s ▁and ▁patient ▁circulation .
▁The ▁aims ▁of ▁the ▁present ▁consensu s ▁report ▁are ▁to ▁strength en ▁the ▁connection ▁between ▁cert ified , ▁experienced ▁center s ▁and ▁those ▁that ▁care ▁for ▁patients ▁ir respect ive ▁of ▁disease ▁phase ▁and ▁health care ▁staff , ▁as ▁well ▁as ▁to ▁raise ▁awareness ▁and ▁provide ▁information ▁regarding ▁conditions ▁in ▁Turkey .
▁Risk ▁for ▁Hospital ized ▁Heart ▁Fail ure ▁Am ong ▁New ▁User s ▁of ▁Sax ag lip tin , ▁Si tag lip tin , ▁and ▁Other ▁Anti hy per gly ce mic ▁Drug s : ▁A ▁Retro spec tive ▁Co hor t ▁Study .
▁BA CK GRO UND : ▁Recent ▁post marketing ▁trial s ▁produced ▁conflict ing ▁results ▁about ▁the ▁risk ▁for ▁hospital ized ▁heart ▁failure ▁( h HF ) ▁associated ▁with ▁di pe pti dy l ▁pep tida se -4 ▁( D PP -4 ) ▁inhibi tors , ▁creating ▁un certa in ty ▁about ▁the ▁safety ▁of ▁these ▁anti hy per gly ce mic ▁agents .
▁OB JE C TIVE : ▁To ▁examine ▁the ▁associations ▁of ▁h HF ▁with ▁sax ag lip tin ▁and ▁si tag lip tin .
▁DESIGN : ▁Popula tion - based , ▁retro spec tive , ▁new - user ▁co hor t ▁study .
▁SET TING : ▁18 ▁health ▁insurance ▁and ▁health ▁system ▁data ▁partners ▁in ▁the ▁U . S . ▁Food ▁and ▁Drug ▁Administration ' s ▁Mini - S enti nel ▁program .
▁PAT IEN TS : ▁Patient s ▁a ged ▁18 ▁years ▁or ▁older ▁with ▁type ▁2 ▁diabetes ▁who ▁initiat ed ▁ therapy ▁with ▁sax ag lip tin , ▁si tag lip tin , ▁pi og lita zone , ▁second - genera tion ▁sul fon yl ure as , ▁or ▁long - ac ting ▁insulin ▁products ▁from ▁2006 ▁to ▁2013.
▁ME AS UR EMENT S : ▁Hospital ized ▁ HF , ▁identified ▁by ▁International ▁Classifica tion ▁of ▁Disease s , ▁Nin th ▁Re vision , ▁Clinic al ▁Modifica tion ▁code s ▁4 02. x 1 , ▁4 04. x 1 , ▁4 04. x 3 , ▁and ▁ 428 . xx ▁record ed ▁as ▁the ▁principal ▁dis charge ▁ diagnos is .
▁RESULT S : ▁78 ▁ 553 ▁sax ag lip tin ▁users ▁and ▁ 298 ▁124 ▁si tag lip tin ▁users ▁contribute d ▁an ▁average ▁of ▁7 ▁to ▁9 ▁months ▁of ▁follow - up ▁data ▁to ▁1 ▁or ▁more ▁pair wise ▁comparison s .
▁The ▁risk ▁for ▁h HF ▁was ▁not ▁higher ▁with ▁D PP -4 ▁inhibi tors ▁than ▁with ▁the ▁other ▁study ▁drugs .
▁The ▁hazard ▁ratio s ▁from ▁the ▁disease ▁risk ▁score ▁( D RS ) - stra t ified ▁analyse s ▁were ▁0 . 83 ▁( 95% ▁CI , ▁0 . 70 ▁to ▁0 . 99) ▁for ▁sax ag lip tin ▁versus ▁si tag lip tin , ▁0 . 63 ▁( CI , ▁0 . 47 ▁to ▁0 . 85) ▁for ▁sax ag lip tin ▁versus ▁pi og lita zone , ▁0 . 69 ▁( CI , ▁0.5 4 ▁to ▁0 . 87) ▁for ▁sax ag lip tin ▁versus ▁sul fon yl ure as , ▁and ▁0 . 61 ▁( CI , ▁0 . 50 ▁to ▁ 0.7 3) ▁for ▁sax ag lip tin ▁versus ▁insulin .
▁The ▁D RS - stra t ified ▁hazard ▁ratio s ▁were ▁0 . 74 ▁( CI , ▁0 . 64 ▁to ▁0 . 85) ▁for ▁si tag lip tin ▁versus ▁pi og lita zone , ▁0 . 86 ▁( CI , ▁0 . 77 ▁to ▁0 . 95) ▁for ▁si tag lip tin ▁versus ▁sul fon yl ure as , ▁and ▁0 . 71 ▁( CI , ▁0 . 64 ▁to ▁0 . 78) ▁for ▁si tag lip tin ▁versus ▁insulin .
▁Results ▁from ▁the ▁1:1 ▁pro pens ity ▁score - match ed ▁analyse s ▁were ▁similar .
▁Results ▁were ▁also ▁similar ▁in ▁sub group s ▁of ▁patients ▁with ▁and ▁without ▁prior ▁cardiovascular ▁disease ▁and ▁in ▁a ▁sub group ▁define d ▁by ▁the ▁2 ▁highest ▁D RS ▁deci les .
▁LI MIT ATION : ▁Res idu al ▁con found ing ▁and ▁short ▁follow - up .
▁CON C LU SION : ▁In ▁this ▁large ▁co hor t ▁study , ▁a ▁higher ▁risk ▁for ▁h HF ▁was ▁not ▁observe d ▁in ▁users ▁of ▁sax ag lip tin ▁or ▁si tag lip tin ▁compared ▁with ▁other ▁selected ▁anti hy per gly ce mic ▁agents .
▁Effective ness ▁of ▁implementation ▁strategie s ▁in ▁improving ▁physician ▁ad her ence ▁to ▁guide line ▁recommendations ▁in ▁heart ▁failure : ▁a ▁systematic ▁review ▁protocol ▁Introdu ction ▁The ▁up take ▁of ▁Clinic al ▁Practic e ▁Guide line ▁( CP G ) ▁recommendations ▁that ▁improve ▁outcome s ▁in ▁heart ▁failure ▁( HF ) ▁remain s ▁sub optimal .
▁We ▁will ▁conduct ▁a ▁systematic ▁review ▁to ▁identify ▁implementation ▁strategie s ▁that ▁improve ▁physician ▁ad her ence ▁to ▁class ▁I ▁recommendations , ▁those ▁with ▁clear ▁evidence ▁that ▁benefits ▁out we igh ▁the ▁risk s .
▁We ▁will ▁use ▁American , ▁Canadian ▁and ▁European ▁ HF ▁guidelines ▁as ▁our ▁reference .
▁Method s ▁and ▁analysis ▁We ▁will ▁conduct ▁a ▁literature ▁search ▁in ▁the ▁database s ▁of ▁MED LINE , ▁ EMBA SE , ▁HE AL TH STAR , ▁C INA HL , ▁Co ch rane ▁Library , ▁Campbell ▁Col labora tion , ▁Joan na ▁Brig gs ▁Institute ▁E viden ce ▁Base d ▁Practic e , ▁Centre ▁for ▁Review s ▁and ▁Disse mination ▁and ▁E viden ce ▁Base d ▁Practic e ▁Centre s .
▁We ▁will ▁include ▁prospect ive ▁studies ▁evaluat ing ▁implementation ▁intervention s ▁ai med ▁at ▁improving ▁up take ▁of ▁class ▁I ▁C PG ▁recommendations ▁in ▁ HF .
▁We ▁will ▁extract ▁data ▁in ▁duplica te .
▁We ▁will ▁class ify ▁intervention s ▁according ▁to ▁their ▁level ▁of ▁application ▁( ie , ▁provider , ▁organisation , ▁systems ▁level ) ▁and ▁common ▁under ly ing ▁character istic s ▁( eg , ▁education , ▁decision - support , ▁financial ▁incentive s ) ▁using ▁the ▁Co ch rane ▁Effective ▁Practic e ▁and ▁Organisation ▁of ▁Care ▁Tax ono my .
▁We ▁will ▁assess ▁the ▁impact ▁of ▁the ▁intervention ▁on ▁ad her ence ▁to ▁the ▁C PG s .
▁Out com es ▁will ▁include ▁proportion ▁of ▁eligible ▁patients ▁who ▁were : ▁pre scribe d ▁a ▁C PG - re com mend ed ▁ pharma c ological ▁treatment ; ▁refer red ▁for ▁device ▁consideration ; ▁provided ▁self - care ▁education ▁at ▁dis charge ; ▁and ▁provided ▁left ▁vent ri cular ▁function ▁assessment .
▁We ▁will ▁include ▁clinic al ▁outcome s ▁such ▁as ▁hospital isation s , ▁read missions ▁and ▁mortal ity , ▁if ▁data ▁is ▁available .
▁We ▁will ▁identify ▁the ▁common ▁elements ▁of ▁successful ▁and ▁fail ing ▁intervention s , ▁and ▁examine ▁the ▁context ▁in ▁which ▁they ▁were ▁applied , ▁using ▁the ▁Process ▁Re design ▁context ual ▁framework .
▁We ▁will ▁synth es ise ▁the ▁results ▁narra tive ly ▁and , ▁if ▁appropriate , ▁will ▁pool ▁results ▁for ▁meta - analys is .
▁Discuss ion ▁and ▁disse mination ▁In ▁this ▁review , ▁we ▁will ▁assess ▁the ▁impact ▁of ▁implementation ▁strategie s ▁and ▁context ual ▁factors ▁on ▁physician ▁ad her ence ▁to ▁ HF ▁C PG s .
▁We ▁will ▁explore ▁why ▁some ▁intervention s ▁may ▁succeed ▁in ▁one ▁setting ▁and ▁fail ▁in ▁another .
▁We ▁will ▁disse mina te ▁our ▁finding s ▁through ▁brief ing ▁reports , ▁publication s ▁and ▁presentation s .
▁Patient ▁percep tions ▁of ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁discussion s : ▁A ▁qualitativ e ▁study .
▁BA CK GRO UND : ▁There ▁is ▁a ▁class ▁I ▁recommend ation ▁for ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁discussion s ▁to ▁occur ▁between ▁physician s ▁and ▁heart ▁failure ▁patients .
▁Fe w ▁studies ▁have ▁reported ▁the ▁patient ' s ▁perspective ▁on ▁the ▁tim ing ▁of ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁discussion s .
▁A IM : ▁To ▁determine ▁patient ▁awareness , ▁preference s ▁and ▁tim ing ▁of ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁discussion s .
▁DESIGN : ▁Ground ed ▁theory ▁was ▁used ▁to ▁collect ▁and ▁anal y ze ▁interview ▁data ▁from ▁25 ▁heart ▁failure ▁patients ▁with ▁an ▁implant able ▁cardio ver ter - de fi br illa tor .
▁SET TING ▁AND ▁PARTI CI PAN TS : ▁Patient s ▁with ▁an ▁implant able ▁cardio ver ter - de fi br illa tor , ▁from ▁the ▁Heart ▁Fun ction ▁Clinic ▁at ▁University ▁Health ▁Network ▁( Tor onto , ▁Canada ).
▁RESULT S : ▁The ▁sample ▁( n ▁= ▁25 ) ▁was ▁predomina tely ▁male ▁(7 6% ) ▁with ▁an ▁average ▁age ▁of ▁62 ▁years .
▁Patient s ▁identified ▁three ▁stage s ▁where ▁they ▁felt ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁should ▁be ▁discuss ed : ▁(1) ▁prior ▁to ▁implant ation , ▁(2) ▁with ▁any ▁significant ▁deteriora tion ▁but ▁while ▁they ▁were ▁of ▁sound ▁mind ▁to ▁engage ▁in ▁and ▁ communica te ▁their ▁preference s ▁and ▁(3) ▁at ▁end ▁of ▁life , ▁where ▁patients ▁wish ed ▁further ▁review ▁of ▁their ▁previously ▁established ▁preference s ▁and ▁decisions ▁about ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion .
▁Most ▁patients ▁( n ▁= ▁17, ▁6 8%) ▁said ▁they ▁would ▁consider ▁de activa tion , ▁six ▁(24 %) ▁were ▁unde cide d ▁and ▁two ▁( 8%) ▁were ▁adam ant ▁they ▁would ▁never ▁turn ▁it ▁off .
▁CON C LU SION : ▁The ▁patient ▁preference s ▁identified ▁in ▁this ▁study ▁support ▁the ▁need ▁to ▁include ▁information ▁on ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁at ▁implant , ▁with ▁change ▁in ▁clinic al ▁status ▁and ▁within ▁broad er ▁discussion s ▁about ▁end - of - life ▁treatment ▁preference s .
▁U sing ▁this ▁process ▁to ▁help ▁patients ▁determine ▁and ▁ communica te ▁their ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁preference s ▁may ▁reduce ▁the ▁number ▁of ▁patients ▁experi en cing ▁di stress ing ▁implant able ▁cardio ver ter - de fi br illa tor ▁shock s ▁at ▁end ▁of ▁life .
▁Comment ▁on ▁" Bar ore flex ▁Activ ation ▁Therapy ▁for ▁the ▁Treatment ▁of ▁Heart ▁Fail ure ▁With ▁a ▁Red u ced ▁E je ction ▁Fra ction " ▁OB JE C TIVE S : ▁The ▁objective ▁of ▁this ▁clinic al ▁trial ▁was ▁to ▁assess ▁the ▁safety ▁and ▁ef fica cy ▁of ▁caro tid ▁baro re flex ▁activa tion ▁ therapy ▁( BAT ) ▁in ▁advanced ▁heart ▁failure ▁( HF ).
▁BA CK GRO UND : ▁Inc rea sed ▁sympa the tic ▁and ▁decrease d ▁para sy mpa the tic ▁activity ▁contribute ▁to ▁ HF ▁symptoms ▁and ▁disease ▁progression .
▁BAT ▁results ▁in ▁central ly ▁media ted ▁re duction ▁of ▁sympa the tic ▁out flow ▁and ▁increased ▁para sy mpa the tic ▁activity .
▁ MET HOD S : ▁Patient s ▁with ▁New ▁York ▁Heart ▁Association ▁( NY HA ) ▁functional ▁class ▁III ▁ HF ▁and ▁e je ction ▁ fraction s ▁< ▁35% ▁on ▁chronic ▁stable ▁guide line - direct ed ▁medical ▁ therapy ▁( GD MT ) ▁were ▁en roll ed ▁at ▁45 ▁center s ▁in ▁the ▁United ▁States , ▁Canada , ▁and ▁Europe .
▁They ▁were ▁random ly ▁assign ed ▁to ▁receive ▁ongoing ▁GD MT ▁alone ▁( control ▁group ) ▁or ▁ongoing ▁GD MT ▁plus ▁BAT ▁( tre at ment ▁group ) ▁for ▁6 ▁months .
▁The ▁primary ▁safety ▁end ▁point ▁was ▁system - ▁and ▁procedure - related ▁major ▁advers e ▁neurologi cal ▁and ▁cardiovascular ▁events .
▁The ▁primary ▁ef fica cy ▁end ▁points ▁were ▁changes ▁in ▁NY HA ▁functional ▁class , ▁quality - of - life ▁score , ▁and ▁6- minut e ▁hall ▁walk ▁distance .
▁RESULT S : ▁One ▁hundred ▁for ty - s ix ▁patients ▁were ▁random ized , ▁70 ▁to ▁control ▁and ▁76 ▁to ▁treatment .
▁The ▁major ▁advers e ▁neurologi cal ▁and ▁cardiovascular ▁event - free ▁rate ▁was ▁97 . 2% ▁( low er ▁95% ▁confidence ▁ bound ▁91 . 4% ).
▁Patient s ▁assign ed ▁to ▁BAT , ▁compared ▁with ▁control ▁group ▁patients , ▁experienced ▁improvement s ▁in ▁the ▁distance ▁walked ▁in ▁6 ▁min ▁(5 9.6 ▁ ± ▁14 ▁m ▁vs . ▁1.5 ▁ ± ▁13. 2 ▁m ; ▁p ▁= ▁0.0 04) , ▁quality - of - life ▁score ▁( – 17 . 4 ▁ ± ▁ 2.8 ▁points ▁vs . ▁2.1 ▁ ± ▁3.1 ▁points ; ▁p ▁< ▁0.0 01) , ▁and ▁NY HA ▁functional ▁class ▁ranking ▁( p ▁= ▁0.0 02 ▁for ▁change ▁in ▁distribution ).
▁BAT ▁significantly ▁reduce d ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁( p ▁= ▁0.0 2) ▁and ▁was ▁associated ▁with ▁a ▁trend ▁toward ▁few er ▁days ▁hospital ized ▁for ▁ HF ▁( p ▁= ▁0.0 8) .
▁CON CL USI ONS : ▁BAT ▁is ▁safe ▁and ▁improve s ▁functional ▁status , ▁quality ▁of ▁life , ▁exercise ▁capacity , ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de , ▁and ▁possibly ▁the ▁burde n ▁of ▁heart ▁failure ▁hospital ization s ▁in ▁patients ▁with ▁GD MT - tre ated ▁NY HA ▁functional ▁class ▁III ▁ HF .
▁Pre li min ary ▁report ▁of ▁using ▁cardio pul mon ary ▁exercise ▁testing ▁guide ▁exercise ▁rehabilita tion ▁in ▁patients ▁with ▁chronic ▁heart ▁failure ▁OB JE C TIVE : ▁The ▁exercise ▁rehabilita tion ▁in ▁patient ▁with ▁chronic ▁heart ▁failure ▁( CH F ) ▁is ▁standard ▁clinic al ▁practice , ▁but ▁it ▁is ▁rare ▁using ▁Card io P ul mon ary ▁Exerci se ▁Test ing ▁( C PET ) ▁guide ▁to ▁pre scribe ▁exercise ▁rehabilita tion ▁in ▁China .
▁ MET HOD S : ▁We ▁perform ed ▁symptom ▁limited ▁maximal ▁C PET ▁in ▁10 ▁patients ▁with ▁CHF , ▁random ly ▁divide d ▁into ▁two ▁groups : ▁5 ▁patients ▁as ▁control ▁without ▁exercise ▁and ▁5 ▁exercise ▁patients ▁used ▁Δ 50% W ▁intens ity ▁to ▁exercise ▁30 ▁min / d , ▁5 ▁d / w , ▁x 12 ▁w . ▁Before ▁and ▁after ▁12 ▁w ▁rehabilita tion , ▁we ▁evaluat ed ▁function s .
▁RESULT S : ▁There ▁were ▁no ▁significant ▁difference ▁between ▁two ▁groups ▁patients ▁( P ▁> ▁0.0 5) .
▁The ▁exercise ▁du ration ▁was ▁increased ▁from ▁8 ▁min ▁to ▁23 ▁min ▁after ▁rehabilita tion ▁( P ▁< ▁0.0 01) ; ▁distance ▁6 ▁minutes ▁walking ▁was ▁increased ▁from ▁ 394 ▁m ▁to ▁470 ▁m ▁( P ▁< ▁0.0 5 ); ▁score ▁of ▁Minnesota ▁quality ▁of ▁life ▁was ▁decrease d ▁from ▁25 ▁to ▁3 ▁in ▁exercise ▁group ▁( P ▁< ▁ 0.01 ).
▁However , ▁there ▁were ▁no signif i cant ▁changes ▁in ▁control ▁group ▁( P > 0.0 5) ▁and ▁their ▁changes ▁were ▁smaller ▁than ▁those ▁in ▁exercise ▁group ▁( P ▁< ▁ 0.01 ).
▁CON C LU SION : ▁The ▁C PET ▁gu iding ▁exercise ▁rehabilita tion ▁is ▁safe ▁and ▁effective ▁for ▁patients ▁with ▁CHF .
▁Management ▁of ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction .
▁Heart ▁failure ▁affect s ▁nearly ▁one ▁million ▁people ▁in ▁the ▁UK .
▁Half ▁of ▁these ▁patients ▁have ▁normal , ▁or ▁near ▁normal , ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁and ▁are ▁class ified ▁as ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( HF p EF ).
▁New er ▁imagin g ▁techniques ▁have ▁confirm ed ▁that ▁sy sto lic ▁function ▁in ▁ HF p EF ▁patients ▁is ▁not ▁completely ▁normal , ▁with ▁reduce d ▁long ▁a xis ▁function ▁and ▁ex tensi ve ▁but ▁sub tle ▁changes ▁on ▁exercise .
▁Patient s ▁are ▁likely ▁to ▁be ▁older ▁women ▁with ▁a ▁history ▁of ▁hyper tension .
▁Other ▁cardiovascular ▁risk ▁factors , ▁such ▁as ▁diabetes ▁mell itus , ▁at rial ▁fi bril lation ▁and ▁corona ry ▁arter y ▁disease ▁are ▁pre valent ▁in ▁the ▁ HF p EF ▁population .
▁Clinic al ▁symptoms ▁and ▁sign s ▁in ▁ HF p EF ▁are ▁often ▁non specific ▁although ▁the ▁primary ▁symptoms ▁are ▁breath less ness , ▁fatigue ▁and ▁fluid ▁re tention .
▁There ▁is ▁still ▁no ▁single ▁diagnostic ▁test ▁for ▁ HF p EF ▁and ▁the ▁corner stone ▁in ▁the ▁assessment ▁remain s ▁a ▁thorough ▁medical ▁history ▁and ▁physical ▁examina tion .
▁The ▁du ration ▁and ▁extent ▁of ▁the ▁symptoms ▁are ▁relevant ▁and ▁it ▁is ▁useful ▁to ▁class ify ▁patients ▁according ▁to ▁the ▁NY HA ▁functional ▁assessment .
▁Physic al ▁examina tion ▁should ▁include ▁the ▁patient ' s ▁B MI ▁and ▁weight , ▁heart ▁rate ▁and ▁ rhythm , ▁ly ing ▁and ▁standing ▁blood ▁pressure ▁and ▁aus cul tation ▁to ▁rule ▁out ▁val vu lar ▁disease ▁and ▁pulmonar y ▁con gestion .
▁Esti ma ting ▁the ▁jugu lar ▁ve nous ▁pressure ▁and ▁the ▁presence ▁of ▁per i pher al ▁oed ema ▁allows ▁assessment ▁of ▁the ▁patient ' s ▁volume ▁status .
▁Patient s ▁with ▁heart ▁failure ▁should ▁be ▁refer red ▁to ▁heart ▁failure ▁nurse s ▁and ▁have ▁follow - up ▁with ▁local ▁card i ology ▁services ▁as ▁these ▁have ▁both ▁been ▁shown ▁to ▁reduce ▁mortal ity .
▁Play ing ▁it ▁safe : ▁exercise ▁and ▁cardiovascular ▁health .
▁Regula r ▁physical ▁activity ▁control s ▁acquire d ▁cardiovascular ▁risk ▁factors ▁such ▁as ▁obes ity , ▁diabetes ▁mell itus , ▁hyper tension ▁and ▁hyper li pida emia .
▁Exerci se ▁is ▁generally ▁associated ▁with ▁a ▁50% ▁re duction ▁in ▁advers e ▁events ▁from ▁corona ry ▁arter y ▁disease ▁( CAD ).
▁The ▁benefits ▁of ▁exercise ▁extend ▁well ▁beyond ▁the ▁cardiovascular ▁system .
▁Recent ▁evidence ▁suggest s ▁that ▁exercise ▁prevent s ▁cell ▁se nesc ence , ▁and ▁active ▁individuals ▁are ▁at ▁lower ▁risk ▁of ▁developing ▁certain ▁malign a ncies ▁including ▁cancer ▁of ▁the ▁prostat e ▁and ▁the ▁colon , ▁osteo por osis , ▁depression ▁and ▁dem entia .
▁Individual s ▁who ▁exercise ▁regularly ▁extend ▁their ▁life ▁expect an cy ▁by ▁three ▁to ▁seven ▁years .
▁Health y ▁individuals ▁should ▁engage ▁in ▁150 ▁minutes ▁of ▁moderat e - inten s ity , ▁aero bic ▁exercise ▁per ▁week .
▁Recent ▁studies ▁have ▁demonstrat ed ▁that ▁even ▁lower ▁volume s ▁of ▁exercise ▁below ▁these ▁recommendations ▁con fer ▁health ▁benefits , ▁which ▁is ▁highly ▁relevant ▁to ▁individuals ▁with ▁established ▁cardiac ▁disease ▁including ▁heart ▁failure .
▁Sud den ▁cardiac ▁death ▁in ▁ath letes ▁under ▁35 ▁is ▁rare ▁with . estima tes ▁rang ing ▁from ▁1 ▁in ▁ 50,000 ▁to ▁1 ▁in ▁200 , 000 .
▁Her edit ary ▁and ▁con geni tal ▁ab normal ities ▁of ▁the ▁heart ▁are ▁the ▁most ▁common ▁cause ▁of ▁non trau matic ▁death ▁during ▁sport ▁in ▁young ▁ath letes .
▁In ▁middle - a ged ▁recrea tional ▁ath letes ▁more ▁than ▁90% ▁of ▁sud den ▁cardiac ▁death s ▁occur ▁in ▁male s ▁and ▁more ▁than ▁90% ▁are ▁caused ▁by ▁a ther os cle ro tic ▁CAD .
▁The ▁ AHA ▁and ▁the ▁ESC ▁advocate ▁pre - parti cip ation ▁screening ▁of ▁young ▁ath letes .
▁The ▁E CG ▁has ▁the ▁ability ▁to ▁detect ▁con geni tal ▁accesso ry ▁path ways ▁and ▁ion ▁channel o pathi es , ▁and ▁is ▁frequently ▁ab normal ▁in ▁individuals ▁with ▁cardio my o pathy .
▁Screen ing ▁with ▁a ▁12- le ad ▁E CG ▁in ▁older ▁ath letes ▁is ▁of ▁limited ▁value ▁given ▁the ▁over w hel ming ▁contribution ▁of ▁a ther os cle ro tic ▁CAD ▁to ▁sud den ▁cardiac ▁death .
▁Robot - assist ed ▁training ▁for ▁heart ▁failure ▁patients ▁- ▁a ▁small ▁pilot ▁study .
▁OB JE C TIVE : ▁The ▁objective ▁of ▁this ▁study ▁was ▁assess ▁robot - assist ed ▁ga it ▁ therapy ▁with ▁the ▁Lok omat ® ▁system ▁in ▁heart ▁failure ▁patients .
▁ MET HOD S : ▁Patient s ▁( n ▁= ▁5) ▁with ▁stable ▁heart ▁failure ▁and ▁a ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁of ▁less ▁than ▁45% ▁completed ▁a ▁four - week ▁aero bic ▁training ▁period ▁with ▁three ▁training s ▁per ▁week ▁and ▁an ▁integrat ed ▁dynamic ▁resist ance ▁training ▁of ▁the ▁lower ▁lim bs .
▁Patient s ▁under went ▁testing ▁of ▁cardiac ▁and ▁infla mma tory ▁bio mark ers .
▁A ▁cardio pul mon ary ▁exercise ▁test , ▁a ▁quality ▁of ▁life ▁score ▁and ▁an ▁evaluation ▁of ▁the ▁muscular ▁strength ▁by ▁me as uring ▁the ▁pe ak ▁quadri cep s ▁force ▁was ▁perform ed .
▁RESULT S : ▁No ▁advers e ▁events ▁occur red .
▁The ▁combine d ▁training ▁result ed ▁in ▁an ▁improvement ▁in ▁pe ak ▁work ▁rate ▁( range : ▁6% ▁to ▁36 %) ▁and ▁pe ak ▁quadri cep s ▁force ▁( range : ▁3% ▁to ▁80% ) ▁in ▁all ▁participants .
▁Peak ▁oxygen ▁consum p tion ▁( range : ▁– 3% ▁to ▁+ ▁6 1%) ▁increased ▁in ▁three , ▁and ▁oxygen ▁puls e ▁( range : ▁– 7% ▁to ▁+ ▁44 %) ▁in ▁four ▁of ▁five ▁patients .
▁The ▁quality ▁of ▁life ▁assessment ▁indicate d ▁better ▁well - be ing ▁in ▁all ▁participants .
▁NT - Pro B NP ▁(+ 233 ▁to ▁– 73 3 ▁ng / ml ) ▁and ▁the ▁infla mma tory ▁bio mark ers ▁( h s CR P ▁and ▁IL 6) ▁decrease d ▁in ▁four ▁of ▁five ▁patients ▁( IL ▁6 : ▁+ 0.5 ▁to ▁– 2 ▁mg / l , ▁h s CR P : ▁+ 0.2 ▁to ▁– 6.5 ▁mg / l ).
▁CON CL USI ONS : ▁Robot - assist ed ▁ga it ▁ therapy ▁with ▁the ▁Lok omat ® ▁System ▁is ▁fe a sible ▁in ▁heart ▁failure ▁patients ▁and ▁was ▁safe ▁in ▁this ▁trial .
▁The ▁combine d ▁aero bic ▁and ▁resist ance ▁training ▁intervention ▁with ▁aug mente d ▁feedback ▁result ed ▁in ▁benefits ▁in ▁exercise ▁capacity , ▁muscle ▁strength ▁and ▁quality ▁of ▁life , ▁as ▁well ▁as ▁an ▁improvement ▁of ▁cardiac ▁( NT - Pro B NP ) ▁and ▁infla mma tory ▁( IL 6 , ▁h s CR P ) ▁bio mark ers .
▁Results ▁can ▁only ▁be ▁considered ▁as ▁preliminar y ▁and ▁need ▁further ▁valida tion ▁in ▁larger ▁studies .
▁Psycho social ▁Factor s , ▁Exerci se ▁Ad her ence , ▁and ▁Out com es ▁in ▁Heart ▁Fail ure ▁Patient s : ▁Insight s ▁From ▁Heart ▁Fail ure : ▁A ▁Control led ▁Tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁( HF - AC TION ).
▁BA CK GRO UND : ▁Psycho social ▁factors ▁may ▁influence ▁ad her ence ▁with ▁exercise ▁training ▁for ▁heart ▁failure ▁( HF ) ▁patients .
▁We ▁ai med ▁to ▁describe ▁the ▁association ▁between ▁social ▁support ▁and ▁barrier s ▁to ▁participation ▁with ▁exercise ▁ad her ence ▁and ▁clinic al ▁outcome s .
▁ MET HOD S ▁AND ▁RESULT S : ▁Of ▁patients ▁en roll ed ▁in ▁Heart ▁Fail ure : ▁A ▁Control led ▁Tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁( HF - AC TION ), ▁2 279 ▁( 97 . 8%) ▁completed ▁survey s ▁to ▁assess ▁social ▁support ▁and ▁barrier s ▁to ▁exercise , ▁result ing ▁in ▁the ▁perc ei ved ▁social ▁support ▁score ▁( PS SS ) ▁and ▁barrier s ▁to ▁exercise ▁score ▁( B TES ).
▁High er ▁PS SS ▁indicate d ▁higher ▁levels ▁of ▁social ▁support , ▁where as ▁higher ▁B TES ▁indicate d ▁more ▁barrier s ▁to ▁exercise .
▁Exerci se ▁time ▁at ▁3 ▁and ▁12 ▁months ▁cor related ▁with ▁PS SS ▁( r = ▁0.0 9 ▁and ▁r = ▁0.1 3 , ▁respective ly ) ▁and ▁B TES ▁( r = -0 . 11 ▁and ▁r = -0 . 12 , ▁respective ly ), ▁with ▁higher ▁exercise ▁time ▁associated ▁with ▁higher ▁PS SS ▁and ▁lower ▁B TES ▁( All ▁P < 0.00 5) .
▁For ▁cardiovascular ▁death ▁or ▁ HF ▁hospital ization , ▁there ▁was ▁a ▁significant ▁interaction ▁between ▁the ▁random ization ▁group ▁and ▁B TES ▁( P = 0.0 35) , ▁which ▁corresponde d ▁to ▁a ▁border line ▁association ▁between ▁increasing ▁B TES ▁and ▁cardiovascular ▁death ▁or ▁ HF ▁hospital ization ▁in ▁the ▁exercise ▁group ▁( haz ard ▁ratio ▁1. 25 , ▁95% ▁confidence ▁interval ▁0 . 99 , ▁1. 59) , ▁but ▁no ▁association ▁in ▁the ▁usual ▁care ▁group ▁( haz ard ▁ratio ▁0 . 83 , ▁95% ▁confidence ▁interval ▁0 . 66 , ▁1. 06) .
▁CON CL USI ONS : ▁Poor ▁social ▁support ▁and ▁high ▁barrier s ▁to ▁exercise ▁were ▁associated ▁with ▁lower ▁exercise ▁time .
▁PS SS ▁did ▁not ▁impact ▁the ▁effect ▁of ▁exercise ▁training ▁on ▁outcome s .
▁However , ▁for ▁cardiovascular ▁death ▁or ▁ HF ▁hospital ization , ▁exercise ▁training ▁had ▁a ▁greater ▁impact ▁on ▁patients ▁with ▁lower ▁B TES .
▁Give n ▁that ▁exercise ▁training ▁improve s ▁outcome s ▁in ▁ HF ▁patients , ▁assessment ▁of ▁perc ei ved ▁barrier s ▁may ▁facilita te ▁individual ized ▁approach es ▁to ▁implement ▁exercise ▁training ▁ therapy ▁in ▁clinic al ▁practice .
▁Heart ▁rate ▁re duction ▁and ▁exercise ▁performance ▁in ▁recent ▁ons et ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction : ▁argument s ▁for ▁beta - block er ▁hypo - respons e .
▁OB JE C TIVE : ▁Beta ▁block ers ▁reduce ▁all - ca use ▁mortal ity ▁and ▁read missions ▁in ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction ▁( HF r EF ), ▁which ▁may ▁be ▁explained ▁by ▁their ▁effect ▁on ▁heart ▁rate ▁( HR ).
▁This ▁study ▁assess ed ▁the ▁impact ▁of ▁HR ▁re duction ▁with ▁beta ▁block ers ▁on ▁exercise ▁capacity ▁in ▁recent ▁ons et ▁H Fr EF .
▁ MET HOD S ▁AND ▁RESULT S : ▁Fi ft y ▁consecutiv e ▁patients ▁with ▁recent ▁ons et ▁H Fr EF ▁( < 30 ▁days ) ▁perform ed ▁a ▁standard ized ▁exercise ▁protocol ▁with ▁respirator y ▁gas ▁analysis ▁at ▁base line ▁as ▁well ▁as ▁after ▁6 ▁and ▁12 ▁months .
▁Patient s ▁participat ed ▁in ▁a ▁quality ▁of ▁care ▁programme ▁ai ming ▁to ▁achieve ▁guide line - re com mend ed ▁target ▁dos es ▁for ▁beta - block er ▁ therapy .
▁At ▁base line , ▁6 ▁and ▁12 ▁months , ▁3 6% , ▁70% ▁and ▁6 2% ▁of ▁patients , ▁respective ly , ▁had ▁a ▁rest ing ▁HR < 70 ▁bp m .
▁Beta - block er ▁dose ▁after ▁12 ▁months ▁was ▁comparable ▁in ▁patients ▁with ▁rest ing ▁HR < 70 ▁versus ▁ ≥ 70 ▁bp m ▁( P ▁value = 0.6 31) .
▁However , ▁with ▁similar ▁dose ▁up tit ration , ▁the ▁former ▁versus ▁the ▁la tter ▁had ▁a ▁significantly ▁larger ▁HR ▁re duction ▁(17 ± 22 ▁versus ▁4 ± 15 ▁bp m ; ▁P ▁value = 0.0 27) .
▁Peak ▁oxygen ▁consum p tion ▁( VO 2 max ) ▁was ▁significantly ▁higher ▁when ▁rest ing ▁HR ▁was ▁< 70 ▁versus ▁ ≥ 70 ▁bp m ▁(1 7.5 ± 5.5 ▁versus ▁14. 4 ± 3.3 ▁m L / min / kg , ▁respective ly ; ▁P ▁value = 0.0 38) .
▁Similar ▁results ▁were ▁observe d ▁after ▁6 ▁months .
▁Patient s ▁in ▁whom ▁rest ing ▁HR ▁decrease d ▁at ▁follow - up ▁compared ▁to ▁base line ▁had ▁a ▁2.0 ± 3.2 ▁m L / min / kg ▁increase ▁in ▁VO 2 max ▁compared ▁to ▁a ▁1.2 ± 7.7 ▁m L / min / kg ▁increase ▁in ▁patients ▁who ▁did ▁not ▁demonstrat e ▁a ▁lower ▁rest ing ▁HR ▁( P ▁value = 0.0 33) .
▁CON CL USI ONS : ▁In ▁recent ▁ons et ▁H Fr EF , ▁exercise ▁performance ▁was ▁better ▁when ▁rest ing ▁HR ▁was ▁control led ▁< 70 ▁bp m ▁with ▁beta - block er ▁ therapy .
▁However , ▁de spite ▁aggressiv e ▁dose ▁up tit ration , ▁many ▁patients ▁did ▁not ▁achieve ▁this ▁target ▁as ▁they ▁had ▁little ▁HR ▁re duction ▁with ▁beta - block er ▁ therapy .
▁Uni direct ional ▁left - to - right ▁inter at rial ▁sh unting ▁for ▁treatment ▁of ▁patients ▁with ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction : ▁a ▁safety ▁and ▁ proof - of - princip le ▁co hor t ▁study .
▁BA CK GRO UND : ▁In ▁patients ▁with ▁heart ▁failure , ▁intervention s ▁to ▁reduce ▁eleva ted ▁left ▁at rial ▁pressure ▁improve ▁symptoms ▁and ▁reduce ▁the ▁risk ▁of ▁hospital ▁ad mission .
▁We ▁ai med ▁to ▁assess ▁the ▁safety ▁and ▁potential ▁ef fica cy ▁of ▁ therapeut ic ▁left - to - right ▁inter at rial ▁sh unting ▁in ▁patients ▁with ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction .
▁ MET HOD S : ▁We ▁did ▁this ▁ proof - of - princip le ▁co hor t ▁study ▁at ▁one ▁centre ▁in ▁Canada .
▁Patient s ▁( a ged ▁ ≥ 18 ▁years ) ▁with ▁New ▁York ▁Heart ▁Association ▁( NY HA ) ▁class ▁III ▁chronic ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction ▁were ▁en roll ed ▁under ▁the ▁Canadian ▁special ▁access ▁programme .
▁Shu nt ▁implant s ▁were ▁done ▁after ▁trans sept al ▁cat heter isation ▁with ▁trans o es op hage al ▁e cho car dio graphic ▁guidance ▁under ▁general ▁ana es the sia .
▁Patient s ▁had ▁clinic al ▁and ▁e cho card i ography ▁evaluation s ▁at ▁base line ▁and ▁months ▁1 ▁and ▁3 ▁after ▁shu nt ▁implant ation .
▁FIN DING S : ▁Bet we en ▁Oct ▁10 , ▁2013, ▁and ▁March ▁27, ▁2015, ▁we ▁en roll ed ▁ten ▁patients .
▁The ▁device ▁was ▁successful ly ▁implant ed ▁in ▁all ▁patients ; ▁no ▁device - related ▁or ▁procedura l ▁advers e ▁events ▁occur red ▁during ▁follow - up .
▁Trans o es op hage al ▁e cho card i ography ▁at ▁1 ▁month ▁showed ▁that ▁all ▁shu nts ▁were ▁patent , ▁with ▁no ▁ thro mbo sis ▁or ▁migration .
▁From ▁base line ▁to ▁3 ▁month ▁follow - up , ▁we ▁record ed ▁improvement s ▁in ▁NY HA ▁classifica tion ▁( from ▁class ▁III ▁to ▁class ▁II ▁in ▁seven ▁[ 7 8% ] ▁of ▁ni ne ▁patients , ▁from ▁class ▁III ▁to ▁class ▁I ▁in ▁one ▁[1 1% ] ▁patient , ▁and ▁no ▁change ▁in ▁one ▁[1 1% ] ▁patient ; ▁p =0 · 000 4 ); ▁quality ▁of ▁life , ▁as ▁assess ed ▁by ▁the ▁Duke ▁Activ ity ▁Status ▁Index ▁( from ▁a ▁mean ▁score ▁of ▁13 ▁[ SD ▁6 · 2] ▁to ▁24 · 8 ▁[ 12 · 9 ] ; ▁p =0 · 016 ) ▁and ▁the ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁( from ▁a ▁mean ▁score ▁of ▁44 · 3 ▁[ SD ▁9 · 8 ] ▁to ▁79 · 1 ▁[ 13 · 0 ] ; ▁p =0 · 0001 ); ▁and ▁6 ▁min ▁walk ▁test ▁distance ▁( from ▁a ▁mean ▁of ▁24 4 ▁m ▁[ SD ▁112 ] ▁to ▁3 18 ▁m ▁[ 134 ] ; ▁p =0 · 016 ).
▁Pul mon ary ▁cap illa ry ▁we dge ▁pressure ▁was ▁reduce d ▁from ▁a ▁mean ▁of ▁23 ▁mm ▁H g ▁( SD ▁5) ▁at ▁base line ▁to ▁17 ▁mm ▁H g ▁(8) ▁at ▁3 ▁months ▁( p =0 · 0 35) , ▁with ▁no ▁changes ▁in ▁right ▁at rial ▁pressure , ▁pulmonar y ▁arterial ▁pressure , ▁or ▁pulmonar y ▁resist ance .
▁No ▁patient ▁was ▁admit ted ▁to ▁hospital ▁for ▁worse ning ▁heart ▁failure .
▁One ▁(10 %) ▁patient ▁was ▁admit ted ▁to ▁hospital ▁with ▁gastro inte stin al ▁ble ed ing ▁at ▁month ▁1 ; ▁one ▁(10 %) ▁patient ▁die d ▁after ▁ince ssant ▁vent ri cular ▁ta chy car dia ▁storm , ▁which ▁led ▁to ▁terminal ▁heart ▁failure ▁2 ▁months ▁post - procedure .
▁INTER P RET ATION : ▁This ▁first - in - man ▁experience ▁with ▁an ▁implant ed ▁left - to - right ▁inter at rial ▁shu nt ▁demonstrat es ▁initial ▁safety ▁and ▁early ▁beneficia l ▁clinic al ▁and ▁ha emo dynamic ▁outcome s ▁in ▁patients ▁with ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction .
▁Fur ther ▁large - s cale ▁random ised ▁studies ▁are ▁warrant ed .
▁Study ▁PARA DIG M - HF ▁- ▁a ▁paradigm ▁shift ▁in ▁the ▁treatment ▁of ▁chronic ▁heart ▁failure ▁Chro nic ▁heart ▁failure ▁is ▁a ▁crucial ▁problem ▁of ▁current ▁card i ology .
▁De spite ▁that , ▁no ▁major ▁development ▁has ▁occur red ▁in ▁the ▁ therapy ▁in ▁recent ▁years .
▁In ▁this ▁regard , ▁first ▁results ▁of ▁studies ▁with ▁AR NI ▁inhibi tors ▁( angi oten sin - recept or ▁nepri ly sin ▁inhibi tors ) ▁may ▁be ▁considered ▁hope ful .
▁Dual ▁inhibi tion ▁of ▁AT 1 ▁receptor s ▁and ▁nepri ly sin ▁block s ▁re nin - angi oten sin - al do ster on ▁( RAS ) ▁a xis ▁and ▁concurrent ly ▁support s ▁natural ▁vaso dila tory ▁and ▁di ure tic ▁effect ▁of ▁na tri ure tic ▁pe pti des .
▁Large - s cale ▁prospect ive ▁random ized ▁multi center ▁trial ▁PARA DIG M - HF ▁with ▁more ▁than ▁8000 ▁individuals ▁with ▁stabil ized ▁chronic ▁heart ▁failure ▁with ▁sy sto lic ▁dys function ▁( LV ▁EF ▁40% , ▁later ▁35% ), ▁mostly ▁in ▁functional ▁class ▁NY HA ▁II - III ▁with ▁eleva ted ▁B NP / NT - pro ▁B NP ▁has ▁shown ▁20% ▁decrease ▁in ▁primary ▁end point ▁( car dio vas cular ▁death ▁or ▁hospital ization ▁for ▁heart ▁failure ) ▁in ▁a ▁group ▁treated ▁by ▁AR NI ▁( LC Z 696 ; ▁sa cubi lt ril ▁- ▁val sar tan ).
▁Benefici al ▁effect ▁of ▁AR NI ▁was ▁consistent ▁also ▁for ▁total ▁and ▁cardiovascular ▁mortal ity , ▁for ▁hospital ization ▁for ▁heart ▁failure ▁and ▁in ▁other ▁pre - spec ified ▁sub group ▁analyse s , ▁including ▁quality ▁of ▁life .
▁The ▁treatment ▁was ▁safe , ▁typical ▁advers e ▁event ▁was ▁hypo tension , ▁however ▁without ▁a ▁need ▁to ▁interrupt ▁the ▁treatment .
▁Dual ▁ RAS ▁and ▁nepri ly sin ▁inhibi tion ▁might ▁thu s ▁after ▁long ▁time ▁become ▁a ▁change ▁in ▁stable ▁chronic ▁heart ▁failure ▁with ▁sy sto lic ▁dys function ▁treatment ▁" para dig m ".
▁Czech ▁Republic ▁significantly ▁contribute d ▁to ▁this ▁study ▁and ▁all ▁study ▁sites ▁should ▁be ▁congratula ted ▁and ▁thank ed ▁for ▁their ▁high - quality ▁work ▁provided .
▁Effect ▁of ▁Cal o ric ▁Re stri ction ▁or ▁Aero bic ▁Exerci se ▁Training ▁on ▁Peak ▁O xy gen ▁Consum p tion ▁and ▁Quality ▁of ▁Life ▁in ▁Ob ese ▁Old er ▁Patient s ▁With ▁Heart ▁Fail ure ▁With ▁Pres er ved ▁E je ction ▁Fra ction : ▁A ▁Rand om ized ▁Clinic al ▁Tri al .
▁IMPORT ANCE : ▁More ▁than ▁80% ▁of ▁patients ▁with ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁( H FP EF ), ▁the ▁most ▁common ▁form ▁of ▁heart ▁failure ▁among ▁older ▁person s , ▁are ▁over weight ▁or ▁obes e .
▁Exerci se ▁in tolerance ▁is ▁the ▁primary ▁symptom ▁of ▁chronic ▁H FP EF ▁and ▁a ▁major ▁determina nt ▁of ▁reduce d ▁quality ▁of ▁life ▁( Q OL ).
▁OB JE C TIVE : ▁To ▁determine ▁whether ▁calor ic ▁restriction ▁( diet ) ▁or ▁aero bic ▁exercise ▁training ▁( exe rci se ) ▁improve s ▁exercise ▁capacity ▁and ▁Q OL ▁in ▁obes e ▁older ▁patients ▁with ▁H FP EF .
▁DESIGN , ▁SET TING , ▁AND ▁PARTI CI PAN TS : ▁Rand om ized , ▁attention - control led , ▁2 ▁× ▁2 ▁factor ial ▁trial ▁conduct ed ▁from ▁February ▁2009 ▁through ▁November ▁2014 ▁in ▁an ▁urban ▁academic ▁medical ▁center .
▁Of ▁ 577 ▁initial ly ▁screen ed ▁participants , ▁100 ▁older ▁obes e ▁participants ▁( me an ▁[ SD ] : ▁age , ▁67 ▁years ▁[5] ; ▁body ▁mass ▁index , ▁39 . 3 ▁[ 5.6 ] ) ▁with ▁chronic , ▁stable ▁H FP EF ▁were ▁en roll ed ▁( 366 ▁exclu ded ▁by ▁inclusi on ▁and ▁exclu sion ▁criteri a , ▁31 ▁for ▁other ▁reasons , ▁and ▁80 ▁decline d ▁participation ).
▁INTER VEN TIONS : ▁T went y ▁weeks ▁of ▁die t , ▁exercise , ▁or ▁both ; ▁attention ▁control ▁consiste d ▁of ▁telephone ▁call s ▁every ▁2 ▁weeks .
▁M AIN ▁ OUT COM ES ▁AND ▁ME A SU RES : ▁Exerci se ▁capacity ▁measure d ▁as ▁pe ak ▁oxygen ▁consum p tion ▁( VO 2 , ▁m L / kg / min ; ▁co - prima ry ▁outcome ) ▁and ▁Q OL ▁measure d ▁by ▁the ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁( ML HF ) ▁Question naire ▁( s core ▁range : ▁0 - 105 , ▁higher ▁score s ▁indicate ▁worse ▁heart ▁failure - related ▁Q OL ; ▁co - prima ry ▁outcome ).
▁RESULT S : ▁Of ▁the ▁100 ▁en roll ed ▁participants , ▁26 ▁participants ▁were ▁random ized ▁to ▁exercise ; ▁24 ▁to ▁die t ; ▁25 ▁to ▁exercise ▁+ ▁die t ; ▁25 ▁to ▁control .
▁Of ▁these , ▁92 ▁participants ▁completed ▁the ▁trial .
▁Exerci se ▁attend ance ▁was ▁8 4% ▁( SD , ▁14% ) ▁and ▁die t ▁ad her ence ▁was ▁99% ▁( SD , ▁1% ).
▁By ▁main ▁effects ▁analysis , ▁pe ak ▁VO 2 ▁was ▁increased ▁significantly ▁by ▁both ▁intervention s : ▁exercise , ▁1.2 ▁m L / kg ▁body ▁mass / min ▁( 95% ▁CI , ▁ 0.7 ▁to ▁1.7 ), ▁P ▁< ▁ . 001 ; ▁die t , ▁1.3 ▁m L / kg ▁body ▁mass / min ▁( 95% ▁CI , ▁ 0.8 ▁to ▁1.8 ), ▁P ▁< ▁ . 001 .
▁The ▁combination ▁of ▁exercise ▁+ ▁die t ▁was ▁addit ive ▁( comp lement ary ) ▁for ▁pe ak ▁VO 2 ▁( jo int ▁effect , ▁2.5 ▁m L / kg / min ).
▁There ▁was ▁no ▁statistic ally ▁significant ▁change ▁in ▁ ML HF ▁total ▁score ▁with ▁exercise ▁and ▁with ▁die t ▁( main ▁effect : ▁exercise , ▁-1 ▁unit ▁[ 95% ▁CI , ▁- 8 ▁to ▁5 ] , ▁P ▁= ▁ . 70 ; ▁die t , ▁- 6 ▁unit s ▁[ 95% ▁CI , ▁ -12 ▁to ▁1 ] , ▁P ▁= ▁ . 08) .
▁The ▁change ▁in ▁pe ak ▁VO 2 ▁was ▁positive ly ▁cor related ▁with ▁the ▁change ▁in ▁percent ▁lean ▁body ▁mass ▁( r ▁= ▁0.3 2 ; ▁P ▁= ▁ . 003 ) ▁and ▁the ▁change ▁in ▁th igh ▁muscle : inter mus cular ▁fat ▁ratio ▁( r ▁= ▁0.2 7 ; ▁P ▁= ▁ . 02) .
▁There ▁were ▁no ▁study - related ▁serious ▁advers e ▁events .
▁Body ▁weight ▁decrease d ▁by ▁7% ▁(7 ▁kg ▁[ SD , ▁1 ] ) ▁in ▁the ▁die t ▁group , ▁3% ▁(4 ▁kg ▁[ SD , ▁1 ] ) ▁in ▁the ▁exercise ▁group , ▁10% ▁(11 ▁kg ▁[ SD , ▁1 ] ▁in ▁the ▁exercise ▁+ ▁die t ▁group , ▁and ▁1% ▁(1 ▁kg ▁[ SD , ▁1 ] ) ▁in ▁the ▁control ▁group .
▁CON CL USI ONS ▁AND ▁RE LEV ANCE : ▁Am ong ▁obes e ▁older ▁patients ▁with ▁clinic ally ▁stable ▁H FP EF , ▁calor ic ▁restriction ▁or ▁aero bic ▁exercise ▁training ▁increased ▁pe ak ▁VO 2 , ▁and ▁the ▁effects ▁may ▁be ▁addit ive .
▁Nei ther ▁intervention ▁had ▁a ▁significant ▁effect ▁on ▁quality ▁of ▁life ▁as ▁measure d ▁by ▁the ▁ ML HF ▁Question naire .
▁Full y ▁Magnet ically ▁Lev itate d ▁Le ft ▁Vent ri cular ▁Assist ▁System ▁for ▁Tre ating ▁Advanced ▁ HF : ▁A ▁Multi center ▁Study .
▁BA CK GRO UND : ▁The ▁Heart Mate ▁3 ▁left ▁vent ri cular ▁assist ▁system ▁( L VAS ) ▁is ▁intended ▁to ▁provide ▁long - term ▁support ▁to ▁patients ▁with ▁advanced ▁heart ▁failure .
▁The ▁centri fu gal ▁flow ▁pump ▁is ▁designed ▁for ▁enhance d ▁hem o com pati bility ▁by ▁incorpora ting ▁a ▁magnet ically ▁le vita ted ▁ro tor ▁with ▁wide ▁blood - flow ▁path s ▁and ▁an ▁artificial ▁puls e .
▁OB JE C TIVE S : ▁The ▁a im ▁of ▁this ▁single - arm , ▁prospect ive , ▁multi center ▁study ▁was ▁to ▁evaluat e ▁the ▁performance ▁and ▁safety ▁of ▁this ▁L VAS .
▁ MET HOD S : ▁The ▁primary ▁end point ▁was ▁6- mont h ▁survival ▁compared ▁with ▁INTER MA CS ▁( Inter age ncy ▁Registr y ▁for ▁Mechanic ally ▁Assist ed ▁Circula tory ▁Support ) - der i ved ▁performance ▁goal .
▁Patient s ▁were ▁adults ▁with ▁e je ction ▁ fraction ▁ ≤ ▁25% , ▁cardiac ▁index ▁ ≤ ▁2.2 ▁l / min / m (2) ▁without ▁in o trop es ▁or ▁were ▁in ot rope - dependent ▁on ▁optimal ▁medical ▁management , ▁or ▁listed ▁for ▁transplant .
▁RESULT S : ▁Fi ft y ▁patients ▁were ▁en roll ed ▁at ▁10 ▁center s .
▁The ▁indica tions ▁for ▁L VAS ▁support ▁were ▁ bridge ▁to ▁transplant ation ▁(5 4% ) ▁or ▁destination ▁ therapy ▁(4 6% ).
▁At ▁6 ▁months , ▁8 8% ▁of ▁patients ▁continued ▁on ▁support , ▁4% ▁received ▁transplant s , ▁and ▁8% ▁die d .
▁Thi r ty - day ▁mortal ity ▁was ▁2% ▁and ▁6- mont h ▁survival ▁9 2% , ▁which ▁exceed ed ▁the ▁8 8% ▁performance ▁goal .
▁Support ▁with ▁the ▁fully ▁magnet ically ▁le vita ted ▁L VAS ▁significantly ▁reduce d ▁mortal ity ▁risk ▁by ▁6 6% ▁compared ▁with ▁the ▁Seattle ▁Heart ▁Fail ure ▁Model - pred i cted ▁survival ▁of ▁7 8% ▁( p ▁= ▁ 0.00 93) .
▁Key ▁advers e ▁events ▁included ▁re opera tion ▁for ▁ble ed ing ▁(14 %) , ▁drive line ▁infection ▁( 10% ), ▁gastro inte stin al ▁ble ed ing ▁( 8%) , ▁and ▁de bilitat ing ▁stroke ▁( mod ified ▁Rank in ▁Score ▁> ▁3) ▁( 8%) .
▁There ▁were ▁no ▁pump ▁exchange s , ▁pump ▁mal function s , ▁pump ▁ thro mbo sis , ▁or ▁hem ol ysis ▁events .
▁New ▁York ▁Heart ▁Association ▁classifica tion , ▁6- min ▁walk ▁test , ▁and ▁quality - of - life ▁score s ▁showed ▁progressive ▁and ▁sustain ed ▁improvement .
▁CON CL USI ONS : ▁The ▁results ▁show ▁that ▁the ▁fully ▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic ▁L VAS ▁is ▁safe , ▁with ▁high ▁30- day ▁and ▁6- mont h ▁survival ▁rates , ▁a ▁favorable ▁advers e ▁event ▁profile , ▁and ▁improve d ▁quality ▁of ▁life ▁and ▁functional ▁status .
▁Tools ▁for ▁Economic ▁Analys is ▁of ▁Patient ▁Management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁Cost - E ff ective ness ▁Model : ▁A ▁Web - based ▁program ▁designed ▁to ▁evaluat e ▁the ▁cost - effect ive ness ▁of ▁disease ▁management ▁programs ▁in ▁heart ▁failure .
▁BA CK GRO UND : ▁Heart ▁failure ▁disease ▁management ▁programs ▁can ▁influence ▁medical ▁resource ▁use ▁and ▁quality - ad just ed ▁survival .
▁Because ▁project ing ▁long - term ▁costs ▁and ▁survival ▁is ▁challenging , ▁a ▁consistent ▁and ▁valid ▁approach ▁to ▁extra pola ting ▁short - term ▁outcome s ▁would ▁be ▁valuable .
▁ MET HOD S : ▁We ▁developed ▁the ▁Tools ▁for ▁Economic ▁Analys is ▁of ▁Patient ▁Management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁Cost - E ff ective ness ▁Model , ▁a ▁Web - based ▁simula tion ▁tool ▁designed ▁to ▁integrat e ▁data ▁on ▁demo graphic , ▁clinic al , ▁and ▁laborator y ▁character istic s ; ▁use ▁of ▁evidence - based ▁medication s ; ▁and ▁costs ▁to ▁generate ▁predict ed ▁outcome s .
▁Sur vi val ▁project ions ▁are ▁based ▁on ▁a ▁modifi ed ▁Seattle ▁Heart ▁Fail ure ▁Model .
▁Project ions ▁of ▁resource ▁use ▁and ▁quality ▁of ▁life ▁are ▁model ed ▁using ▁relationships ▁with ▁time - var ying ▁Seattle ▁Heart ▁Fail ure ▁Model ▁score s .
▁The ▁model ▁can ▁be ▁used ▁to ▁evaluat e ▁parallel - group ▁and ▁single - co hor t ▁study ▁design s ▁and ▁hypothe tical ▁programs .
▁Simula tions ▁consist ▁of ▁10,000 ▁pair s ▁of ▁virtual ▁co hor ts ▁used ▁to ▁generate ▁estima tes ▁of ▁resource ▁use , ▁costs , ▁survival , ▁and ▁incrementa l ▁cost - effect ive ness ▁ratio s ▁from ▁user ▁input s .
▁RESULT S : ▁The ▁model ▁demonstrat ed ▁acceptable ▁internal ▁and ▁external ▁valid ity ▁in ▁replica ting ▁resource ▁use , ▁costs , ▁and ▁survival ▁estima tes ▁from ▁3 ▁clinic al ▁trial s .
▁Simula tions ▁to ▁evaluat e ▁the ▁cost - effect ive ness ▁of ▁heart ▁failure ▁disease ▁management ▁programs ▁across ▁3 ▁scenario s ▁demonstrat e ▁how ▁the ▁model ▁can ▁be ▁used ▁to ▁design ▁a ▁program ▁in ▁which ▁short - term ▁improvement s ▁in ▁function ing ▁and ▁use ▁of ▁evidence - based ▁treatment s ▁are ▁ sufficient ▁to ▁demonstrat e ▁good ▁long - term ▁value ▁to ▁the ▁health ▁care ▁system .
▁CON C LU SION : ▁The ▁Tools ▁for ▁Economic ▁Analys is ▁of ▁Patient ▁Management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁Cost - E ff ective ness ▁Model ▁provides ▁research ers ▁and ▁provider s ▁with ▁a ▁tool ▁for ▁conduct ing ▁long - term ▁cost - effect ive ness ▁analyse s ▁of ▁disease ▁management ▁programs ▁in ▁heart ▁failure .
▁Heart ▁Fail ure : ▁Path o phy si ology , ▁ Diagnos is , ▁Medical ▁Treatment ▁Guide lines , ▁and ▁Nur sing ▁Management .
▁Heart ▁failure ▁( HF ) ▁is ▁a ▁de bilitat ing ▁chronic ▁disease ▁and ▁is ▁expected ▁to ▁increase ▁in ▁up com ing ▁years ▁due ▁to ▁demo graphic ▁changes .
▁Nur ses ▁in ▁all ▁setting s ▁have ▁an ▁essential ▁role ▁in ▁support ing ▁patients ▁in ▁man aging ▁this ▁disease .
▁This ▁article ▁describe s ▁the ▁pat ho phy si ology ▁of ▁ HF , ▁ diagnos is , ▁medical ▁management , ▁and ▁nur sing ▁intervention s .
▁It ▁is ▁crucial ▁for ▁nurse s ▁to ▁understand ▁the ▁pat ho phy si ology ▁of ▁ HF ▁and ▁the ▁importance ▁that ▁nur sing ▁actions ▁have ▁on ▁en han cing ▁medical ▁management ▁to ▁alle via te ▁symptoms ▁and ▁to ▁de ter ▁the ▁advance ment ▁of ▁the ▁pat ho phy si ologic ▁state .
▁Such ▁an ▁understanding ▁can ▁ultima tely ▁reduce ▁morbi d ity ▁and ▁mortal ity ▁and ▁optim ize ▁quality ▁of ▁life ▁in ▁patients ▁with ▁ HF .
